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Solid phase microextraction (SPME) has been rapidly developing since its invention in 1990. Due to a 
flexible design and the ability to implement various extractive coatings, SPME has found use in 
numerous applications. One such application is the coupling of SPME to Direct Analysis in Real Time 
(DART), an ambient ionization mass spectrometry (AIMS) technique. AIMS techniques completely 
eliminate the use of chromatography, reducing lengthy workflows and improving time-efficiency. SPME 
coupled to DART-MS has been quite successful in achieving low detection limits and reproducible 
results in bioanalytical applications. These successes are mostly due to the excellent preconcentrating 
and interference resisting abilities of SPME coatings and detection capabilities of DART-MS. Certainly, 
as a novel technique, many aspects of SPME-DART-MS are yet to be explored. Hence, this thesis 
investigated fundamental aspects of SPME-DART-MS, in addition to exploring novel applications, such 
as detection of prohibited substances in small bio-volumes (i.e., ≤ 25 µL of oral fluid (OF) and human 
blood) and implementation of SPME-DART-MS as high-throughput technology for quantitation of 
opioids in urine and human plasma in less than 1.5 h for a set of 96 samples. Coupling of SPME to 
portable DART-MS instrumentation was investigated for on-site, in vivo drug detection in samples of 
OF as a potential tool of law enforcement, reporting detection limits that are below those proposed by 
regulatory agencies. Additionally, the use of biocompatible plastic materials such as 
polyetheretherketone (PEEK) was investigated as a potential alternative material for the manufacturing 
of SPME devices for DART-MS, which are usually made of stainless steel (SS). Performance of the 
PEEK devices was similar to those of SS, allowing for their use in quantification of drugs-of-abuse 
(DoAs) in OF and urine at low parts-per-billion levels (ppb). In addition, OF samples following coffee 
consumption from a female volunteer were used to monitor caffeine half-life. The results were in 
compliance with established half-life of caffeine reported in literature, and highlighted the potential of 
the PEEK devices for in vivo buccal swabbing testing.  
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Another novel application of SPME described in this thesis was the development of miniaturized SPME 
devices “minitips” for analysis of small volumes. The analysis of small sample volumes (biofluids, 
tissues, and cells) has become more common within the scientific community in the last few years. For 
this type of analysis, very sensitive instrumental platforms and sample preparation methods are required 
to obtain qualitative and quantitative information. Hence, the SPME minitip format was introduced, and 
the tip apex was coated with 1 millimeter (mm) of polyacrylonitrile (PAN) and in-house-synthesized N-
vinylpyrrolidone-co-divinylbenzene, also known as hydrophilic lipophilic balance (HLB) particles. 
Robustness, extraction efficiency, repeatability, reusability, and matrix effect (ME) assessment yielded 
good results. Benzodiazepines were extracted from 15 µL of phosphate buffer saline (PBS) and urine, 
and certain DoAs were extracted from 1 µL of OF using LC-MS/MS. Very good figures of merit were 
obtained, with limits of detection (LODs) and quantitation (LOQs) in the lower ppb range. DoAs were 
also extracted from 1 µL of blood by directly coupling the SPME minitips to nanoelectrospray ionization 
(nESI) devices. The SPME HLB minitips were also used for untargeted metabolomic profiling of caviar 
eggs via liquid chromatography high resolution mass spectrometry (LC/HRMS), thereby showing that 
despite introduced dilution, satisfactory results can be obtained. Indeed, good statistical separation of 
caviar eggs was observed, in addition to extracting well over a hundred significant features.  
Lastly, this thesis also details application of SPME for untargeted metabolomics profiling of patient 
affected with a genetic condition known as malignant hyperthermia (MH). Small human muscles 
obtained from Toronto General Hospital were sampled using SPME fibers and analysed via LC/HRMS 
using an untargeted metabolomics approach. Potential disease related compounds (i.e., biomarkers) were 
found, aiding in the elucidation of the biochemical pathways affected in patients with MH. The accepted 
diagnostic tool of MH is a highly invasive procedure which involves excision of a portion of the Gracilis 
muscle. Hence the prospect of using SPME as minimally invasive diagnostic tool was discussed.   
As this thesis shows, the opportunities of SPME are many; and its continuous development will most 
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 The importance of analytical chemistry 
 
Many researchers in scientific- and engineering-based fields often seek the aid of analytical chemists to 
identify and quantitate specific compounds. The obtained results often contribute significantly to the 
research in question, as they can play a large role in establishing conclusions and/or next step(s). This 
involvement extends to a variety of areas, including monitoring and evaluating the safety and quality of 
water, food(s), and pharmaceutical products. For example, analytical chemists can evaluate the extent of 
meat spoilage by examining compounds like glucose and lactic acid, which can be found in bacterial 
microflora.1 Analytical chemists also play a key role in criminal trials, as their forensic findings are often 
critical in determining whether or not a defendant is innocent. Specialized investigations can also aid in 
solving particular analytical problems. For instance, the causes of cracks and fissures in roads and 
sidewalks can be determined by examining the chemical composition of the asphalt that was used to 
make them. Such approaches not only allow the asphalt to be accurately characterized, but they also 
allow us to better understand the factors that impact asphalt quality.2 Furthermore, analytical chemists 
can help to study the underlying mechanisms of cancer by screening and quantifying the chemical 
markers, known as biomarkers, associated with the disease.3 Most recently, the legalization of marijuana 
use in Canada has created a need for research by analytical chemists, especially in relation to quality 
control of cannabis products, which is being strictly regulated by Health Canada.4,5 Such analytical work 
could include testing for unauthorized pesticides, microbial/chemical contaminants, solvent residues, 
percentage of Δ-9-tetrahydrocannabinol (Δ-9-THC), Δ-9-tetrahydrocannabinolic acid, cannabidiol, and 
cannabidiolic acid.4,5 Certainly, none of the above-mentioned applications would be possible without the 
continuous effort of scientists around the world to advance analytical technology. It is clear that analytical 
chemistry (AC) aims to improve quality of life by developing strategies that allow us to analyze a number 
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of different compounds. The work presented in this thesis reflects some of the most popular areas of 
inquiry in modern 21st century AC.    
 The basic protocol of analytical chemistry 
 
AC is a branch of chemistry that focuses on the qualification and/or quantification of various compounds 
(analytes) in different media, commonly referred to as “matrices” (matrix, sing.). Matrices range in 
complexity from pure, interference-free samples (e.g., H2O), to solid matrices containing high amounts 
of endogenous/exogenous components (e.g., biologicals, foodstuff, soil, crude oil, etc.) that can interfere 
with analytical measurements. For example, analyzing Δ-9-THC in “pot brownies” is challenging due to 
the complexity of the matrix (i.e., high level of fats and carbohydrates).6 In order to develop a robust 
method for analyzing target analyte(s), it is imperative to devise a comprehensive protocol that includes 
an adequate sampling strategy (proper sampling of sufficient amounts of the true matrix representative), 
sample preparation method (isolating and preconcentrating the compounds of interest from the matrix), 
separation technique (partitioning complex mixtures into smaller fractions, which is also known as 
chromatography), identification/quantitation approaches (use of analytical instrumentation and statistical 
tools to establish the presence of specific compounds and to assess their quantities), and decision-making 
processes (the use of obtained data to form a conclusion and, if needed, to determine the next step).7 It is 
critical to optimize each step in the protocol, as they are prone to a “domino effect”; that is, the actions 
performed in each step impact all subsequent steps.7 For example, an error in the sample preparation 
stage could result in errors in the quantitation of target compound(s). While the sampling protocol is 
often considered to be the least difficult step, certain situations can make it very challenging to obtain a 
true representation of the matrix (in proper amounts). One example of this occurs when a tiny needle 
must be maneuvered in order to sample a specific area of a microscopic cell.8 As mentioned above, 
sample preparation aims to provide a truly “representative, reproducible and homogeneous solution” that 
is appropriate for instrumental analysis.9 Figure 1.1 outlines some of the main points to consider when 
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choosing a sample preparation strategy, including the physical state of the matrix (gaseous, solid, liquid, 
mixtures), the available volume and/or mass, and the presence of interfering components.  For example, 
certain sample preparation approaches will not be applicable if the matrix is a gas (e.g., human breath, 
car exhaust, roasted coffee). Similarly, analysts should avoid exhaustive approaches- which destroy 
and/or consume the sample when sufficient amounts of matrix are unavailable.7 
Figure 1.1 Outline of major considerations in choosing a sample preparation approach. 
If the matrix is highly complex, yet valuable (e.g., meconium—the first feces of a newborn), its impact 
on the extraction process and the qualitative/quantitative analysis of target compounds should be 
assessed.10 For example, some matrices can even “stick” to sample preparation tools, thus interfering 
with their capabilities. 
The selection of analytical instrumentation usually involves carefully assessing a given platform’s 
suitability for analyzing the compounds of interest. This is an important consideration, as certain 
techniques are inappropriate for analyzing certain compounds. For example, determining concentrations 
of metallic species (e.g., As, Cd, Cu, Pb, Mo, Se, and Zn) requires instruments capable of very low 
detection limits (parts-per-trillion), as these analytes are often toxic at very low levels. Hence, inductively 
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coupled plasma MS is often used to analyze metallic species due to its excellent detection capabilities. 
Instrumental run time should also be determined and, if possible, measures should be taken to reduce it. 
This is particularly important for assays wherein a large number of samples must be analyzed. 
Furthermore, the instrument’s sensitivity and detection limits should also be evaluated, particularly in 
cases where specific performance requirements must be satisfied, for example, the Food and Drug 
Administration’s (FDA) bioanalytical method validation guidance.11 
Ultimately, the choice of sample preparation method and analytical instrumentation will depend on the 
requirements of the evaluation. In other words, is the method being used for screening applications 
(qualitative analysis), or is it being used to determine the actual concentrations (quantitative analysis) of 
target analytes? The answers to these questions play a central role in determining the complexity of the 
sample preparation step and the level of sophistication required for the analytical instrumentation. 
Finally, the accuracy and precision of the analytical method should be provided, as these metrics allow 
for a fair assessment of the method’s success and allow for suggestions on future improvements. 
1.2.1 Common sample preparation strategies 
 
According to Pawliszyn, sample preparation consists of an “extraction procedure that results in isolation 
and enrichment of components of interest from a sample matrix.”12 The extraction procedure primarily 
depends on the choice of the extraction phase, which is directly responsible for analyte isolation.12 The 
extraction phase and the matrix may be in different phases (i.e., solid, liquid, or gas), but they remain in 
contact with each other during the extraction procedure while the analytes are being transported between 
the two.7,12 For example, liquid-solid extraction uses a liquid (e.g., a strong solvent like MeOH) to extract 
analytes from a solid matrix (e.g., soil).  The extraction rate and the distribution of the analyte(s) between 
the two phases will depend on the distribution constant, temperature, and volume of the phases, and their 
diffusion rates.7,12,13 A summary of commonly employed sample preparation strategies can be seen in 
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Figure 1.2.13,14 As mentioned above, liquid-based extractions rely on the use of a solvent to perform 
extractions. These methods—which include liquid-liquid extraction (LLE), liquid-solid extraction, 
enhanced liquid extraction, single drop extraction, and “assisted” liquid extraction—are easy and cheap, 
but it is necessary to evaluate their specificity and sensitivity for target compounds prior to performing 
any experiments, as their preconcentrating ability is limited. Additionally, liquid-based methods offer 
little to no sample clean-up, which progressively contaminates the MS and results in elevated 
instrumental noise.   
 
Figure 1.2 Summary of commonly used sample preparation approaches. 
Solid-based extractions, which include solid-phase extraction (SPE), stir-bar sorptive extraction, and 
membrane extraction, rely on the use of an extractive solid phase to isolate/preconcentrate analytes of 
interest. The most popular solid-based approach is SPE, which consists of an extractive solid phase (also 
known as a cartridge) that is immobilized within a plastic container. However, SPE is hampered by a 
number of drawbacks, including a laborious, time-consuming workflow that becomes even more arduous 
when sample pretreatment is required for more complex matrices (e.g., blood, plasma, tissue).  
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In contrast to the aforementioned strategies, which are mostly exhaustive, microextraction-based 
approaches only require the extraction of a small portion of the analyte. The extraction phases used in 
microextraction are quite small (< 100 µL or 100 mg) and are usually insufficient for exhaustive analyte 
removal.7,15  In recent years, microextraction approaches have begun to be utilized more frequently due 
to their simplicity, need for fewer resources, cost-effectiveness, and increased sample throughput, which 
is largely due to the elimination of the time-consuming steps required for traditional sample preparation 
methods (i.e., LLE or SPE). Examples of microextraction approaches include dispersive liquid-liquid 
microextraction, hollow-fiber microextraction, microextraction by packed sorbent, solid-phase dynamic 
extraction, packed-needle microextraction, and SPME.7,14 
 SPME: the fundamentals  
 
SPME is sample preparation technique that was developed by Arthur and Pawliszyn in 1990, and it has 
become a source of inspiration for researchers in many fields in the nearly 30 years since that time.7,16 
SPME’s appeal is largely due to its simple operation (i.e., a minimal number of steps implemented in the 
workflow), which provides significantly improved accuracy and precision. As its name suggests, SPME 
consists of a solid phase (i.e., extractive phase, also referred to as a coating), which is firmly fixed onto 
a support/base.7,16 The support can be made of many different materials (optical fiber,16 nickel-titanium 
(nitinol),17 SS,18 plastics,19 etc.) with the coating typically being deposited onto it externally. Most SPME 
configurations utilize this “open-bed” format,7 with the exception being in-tube SPME wherein the 
coating is deposited inside of a capillary.20 The most popular SPME format is the SPME fiber. Figure 
1.3 shows an example of a fiber used for LC-SPME applications, wherein the support consists of a 
flexible nitinol fiber and a solid C18 coating. A variety of other SPME formats are also available for a 
number of different applications (Figure 1.4).20–30 For example, membrane SPME probes can be placed 
directly on human skin for the in vivo detection of skin volatiles.21 In general, two main extraction 
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strategies are used in SPME: direct exposure to the matrix (e.g., immersion into urine), or indirect 
exposure via headspace sampling (e.g., extraction of volatiles).7    
Figure 1.3 Example of one of the most popular formats of SPME, the “fiber.” The depicted device 
consists of a C18 coating and a nitinol support. 
 
Figure 1.4 Various different formats that were inspired by the original design of the SPME fiber 
(represented in the white circle). 
8 
 
When the device is ready for use, it is exposed to a sample of interest for a pre-determined amount of 
time in order to extract the analytes. Figure 1.5A contains a schematic of an SPME used for direct-
exposure extraction from a liquid sample, with ‘a’ denoting the fiber support’s inner radius, ‘b’ denoting 
the coating’s radius, and ‘L’ denoting the entire coating length.7 The sample volume to which the fiber 
is exposed is labeled ‘Vs’, while the initial analyte concentration in the sample is labeled ‘𝐶𝑠
0’.7 The 
coating volume is labeled ‘Ve or Vf’, and the interaction between the coating and the analytes can be 
described using ‘𝐾𝑒𝑠 or 𝐾𝑓𝑠’, which are known as the fiber partitioning coefficient/constant.
7 The 
analytes present in the sample have their own diffusion coefficients ‘Ds’ as well as diffusion towards the 
fiber, which is labeled ‘Df’.
7 The kinetic theory of SPME states that the amount of analyte that can be 
extracted depends on their diffusion constants and the agitation (convection) conditions present in the 
system.7,12 
Figure 1.5 Schematic of SPME components and main principles governing its extraction mechanism. 
Figure 1.5A. shows the basic configuration of an SPME being used in direct-exposure mode with a liquid 
solution. Figures 1.5B-C. show some thermodynamic and kinetic principles of SPME. 
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Although SPME can use either static or agitated extraction to suit the situation, the fluid contacting the 
fiber surface will always be stationary, regardless of which one is chosen.7 The stationary fluid labeled δ 
and represented by an orange coating in Figure 1.5B is known as Prandtl’s boundary layer.7 This layer 
can have different thicknesses depending on the agitation and diffusion of the analytes. The concentration 
gradient in Figure 1.5B shows that analyte concentration tends to drop as it approaches the δ, resulting 
in a lower concentration near the fiber surface.7 The amount of analyte ultimately extracted by SPME is 
largely time dependent, as analyte molecules diffuse progressively deeper into the coating as extractions 
increase in duration.7 Hence, the amount of analyte extracted by the SPME coating (which is also the 
basis of its quantitative application) can be expressed using the following equation: 




 is the amount of analyte extracted at equilibrium conditions.7 According to physical chemistry, 
chemical equilibrium is a state in which “both reactants and products have no tendency to change their 
concentrations over time”; but dynamic fluctuations can still exist in the system.31 Once the SPME device 
has been exposed to the sample, the analytes will diffuse into the coating until only an insignificant 
amount is extracted. This condition is known as equilibrium extraction.7 Performing extractions past the 
equilibrium point will not increase the amount of analyte that is extracted. As Pawliszyn notes, 
“equilibration time is assumed to be achieved when 95% of equilibrium amount of the analyte is extracted 
from the sample,” with the 5% accounting for the possibility of experimental error.7 However, it is not 
always necessary to achieve equilibrium, particularly when sampling is challenging (e.g., in vivo 
sampling of live animals). In such cases, a kinetic or linear regime, also known as pre-equilibrium, can 
be employed.7 Figure 1.5C shows a typical SPME extraction-time profile, where the x-axis represents 
the extraction time and the y-axis represents the amount of analyte extracted. A kinetic regime is defined 
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by a steady increase in the amount of analyte extracted, while an equilibrium regime exhibits an 
extraction plateau after a specific period.7 The main factors that influence the time required to achieve 
equilibrium can be expressed using the following equation: 
Equation 1.2  
 
where t95% denotes the time required to extract 95% of the analytes under equilibrium conditions.
7 As 





boundary layer, δ, and the thickness of the extraction phase, b-a.7 In other words, extraction times can be 
very long if analytes have very high affinity for the coating (high Kfs value); δ is too large (e.g. no 
agitation); and the coating on the SPME device is too thick. These factors must be carefully considered 
and adjusted accordingly prior to any experiments. Once the analytes have been extracted through SPME, 
they are removed from the coating via a desorption step, which can be done with a heated gas (e.g., GC 
applications) or a strong solvent (e.g., LC applications).7 The desorption-time profile is often derived by 
examining different desorption time points and it is crucial for ensuring that the extracted analytes are 
completely removed from the SPME device. 
Lastly, it is important to note that SPME extracts via free concentration, which refers to the fraction of 
the analyte(s) that are not bound to matrix components.7 When analytes are present in a specific matrix, 
they do not simply “drift” within it; rather, they tend to bind to matrix components.7 For example, 
analytes spiked to matrices like water and PBS have high free concentrations, as they do not contain 
significant analyte-binding components. In contrast, analytes have a tendency to bind to human plasma 
because it is made of plasma proteins (~7 to 8% v/v), which have analyte-binding properties.7,32 Analyte-







matrix binding reduces the amount of free concentration available for SPME extraction, which can result 
in decreased sensitivity for SPME methods.7,15 
1.3.1 Commonly employed calibration methods of SPME  
 
A number of calibration options have been devised for SPME that allow it to be used in different sampling 
scenarios. For example, SPME has successfully been used to determine an average 3-month 
concentration of biocides and UV-blockers in wastewater,33 the presence of the “earthy” off-flavor 
compounds, geosmin and 2-methylisoborneol, in live fish,34 and concentrations of the anti-cancer drug, 
doxorubicin, in pig lungs.35 While a number of different calibration strategies exist for SPME, the present 
discussion will be limited to “traditional” calibration methods, specifically the spiking of external 
standards and the use of ISs for correction. A detailed review on SPME calibration methods is available 
for those interested.36  
External-standard calibration involves preparing standard solutions of working analytes at a range of 
concentrations and then spiking them into the matrix. The spiked analytes are then extracted by SPME, 
and a calibration plot is obtained by plotting the response for the amount extracted (y-axis) against the 
spiked concentration (x-axis). This approach is also known as matrix matched calibration, as the matrix 
is used in the construction of the calibration plot.7,36 Matrix matched calibration is valuable because it 
considers the extent to which the matrix influences the amount of analyte that is extracted. Extractions 
from a “blank matrix” are also performed in order to determine the level of instrumental noise. If an IS 
is used for a matrix matched external-standard calibration, it is usually spiked at a single concentration 
across the range of the spiked external standards.  The calibration plot is then obtained by plotting the 





1.3.2 SPME coatings 
 
Coating type is a major factor that impacts SPME sensitivity. Since compounds have greater affinity for 
coatings with similar polarities, their logP values (octanol-water partition coefficient, often used to 
describe polarity)37 can be used as an indicator for selecting an appropriate coating.7,38 Another critical 
aspect to consider when selecting a coating is durability. For example, if the coatings are to be used in 
applications involving thermal desorption, robust heat-stable coatings should be employed. If desorption 
is to be done using a strong solvent, then it is important to select a coating that will not crack, swell, or 
strip-off upon solvent exposure. Device robustness and flexibility are also critical, particularly when the 
coating is being used to penetrate solid materials; for such applications, it is important to ensure that the 
coating will not strip off during withdrawal from solid matrices, such as tissue or animal skin.7  In 
addition, it is imperative that the coatings maintain adequate repeatability, which can be assessed by 
evaluating inter (many) and intra-device (single) reproducibility.7 In some cases, SPME coatings can be 
re-used if a proper cleaning procedure is employed. 
In the last decade, there has been a tremendous increase in the number of coatings reported for SPME 
use. These materials consist of either solid or liquid polymers,15 nanomaterials (e.g., metal organic 
frameworks),39,40 specialized coatings (e.g., molecularly imprinted polymers),41 conductive polymers42 
and ionic liquids.43 Various approaches have also been devised for depositing the coatings onto the 
support, including dipping,24 brush-painting,44 spraying,44 electrodeposition,25 sorbent adhesion45 and 
sol-gel.46 Over the last few years, the Pawliszyn group has been investigating the use of SPE sorbent 
particles as SPME coatings.44,45,47–50 These particles, which have a powder-like consistency, can be 
mixed with a binding material to create a coating slurry. This idea originated in the work of Musteata et 
al., who proposed using biocompatible polymer PAN as a binding material for the sorbent particles.48 By 
definition, biocompatible materials are materials that do not cause toxic shock within living systems.48 
Conveniently, PAN contains nitrile groups with hydrophilic and negatively charged properties that 
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prevent unwanted biologicals from adhering to the surface; thus, PAN acts as a restricted access 
material.7,15,49,51,52 A schematic detailing PAN’s action is presented in Figure 1.6. When foreign material 
is exposed to blood, the first event that occurs is the adsorption of hydrophobic materials and proteins to 
its surface.53 This poses a problem, as the adsorption of unwanted material to the SPME coating hinders 
the extraction process by slowing the transfer of analytes. Fortunately, the electronegative nitrogen in 
PAN significantly reduces the attachment of biomolecules.49 The development of biocompatible coatings 
has allowed SPME fibers to be used in minimally invasive applications, such as the in vivo sampling of 
beagles54 and muskellunge fish,55 which provides SPME with a distinct advantage over other commonly 
employed techniques, such as SPE and LLE.  
Figure 1.6 Schematic representation of the application of PAN in blood.48 
1.3.3 SPME’s growth in bioanalytical chemistry and metabolomics 
 
The term bioanalytical chemistry (also known as bioanalysis) refers to the “analysis of drugs, their 
metabolites and low molecular weight biomarkers in biological matrices such as plasma, serum, whole 
blood, urine, oral fluid, tissues, etc.”9 Bioanalysis is somewhat challenging due to the complexity of 
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biological matrices, which consist of numerous components, such as salts, acids, bases, proteins, cells, 
lipids, and lipoproteins.9 Each bio-matrix contains different degrees of interference and should be 
carefully assessed in terms of matrix effects (ME),56 which is a phenomenon that occurs when matrix 
components interfere with the analysis of compounds of interest.56 These components either increase 
(matrix-enhancement) or decrease (matrix-suppression) signals that arise from the analyte(s) of interest.56 
Fortunately, SPME employs a small amount of extractive phase, which limits the amount of interferences 
co-extracted, thus reducing ME. In addition, the use of PAN coatings mentioned in the previous section 
is crucial in reducing the adherence of unwanted biologicals, which also contributes to the reduction of 
the ME. Since Musteata et. al.’s 2007 publication on the use of PAN, a number of studies have detailed 
its use with SPME for analysis of urine,26 plasma,44 OF57 and blood.49  Another important characteristic 
of SPME is its ability to equally extract analytes of varying polarities, also known as “balanced 
coverage.”15 Nonpolar (hydrophobic) compounds have a greater tendency to bind to matrix components, 
thus having a lower free concentration in the matrix.15 In contrast, polar (hydrophilic) compounds bind 
less to matrix components, resulting in a higher free concentration in the matrix.15 Hence, analytes with 
a lower binding constant for the matrix are extracted more rapidly by SPME, while analytes with higher 
binding constants require more time to be extracted in the same amounts.15 Hydrophilic analytes that 
have already been extracted do not become displaced by hydrophobic analytes due to their extended 
extraction times and reduced free concentrations.15  
SPME’s ability to provide balanced coverage has enabled it to be used successfully in the field of 
metabolomics. Metabolomics is concerned with extraction of small molecules (MW ≤ 1000 Da) called 
metabolites, which provide a representative snapshot of a particular subject’s metabolism at the time of 
extraction.58 As such, metabolites can provide insight into the healthy and diseased states of humans by 
revealing important information about the biochemical pathways involved with a given disease, which 
can ultimately be used in therapy development.58 Global (untargeted) metabolomics (i.e., fingerprinting) 
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aims to extract as many metabolites as possible,15 while targeted (i.e., profiling) metabolomics seeks to 
examine specific metabolite(s).15 For untargeted metabolomics, the idealistic aim of an extraction 
protocol, or sample preparation strategy, is to be as unselective as possible.59 In 2010, Vuckovic and 
Pawliszyn provided support for the balanced coverage theory of SPME by showing that mixed-mode 
coatings (C18 with benzenesulfonic acid group as cation exchanger (C6H6O3S)) are capable of extracting 
a range of metabolites with logP values ranging from −7.9 to 7.4.45 In the time since Vuckovic and 
Pawliszyn published their findings, SPME has been used in a variety of untargeted metabolomics 
investigations.50,57,60–62   
1.3.4 General workflow of SPME method development in bioanalysis  
SPME method development begins with the selection of a coating. To this end, analysts must consider 
the logP values of the analytes of interest, and then choose a coating with a proper affinity for these 
analytes. If sensitivity is problematic, other SPME formats with greater surface areas (e.g., SPME thin-
films)23 could be a viable option. Once a coating has been determined, a preconditioning procedure is 
used to “wet” the coating surface to ensure that the material is primed prior to extraction. Before 
extraction, the SPME device should be washed with H2O to remove any residual solvent, as this could 
interfere with the partitioning equilibria if it comes into contact with the sample.7 The total volume of 
standards spiked into the sample should not exceed 1% of the sample’s total volume in order not to 
disturb partitioning equilibria.7 The extraction process is then optimized with respect to sample volume, 
extraction time, agitation, and potential matrix modifications.38 Sample volume and the number of 
replicates that can be achieved both depend on the quantity of available matrix. Extraction-time profiles 
are built by assessing whether adequate sensitivity was obtained at different time points. While extraction 
times can be decreased by using agitation, static extraction is more appropriate in certain scenarios (e.g., 
in vivo sampling). In addition, matrix modifications might be required if there is significant sample-to-
sample variation (e.g., normalization of urine pH when samples from multiple individuals are used).63 
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After the extraction is completed, the devices should be washed with H2O for a pre-determined amount 
of time to remove any unwanted biologicals. Finally, the optimum desorption solution or mixture is 
identified in order to guarantee that the analytes will be completely removed from the SPME device. 
Desorption conditions must be evaluated to identify the optimum solvents or mixtures, which guarantees 
that the analytes are completely removed from the SPME device. Additionally, failure to optimize the 
volume of the desorbing solution can result in excessive analyte dilution. Lastly, the presence of carry-
over should be examined. This is particularly important in cases of “sticky compounds,” which are those 
with very high logP values.64   These steps are summarized in Figure 1.7.   
 
 General workflow of untargeted metabolomics 
As mentioned in section 1.3.3, untargeted metabolomics aims to extract as many metabolites as possible 
in an effort to understand the biochemistry of living systems. Although metabolomics research  often 
occurs within the context of  biological investigations, environmental65 and food66 metabolomics have 
also been reported. SPME has been coupled to both GC and LC platforms for metabolomics; for such 
couplings, the platform choice is dictated by the physico-chemical properties of the metabolites (i.e., 
volatile, semi-volatile or non-volatile).67 Since chapter 4 of this thesis is solely devoted to an untargeted 
metabolomics investigation, it is important to provide some background relating to its basic workflow 
(Figure 1.8). Every investigation begins with the selection of a biological matrix, which in turn 
establishes the working volumes. Next, metabolite extraction is performed. While most of the sample 
preparation options discussed in Section 1.2.1 can be used during this step, it is important to be mindful  




Figure 1.8 Typical workflow of an untargeted LC/MS-based metabolomics investigation. 
of the fact that the sample preparation method can impact metabolite extractability.59  After extraction, 
the metabolites are converted to a form that is suitable for instrumental analysis. In the case of SPME, 
this conversion process simply consists of desorbing the extracted materials from the device into a 
desorbing solution. Once instrumental analysis has been completed, an immense amount of data is 
generated. In LC-MS based metabolomics, this data consists of chromatograms containing thousands of 
different peaks, which can be attributed either to system noise (also known as artifacts, and can include 
solvents, instrument plumbing, glass or plastic vials, etc.) or to the sample itself. The next step entails 
time-consuming data analysis consisting of preliminary data processing, statistical analysis, and 
metabolite identification. Preliminary data processing involves converting the instrument’s raw output 
into a format that can be read by the software used for metabolomics data processing. One example of 
such software is R, which can be used in conjunction with a special XCMS package that was specifically 
developed to process metabolomics data.68,69 Once the raw output has been converted, filters can be 
applied to the data in order to reduce irrelevant information, such as noise peaks arising from the mobile 
phase, vials, and LC tubing. Next, statistical analysis is conducted to determine which metabolites are 
statistically significant (i.e., much more elevated in disease samples). Univariate analysis consists of 
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statistical tests (e.g., Mann-Whitney, Wilcoxon signed rank, Kruskal-Wallis, Friedman, etc.) that 
examine the integrated peak areas of two groups of samples (control vs disease) and calculate whether 
the difference between them is significant.68 If the difference is significant, the m/z values are placed into 
a separate group. Further statistical analysis can be performed using multivariate tools like principal  
component analysis (PCA) and partial least squares discriminant analysis (PLS-DA). PCA and PLS-DA 
are tools of exploratory data analysis, which is an approach that summarizes main data characteristics 
using visual methods. Within the context of metabolomics, PCA and PLS-DA are used to examine 
whether there is any separation or clustering between the data obtained from control and diseased 
samples. PCA is an unsupervised method, which means that the samples are not assigned any classes; in 
contrast, PLS-DA is a supervised method, which means that samples are assigned classes. In other words, 
the software “tells” PLS-DA that some samples come from the control group and that others come from 
the diseased group. An example of a PLS-DA plot used to examine data clustering in vitreous humor 
samples from healthy (control) and diseased subjects (rhegmatogenous retinal detachment (RD) and 
diabetic retinopathy (DR)) can be seen in Figure 1.9.70 A strict validation of models generated by PLS-
DA should be done. Namely, PLS-DA has a tendency to “over-fit” data, or in other words, separate 
samples due to class assignment and not the inherent biological differences. Simply put, PLS-DA can 
make the data “look better” than it actually is. To assess whether PLS-DA models are true, different 
validation strategies can be used; they usually depend on the type of data processing software. Since 
Metaboanalyst was predominantly used in this thesis (Chapters 3 and 4), its tools will be mentioned. The 
first PLS-DA validation test is done by looking at the predictive ability of the model. The data is often 
partitioned into two different sets, whereby one is used to build a training set, while the other is used to 
test the model, as is often referred to as a validation set. Two strategies are often employed to perform 




Figure 1.9 An example of a PLS-DA plot used to examine similarities/differences between vitreous humor 
of heathy (control), rhegmatogenous retinal detachment (RD), and (diabetic retinopathy) DR samples. 
Adapted from Haines et al., and reprinted with permission from Haines, Nathan R., et al. Journal of 
Proteome Research, vol. 17, no. 7, 2018, pp. 2421–2427, doi:10.1021/acs.jproteome.8b00169. Copyright 
(2019) American Chemical Society. 
 (LOOCV). The default k-fold cross-validation of Metaboanalyst is 10-fold cross-validation, whereby 
the data is split into 10 different subsets. The predictability of the model (for a set number of components) 
is then tested by building a training set consisting of 9 subsets, while 1 subset is used to assess the 
model.436 LOOCV is similar to k-fold cross-validation, whereby a training set is made of n samples, 
while the left out sample is used to assess the model.436 In either case, both cross-validation strategies 
generate R2 and Q2 values.436 R2 is defined as a goodness of fit whereby R2 = 1 indicates a perfect fit, 
while Q2 is used to assess the predictability of the model and Q2 = 1 indicates a perfect predictability.436 
While a general consensus of the scientific community has not yet been reached, it is generally acceptable 
that a Q2 value ≥ 0.4 is acceptable for biological models and that difference between R2 and Q2 should 
not be ≥ 0.2.71 Large discrepancy between R2 and Q2 values means that the model has been over fitted 
due to use of too many components.436 The second validation test is a permutation test; whereby statistical 
significance of the PLS-DA model is examined by looking at its Q2 value and comparing it to its null 
reference distribution which can be obtained through H0 testing.
437  For permutation tests, the sample 
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labels are permuted (random) and a new classification is generated, hence model performance can be 
assessed by examining the Q2 value.437 By repeating the permutation N times, H0 becomes a distribution 
of Q2 values.437 The statistical significance of the PLS-DA model can then be examined by assessing the 
Q2 values of the model calculated with the original (non – permuted data set) set to H0 distribution of 
the Q2 values which have been obtained for the permuted data set.437 In Metaboanalyst, permutation test 
can be done based on separation distance based on sum of squares between and sum of squares within 
ratio (B/W).438    
Once statistical analysis is completed, metabolites must be identified. This can be aided using search 
engines (HMDB, Metlin)72,73 that generate potential identifications based on the obtained m/z values. 
This is known as tentative identification. While these search engines are useful, it is widely agreed that 
the best way to identify a metabolite is through targeted MS/MS experiments, also known as validation. 
In this stage, significant metabolites are broken down in order to examine fragment production. These 
fragments are then compared for potential matches using open-source databases (e.g., Metlin & HMDB). 
Ultimately, the goal of the entire investigation is to understand which biochemical pathways are involved 
with a particular disease or condition. If a certain set of metabolites is found to be linked to a disease, 
special therapies can be devised to target them or the biochemical pathway they affect. For example, 
metabolomics has already been used as a tool in pre-clinical and clinical trials aimed at assessing the 
glutamate, antioxidant, lipid, and creatinine levels of patients with amyotrophic lateral sclerosis.74–76  
 Advancements in mass spectrometry: ambient ionization mass spectrometry  
 
Progress in the development of MS technologies has been crucial for the advancement of modern AC. In 
particular, developments in MS that allow the identification of compounds through ionization and m/z 
ratios have proved to be extremely valuable, as they have enabled the use of MS for applications such as 
trace analysis,77 radiocarbon dating,78,79 clinical diagnostics,80 space exploration81 and proteomics82 were 
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possible thanks to MS. One of the most interesting newer developments in MS has been AIMS.83 In 
conventional MS, samples are ionized using an enclosed ion source before entering the vacuum region 
of the mass spectrometer. However, AIMS does not require an ion source in order to ionize the samples; 
rather, as its name suggests, sample ionization in AIMS occurs in the open, atmospheric air.84 Although 
AIMS is sometimes viewed as a “direct-to-MS” approach, the two should not be combined as the latter 
involves directly injecting the sample into the instrument (e.g., infusions, loop injections) and offers a 
lower degree of “ambience”84, i.e., sample ionization does not occur in open air.   
The term, AIMS, first appeared in a publication by Takats et al. in 2004 to describe a novel approach 
called desorption electrospray ionization (DESI). In DESI, charged solvent droplets are deposited onto 
surfaces of different materials in order to extract, desorb, and ionize compounds of interest, which are 
then “sucked-in” by the vacuum pull of the MS for analysis in real time.85 The development of techniques 
like DESI is largely aimed at minimizing lengthy workloads associated with sample preparation and 
chromatographic analysis. Figure 1.10 provides a generalized comparison of the time required to 
complete sample preparation, instrumental runs, and data interpretation for conventional 
chromatographic approaches and AIMS. Sample preparation and instrumental run time are usually main 
sources of bottlenecks in chromatographic investigations. In contrast, AIMS is easier to operate, produces 
results more rapidly, and is less likely to contaminate instrumental interfaces, thus minimizing carry-
over.84 Since Takats’s initial publication in 2004,85 many different AIMS approaches have been 
developed; the various AIMS approaches and their classifications are discussed in detail in an excellent 
review by Venter et al.84 In general, AIMS can be divided into methods that use liquid extraction, laser 
ablation and thermal desorption for sample processing.84 For example, ambient nanoelectrospray (nESI) 
can be classified as a liquid extraction. In nESI, sharp, extremely small (2-100 µm tip diameter) hollow 
tips are used for sampling, with electrospray being performed on the extracted components by filling the 
tips with solvent and applying HV to achieve ionization (Figure 1.11).86 Such techniques can also be 
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referred to as substrate spray, as a “substrate” (nESI emitter in this case) is used to induce an 
electrospray.84 DESI is also classified as a liquid extraction approach because its sample processing 
procedure uses a strongly charged solvent to extract components from a sample.84 Even though no 
extensive sample preparation takes place, one could argue that some sample preparation (liquid-solid 
extraction) does take place during both nESI and DESI (liquid-solid extraction). In fact, the term, “sample 
preparation,” is avoided in some AIMS publications due to its association with laborious workflows, 
with authors instead preferring to use the term, “sample processing”. Indeed, there are AIMS approaches 
that allow analysts to process a sample without the need for significant sample preparation. For example, 
Figure 1.11 Schematic of a nESI emitter used as a “substrate” spray. 
Figure 1.10 Overview of steps involved in the development of conventional chromatographic 
approaches and AIMS methods.   
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DART uses heated gases to thermally desorb analytes of interest from various surfaces (e.g., pesticide 
residues on a whole orange). 87  
1.5.1 Direct analysis in real time (DART) 
 
DART is a thermal desorption/ionization ambient mass spectrometric technique co-invented by Cody 
and Laramée.87 The rights to this technology are currently under the ownership of Jeol USA (Peabody, 
MA, USA) and IonSense, Inc. (Saugus, MA, USA).88 DART grew to prominence rather quickly in 2005 
following its introduction in an article published in Analytical Chemistry; indeed it is one of the few 
analytical chemistry technologies to be featured on a TV show (“CSI:NY”).88 DART is a rapid, simple-
to-use, reliable tool that offers tremendous potential for on-site applications. In addition, DART-MS does 
not require the use of solvent in the desorption process, which also makes it environmentally friendly. A 
schematic of a DART source can be seen in Figure 1.12.88 The left portion of the source contains an 
opening that fits a gas line (typically N2 or helium (He)) which introduces the gas into the chamber, as 
Figure 1.12 Schematic of DART source and its inside components. Lower portion of the schematic 
reprinted from “Ambient Ionization Mass Spectrometry”, Chapter 2. (Reprinted with permission from 
Royal Society of Chemistry. Copyright Royal Society of Chemistry, 2015). 
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shown in Figure 1.12.  As gas is pumped during operation, the needle electrode in the first chamber is 
exposed to a high potential (−3.5kV) while the perforated counter-electrode remains grounded.88 The 
high potential creates a discharge containing metastable (excited-state) species, which ionize the 
samples.88 The gas heater heats the gas (50-550 °C), which exits the source and aids in the desorption of 
less volatile analytes.88 The exit (grid) electrode is thought to prevent plasma recombination (positive 
ions combining with free electrons or negative ions to release neutral species) arising from Penning 
ionization.88 In Penning ionization, an electronically excited atom or molecule in gas phase (E*) interacts 
with a neutral species (N) to yield positive ions (N+●) and electrons (e-).88 This can be expressed with the 
chemical equation:88 
E* + N → N+● + e- + E 
In order for Penning ionization to occur, the ionization energy (IE) of ‘N’ must be lower than the internal 
energy of ‘E*’.88 He is the most commonly used gas (E*) for DART. He has an energy of 19.8 eV in the 
23S1 state, with a lifetime of ~8000 s, which is enough to ionize many organic compounds.
88,89 The DART 
source can ionize compounds in both positive (+ve) and negative (−ve) ionization modes. Since +ve 
ionization mode was maintained for all the DART-MS research in this thesis, −ve ionization mode will 
not be discussed. Ions generated by DART-MS in +ve ionization mode are usually the product of 
atmospheric H2O undergoing Penning ionization:
88  
He (23S) + H2O → H2O
+● + He (11S) + e- 
H2O
+● + H2O → H3O
+ + OH● 
H3O
+ + nH2O → [(H2O)nH]
+ 
[(H2O)nH]
+ + M → [M+H]+ + nH2O 
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H2O has an IE of 12.62 eV,
90 and as the above equations indicate, protonated H2O clusters [(H2O)nH]
+ 
can readily undergo proton transfer reactions with molecules/analytes (M) that have proton affinities 
(PA) higher than those of H2O clusters.
88 A schematic of DART’s ionization process can be seen in 
Figure 1.13. Analytes of interest (M) are formed mostly through protonation reactions. Current 
commercial DART sources also incorporate nitrogen (N2) to keep the source purged while in stand-by 
mode. Finally, the insulator cap is a safety feature that prevents the user from coming into contact with 
exit electrode.88  
 
1.5.1.1  Interfacing DART to MS  
DART sources are commercially available with an atmospheric pressure interface known as the Vapur® 
interface. This interface was designed to allow the MS vacuum pump to efficiently handle the entrance 
of He, as too much He can compromise the vacuum system’s operating pressure. In addition, newer 
DART sources are equipped with an SVP® source with pre-optimized voltage and pressure. Figures 1.14 
and 1.15 illustrate the coupling of a DART-SVP® Vapur® interface and an MS. The DART source is 
always placed directly in front of the MS inlet. Hollow Teflon tubing is inserted into the aperture in the 
middle of the Vapur® interface in order to allow the passage of the ions formed in the gap between the 
DART source and the MS inlet.  This tubing is also secured by a special ring.91  The vacuum and the  




Figure 1.15 Schematic of Vapur® interface components. 
additional pull provided by the roughing pump “sucks” the sample into the MS for analysis. As shown 
in Figure 1.14, the interface is also equipped with a motorized linear rail that can be adjusted/modified 
for movements in x, y and z-directions. This is a particularly useful feature, as special holders can be 
immobilized onto the rail to carry several samplers at the same time for enhanced analysis throughput. 
 
Figure 1.14 Schematic of DART-SVP Vapur interface coupled to a MS. 
27 
 
1.5.1.2 Sample preparation for DART-MS 
Since first being reported in 2005, a number of publications have detailed the use of DART-MS for a 
variety of applications, including forensics,92 food and beverage quality control,93 environmental 
assesments,94 art conservation,95 natural product analysis96 and pharmaceutical97 and material analysis.98 
As mentioned in Section 1.5, DART allows intact samples to be analyzed in their native state(s); as such, 
many publications report the use of the source in this manner.47,99–104 While this approach is useful, it is 
also somewhat underwhelming because it does not capitalize on DART-MS’s highly sensitive analytical 
capacities. Many drug regulatory agencies [e.g., the World Anti-Doping Agency (WADA)] have 
established minimum concentration levels (also known as cut-offs), which are on the parts-per-billion 
(ppb) scale.105 An analytical method can demonstrate its practicality by meeting or providing even lower 
detection limits than the imposed cut-offs. Native sample analysis via DART-MS insufficiently 
isolates/preconcentrates analytes of interest, yielding mostly qualitative information on the parts-per-
million (ppm) detection scale. As noted in Section 1.5, significantly lower detection limits can be 
achieved by combining sample preparation with AIMS. This is especially true for complex samples (e.g., 
blood or plasma), as detection limits tend to increase in these cases. Therefore, numerous efforts have 
been made to devise sample preparation strategies for DART-MS. To this end, several authors have 
attempted to pre-concentrate analytes prior to analysis, but these approaches proved to be technically 
cumbersome.106–108 For example, Jagerdeo et al. used microextraction by packed sorbent (MEPS), which 
consists of sorbent conditioning, sample loading, washing, and, finally, elution.107 Following elution, a 
glass capillary is dipped into the eluted solvent and desorbed in front of DART-MS for analysis.107 Others 
have reported semi-quantitative results with higher detection limits (mg L-1)109–111 while fully 




1.5.1.3 SPME in DART-MS 
It is somewhat unsurprising that SPME has emerged as an excellent sample preparation tool for DART-
MS. Besides its preconcentrating ability, SPME devices can easily be placed in a holder for a higher 
sample throughput using the DART-MS’s motorized linear rail. The main SPME format for DART-MS 
is SPME-TM meshes. In essence, TM technology utilizes a controlled device geometry (i.e., reproducible 
nets and/or meshes) to normalize the introduction of samples into the MS, which allows for a more 
repeatable response from the DART-MS system.115 Figure 1.16 provides a schematic of the mesh’s 
structure, which consists of a woven, intertwined network of wires with a diameter ‘d’. The area between 
two adjacent wires is the aperture width, w, while pitch denotes the distance between the center points of 
two adjacent wires. The coated wires are used to extract the analytes, which are then desorbed via 
exposure to heated He. The open area of the meshes allows the analytes to pass safely into the MS, thus 
ensuring successful transmission (hence the name, TM). The open areas vary in size and are usually 
expressed in percentages that define the total hole area to total screen area of the mesh. The TM format 
was utilized in the first two publications to document the use of DART-MS-SPME. The first two attempts 
Figure 1.16 Schematic representation of the mesh format. 
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to use DART-MS-SPME, published by Mirnaghi et al.49 and Rodriguez-Lafuente et al.116 were conducted 
using the TM format and used SS meshes coated with C18-PAN (Figure 1.17). However, the coating 
strategy was not completely optimized in either study; specifically, the coating was applied using a brush-
painting procedure,49 which is not optimum for the mesh as it results in an incomplete coating. Mirnaghi 
et al. used meshes to extract diazepam from 5 µL of blood and were able to achieve an LOD of 0.3 mg 
L-1.49 The high LOD was probably partially attributable to blood’s complexity, but the lack of coating 
material on the mesh very likely undermined the extraction process as well. As seen in Figure 1.17, the 
SS strands were not completely covered by the coating slurry; instead the coating tends to be localized 
around the wire junctures.49  Despite the flaws in Mirnaghi et al.’s design, it would nevertheless provide 
a blueprint for the future development of the device. In 2014, Gómez-Ríos et al. enhanced the mesh’s 
analytical performance by devising a dip-coating protocol in order to improve the distribution of coating 
on the mesh’s individual wires (Figure 1.18). For easier handling, an electric soldering tool was used to 
attach the meshes to a SS blade (Figure 1.19).26 Gómez-Ríos et al.’s design significantly improved the 
preconcentrating abilities of SPME-TM, enabling extremely low detection limits (pg mL-1) for cocaine 
Figure 1.17 SS mesh coated with PAN-C18 particles, suited for use in TM-DART-MS. Original design 
by Mirnaghi et al.. Reprinted with permission from Mirnaghi, Fatemeh S., and Janusz Pawliszyn. 
Analytical Chemistry, vol. 84, no. 19, 2012, pp. 8301–8309, doi:10.1021/ac3018229. Copyright (2019) 
American Chemical Society. 
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and diazepam in urine26 and pesticides in environmental and food matrices117 were reported using an 
extraction time of only one minute.   
 
Figure 1.18 SS mesh coated with PAN-C18 using a dip-coating procedure devised by Gómez-Ríos et al. 
Figure A shows the uncoated mesh, B shows the mesh coated by C18-PAN, while D-C show the SEM 
images of the coated mesh. Reproduced with permission from Gómez-Ríos, German A. and Janusz 
Pawliszyn. Chemical communications, vol. 50, no. 85, 2014, pp. 12937-12940. doi: 
10.1039/C4CC05301J.  Published by The Royal Society of Chemistry under the Creative Commons 
license (CC BY 3.0). 
 
Figure 1.19 Schematic representation of the SPME-TM design by Gómez-Ríos et al. An SS blade is 
attached to the mesh via an electric soldering tool. 
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 Small volume analysis 
Small volume analysis is one the most challenging tasks in contemporary analytical chemistry. Small 
volume analysis aims to minimize the overall amount of sample required for a particular analysis, while 
still yielding sufficiently sensitive and reliable data.118 Reducing sample volumes is beneficial, especially 
in scenarios that require individuals to frequently provide biological samples for monitoring purposes, 
such as therapeutic-drug monitoring (TDM)119-120 and neonatal screening.119,121 Small-volume analysis 
can also be useful for applications involving animals, as the  reduction of sample volumes would allow 
individual animals to be monitored over extended periods of time.122 Hence, the pharmaceutical industry 
is expending considerable effort to develop analytical methods that will allow scientists to work with 
very small sample volumes. 
Two emerging fields that fit within the small-volume scope are single-cell and cell-population analysis. 
As its name suggests, single-cell analysis aims to obtain meaningful information from tiny cellular 
organisms in order to elucidate the cellular activities involved in metabolic pathways.123  While there is 
no consensus as to what qualifies as a “small volume,” a large number of publications within this field 
work with volumes that are ≤ 20 µL. Small-volume analysis is particularly important for matrices like 
blood and plasma, which are more difficult to obtain. Techniques like SPE and LLE are inappropriate 
sample preparation strategies for small volume analysis, since they are developed to work with much 
larger sample volumes. In some publications, the term, “microsampling,” is sometimes used to describe 
small-volume analysis techniques.124–126 Figure 1.20 provides an overview of these microsampling 
approaches, as well as the strategies implemented for single-cell analysis.8,127–133 It is important to point 
out that the microsampling approaches described in Figure 1.20 (with the exception of some microfluidic 
approaches) cannot be construed as sample preparation approaches, as they are more concerned with 
sample collection rather than preconcentration and clean-up. Cell-analysis approaches can utilize 
microfluidics or different probe approaches, wherein a probe is used to extract meaningful compounds 
32 
 
directly from a cell. However, since the majority of probe-based approaches do not use preconcentrating 
materials, the extraction is based on unselective interaction between cell materials and the probe. Hence, 
there is a need to develop a miniaturized coated probe that can handle both small volumes and single 
cells, while providing adequate extraction for analytes of varying polarities and yielding robust 
qualitative and quantitative results. A microextraction technique like SPME is an ideal choice for small-
volume sampling because it requires fewer sample preparation steps. This is significant because reducing 
the number of sample preparation steps helps to reduce errors and improve accuracy and precision, which 
is crucial for small-volume analysis.   
 
 Research objectives  
At the forefront of every scientific discipline is the eagerness to improve people’s day-to-day lives. Some 
of the more prominent topics currently being explored in AC are direct-to-MS technology, small-volume 
analysis, and metabolomics. The push to refine AIMS technology reflects the need to develop strategies 
that will allow us to obtain quality results more rapidly, which is significant as laboratories are becoming 




increasingly strained in terms of workload by the ever-growing population. Many tests in these 
laboratories are still being performed via conventional chromatography, which requires considerable 
time and materials and yields long turnaround times. The criminal and forensic sectors would also benefit 
from AIMS technologies, as timely results are of the highest importance in the early resolution of 
casework. Thus, coupling technology like DART-MS to an efficient sample preparation approach like 
SPME could be an immense help in achieving robust results and faster throughput. With respect to small-
volume analysis, it must be remembered that it is a humane approach that is dedicated to preserving the 
well-being of animals and humans alike. As such, it is particularly valuable for patients who are required 
to provide blood samples every day. However, the analysis of small volumes (including cells) is not 
straightforward; it requires elevated levels of analytical sensitivity, accuracy, precision, and robustness. 
Even the sampling process can be challenging for inexperienced analysts. Hence, the development of a 
miniaturized SPME tool that satisfies the above-described criteria and that can comfortably be used with 
small volumes is highly desirable, though it will be equally important to examine its limitations and 
shortcomings in order to continue to refine it. Lastly, advancements in mass spectrometry and sample 
preparation have allowed metabolomics to flourish as a field, which has enhanced our ability to 
understand the mechanisms of diseases through the identification of various biomarkers. Thus, the 
continued development of techniques like SPME could be critical in furthering our ability to understand 
the metabolic profiles of individuals and ultimately lead to the development of more powerful diagnostic 
tools in the medical field.  
The main objectives of this thesis include examining studies and developments dedicated to the coupling 
of SPME and DART-MS, and advancing the application of SPME technology for the analysis of small 
sample volumes. Chapter 2 exclusively focuses on the work that has been done on SPME-DART-MS. 
Specifically, Chapter 2 examines prior work that details the experimental basics of SPME-DART-MS, 
as well as work that has broadened its scope of applications. Section 2.2 investigates certain experimental 
34 
 
factors that must be considered for SPME and DART-MS, and how they impact signal responses. A 
deeper understanding of these factors’ effects is important because it will allow scientists to optimize the 
experimental parameters for SPME-DART-MS more efficiently. Section 2.3 provides a comparison of 
the analytical performance of the two most popular SPME formats for DART-MS: fibers and meshes 
(SPME-TM). One of this section’s main goals is to identify applications where meshes outperform fibers, 
and applications where fibers outperform meshes. Sections 2.4-2.7 focus on novel 
developments/applications of the SPME-DART-MS technology. Section 2.4 examines the coupling of 
SPME meshes to a portable MS (Waters-QDa) for the on-site, in vivo, roadside drug testing of samples. 
Section 2.5 assesses the sensitivity of both formats by examining their suitability for the analysis of small 
volumes (Vs ≤ 25 µL) such as OF and blood. One of the greatest benefits of DART-MS is that it enables 
high sample throughput; thus, in Section 2.6 we demonstrate how SPME-TM can be coupled to DART-
MS in a 96-format in order to quantify opioids in 96 biological samples in less than 1.5 hours. While SS 
mesh is most commonly used to fabricate SPME-TM meshes, alternative materials like biocompatible 
plastics are worth investigating as they can be less costly and more comfortable when used for in vivo 
buccal swabbing. As such, Section 2.7 details the development and application of SPME-TM meshes 
made of PEEK for OF and urine sampling. Chapter 3 is dedicated to the development and application of 
SPME miniaturized tips, or minitips, which were specifically designed to be used in small volume 
analysis. This chapter details all aspects of the challenging production process, from the dip-coater 
designed at UW’s machine shop to the development of the formulation for the coating-slurry. The results 
of preliminary performance assessments, as well as the devices’ limitations are also addressed in Chapter 
3. Furthermore, three different minitip applications are presented, each highlighting different aspects of 
the device’s analytical ability. These include the analysis of DoAs in 1 µL of OF via LC-MS/MS; directly 
coupling the minitips to nanoelectrospray (nESI), and metabolomics sampling of four different types of 
fish eggs (caviar). Chapter 4 details an untargeted metabolomics investigation conducted in collaboration 
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with the Toronto General Hospital (TGH). This chapter describes the use of SPME fibers to collect 
miniscule muscle samples from patients with the metabolic disorder, MH. The purpose of this study 
aimed to investigate the biochemical pathways that define the pathophysiology of the MH condition and 
to examine the SPME’s potential as a diagnostic tool. As a part of the examination of the diagnostic 
aspect of SPME, extensive validation of the PLS-DA models generated is provided. Finally, Chapter 5 
summarizes the main findings of the current work and proposes future directions and potential challenges 
that might arise.   
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 Studies, developments and applications of SPME coupled to DART-MS 
 
 Preamble  
 
Chapter 2 consists of 6 sections out of which 3 have been published in Analyst, Analytical Chemistry, 
and Rapid Communications in Mass Spectrometry. Two sections have been submitted to journals 
Analytical Methods and Journal of Separation Science. Most of the data presented herein has already 
been included in the manuscripts mentioned below. Section 2.2 is not published anywhere as it is an on-
going investigation which focuses on the impact of different factors which influence the sensitivity of 
the SPME-DART-MS. Section 2.3 compares the analytical performance of SPME meshes against those 
of SPME fibers by examining sensitivity for a set of model analytes spiked to PBS and was submitted to 
Journal of Separation Science. Section 2.4 describes the application of a portable DART-MS system 
Waters-QDa which was used for semi-quantitation of 7 DoAs in OF and has been published in Analyst.134 
Section 2.5 describes the applicability of SPME-TM meshes for analysis of DoA(s) in small volume 
biofluids like OF and blood, and has been submitted for potential publication to Analytical Methods. 
Section 2.6 details the development and application of a HT 96-SPME-TM system coupled to DART-
MS for quick detection and quantitation of opioids in urine and plasma and has been published in Rapid 
Communications in Mass Spectrometry.135 Section 2.7 describes the development and application of 
plastic SPME-TM meshes, made of PEEK which were used for analysis of DoAs in OF and urine and 
has been published in Analytical Chemistry.136  
Section 2.2 includes the following portion:  
“Some investigations of factors impacting the sensitivity of DART-MS coupled to SPME” 




Section 2.3 includes the following submitted manuscript: 
“On the performance of solid-phase microextraction (SPME) fibers vs transmission-mode (TM) meshes 
for direct analysis in real time (DART) coupled to mass spectrometry (MS): Differences in analytical 
sensitivity.” 
I participated in all stages of experimental design including its planning, execution, data analysis and 
interpretation. The manuscript was entirely written by me and submitted to Journal of Separation 
Science. 
Section 2.4 includes the following manuscript: 
Gómez-Ríos, G.A., Vasiljevic, T., Gionfriddo, E., Yu, M., Pawliszyn, J., Towards on-site analysis of 
complex matrices by solid-phase microextraction-transmission mode coupled to a portable mass 
spectrometer via direct analysis in real time, Analyst, 2017, 142, 2928-2935, doi: 10.1039/C7AN00718C 
Text, tables and figures are reprinted from this publication with permission from the Royal Society of 
Chemistry (Copyright 2017 Royal Society of Chemistry). 
This manuscript was published under an agreement of equal contribution by Dr. German A. Gómez-Ríos, 
Tijana Vasiljevic and Dr. Emanuela Gionfriddo. Dr. German A. Gómez-Ríos used the material discussing 
pesticide detection and milk profiling in his thesis, while Tijana Vasiljevic is using the material 
discussing detection of DoA(s) in OF for her thesis. The authors had already agreed on this before 
conducting any experiments. Dr. German A. Gómez-Ríos and Dr. Emanuela Gionfriddo participated in 
experimental planning, execution, data interpretation, analysis and manuscript writing for the pesticide 
data and milk profiling. Tijana Vasiljevic participated in experimental planning, execution, data 
interpretation, analysis and manuscript writing for the drug detection in OF portion. Dr. Miao Yu 
participated in the statistical analysis of the data which was used for milk profiling (not presented herein, 
used for Gómez-Ríos’s thesis).  
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I, German A. Gómez-Ríos, authorize Tijana Vasiljevic to use this material for her thesis. 
I, Emanuela Gionfriddo, authorize Tijana Vasiljevic to use this material for her thesis. 
I, Miao Yu, authorize Tijana Vasiljevic to use this material for her thesis.  
Section 2.5 includes the following submitted manuscript: 
DART and SPME-TM: A Suitable Platform for Analysis of Prohibited Substances in Small Volumes 
I participated in all stages of experimental design including its planning, execution, data analysis and 
interpretation. The manuscript was entirely written by me and submitted to Analytical Methods. 
Section 2.6 includes the following manuscript: 
Vasiljevic, T.; Gómez-Ríos, G.A.; Li, Frederick; Liang, P. and Pawliszyn, J. High‐Throughput 
Quantification of Drugs of Abuse in Biofluids via 96‐Solid‐Phase Microextraction–Transmission Mode 
(SPME‐TM) and Direct Analysis in Real Time‐ Mass Spectrometry (DART‐MS), Rapid Com. in Mass 
Spectrometry, doi: 10.1002/rcm.8477 
Text, tables and figures are reprinted from this publication with permission from Wiley (Copyright 2019 
Wiley). 
Tijana Vasiljevic participated in all stages of the experimental design, its execution, data interpretation 
and manuscript writing. Dr. German A. Gómez-Ríos participated in some experimental design, data 
interpretation and aided in the manuscript writing. Mr. Frederick Li and Mr. Paul Liang aided in certain 
aspects of experimental design (3D-printed holder) and portions of the manuscript writing.  
I, German A. Gómez-Ríos, authorize Tijana Vasiljevic to use this material in her thesis. 
I, Frederick Li, authorize Tijana Vasiljevic to use this material in her thesis. 
I, Paul Ling, authorize Tijana Vasiljevic to use this material in her thesis. 
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Section 2.7 includes the following manuscript: 
Vasiljevic, T.; Gómez-Ríos, G.A. and Pawliszyn, J. Single-Use Poly(etheretherketone) Solid-Phase 
Microextraction–Transmission Mode Devices for Rapid Screening and Quantitation of Drugs of Abuse 
in Oral Fluid and Urine via Direct Analysis in Real-Time Tandem Mass Spectrometry, Anal. Chem., 90 
(1), 952-960, doi: 10.1021/acs.analchem.7b04005  
Text, tables and figures are reprinted from this publication with permission from American Chemical 
Society (Copyright 2018 American Chemical Society). 
Tijana Vasiljevic participated in all stages of the experimental design, its execution, data interpretation 
and manuscript writing. Dr. German A. Gómez-Ríos participated in some aspects of experimental design, 
data interpretation and aided in the manuscript writing.  









For nearly 30 years, SPME has been on the forefront of novel developments and applications in the world 
of sample preparation. Part of SPME’s continued success is the fact that its format can be altered to fit 
the needs of different sampling strategies. One of such formats with a rising number of publications is 
SPME-TM coupled to DART-MS.26,117,137–139 DART-MS is a relatively novel, simple to operate, thermal 
desorption AIMS technique whose operational mechanisms are still being investigated.87–89 There are 
even some studies suggesting that thermal desorption is not the only ionization mechanism of DART-
MS, as evidence of chemical sputtering has also been reported.140,141 It is known that the primary 
ionization mechanism of DART-MS is Penning ionization, which leads to protonation of target analytes 
([M+H]+) when used in +ve ionization mode.88 Deprotonation is the main ionization mechanism of –ve 
ionization mode ([M−H]−).88 Indeed, DART-MS is capable of forming other ions such as [M+NH4]
+, 
[M]+, [M]− and [M+Cl]− which is largely influenced by compound properties.88,89 For example, alcohols, 
large alkenes, mono- and di-triglycerides are thermally labile and not easily ionized by DART-MS.88 
Certain alcohols, carbohydrates, compounds with labile phosphate/sugar groups, metals and proteins are 
incapable of desorption due to large MWs and lack of volatility.88 Hence, it is important to acknowledge 
that compound specific parameters are crucial for determining their ionization success by DART-MS. 
These factors include proton affinity (PA), thermal stability, ionization energy  (IE), vapor pressure (VP), 
MW, ME(s), internal energy (IU), electron affinity (EA), anion affinity and acidity/basicity. These are 
summarized in Figure 2.1 as compound properties.88 It is also important to understand that signal 
responses in DART-MS are governed by additional factors which include hardware settings (or system 
properties), sample preparation specifics and even ambient air (i.e., moisture which aids in analyte 
protonation).88,89 These can also be seen in Figure 2.1. System properties such as DART gas142,143 and its 
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flow,144,145 temperature,93,146,147 rail speed,143,148 angle desorption,115,149,150 sample positioning,115,150,151 
choice of mass analyzer,152 Teflon tubing diameter and dopant use104 for enhancement of ionization. For 
example, Dane et al. have used argon gas (instead of commonly employed He) in combination with 
acetylacetone and pyridine to selectively ionize melamine.142 Vaclavik et al. used NH4 to enhance 
protonation and analysis of triacylglycerols in olive oil.104  Additionally, Duvivier et al., compared 
different mass analyzers (Q-TOF, QqQ, orbitrap and QqQ-orbitrap) for forensic hair analysis, finding 
that highest sensitivity was obtained using a high resolution QqQ.152 Sample preparation also contributes 
significantly to the analytical capabilities of DART-MS153 and discussions are strictly limited to SPME 
in this thesis. The main contributors to system response with respect to SPME include coating and 
substrate choice and extraction settings. Coating choice is the key factor which determines the sensitivity 
of any SPME approach, and polarity of target analytes should be considered when choosing coating 
chemistry.  Essentially, non-polar coatings (e.g., C18) work well for hydrophobic compounds while 
hydrophilic compounds have better affinity for polar coatings (e.g., HLB).  Substrate refers to the choice 
of the SPME format for DART-MS analysis (i.e., fibers, meshes, in-tube SPME, stir-bars, etc.) and is 
Figure 2.1 Summary of main factors which influence the response of DART-MS. 
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usually chosen based on the sampling requirements.7 For example, for in vivo sampling SPME fibers are 
the most appropriate choice due to easy insertion in living systems. Ultimately, extraction settings (e.g., 
extraction time, agitation, matrix pH, etc.) also contribute. Hence, the goal of research in this section is 
to use SPME-TM meshes to investigate influence of some (but not all) of the factors listed in Figure 2.1. 
Compound dependent properties such as PA and IE can be calculated using computational ab initio 
approaches,154 which are complex calculations that require a higher level of mathematical and 
programming skills. For this reason, such properties were not evaluated but will be considered in the 
future.  Considering the number of factors involved, investigation was simplified, using a one-at-a-time 
factor155 investigation approach. DART source temperature, SPME coating chemistry, positioning of the 
meshes between the DART source and the MS inlet and the impact of pH manipulation were investigated. 
DART source temperature was evaluated in the 250-500 ˚C range, while coating’s influence was 
examined using C18, HLB and MM chemistry. MM coatings were made by mixing C18 and HLB 
particles (5µm) in a 1:1 ratio. Positioning of the mesh was examined by placing the mesh at different 
locations with respect to the DART source and the MS entrance. Additionally, the desorption angle of 
the mesh was investigated. To examine the influence of pH, samples were adjusted to acidic, neutral and 
basic conditions. The results obtained indicated that each factor contributes to the analytical sensitivity, 
yet our findings also pointed that these factors interact with each other, thus displaying a synergistic 
effect during DART desorption/ionization.  
Additionally, 3 consecutive desorption tests were done from the same position of SPME-TM mesh to 
examine the extent of release of analytes during exposure to heated gas. The goal was to observe whether 
incomplete desorption of SPME-TM meshes was occurring. Indeed, it was found that some analytes 




2.2.2 Experimental section 
Materials/Chemicals  
 The following chemicals were purchased from Cerilliant (Round Rock, TX, USA) as certified reference 
standards (in methanol) at a concentration of 1000 mg L-1: 2-Ethylidene-1,5-dimethyl-3,3-
diphenylpyrrolidine (EDDP), cocaethylene, methamphetamine, nicotine, codeine, methadone, 
oxycodone, cotinine, morphine, 3,4-Methylenedioxymethamphetamine (MDMA), cocaine, lysergic acid 
diethylamide (LSD), fentanyl, RSC-4, RSC-8, JWH-210; JWH-015, JWH-250, JWH-203, JWH-200, 
AM-2233, and heroin. PAN, DMF, sodium chloride (NaCl), potassium chloride (KCl), potassium 
phosphate (K3PO4) and sodium phosphate (Na3PO4) were obtained at ≥ 99 % purity from MilliporeSigma 
(Burlington, MA, USA). MeOH, IPA, ACN, FA, ammonium hydroxide (NH4OH) and H2O were 
obtained from Fisher Scientific (Hampton, NH, USA). FA and NH4OH were used to adjust the pH of the 
samples. SS meshes (74x74 wire inch-1, diameter: 0.004 inch, length: 30 mm, width: 4 mm) were 
obtained from IonSense (Saugus, MA, USA). PBS was made by combining 8 g of NaCl, 0.2 g of KCl, 
0.2 g of K3PO4, and 1.44 g of Na3PO4 with 1L of LC/MS grade H2O.  
Preparation of the meshes  
The original recipe for coating of the meshes was adapted from Musteata et al.48 PAN solution was 
prepared by dissolving 7 g of PAN powder in 100 mL of DMF via periodical vortexing to ensure uniform 
dissolution without “dry patches” (clusters of undissolved PAN powder). C18 particles (5 µm size) were 
obtained from MilliporeSigma while 5 µm Oasis HLB particles were obtained from Waters (Milford, 
MA, USA). MM coatings were made by mixing 0.5 g of C18 and 0.5 g of HLB particles. Then, 1 gram 
of C18, HLB and MM particles were mixed (separately) with 10 mL of PAN solution to obtain 10% 
C18-PAN, HLB-PAN and MM-PAN slurry. The slurries were then agitated with stir-bars for 12 hours 
at 1800 rpm in order to ensure adequate mixing of PAN with the extractive particles. The SS meshes 
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were then etched in concentrated HCl for 5 minutes using the aid of a sonicator, followed by 5 minute 
sonicated washes in MeOH (1x) and deionized H2O (2x). The etched meshes were then dried at 100 ˚C 
for 30 minutes, purged with N2 and kept in a desiccator to prevent surface oxidation.  The slurries were 
deposited on the meshes via dip-coating method published by Gómez-Riós et al.26 After the mixture had 
been deposited, excess slurry was removed by blasting the open area with pressurized gas. This prevents 
blockage of the open area, i.e., transmission holes. The coating was then cured at 100 °C for 1 minute 
and the whole procedure was repeated for the other side. The meshes were then cleaned twice in a solvent 
mixture consisting of MeOH/IPA/ACN (50/25/25) at 1500 rpms for 15 minutes to remove potential 
interferences which could have occurred due to the dip-coating procedure. To activate the extractive sites 
on the particles, the meshes were preconditioned in MeOH/H2O (50/50) and kept in it until use.  
Extraction procedure for PBS 
Methanolic stock solution of the analyte standards were made to a concentration of 100 mg L-1. The stock 
solution was then diluted to proper concentrations used to spike PBS. PBS was used as extraction media 
due to lack of interfering components. Spiking was done in such a manner that the percentage of organic 
solvent spiked was below 1% in order not to disturb any partitioning equilibria between SPME and PBS.7 
No IS(s) were used in this investigation, and all the data represented in this section is the raw uncorrected 
data obtained from the ion chronograms. All extractions were carried out according to a procedure 
published by Gómez-Riós et al.,26 which consists of rapid agitation of a single mesh (3200 rpm) in a glass 
or plastic vial filled with 1500 µL of the sample. Except for pH experiments, all extractions were carried 
out from PBS samples spiked with 25 ng mL-1 of target analytes. For the pH experiments, extractions 
were carried out from a PBS sample spiked at 200 ng mL-1. After the extractions were completed, a brief 
5-sec wash in H2O was used to clean the mesh. The meshes were then gently blot-dried with a KimWipe 
(to remove H2O residues) and inserted into a custom-made holder (UW-12) able to allocate up to 12 
SPME-TM devices.26 DART source temperatures were evaluated by examining the responses at 250, 
45 
 
300, 350, 400, 450 and 500 ˚C.  Sample positioning was assessed with respect to the distance of the 
SPME-TM mesh from the DART source and MS entrance. Additionally, we examined whether changes 
in mesh angle impact the signal. Figures 2.2-2.3 provide a schematic of how the positioning experiments 
were done. As seen in Figure 2.2, position ‘1’ describes the position in which the mesh is closest to the 
DART source. In position ‘2’ the mesh is located in the middle, i.e., between the DART source and MS 
inlet. In position ‘3’ the mesh is located closest to the MS entrance. The impact of mesh angle on signal 
was assessed by performing desorption in 2 different ways (Figure 2.3). In scenario I., the gas hits the 
mesh at an angle about 90 ˚ horizontal to the mesh surface, which is the commonly used desorption 
Figure 2.3 Schematic of 2 different angles of SPME-TM meshes used for desorption of SPME-TM meshes 
via DART-MS. 
Figure 2.2 Schematic representation of sampling for determination of the optimum signal response with 
respect to mesh positioning between the DART source and the MS inlet. The distance between the DART 
source and the MS inlet is 1 cm. In position 1, the mesh is 0.1 cm away from the DART source. In position 




approach.  However, in scenario II., the mesh’s angle is shifted by 90˚, so the gas hits the mesh at an 
angle corresponding to the gas flow. Impact of pH on signal response was assessed by modifying the pH 
of PBS by directly spiking small amounts (~5 µL) of FA or NH4OH. The pH of PBS was evaluated using 
pH strips from MicroEssential Laboratory (Brooklyn, NY, USA).  All of the experiments were done in 
triplicates (n = 3). 
DART-MS/MS 
A DART-SVP® model from IonSense, Inc. was coupled to a QqQ mass spectrometer (TSQ Vantage) 
from Thermo Scientific (San Jose, California, USA) via Vapur® interface (IonSense, Inc.) and an 
auxiliary membrane pump. The needle valve of the membrane pump used with the Vapur® interface was 
adjusted according to the “Vapur Pump Optimization Protocol” suggested by the manufacturer whereby 
blue indicator at position 4 was used to maintain adequate vacuum in the MS and provide sufficient 
sensitivity via DART-TM. Table 2.1 provides logP values of the analytes used for the research, alongside 
their parent and product m/z values and settings (S-lens & CE) for experiments on TSQ-Vantage. DART-
SVP was fitted with a single-dimensional motorized linear rail that was controlled through the web-based 
software of IonSense, Inc. The custom-made holder was then immobilized into the linear rail, which was 
operated at a speed of 0.2 mm s-1 for all the experiments. DART source temperature was maintained at 
450 ˚C for all the experiments, with the exception of the temperature experiment. Desorptions were then 
done by operating the DART source in +ve ionization mode using the following voltage conditions: high-




Table 2.1 Details of the model analytes used, including logP, parent and product m/z values as well as 
S-lens and CE values adjusted for TSQ Vantage. Class and logP information was obtained from 
PubChem.156 
2.2.3 Results and discussion 
Impact of DART source temperature on signal response 
Certain authors, such as Maleknia et al. examined desorption of volatile organic compounds (VOCs) 
from surfaces of eucalyptus leaves, demonstrating that progressive increases in temperature led to 
desorption of semi-volatile, higher MW terpenes.147 They concluded that lower boiling point compounds 









Oxycodone Morphinans 0.30 316.1 241.1 124 28 
Cotinine - 0.39 177.1 80.1 98 24 
Nicotine - 0.87 163.1 117 75 28 
Morphine Morphinans 0.89 286.1 152.1 121 59 
Codeine Morphinans 1.21 300 152.1 120 60 
MDMA Benzodioxoles 1.65 194.1 135 55 20 
Methamphetamine Benzenes 2.23 150 91.1 63 20 
Heroin Morphinans 2.3 370.1 165 165 29 
Cocaethylene - 2.53 318.1 195.7 78 20 
LSD Ergolines 2.95 324.1 223 118 23 
Methadone Benzenes 3.93 310.2 265.1 93 14 
Cocaine Benzenes 3.93 304.1 182.1 91 19 
Fentanyl Piperidines 4.05 337.1 188 101 22 
JWH-200 Cannabinoids 4.21 385 155 123 20 
EDDP - 5.26 278.1 233.9 78 31 
JWH-250 Cannabinoids 5.30 336 121.1 114 19 
JWH-015 Cannabinoids 5.66 328 155.01 115 22 
RCS-4 Cannabinoids 5.68 322.1 135 135 23 
RCS-8 Cannabinoids 6.12 376.1 121.1 141 23 
JWH-203 Cannabinoids 6.22 340 125 114 33 
AM-2233 Cannabinoids 6.44 459 98 82 33 
JWH-210  Cannabinoids 7.47 370.1 183 112 25 
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were desorbed at lower temperatures while higher boiling point compounds were desorbed at higher 
temperatures.147 It is important to acknowledge that the temperature set up in the DART software and 
the one which exits the hot source are not of the same value. In fact, Prof. Fernandéz’s group found that 
the temperature which leaves the source is nearly half of the value set up in the DART software (i.e., 250 
˚C set in software, 125-150 ˚C exits the source).145 In fact, the heat becomes attenuated by the ambient 
air as it exits the source. During experimental optimizations, the temperature of the DART source can be 
increased incrementally (i.e., 50 °C) to desorb the less volatile analytes or to simply desorb greater 
amounts of the analytes. Setting the DART gas source to highest temperature offered (550 °C) does not 
necessarily equate to the best response. This is evidenced by Figure 2.4, whereby signal responses for a 
set of model analytes were tested in 50 °C increments, ranging 250 to 500 °C. As it can be seen, increasing 
the source temperature does not lead to an increased signal intensity for all the analytes involved. 
Cotinine (with exception of 250 °C) maintains a signal that changes insignificantly over the range of 
Figure 2.4 Assessment of signal responses (n = 3) for a set of model analytes spiked at 25 ng mL-1 and 




temperatures tested. Oxycodone, morphine, LSD and MDMA display similar signal patterns, i.e., steady 
lower intensities up to 400 °C followed by an increase at 450 °C and 500 °C. Fentanyl and RCS-4 display 
the highest intensity for all the analytes examined, with an almost consistent increase in signal intensity 
up to 500 °C. In case of RCS-4 a drop is observed at 500 ˚C. In fact, RCS-4, RCS-8 and JWH 210 share 
similarities in signal behavior. Their signals are somewhat low until a temperature of 400°C is reached. 
This indicates poorer volatility of RCS-4, RCS-8 and JWH-210 at lower temperatures. Regardless, it 
would appear that increasing the source temperature benefits the analysis of some, but not all analytes. 
Another observation is tendency of polar to mid-polar analytes (oxycodone, morphine, MDMA at 0.3, 
0.89 and 1.65 logP, respectively) to yield lower intensities. Figure 2.5 shows the structure of oxycodone, 
morphine and MDMA as well as fentanyl and RCS-4, which yielded the most sensitive responses. The 
poorer response of polar analytes could be related to the fact that oxycodone, morphine and MDMA 
Figure 2.5 Chemical structures of oxycodone, morphine, MDMA, fentanyl and RCS-4. Structures were 
obtained from DrugBank. 
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contain polar functional groups (-OH, -NH), which require higher temperatures to increase the volatility.  
Interestingly, LSD (2.95 logP) and RCS-8 (6.12 logP) are mid to non-polar analytes whose sensitivity is 
lower or comparable to MDMA and oxycodone, suggesting involvement of other more sophisticated 
factors such as PA, IE and thermal stability. 
Evaluation of coating chemistry 
Selection of coating chemistry is the most important factor determining the sensitivity of the SPME 
method.7 As mentioned in the experimental section, three different coating chemistries consisting of MM, 
C18 and HLB extractive particles were used. MM coatings were used to examine whether a combination 
of non-polar and polar material would result in balanced extraction of polar and non-polar analytes. For 
example, Mousavi et al. already investigated mixing of different chemistries (polystyrene, 
divinylbenzene (DVB), HLB, ionic liquids, etc.) in an effort to find the optimum coating recipe for 
extraction of a range of metabolites from Escherichia Coli (E.Coli) cultures.50 C18 coating has more 
affinity towards non-polar compounds, owing to its long hydrocarbon chain (Figure 2.6, ChemDraw).157 
HLB is a polar polymer which contains hydrophilic N-vinylpyrrolidone (NVP) and hydrophobic DVB 
groups (Figure 2.7, ChemDraw),157 making HLB suitable for extraction of polar, mid-polar and some 
non-polar analytes.158 Figure 2.8 shows the results obtained for comparison of signal areas obtained by 
extracting via HLB, MM and C18 coatings from a PBS sample spiked at 25 ng mL-1. It is noticeable that 
polar compounds (oxycodone, cotinine, morphine, MDMA) produce a higher signal area when extracted 
with HLB coatings. As expected, C18 provided a better signal for the non-polar compounds (cocaine, 
Figure 2.6 Basic chemical structure of the C18 chain. Drawn using ChemDraw JS. 
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LSD, fentanyl, RSC-4, RSC-8, JWH-210). MM does not significantly outperform C18 or HLB in terms 
of intensity for polar and non-polar analytes. In case of morphine, a significant difference in signal 
intensity between all three coatings  is not observed. Morphine is a polar compound, and by inspecting 
its response more closely (Figure 2.8 cut-out) one can note that a somewhat higher response is obtained 
(although statistically insignificant, one-way ANOVA, p = 0.29) using HLB. Interestingly, for 
Figure 2.7 Chemical structure of the HLB polymer, consisting of hydrophobic DVB and hydrophilic 
NVP groups. Drawn using ChemDraw JS. 
Figure 2.8 Assessment of signal responses (n = 3) for the model analytes spiked at 25 ng mL-1 to PBS 
and extracted using C18, HLB and MM coatings.The right side of the chart indicates the logP values of 
the analytes used. logP information obtained from PubChem. 
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oxycodone, morphine, LSD and MDMA coating choice does not appear to contribute significantly to 
the sensitivity. In the previous investigation (influence of temperature), it was discovered that the 
same analytes produced the lowest intensities. This furthers the notion that compound specific factors 
(PA, VP, IE, etc.) play a key role in influencing the signal sensitivity.   
Mesh positioning and its influence on the signal  
In DART-MS, responses typically depend on the proximity of the sample to the source and the MS inlet.  
This can be very problematic because slight variation in sample positioning could lead to  also a problem 
because slight variation in sample positioning or turbulences could lead to increased  % RSDs.159 To 
determine the influence of mesh positioning on the signal, 2 different types of experiment were done. As 
mentioned in Section 2.2.2, the first experiment consisted of mesh placement in different positions with 
respect to the DART source and the MS inlet.  In position 1, the mesh was closest to the DART source 
and furthest from the MS inlet. Theoretically, position 1 would likely result in the fastest thermal 
desorption of the analytes as it is closest to the gas source. Position 2, whereby the mesh was placed 
between the DART source and the MS inlet was used as compromise of positions 1 and 3.  The results 
obtained for this test can be observed in Figure 2.9. As it can be seen, position 3 gives the least sensitive 
response, while 1 and 2 yielded comparable responses. Position 3 is not optimal for efficient thermal 
desorption of the analytes due to its proximity to the MS inlet.  Positions 1 and 2 yielded somewhat 
similar responses, demonstrating that mesh proximity to the heated ionizing source is more important 
than its proximity to the MS inlet. Newsome et al. have also found that analyte signals decrease 
significantly when the source is furthest from the sample surface.160  
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Influence of mesh angle on signal response was examined in the second part of the investigation. By 
changing the mesh angle, the interaction of the gas plume with the sample is changed. The question is 
whether different mesh desorption angle produces a more sensitive response? Recall, in scenario I gas 
hits the mesh at an angle about 90 ˚ horizontal to the mesh surface, while in scenario II, the mesh’s angle 
is shifted by 90˚, so the gas hits the mesh at an angle corresponding to the gas flow, i.e., gas  flow is 
parallel to mesh surface. Ion chronograms of MDMA were monitored for this purpose, and as it can be 
seen from Figure 2.10II., a change in the angle yielded a sharper, but not a more sensitive chronogram 
Figure 2.10 Ion chronograms obtained for extraction of 25 ng mL-1 of MDMA spiked to PBS and 
analyzed using two different mesh angles in I. and II. 
Figure 2.9 Signal areas [AU] obtained for a set of model compounds (n = 3) tested at three different 
positions with respect to DART source and MS inlet. 
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peak, as evidence by signal area shown inside the chronograms. The response is better when the stream 
is perpendicular to the SA of the mesh, as it can be seen in Figure 2.10I. This proves that SPME-TM-
DART-MS responses and are heavily influenced by the angle of incidence of the gas flow. In other words, 
the greater the SA of the coated SPME device, the greater the response obtained from DART-MS.  
Impact of pH manipulation 
The pH is an important extraction parameter of SPME.7 According to the theory of SPME, only the 
undissociated (neutral) form of the analyte can be extracted by the coating.7 If the analyte is charged, 
coatings with anion or cation exchanger sites can be used. In this section, experiments were done using 
a PBS sample spiked with 200 ng mL-1 of methadone, EDDP, cocaine, cocaethylene, and codeine. HLB 
meshes were used for the extraction (n = 3).  The results obtained can be seen in Figure 2.11, alongside 
respective pKa values of the analytes (obtained from DrugBank).161 Noticeably, the least sensitive 
response is obtained when the samples are acidified (pH = 3). The majority of the analytes are present in 
a dissociated state at this pH, which leads to reduction of extraction capability of the HLB meshes. EDDP 
is the only analyte that does not show major changes in signal response at the different pH values tested. 
Figure 2.11 Signals obtained for methadone, EDDP, cocaine, cocaethylene and codeine (200 ng mL-1) 
at pH’s of 3, 7 and 10 using SPME HLB meshes coupled to DART/MS (n = 3). pKa values are shown 
on the right.  
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It is possible that other factors (e.g., PA) are responsible for this observation. Codeine’s response was 
the least sensitive out of all of the analytes examined, particularly at the pH of 3. Methadone, cocaine 
and cocaethylene yielded the highest responses, which were most apparent at the pH of 10. However, 
adjustment of sample pH may not be necessary in every sampling scenario. Nonetheless, it is important 
to keep in mind that certain matrices like urine (tends to vary with different lots) may require a dedicated 
evaluation of the impact of pH on responses of DART-MS-SPME-TM.   
Multiple desorption tests  
In order to examine the extent of “loss” of target analytes during DART desorption, three consecutive 
desorptions of the same mesh (at the same location) were done for MM, C18 and HLB coatings. The 
main concern was that incomplete desorption of the analytes was occurring after/during the initial 
desorption. Due to the volume of the data, a table representing the signal area (in AU) after three 
consecutive desorptions for C18, HLB and MM is shown in Table 2.2. Please note that the values 
provided are the averages of three different meshes used. The blank desorption (desorption from unused 
mesh) was used as a control. As it can be seen from Table 2.2, complete desorption of all analytes does 
not occur upon initial exposure to the heated gas. While the large majority of the extract is desorbed 
during initial exposure, 2nd and 3rd desorption indicate that some analyte still remains on the mesh. This 
is more apparent in the case of the 2nd desorption, since signal for the 3rd desorption is only slightly higher 
or comparable to the blank for the majority of the analytes. Examination of Table 2.2 reveals that C18 
coating (with the exception of methadone and JWH-250) does not yield the same responses as the blank 
by the time that 3rd desorption is done. It is also possible that heat permeation through the steel wires of 
the mesh causes partial desorption of the surrounding area of the mesh thus potentially resulting in 
elevated signal areas for the 3rd desorption. From Table 2.2 it can be seen that HLB’s signal for 3rd 
desorption is comparable to blank desorption in case of nicotine, cotinine, morphine, codeine, RCS-8, 
JWH-250, and JWH-203. MM coatings reach a near-blank signal for methamphetamine, morphine, 
56 
 
codeine, methadone, RCS-4, JWH-015, JWH-250 and JWH-203 by the time 3rd desorption is done. 
Interestingly, JWH-250 reaches a near-blank value by the 3rd desorption for all 3 coating chemistries. To 
provide a better visualization of these trends, a few analytes were selected to show signals from all 
desorptions involved. These can be seen in Figure 2.12, whereby the left side shows results for the blank 
and all 3 desorptions, while the right side shows the blank, 2nd and 3rd desorption signals. Figure 2.12A. 
shows methamphetamine’s response with a noticeable comparability between signals of 2nd, 3rd and blank 
desorption for all 3 coating types. In case of codeine (Fig. 2.12B.), a comparable signal upon 1st 
desorption for HLB and MM coatings are observed, while 3rd desorption is comparable to the blank 
Table 2.2 Signals obtained (in AU, n = 3) for blanks, first, second and third desorption from C18, HLB 
and MM coatings for a set of selected analytes. 
Desorption Blank First desorption Second desorption Third desorption 
Analyte C18 HLB MM C18 HLB MM C18 HLB MM C18 HLB MM 
Methamphetamine 8.4E+04 7.4E+04 1.1E+05 1.5E+06 7.1E+05 9.5E+05 9.4E+04 6.4E+04 5.3E+04 1.1E+05 9.5E+04 1.1E+05 
Nicotine 9.1E+04 1.1E+05 1.0E+05 2.5E+05 1.2E+05 1.4E+05 1.2E+05 1.3E+05 1.1E+05 1.1E+05 1.2E+05 1.3E+05 
Cotinine  2.0E+04 2.5E+04 1.6E+04 4.1E+05 7.5E+04 7.1E+04 5.9E+04 3.4E+04 2.9E+04 3.6E+04 2.9E+04 2.9E+04 
Morphine 1.0E+04 9.2E+03 1.2E+04 1.1E+05 9.3E+03 8.7E+04 2.4E+04 6.7E+03 1.9E+04 1.8E+04 5.7E+03 1.4E+04 
Codeine 5.5E+03 7.3E+03 7.0E+03 1.3E+05 3.1E+04 1.3E+05 1.5E+04 1.0E+04 1.0E+04 1.0E+04 6.8E+03 7.2E+03 
Cocaine  4.0E+03 3.5E+03 6.7E+03 2.5E+06 8.9E+05 4.3E+06 7.6E+04 2.1E+04 2.0E+04 3.6E+04 8.5E+03 1.1E+04 
Methadone 1.3E+05 8.3E+04 4.9E+05 1.7E+06 1.3E+06 3.4E+06 1.5E+05 1.3E+05 3.5E+05 1.5E+05 1.1E+05 3.7E+05 
Oxycodone 3.0E+03 4.5E+03 3.3E+03 2.2E+05 4.7E+04 3.6E+05 3.0E+04 1.7E+04 2.5E+04 1.9E+04 1.2E+04 1.3E+04 
RCS-4 1.7E+04 1.6E+04 9.9E+04 1.0E+06 6.3E+05 2.0E+06 1.5E+05 7.4E+04 1.6E+05 9.9E+04 4.0E+04 9.9E+04 
RCS-8 1.5E+04 1.1E+04 2.8E+04 2.5E+05 1.6E+05 5.6E+05 5.9E+04 2.0E+04 9.2E+04 4.3E+04 1.3E+04 5.3E+04 
LSD 8.4E+03 5.2E+03 5.3E+04 3.2E+05 6.1E+04 1.5E+06 4.7E+04 7.4E+03 5.7E+04 2.2E+04 6.3E+03 3.3E+04 
Heroin 1.5E+03 1.9E+03 3.1E+03 1.7E+05 6.5E+04 2.7E+05 1.3E+04 9.8E+03 6.9E+03 7.4E+03 5.1E+03 4.4E+03 
JWH-015 1.7E+04 8.4E+03 1.1E+05 9.5E+05 5.3E+05 2.1E+06 1.5E+05 6.9E+04 1.7E+05 9.9E+04 3.5E+04 1.1E+05 
JWH-250 1.1E+03 1.1E+03 1.6E+03 5.1E+03 4.3E+03 1.4E+04 2.0E+03 9.7E+02 2.1E+03 1.8E+03 1.0E+03 1.8E+03 
JWH-203 8.8E+03 1.1E+04 4.0E+04 3.7E+05 2.2E+05 4.6E+05 6.8E+04 1.9E+04 7.4E+04 4.7E+04 1.2E+04 5.3E+04 
JWH-210 4.2E+03 5.3E+03 1.3E+04 1.9E+05 1.5E+05 4.7E+05 5.3E+04 2.3E+04 8.9E+04 3.7E+04 1.3E+04 5.7E+04 
JWH-200 6.9E+03 4.7E+03 1.3E+04 6.6E+05 4.1E+05 1.7E+06 2.0E+05 5.3E+04 3.3E+05 1.3E+05 2.3E+04 1.7E+05 
AM-2233 1.5E+03 1.2E+03 5.4E+03 1.4E+05 1.6E+05 4.3E+05 3.9E+04 1.8E+04 2.8E+04 1.9E+04 7.5E+03 1.3E+04 
signal. For cocaine (Fig. 2.12C.), C18 and MM coatings have desorbed the majority of the extracted 
analyte by the 3rd desorption while HLB retains some of the analyte past 3rd desorption.  In case of JWH-
250 (Fig. 2.12D.), a progressive drop in signal can be observed for all 3 coatings, although HLB and MM 
appear to retain only slightly more in comparison to C18.  JWH-200 retains a larger amount of analytes 
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after 1st desorption, particularly for HLB and MM, and even after 3rd desorption, signals are still elevated 
for HLB and MM coatings (Fig. 2.12E.). Certainly, it is apparent that incomplete desorption of the 
analytes occurs after 1st desorption for all 3 coating types. It must be kept in mind that a 0.2 mm sec-1 
speed was used to move the meshes in front of the DART source, and it possible that this speed is not 
suitable for desorption of all analytes. In fact, a longer exposure time would likely be required to desorb 
all of the analytes. For example, Harding et al. analyzed transmission of N-(4-hydroxyphenyl)ethanamide 
(HPE) and N-phenylbenzamide (PB) on bare SS meshes.146 The standards were directly deposited onto 
the SS mesh and desorbed over 60 mins to examine the desorption behavior.146 Interestingly, signal 
intensity peaked after 2-3 mins of exposure and continued to release the analytes with a progressive drop 
up to 60 mins.146 Of course, signal intensity from desorption of a pure standard tends to be high, but 
desorption occurring after nearly an hour of exposure indicates that incomplete desorption should not be 
directly linked to SPME only. It is likely that compound and specific factors play a role too. Certainly, 
using longer exposure times would allow for a more complete desorption but this becomes time 
consuming. In fact, it would defeat the whole purpose of AIMS, which are rapid quality results. 
58 
 
   
A future perspective: factorial experimental design  
Considering the number of different factors that influence the signal response of DART-MS, it is fair to 
say that the best way to investigate their impact would be through the use of factorial experimental 
designs.155 The aforementioned allows investigators to choose several different factors at fixed levels 
(e.g., high, medium or low) to determine which factors have the greatest impact on the result.155 Using a 
“one-at-a-time” approach is acceptable towards examination of a single factor, but it provides responses 
at selected and/or fixed conditions of other factors and it must be assumed that the outcome is the same 
Figure 2.12 Individual charts showing signals obtained (n = 3) for methamphetamine (A.), codeine (B.), 
cocaine (C.), JWH-250 (D.) and JWH-200 (E.) for blank, 1st, 2nd and 3rd desorption on the left and for 
blank, 2nd and 3rd desorption  for better visualization of signal comparability to the blank on the right.  
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at all other settings for the remainder of the factors.155 In case of DART-MS, it is more than likely that 
the factors mentioned in Section 2.2.1 interact with each other. Hence factorial experimental design 
would allow for detection of interactions between the factors, in addition to saving both time and 
resources. As mentioned in the introduction, calculation of certain parameters such as PAs require 
computational skills, so efforts from programmers, mathematicians and analytical chemists are required 
to obtain a more complex understanding of DART-MS mechanisms.     
2.2.4 Conclusion for Section 2.2 
Impact of different DART and SPME parameters with respect to source temperature, coating chemistry, 
sample positioning, and pH were investigated in this section. Additionally, a multiple desorption test was 
done to examine the extent of loss of analytes during the desorption process. It has been found that all of 
the aforementioned factors influence responsiveness of SPME-TM-DART-MS system. These findings 
highlight the importance of proper optimization of experimental factors before conducting any work. 
Considering the number of factors involved, the use of full factorial experimental designs would be an 




 On the performance of solid-phase microextraction (SPME) fibers vs transmission-
mode (TM) meshes for direct analysis in real time (DART) coupled to mass 
spectrometry (MS): Differences in analytical sensitivity 
 
2.3.1 Introduction 
Invented by Cody in 2005, DART quickly became popular in numerous fields due to its friendly interface 
and ability to provide rapid results.87 DART can be used to analyze unaltered samples, but this approach 
hinders the achievement of trace-level detection limits. However, the use of a sample-preparation 
strategy162 can significantly reduce detection limits and bring them in line with the levels offered by GC 
and LC-MS. Of the various reported sample preparation options that can be coupled to DART-MS, 
SPME has proven to be one of the most efficient, as it combines preconcentration, sampling, clean-up, 
and desorption into a single step.7,26,49 Different formats of SPME have been coupled to DART-MS, 
including in-tube SPME,163 stir bars,164 fibers,165,166 and meshes.26,117,134,136–139 In-tube SPME, which 
consists of a coating deposited within a capillary device,7,163 has great potential for application in small 
volume analysis.167 Despite this potential, in-tube SPME has some drawbacks; for example, it is 
relatively cumbersome to  prepare, and it is prone to tubular clogging when used with complex matrices, 
like blood.163 Stir-bar sorptive extraction has been used for the detection of organic UV filters164  and 
phosphoric acid esters.106 While the detection limits offered by this technique are on the lower side of 
the ppb scale, its application can sometimes be limited due to the size of the stir bar. For example, it 
would be challenging to perform small-volume extractions with stir bars, even though smaller-sized stir 
bars are also available. Additionally, the stir bars are usually manually held or placed inside specially 
designed glass tubes for introduction within DART’s desorbing stream,106,164 which could pose problems 
with regards to reproducibility and sample-throughput. Other researchers, such as LaPointe et al. and 
Cajka et al., have used fibers for detecting synthetic cathinones in urine (synthetic source) and beer 
profiling, respectively.165,166 Conversely, Pawliszyns’ and Sacks’ groups have been diligently using the 
SPME mesh format for drug, food, and environmental analyses.26,117,134,136–139 The idea to use a “net-
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like” or “mesh-like” device to introduce the sample into AIMS was first reported by Pérez et al., who 
used it for DESI and DART. This method is known as TM.115  By depositing samples onto nets or meshes 
with controlled geometries, Pérez et al. were able to normalize sample introduction into the MS, therefore 
allowing better analyte “transmission”. The major outcome of this approach was enhanced 
reproducibility.115 Since fibers and meshes are the two SPME formats most amenable to DART-MS, we 
conducted a study that aimed to concomitantly examine and compare their analytical performance. To 
the best of our knowledge, such a study has not yet been published. Obtaining greater insight into the 
analytical performance of fibers and meshes is desirable because it can provide a more robust 
understanding of the operating principles of SPME coupled to DART-MS. To examine the performance 
of these two formats, two separate studies were conducted using two randomized protocols. Protocol #1 
was designed to investigate the analytical sensitivity of custom-made fibers and meshes. Both devices 
were dip-coated in a slurry consisting of 10% PAN binder and 7% of 5 µm C18 particles using a uniform 
procedure. Nitinol wire served as support for the fibers, while stiff SS mesh with a dense network, named 
“wire-mesh,” was used as a substrate. Analytical performance was then examined using a set of model 
compounds spiked to PBS, which were then extracted via agitation and a static approach and examined 
using MRM mode. Ultimately, the meshes outperformed the fibers, reaching lower detection limits and 
providing sensitivity that was nearly 10x higher. Protocol #2 used commercial SPME fibers (SPE-its™) 
coated with C18 particles and meshes made of thin metallic sheets with large hexagonal apertures, which 
were aptly named “sheet-meshes.” This mesh design contrasted that of meshes used in Protocol #1. The 
sheet-meshes were coated in-house using dip-coating (10% PAN, 7% 5 µm C18 particles). PBS was also 
used as the model matrix, and the analysis was performed using full-scan mode. The results of Protocol 
#2 were more ambiguous, with the fibers outperforming the meshes in some instances, and the meshes 
outperforming the fibers in others. Overall, however, the meshes and the SPE-its™ fibers produced 
comparable results. We postulate that these results were likely related to the mesh design, which indicates 
62 
 
that the wire-mesh format is the superior option for DART-MS-SPME-TM analysis. A discussion of the 
applications of these two formats (mesh and fiber) is also presented herein, as each contain factors that 
may limit their applicability.  
2.3.2 Experimental 
Materials/Methods 
The chemicals used in Protocol #1 were ordered from Cerilliant at a concentration of 1000 mg L-1. These 
chemicals included: fentanyl, oseltamivir, oxycodone, pseudoephedrine, and methadone. The chemicals 
used in Protocol #2 were also ordered from Cerilliant (1000 mg L-1) and included: EDDP perchlorate, 
cocaine, cocaethylene, methadone, and codeine. All the chemicals were ordered as methanolic standards. 
NaCl, KCl, K3PO4, Na3PO4, PAN, and DMF were obtained from MilliporeSigma at a purity ≥  99 %. 
C18 particles (5 µm) were also ordered from MilliporeSigma. LC/MS-grade solvents were obtained from 
Fisher Scientific, including:  IPA, ACN, MeOH, and H2O. Wire-format SS mesh was purchased on 
Amazon (see Figure 2.13 for a detailed visualization of this format; aperture: 280 µm, wire diameter: 
140 µm, pitch: 400 µm, 39% percent open area (POA). Nitinol wire (diameter: 198 µm, lot #2086856-
2A) was purchased from Confluent (Freemont, CA, USA). SS meshes in sheet format (see Figure 2.14) 
were obtained from IonSense, Inc. The sheet meshes had a diameter of 843 µm, a length of ~ 5mm, and 
an estimated POA of ~ 62%. The SPE-its™ fibers were also obtained from IonSense, Inc. and can be 
seen in Figure 2.15. PBS was prepared according to procedure described in Section 2.2.2. The 
preconditioning and cleaning solutions for the devices were made by combining 50/50 of MeOH/H2O 
and 50/25/25 of MeOH/ACN/IPA, respectively. Human urine was obtained from a female volunteer. 
Optical images were taken with an Olympus microscope (SZX10) with a SC30 digital camera (Olympus, 









Figure 2.14 Design of SS mesh used for Protocol #2. Image a. shows the basic design of the aperture, 
which is structured with very characteristic hexagonal shape. Images b. and c. show the uncoated mesh, 
with c. providing a highly-magnified view of the structure. As can be seen, the width of the aperture is 
~843 µm. 
Figure 2.13 The basic design of the SS wire mesh is shown in image a., which provides an enlarged 
view of one section of the mesh and its structural features. Image b. shows the bare mesh substrate that 
was used in this research. Figure c. provides highly magnified view of the mesh, along with its aperture 




Preparation of meshes and fibers 
The wire-format meshes were prepared according to the protocol developed by Gómez-Riós.26 Briefly, 
the meshes were carefully cut into 2.5 x 0.5 cm strips, etched in concentrated HCl (5 min), cleaned in 
MeOH and deionized H2O (5 min, 2x), dried in an oven at 100 °C, and then stored in IPA (to prevent 
oxidation) until the coating process. The fibers were prepared by cutting the nitinol wires to a length of 
5 cm, cleaning them in the cleaning solution, drying at 100 °C, and then storing them in IPA until use. A 
coating slurry was made by dissolving 10% of PAN powder in DMF and then heating the solution to 
100 °C to obtain a uniform glue-like consistency. Once the desired consistency had been achieved, 7% 
of C18 particles were added and the solution was vigorously agitated and vortexed overnight (12 h, 
1500 rpm) with a stir-bar. This slurry was used to coat fibers and meshes used in Protocol #1. The meshes 
and fibers were immersed in the coating solution and then carefully withdrawn in order to ensure a  
uniform layer on the device surface. Following dipping, the fibers were immediately placed in the oven 
for drying (100 °C), while the meshes were blasted with pressurized N2 to remove any excess slurry from 
the openings between the wires. Afterwards, the meshes were also placed in the oven for drying (100 °C). 
This constituted 1 preparation cycle, with a total of 4 cycles being employed for both devices. Coating 
Figure 2.15 Optical image of SPE-its® coated with a C18 extractive phase. 
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length was maintained at 1 cm for both devices. For convenient desorption in front of DART source, the 
fibers were immobilized into plastic 200 µL pipette tips using epoxide glue. 
The metallic sheet meshes for Protocol #2 were etched using the following sequence: MeOH (2x, 
20 min), HCl (1x, 20 minutes with brief shaking every 5 min), MeOH again (1x, 10 min), and, finally,  
deionized H2O (2x, 10 min). Following this procedure, the meshes were dried for 30 minutes at 100 ˚C 
and kept in a desiccator (under N2) until use. A slurry made of 10% PAN and 7% C18 particles (different 
than one used in Protocol #1 as different batches of the material were used) was implemented to coat the 
sheet meshes with the exception that 2 dip-cycles were implemented (due to a visually acceptable 
adherence of C18 particles). The coating procedure consisted of dispensing 1 mL of coating slurry (via 
plastic disposable pipettes) into 12 slots of a 96-well plate (2 mL capacity). This allowed for immersion 
of 12 pins simultaneously followed by a careful manual withdrawal and blasting with N2 to remove 
excess slurry. Once all the devices had been fabricated, cleaning solution was used to remove any 
interference attachments and the devices were stored in a preconditioning solution until use.  
DART-MS/MS 
A TSQ-Vantage from Thermo Scientific was used to perform the MRM analysis (+ve ionization mode) 
in Protocol #1. Table 2.3 provides selected details of the analytes’ physico-chemicals properties, as well 
as the settings that were used for their analysis in Protocol #1. Protocol #2 utilized an Exactive Orbitrap 
(Thermo Scientific) which was operated in full scan +ve ionization mode (Table 2.4-2.5). A DART 
SVP® source with a Vapur® interface was obtained from IonSense, Inc. and coupled to both instruments. 
The DART source was operated at a temperature of 400 °C for Protocol #1, and a temperature of 350 °C 
for Protocol #2. Custom-made holders (UW) were used for the wire-meshes26 and the sheet-meshes 
(Figure 2.16), while fibers were immobilized into a holder made by IonSense, Inc. (Figure 2.17). A linear 
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rail was used to move the holders along the x-plane at a speed of 0.2 mm s-1 for Protocol #1, and a speed 
of 0.3 mm s-1 for Protocol #2.   
Table 2.3 Details relating to the analytes chosen for Protocol #1, including their respective classes, logP 
values, parent and product m/z values, along with the S-lens and collision energy used on the TSQ-
Vantage. Compound details obtained from PubChem.  







Fentanyl Piperidines 4.05 337.1 188 101 22 
Oxycodone Morphinans 0.30 316.1 241.1 124 28 





1 313 166 70 18 
Pseudoephedrine Benzenes 0.89 166 148.1 64 11 
 
Table 2.4 Exactive-Orbitrap settings used for the experiments in Protocol #2. 
 
Table 2.5 Details relating to the analytes used in Protocol #2, along with their respective classes, logP 
values, vapor pressure, and boiling and melting points (PubChem).156 Parent m/z values are also 
provided. 







point Parent m/z 
Methadone Benzenes 3.93 1.21e-6 - 235°C 310.2171 
Cocaine Benzenes 3.93 1.91e-7 - 219°C 304.1549 
EDDP n/a 5.26 n/a - - 278.1909 
Cocaethylene n/a 2.53 n/a - - 318.1705 
Codeine Morphinans 1.21 5.54e-9 482°F 309-313°F 300.1599 
Resolution 50,000 
Mass range 100 - 500 
Polarity +ve  
Microscans 1 
Capillary temperature 250 °C 
S-lens RF level - 
AGC target 1,000,000 





Extraction procedure  
A 100 mg L-1 stock solution of analytes (Protocol #1 and #2) was prepared in MeOH and then diluted to 
adequate concentrations, which were used to spike PBS. Spiking was performed carefully in order to 
ensure that the percentage of organic solvent content in the PBS comprised ≤ 1 % of the total sample 
volume.7 Since the aim of this study was to examine sensitivities at a lower concentration range, the 
following spiking points were used for Protocol #1: 0.01, 0.05, 0.1, 0.5, 1, 2.5, 5, 10, 15, 20, 35, and 
50 ng mL-1. The extractions in Protocol #1 were carried out from a 1 mL sample using agitated (vortex, 
3000 rpm, 1 min) and static approaches (10 min) for meshes and fibers. Both approaches were used in 
conjunction with each device. For Protocol #2, the 100 mg L-1 stock mixture was further diluted so that 
Figure 2.16 Holder used for the sheet-format SS meshes. 
Figure 2.17 Holder used to immobilize the SPME fibers for DART-MS. 
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spiked PBS concentrations equated to 0.1, 1, and 10 ng mL-1. The mesh and fiber extractions were 
performed using a 96-well-plate with 1.5 mL of spiked PBS in each well for a total of five repetitions 
(n = 5) per point. The extraction was carried out for 10 minutes on an orbital shaker (~500 rpm). For both 
protocols, a 5-10 second agitated wash in LC/MS-grade H2O was performed once the extractions had 
been completed. The devices were then blotted with a KimWipe to remove any remaining H2O, dried, 
and placed into holders to carry out DART-MS desorption. Signals obtained from blank PBS were 
acquired for both formats to establish the S/N ratios. Since the aim of this study was to examine raw 
signal responses, no ISs were used. A summary of details pertaining to the instruments and extraction 
procedures used in Protocol #1 and #2 is provided in Table 2.6.  
Table 2.6 Summary of experimental parameters used in Protocol #1 and #2. 
 Protocol #1 Protocol #2 
Instrument TSQ-Vantage Exactive-Orbitrap 
Scan mode (+ve ionization) MRM Full scan 
Matrix (volume used) PBS (1 mL) PBS (1.5 mL) 
Analytes 
Fentanyl, oxycodone, 
oseltamivir, methadone and 
pseudoephedrine 
Cocaine, cocaethylene, EDDP, 
methadone and codeine 
Choice of fiber Custom-made Commercial, SPE-its® 
Meshes Custom made, wire design 
Custom made, metallic sheet 
design 
Coating chemistry C18 (5 µm) C18 (5 µm) 
DART source temperature 400 °C 350 °C 
DART rail speed 0.2 mm s
-1




Agitated (vortex ~ 3200 rpm, 1 
min) & static (10 min) 
Agitated (orbital shaker ~ 500 
rpm, 10 min) 
Wash time 5-10 sec (vortex ~ 3200 rpm) 








According to the theory of SPME, increasing the SA of the extraction phase should improve sensitivity, 
as it will allow the device to extract more analyte in a shorter period of time.7,23,168 Thinner coatings are 
also more desirable since thicker coatings take longer to equilibrate.23,168 This is particularly true for 
SPME thin films developed for GC (also known as membranes) and LC. A comparison of the analytical 
performance of SPME fibers, thin-films, and stir-bars has already been done by Qin et al. using GC-
electron impact.168 In their study, Qin et al. showed that thin films outperformed both fibers and stir bars 
due their relatively larger SA and thinner coatings.168 Given these findings, it is worthwhile to investigate 
whether this same principle (i.e., higher SA = higher sensitivity) applies within the context of DART-
MS analyses of meshes and fibers. Aside from the apertures on the mesh surface that contribute to POA, 
meshes and thin films are structurally similar. POA, which can be defined as the percentage (or ratio) of 
the mesh’s total hole area to total screen area,169 is important for the efficient transmission of analytes 
into the MS. The smaller the POA, the greater the extent to which the wires intertwine (see Figure 2.18 
for a visualization). The meshes used in Protocol #1 contained an intertwined network of solid wires 
(Figure 2.13), with each wire providing a unique desorption point. A visual comparison of meshes and 
fibers is available in Figure 2.19. Since DART relies on the interaction between a heated gas and an 
exposed surface (i.e., mesh or fiber) to attain a signal, it was of interest to examine the surface topology 
Figure 2.18 Visualization of how POA changes in response to varying levels of wire intertwining. Note 




of both devices. Specifically, we were interested in examining the distribution of C18 particles on the 
individual wires of the meshes and fibers. We wanted to see whether the surface of the devices contained 
irregularities in the dispersion of the particles. Figure 2.20 provides a detailed illustration of the mesh 
network. Figure 2.20a. shows an optical image of a network of solid wires coated with C18 particles, 
while Figure 2.20b. shows an enlarged segment of the mesh. As can be seen, there are slight coverage 
imperfections along the junction portions of the wires. Optical images of the mesh taken prior to and 
after coating were used to estimate the thickness, which was found to be ~20 µm. Figures 2.20c-h. show 
detailed SEM images of the mesh. As can be seen, a dense network of C18 particles is present on the 
surface. An examination of individual portions of the wire (Figure 2.20f-h.) also revealed uniform 
particle distribution on the surface. As noted earlier, each individual wire provides a desorption point; 
hence, adequate extractive particle coverage is important for producing a robust ion chronogram. In 
addition, the mesh’s length of ~5mm allows a greater amount of extracted material to come into contact 
with the desorbing gas of the DART-MS. Furthermore, the rail speed also contributes to the ion 
chronogram. Specifically, lower speeds produce broader peaks by allowing for longer interaction times 
between the desorbing gas and the exposed material. In contrast, the fiber does not have an intertwined 
wire-network, and instead relies on desorption from a single substrate. Hence, ion chronograms for fibers 
Figure 2.19 SPME meshes and fibers (both coated to a length of ~10 mm). 
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tend to be taller and narrower with sharper peaks. Figure 2.21 provides optical and SEM images of the 
fibers used in Protocol #1. Figures 2.21a-b. provide optical images of nitinol and a coated fiber, 
respectively.  Figures 2.21c-d., which were obtained via SEM analysis, show images of a coated fiber 
with a surface topology that features a dense network and distribution of C18 particles. Coating thickness 
was evaluated by stripping-off a portion of the coating (Figure 2.21e.-f.). An estimation obtained via 
SEM analysis revealed that the coating thickness was ~ 12.4-13.8 µm.  As discussed above, the devices 
used in Protocol #1 were prepared using the same coating slurry in an effort to eliminate and/or reduce 
batch effects. This is an important measure because the presence of batch effects (different lot of C18 
particles and PAN, differences in slurry preparation) could lead to variation in coating homogeneity, 
which could potentially lead to erroneous conclusions. One major difference between DART-SPME and 
GC and LC applications using SPME thin-films is the manner in which desorption is conducted. In the 
Figure 2.20 Optical and SEM images of a wire-format SS mesh. Images a. and b. are optical images, 
with b. providing a magnified view of a mesh segment. Images c-e. show the wire strands adequately 
covered by C18 particles. Images f-g. provided a highly magnified view of a section of SPME wire, while 
Image h. provides shows a condensed area of C18 particles. 
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latter applications, the entire coating is usually exposed to a desorbing gas or solution, ideally removing 
all of  the extracted analytes.7 During DART acquisition, the ion chromatogram is created via desorption 
Figure 2.21 Optical and SEM images of the fibers used in Protocol #1. Image a. shows a bare nitinol 
wire, which was used as a substrate for the SPME fibers. Image b. shows the coated SPME fiber. Images 
c-d. show SEM images of the fiber depicted in a. and b. Image e. shows the fiber with a section stripped-
off in order to enable an estimation of thickness, as indicated in image f. 
Figure 2.22 Schematic representation of the desorption strategies used for GC, LC, and DART-MS. GC 
and LC thin-films are entirely exposed to thermal and solvent desorption, while only a segment of mesh 
or fiber is exposed to desorbing He* gas in DART-MS. 
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from only a segment of the mesh or fiber (illustrated by Figure 2.22). Hence, only a portion of the 
extracted analytes are analyzed when DART-MS is used. Although the surrounding area may contribute 
to the signal due to heat transfer, it is unlikely that this would account for signal from the entire coating. 
Figure 2.23 provides an ion chronogram and the signal areas for agitated extractions performed with a 
mesh and a fiber using PBS samples spiked with 20, 30, and 50 ng mL-1 of methadone. As can be seen, 
the response of the mesh was nearly a magnitude larger than those of the fiber, with much broader ion 
chronograms. Figure 2.24 provides a summary of the S/N ratios for the mesh and the fiber, with meshes 
evidently yielding higher ratios and therefore lower detection limits. For methadone, LODs were 
achieved at 0.5 and 10 ng mL-1 for mesh and fiber, respectively. Detectable signals for fentanyl were 
observed at 0.01 (S/N of 5) and 0.5 ng mL-1 (S/N of 24) for mesh and fiber, respectively. Nonetheless, 
these findings were based on raw signals (n = 3) obtained without IS correction. In addition, some 
Figure 2.23 Ion chronogram obtained for methadone (310 → 265) in PBS at concentrations of 20, 35, 
and 50 ng mL-1 using SPME fiber (a.) and mesh (b.). 
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discrepancies were observed in the S/N ratios; for example, the S/N ratios were slightly higher at lower 
spiked-concentration points. Such discrepancies tend to be more prevalent when signal correction (no 
IS) is not employed. While other factors may have contributed to these errors (extraction irregularities 
and coating imperfections), ambient-air turbulence during analysis can be considered as one of the main 
culprits for such errors. LODs of 15 and 20 ng mL-1 were achieved for oseltamivir and oxycodone, 
respectively, while pseudoephedrine went undetected. In the case of the meshes, LODs of 0.5, 0.5, 
and 35 ng mL-1 were achieved for oseltamivir, oxycodone, and  pseudoephedrine, respectively. 
The performance of the devices was also tested using a static approach, which produced S/N ratios that 
indicated a slight drop in sensitivity for both formats. However, the static tests also revealed that the 
meshes yielded better responses than fibers (Figure 2.25), as the fibers were unable to produce a signal 
for oxycodone and pseudoephedrine. In general, it is not surprising that the meshes outperformed the 
fibers, as they offer a much larger SA for desorption. After all, DART-MS is a thermal-desorption 
technique in which response quality depends on time and surface exposure. Several authors have already 
Figure 2.24 S/N ratios obtained for the extraction and analysis of fentanyl, oseltamivir, oxycodone, 
methadone, and pseudoephedrine from PBS spiked at 11 different concentrations for meshes and fibers. 
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demonstrated DART’s tremendous ability in surface analysis.101,149,170 For example, Chernetsova et al. 
showed that performing angled DART desorptions allowed for greater interaction between the desorbing 
gas and the sample, thus improving sensitivity.149 In the case of SPME-TM wire meshes, a greater 
proportion of the particles are exposed to the desorbing gas, which ultimately yields a better response.  
  
Figure 2.25 Responses of meshes and fibers (Protocol #1) used for static extractions of fentanyl (A.), 




The goal of Protocol #2 was very similar to the goal of Protocol #1; that is, we sought to examine whether 
more SA would provide an increase in sensitivity, even with changes in the experimental parameters. 
Specifically, Protocol #2 used different instruments, DART settings, and extraction strategies, as well as 
C18 particles from 2 different purchasing sources. Perhaps the biggest change was the use of a different 
mesh format (Figure 2.14). For these tests, we used a thinner substrate that was made of smooth metallic 
sheets, which had been perforated with hexagonal apertures approximately ~ 0.8 mm in diameter. 
Hexagonal apertures were recommended by the manufacturer due to their better “structural stability” 
when dealing with complex samples and high agitation speeds. These characteristics have not yet been 
investigated, but will be examined in future studies. In addition, the sheet mesh had relatively fewer 
desorbing points compared to the wire-mesh. Figures 2.26 and 2.27 provide detailed images of the 
surface topologies of the sheet meshes and SPE-its®. Figures 2.26a-b. provide optical images of the 
coated sheet mesh, showing what appears to be a good coating. Figures 2.26c-g. show the SEM images 
used to perform a thorough visual examination of surface topology, while Figure 2.26c. shows that the 
sheet mesh appears to have a slightly less dense network of C18 particles, unlike wire-meshes of Protocol 
#1. As can be seen in Figure 2.26d., the lower section of the three-point junction highlighted in purple 
appears to have minor variability in the amount of deposited C18 particles, which is likely caused by 
smoother surface of the photochemically etched sheet-mesh. Exposing the mesh to longer or more 
aggressive etching could have made the surface rougher, but it could have also compromised its structural 
integrity. Figure 2.26e. shows a portion of the coated mesh with variations in how the particles 
“protrude.” For example, i. shows a dense area of particles and ii. shows particles that are more embedded 
within the PAN glue. Figures 2.26f-g. show the mesh with portions of coating removed, indicating an 
estimated thickness of ~18-22 µm. Figure 2.27 shows the SEM image obtained for a stripped-off portion 
of the SPE-it®, which had an estimated thickness of ~ 69-77 µm. The findings of Protocol #2 revealed 
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comparable performance for both devices, with the meshes and fibers outperforming each another for 
specific concentrations and/or analytes. Figure 2.28 provides a chart showing the signal response (in AU) 
for sheet-meshes and SPE-its® for 0.1, 1, and 10 ng mL-1 of model analytes extracted from PBS. As can 
be seen, neither format produced a signal for methadone at 0.1 ng mL-1, but the fibers produced an 
elevated response (6e3) at 1 ng mL-1 when compared to the sheet mesh (1e3). However, sheet mesh’s 
Figure 2.26 Visual examination of meshes used for experiments conducted in Protocol #2. Figures 2.26a-
b. show the pin coated with C18 particles. Figures 2.26c-d. show SEM images of the mesh, with d. depicting 
an enlarged portion of a three-point junction. This junction point is highlighted with purple in c. Figures 
2.26e., 2.26i., and 2.26ii. show an enlarged image of a cluster of C18 particles obtained from the mesh, 
while f. and g. show cross-sections of the mesh. 
Figure 2.27 SEM image obtained from a stripped-off section of an SPE-it® fiber, providing an estimated 
coating thickness between ~ 69 and 77 µm. 
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response at 10 ng mL-1 (2.4e5) was greater than that of SPE-its® (1.4e5). No signal was observed for 
EDDP at 0.1 ng mL-1, while SPE-its® showed a better response at 1 ng mL-1 and the sheet meshes 
provided superior response at 10 ng mL-1. Furthermore, sheet mesh was able to detect cocaine at 0.1 ng 
mL-1, while SPE-its® was able to do so at 1 ng mL-1 and 10 ng mL-1. In fact, at 10 ng mL-1 of cocaine, 
SPE-its® produced a greater response than sheet-mesh. 
In the case of cocaethylene and codeine, SPE-its® showed a greater response for all the spiked 
concentrations.  Figure 2.29 also provides ion chronograms obtained for 10 ng mL-1 of EDDP monitored 
via sheet-mesh and SPE-its®; it is clear that SPE-its® performed better in this scenario. As it can be 
seen, the sheet-mesh yields a non – linear response, which could be potentially related to turbulence that 
occurs during introduction of He* gas. As the SEM image in Figure 2.27 clearly shows, SPE-its® has a 
dense distribution of C18 particles on the surface. Although the sheet mesh also appears to have adequate  
 
Figure 2.28 Chart obtained from the experiments conducted in Protocol #2. The bars (log scale) indicate 
signal response (in AU) of sheet meshes and SPE-its® for extractions from PBS samples spiked with of 
0.1, 1, and 10 ng mL-1 of methadone, EDDP, cocaine, cocaethylene and codeine.  
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Figure 2.29 Ion chronogram obtained on an Exactive-Orbitrap for the monitoring of EDDP (278.1909) 
via mesh and fiber. 
particle distribution, a large POA, combined with fewer desorption points and much thinner coatings, 
may be to blame for its sub-par performance. Protocol #1 used SS meshes that consisted of a dense 
network of cylindrical wires, which significantly contributed to the signals of the ion-chronogram; in 
contrast, Protocol #2 used meshes made from metallic sheets with wider open areas, thus reducing the 
mesh’s interaction with the desorbing gas. Figure 2.30 provides a side-by-side comparison of two types 
of mesh [Canadian 10-cent coin used to emphasize the size (1.8 cm diameter)]. It is also possible that 
the mesh design—that is, the circular geometry of the wire-mesh vs the “flat”geometry of sheet 
mesh (Figure 2.31)—interacts differently with the heated gas, thus resulting in different heat transfers. 
Figure 2.30 SPME-TM meshes: “wire-mesh” design represented on the left and “sheet-mesh” 
represented on the right. 
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As such, it may be useful to investigate “depth of penetration” of the desorbing gas in order to determine 
how deeply the gas penetrates the extraction phase. Although studies focusing on heat transfer are beyond 
the scope of this investigation, it is nevertheless important to consider this aspect, perhaps via modelling 
studies and follow-up experiments.    
A consideration of both approaches  
When evaluating SPME formats for coupling to DART-MS, it is important to ascertain the differences 
between them with regards to performance and compatibility. Ignoring the application aspect for the 
moment, one must be cognizant of the fact that, while the larger SA offered by the mesh may enhance 
sensitivity, it may also extract more interferences from biological matrices. Although protecting the 
coating using PAN and an optimized wash step can reduce the attachment of interferences, this approach 
can become challenging for increasingly complex matrices (i.e. viscous, fatty and/or solid). Figure 2.32 
shows an excerpt of an ion chronogram obtained for monitoring of pseudoephedrine and fentanyl 
transitions in blank urine via mesh (2.32a-b., 3x) and fiber (2.32c-d., 3x). Notably, mesh yielded greater 
noise levels for extractions from blank urine. Therefore, preliminary investigations to evaluate noise 
levels should be conducted before using meshes. These tests could be done by performing extractions 
from a blank sample and a sample spiked at the lowest concentration point, which is based on the  
Figure 2.31 Visualization of the wire mesh’s “circular” geometry (left, 0.12 mm thickness), and the 
sheet mesh’s “flat” geometry (right, 0.06 mm thickness). 
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Figure 2.32 Ion chronograms obtained for blank extractions from urine for pseudoephedrine with 
meshes (A.) and fibers (B.). Images C. and D. show ion chronograms obtained for blank urine extractions 
for fentanyl with mesh and fiber, respectively. 
predetermined analytical cut-offs of established techniques like GC and LC-MS. This preliminary step 
would help ensure that realistic detection goals can be established.  
 As this research has shown, mesh’s properties can be best taken advantage of by employing adequate 
design and coating topology. In other words, when it comes to trace-level detection, meshes will likely 
provide better sensitivity than fibers. SPME-TM’s ability to yield very low detection limits in biological, 
food, and environmental matrices has already been demonstrated.26,117 Metabolomics, for example, is a 
field that has not yet been sufficiently explored via SPME-TM. In addition, while Gómez- Ríos et al. 
have profiled different types of milk (from dairy and non-dairy sources) using a portable MS,134 no 
large-scale studies have been reported thus far. As Mousavi et al. have shown,50 using thin films for 
metabolomics significantly enhanced sensitivity, proving capable of reporting well over 1000 cellular 
metabolites of E.Coli. Hence, it would be worthwhile to investigate how metabolomics would respond 
to SPME-TM coupled to a thermal-desorption platform like DART-MS.   
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With respect to fiber applicability, it is fair to say that they have great potential for in-vivo sampling. In 
fact, SPME fibers have already been used to obtain samples from living systems in multiple 
studies.34,171,172 Compared to fibers, the use of SPME meshes might be more challenging for in vivo 
analysis, as their design is somewhat inconvenient for insertion into living systems. Nonetheless, this 
does not completely preclude the use of meshes for in vivo sampling. For instance, meshes could be used 
in biological surface analysis, such as skin sampling21  or oral swabbing. Jiang et al. used 
polydimethylsiloxane SPME thin films for GC analysis of in vivo profiling of skin volatiles,21 while Park 
et al. demonstrated the applicability of DART-TOF-MS for profiling of skin metabolites in mice 
following UVB irradiation.167  Furthermore, HLB-coated SPME-TM meshes have been used for a 
simulated semi-quantitative in vivo analysis of caffeine in OF136 wherein OF samples were collected 
from a volunteer at different time points; this study was able to confirm that caffeine has a half-life of 
about 5-6 h after initial consumption. In addition, meshes also have great potential for small-volume 
analysis such as biofluidic spot sampling. Spot sampling allows meaningful information to be obtained 
from very small sample volumes (Vs ≤ 20 µL), as the sample (i.e., blood, plasma, OF) can be deposited 
as a droplet onto the mesh for fast extraction and desorption. The Pawliszyn group has recently designed 
“miniaturized tips,” which allow the detection of analytes in as little as 1-20 µL of biofluids.25,173 
However, desorption of the afore-mentioned devices in front of DART-MS is challenging due to size of 
the miniaturized tip ( < 1000 µm), which has to be carefully aligned between the heated gas output and 
the MS inlet. Hence, using SPME-TM meshes for biofluidic spot analysis would be more feasible. 
2.3.4 Conclusion for Section 2.3 
 
In this research, meshes (wire and sheet format) and fibers (custom-made and SPE-its®) were tested 
using two different protocols to examine which format yielded better results with respect to sensitivity 
and detection limits. All devices were manufactured under tightly controlled conditions in order to 
eliminate batch effects. The results of Protocol #1 revealed that the wire meshes yielded better responses 
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than the custom fiber, while the results of Protocol #2 indicated that the SPE-its® fiber slightly 
outperformed the sheet meshes. This result suggests that the SPME sheet mesh is not optimal for DART-
MS applications. These results highlight the importance of investigating different parameters that may 




 Towards on-site analysis of complex matrices by solid-phase microextraction-





Within the setting of a forensic laboratory, the analysis of controlled substances has a major impact on 
both the workload and evidence back-log.174 Controlled substance analysis can be time consuming, which 
is inconvenient for the criminal justice system. Hence, increasing the throughput of routine drug evidence 
analysis is of great interest.174 The “golden standards” or established laboratory methods (i.e., hyphenated 
techniques like GC and LC) are known for their accuracy and robustness but are very time and material 
consuming.174 Over the course of the last few years, the scientific community has invested significant 
effort in the development of AIMS techniques. In AIMS, sample processing occurs in the open air, 
thereby removing the need for chromatography and significantly decreasing analysis times.84 AIMS 
could be done without sample preparation, but sample preparation substantially decreases detection limits 
allowing analysts to approach trace-level detection limits, even with very complex matrices.162 
Considering the reduction in analysis time and implementation of a facile sample preparation technique, 
AIMS would be an ideal workhorse for forensic experts and law enforcement.  In fact, portable MS 
instrumentation amenable to ambient analysis would provide great benefits to forensics.174 Portable MS 
are miniaturized instruments ideal for in-situ analysis.175 An exact definition of a miniature MS is not 
available, but the term is typically used to describe analyzers that are significantly smaller than those 
used in conventional laboratories.175 Such analyzers would enable efficient field testing by performing 
immediate evidence analysis at the crime scene and thus allowing for an increase in sample throughput,174 
thereby creating an opportunity to prevent delays which happen when evidence is dispatched to forensic 
laboratories.176 In fact, the first few hours of a crime scene investigation are of crucial importance for 
obtaining important information as timely responses of law enforcement are vital for establishment of 
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criminal intent.174,176 Many miniaturized platforms for analysis of forensic-related samples already exist 
and include electrochemical sensors, paper-tests, microfluidics and portable systems (Raman and near-
infrared).176 However, portable MS offers greater specificity and sensitivity. Some of them are already 
implemented in airports, sea-ports, police operations, and border inspections.176 Several researchers have 
already investigated portable MS in forensic applications. O’Leary et al. used an ion-trap for monitoring 
of clandestine synthesis of methamphetamine177 and building of reference libraries for the portable MS. 
178 Mach et al. even mounted a portable MS to vehicles for detection of residues associated with 
clandestine laboratories.179 Some applications relied on strict analysis of chemical standards,179 while 
some attempted to employ a sample introduction strategy like Bruno et al., who used swab analysis prior 
to portable MS coupling.180 In order to efficiently use a portable MS outside of a laboratory setting, one 
should implement simple procedures that allow for proper sample introduction to the MS.181 For 
example, Zhang et al. reported LOQs of 10-20 µg L-1 for a set of selected drugs using DBS coupled to 
Mini 11, a portable ion trap MS.182 Ren et al. also used DBS for analysis of sitaglipin in whole blood, 
reporting an LOQ of 10 µg L-1.183 Another increasingly popular technique amenable for on-site analysis 
is DART-MS. DART has already been extensively introduced in Section 1.5.1, so its basics will not be 
provided here. Portable DART-MS has been employed by Brown et al.184 for testing of pure drug 
standards and mixtures (Percocet tablets and cherry cough syrup); and by Bernier et al.185 whereby 
DART-MS was used for fingerprinting of falsified anti-malarial medicines. Reports of quantitative work 
via portable DART-MS are still scarce, due to lack of use of preconcentrating, interference isolating 
sample preparation techniques. In this section, coupling of a portable DART-MS system Waters Q-Da 
to SPME-TM is presented. Previous DART-MS-SPME-TM publications demonstrated very good results 
for analysis of complex matrices.26,117 Therefore, the goal was to investigate both specificity and 
sensitivity of the aforementioned portable system when coupled to a concentration enriching technique 
such as SPME-TM. OF was used as a matrix of interest due to its potential for use in drug detection 
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following recent drug use. SPME-TM meshes were coated with 5 µm HLB particles which were 
imbedded within 10% of PAN binder. Extractions were carried out for one minute prior to analysis by 
DART-Waters-QDa. Satisfactory semi-quantitative results were obtained for a total of seven drugs, with 
LODs ranging from 10-25 µg L-1 and LOQs ranging from 25-75 µg L-1. Acceptable accuracy (83-119%) 
and precision (2-13% was also achieved) for the validation point examined (100 µg L-1). The results of 
this research highlight the potential that SPME-TM has for use in scenarios amenable to portable MS 




OF was obtained from five male and five female volunteers (n = 10) and pooled together. A set of DoAs 
was obtained from Cerilliant at a concentration of 1000 mg L-1: morphine, oxycodone, codeine, heroin, 
cocaine, methamphetamine and methadone. The respective ISs were also obtained from Cerilliant at a 
concentration of 100 mg L-1: morphine-d6, oxycodone-d3, codeine-d3, heroin-d9, cocaine-d3, 
methamphetamine-d5 and methadone-d3. A stock solution consisting of aforementioned analytes was 
made in MeOH at a concentration of 100 mg L-1, while the IS stock solution was made to 10 mg L-1. The 
IS stock was spiked to a final concentration of 100 µg L-1 for all samples, while DoAs were spiked at 25, 
50, 75, 100, 250, 500, 750, and 1000 µg L-1 to build matrix matched IS-corrected calibration plots. A 100 
µg L-1 was used as a QC for the validation. After spiking, OF was gently agitated (800 rpm) on an orbital 
shaker to allow for analyte and matrix binding to occur. The percentage of organic content spiked to OF 
was ≤ 1%. SS meshes were obtained from IonSense, Inc. and HLB particles were obtained from Waters, 
Inc. PAN and DMF were obtained from MilliporeSigma. LC/MS grade MeOH, H2O, ACN, and IPA 




The SPME-TM meshes were kept in a preconditioning solution (MeOH/H2O, 50/50). Before use, they 
were removed from the solution and washed with H2O to remove solvent residuals. Afterwards, the 
meshes were placed in vials containing 1.5 mL of OF and the extraction was carried out for 1 minute 
under strong agitation (3000 rpm). After completion of extraction, the meshes were washed with 1.5 mL 
of H2O (under agitation as well), dried and placed in the mesh holder. The whole procedure was adapted 
from Gómez-Riós.26 A schematic of the process is provided in Figure 2.33.  
 
DART-MS analysis  
DART-SVP® with a Vapur® interface was obtained from IonSense, Inc. and coupled to a single 
quadrupole Waters-QDa with an Acquity Q-Da mass detector. Full scan and single reaction monitoring 
(SIR) mode were explored for the semi-quantitative experiments with full scan mode yielding better 
results. Details on performance specifications of Acquity Q-Da are available elsewhere.186 DART was 
run in +ve ionization mode, over a 50-500 m/z range. The source temperature was maintained at 350 °C 
while the linear rail was operated at a speed of 0.2 mm s-1. MassLynx software was used to monitor the 
runs in real time and perform the data analysis.  
Figure 2.33 Schematic of the workflow used for detection of DoAs in OF via SPME-TM and DART-
QDa mass analyzer. 
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2.4.3 Results/Discussion     
The ability to perform on-site testing of suspects would allow law enforcement to exercise immediate 
administrative and precautionary measures, including driving suspension, thereby reducing the chance 
of an accident occurring.187 OF is a good alternative matrix choice, its collection is non-invasive and the 
matrix has little potential for adulteration.188 Certain weakly basic and smoked drugs might even have a 
larger detection window in OF.188 However, OF collection might yield small volumes due to reduced 
salivary flow after use of certain drugs (amphetamines and/or cannabis).187 In this case, SPME-TM would 
be an ideal tool for OF analysis due to its ability to work with small volume samples. Although previous 
DART-MS-SPME-TM publications of the Pawliszyn group have demonstrated good quantitative 
results,26,117 it is important to point out that those were obtained on benchtop instruments, which are 
analytically superior with regards to sensitivity and specificity. Hence, results presented herein can be 
deemed as semi-quantitative, as the technology still requires further investigations of its ability to provide 
accurate analytical responses on-site. In the preliminary experiments, a high background noise was 
noticed in the spectra using SIR mode. The noise level in the SIR mode was overlaying the signal from 
the actual analytes at low to mid-concentrations and yielding higher LOD values. Full scan mode proved 
to be more useful, as lower LODs were achieved using this approach. The full spectrum of an OF sample 
spiked with 500 µg L-1 of methamphetamine, morphine, codeine, cocaine, methadone, oxycodone, and 
heroin can be seen in Figure 2.34. It was also important to maintain adequate spiking concentrations, 
since detector saturation started occurring for certain analytes at higher concentration points. For 
example, methamphetamine started saturating the detector at 500 µg L-1 (see Figure 2.35A.). As can be 
seen, the inclusion of a 1000 µg L-1 point for methamphetamine calibration led to detector saturation and, 
consequently, to cumbersome calibration at higher concentration levels. Hence, the 1000 µg L-1 
calibration point was excluded from the plot (Figure 2.35A.i).  In addition, one may note a progressive 
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drop in the IS response as the target analyte concentration increases (Figure 2.35A.ii). In other words, if 
the concentration of the spiked standard is too high, the signal area of the IS drops significantly and 
nearly equates to the ambient air signal. At that point, data correction would no longer be feasible. This 
demonstrates that the selection of the IS concentration must be carefully evaluated, as certain analyte 
correction might require higher IS concentrations. Similar pattern is also observed in case of codeine 
(Fig. 2.35B.), whereby saturation appears to occur at 800 µg L-1. Hence, the LDR was maintained in the 
50-500 µg L-1 range (Figure 2.35B.i).  Examination of codeine-d3 area at 500, 750, and 1000 µg L-1 
reveals a higher signal (7.5e5, 1.1e6 and 8.6e5, respectively) in comparison to the area obtained for  
Figure 2.34 Mass spectrum profile obtained on a Waters-QDa after 1 min extraction from OF sample spiked 
with DoAs at 500 µg L-1. The gray arrows represent the analytes of interest. 
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concentrations spiked for lower levels (50, 75, and 250 µg L-1 at 5.6e5, 6.3e5, and 7.7e5, respectively 
(Figure 2.35B.ii)). Ideally, the IS area should be dropping at higher concentration points and not vice-
versa. The calibration plots for the remainder of the drugs can be seen in Figure 2.35C-G.  The results 
are summarized in Table 2.7, which also showcases the analytes’ logP values, LOD, LOQ, accuracy, and 
precision at 100 µg L-1. In fact, the LODs obtained for the analytes were lower than the cut-off levels 
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used by the Substance Abuse and Mental Health Services Administration (SAMHSA)189 as seen from 
Table 2.7. In addition, the LODs obtained can be compared to cut-off levels used the by the Driving 
under the Influence of Drugs, Alcohols and Medicines (DRUID)190 project (Table 2.7). The cut-off levels 
imposed by the DRUID project have been met in this study, with some of the LODs being below what 
is required (morphine, codeine, cocaine, methamphetamine) by the regulatory agencies. The observed 
accuracy (83-119 %) and precision (<13 %) for the tested validation point (100 µg L-1) was good, which 
demonstrates this approach’s potential for on-site use. Certainly, modifications to the workflow of SPME 
(i.e., greater extraction times and different coating chemistries) could be used towards improving the S/N 
Figure 2.35 Calibration plots and signal areas of methamphetamine and codeine in OF in A., and B., 
respectively. Calibration plots of cocaine, methadone, oxycodone, morphine, and heroin are shown in C., 
D., E., F., and G., respectively. 
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ratios. However, the hardware components of Q-Da contribute the most in this case. As stated in the 
beginning of this section, Waters Q-Da is a single quadrupole MS analyzer. Its detection limits could be 
improved by using noise filtering components, i.e., MS/MS. For example, Wright et al. developed a 
miniaturized portable QqQ MS system, which yielded a 10 µg L-1 LOD for detection of thiabendazole in 
apple homogenate.191 It is fair to say that analysis of complex matrices via portable MS has not yet been 
fully explored due to technical difficulties. Maintaining reproducible responses and simple 
instrumentation at the same time is challenging.192 Regardless, this study represents the first application 
of SPME-TM for on-site detection of DoAs in OF samples using a portable MS, and the promising results 
demonstrated this approach’s potential in roadside drug testing and crime scene investigations contexts 
where obtaining rapid and reliable information is of crucial importance. 
Table 2.7 Figures of merit for the semi-quantitation of several DoAs spiked to OF by using SPME-TM 
coupled to a portable MS (Waters-QDa) via DART. 
2.4.4 Conclusion for Section 2.4 
In this research, the first reported application of SPME-TM for coupling to a portable single quadrupole 
MS system DART-QDa for detection and semi-quantitative analysis of drugs in OF is presented. 
Satisfactory figures of merit were obtained for seven different drugs used in the study. Accuracy and 




 [µg L-1] 
LOQ 
 [µg L-1] 




Morphine 0.90 Morphine-d6 
2000**, 
95*** 
25 75 83 2.7 
Oxycodone 1.04 Oxycodone-d3 - 25 50 117 13 
Codeine 1.20 Codeine-d3 
2000**, 
94*** 
25 50 112 5.5 
Heroin 1.54 Heroin-d9 - 10 25 97 1.9 






10 25 99 8.4 
Methadone 4.14 Methadone-d3 22*** 25 50 119 4.4 
*Data source: https://www.drugbank.ca 
**SAMHSA. Analytes and their cut-offs.189 
*** Schulze, H.; Schumacher, M.; Urmeew, R.; Auerbach, K. Final Report: Work performed, main results and recommendations.190 
93 
 
precision were very good for the tested validation point. Further improvements could be made to some 
aspects of sample preparation involved in SPME-TM, but use of a portable MS with MS/MS abilities 




 DART and SPME-TM: A Suitable Platform for Analysis of Prohibited Substances 
in Small Volumes 
 
2.5.1 Introduction 
Interest in small-volume analysis has largely increased due to advancements in personalized medicine, 
which includes disease diagnostics and therapeutic drug monitoring (TDM).153,193 TDM is used to 
develop optimal therapy programs for patients based on individual phenotypes.153 Unfortunately, this 
form of therapy requires blood to be withdrawn from the patient each day, which can become physically 
and mentally taxing over extended periods of time. The development of novel drugs would also benefit 
from new approaches that require lower sample volumes. For example, many clinical trials and 
pharmacokinetic studies are performed using blood, which requires large volumes of blood and/or plasma 
to be collected from small animals.118 With animal welfare becoming a more prominent concern, 
attention is shifting to a focus on developing methods that reduce the need for animal subjects.194 
Immunoassays and chromatography are two analytical approaches that have previously been used for 
small-volume processing.195 However, both of these methods require relatively large amounts of time 
and materials in addition to being expensive and unsuitable for analysing a large number of samples. In 
contrast, stand-alone MS is capable of providing good results at trace levels in a matter of minutes, even 
for complex matrices.153 Furthermore, one stand-alone MS format, known as AIMS,84 may offer a fool-
proof method for small-volume analysis. As the name suggests, AIMS approaches ionize/desorb samples 
in open/ambient air.84 Moreover, AIMS techniques are able to rapidly analyse numerous samples in 
addition to offering unique methods for introducing/processing small-volume samples. Although a partial 
understanding of AIMS may lead one to believe that it does not involve sample preparation, this 
assumption would be erroneous as the scientific community has been expending considerable effort to 
developing/improving sample preparation strategies for AIMS.162 Many AIMS strategies have been used 
for small-volume analysis, but one of the more commonly used approaches is the coupling of dried blood 
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spots (DBS) with DESI or paper spray (PS).120,196,197 Notably, plasma198 and OF199 have also been 
analysed using a paper-drying approach. DBS coupled to PS (DBS-PS) is an enticing, low-cost approach 
that features a simplified operation protocol. Small biofluidic volumes are spotted onto a paper matrix, 
where they are dried and then analysed via spray desorption, which is induced through the addition of a 
strong solvent and the application of a high voltage (HV).196 Although DBS-PS lacks a sample clean-up 
step (which could be accomplished by incorporating an extra SPE step),200 it nevertheless provides 
satisfactory quantitative performance.201 Despite its advantages, DBS-PS is hampered by some minor 
workflow-related inconveniences. For example, paper drying,  accurate biofluid spotting, and the manual 
deposition of strong solvent are inconvenient and/or harmful to the environment.201,202 Other suitable 
AIMS approaches for small-volume analysis include microfluidic interfaces,203–205 nESI,206 coated-blade 
spray (CBS),27 thermal desorption ESI,207 and DART.87 Selecting the best approach to use in a 
clinical/drug-development setting will necessarily depend on difficulty level with respect to the approach. 
In general, techniques featuring easy operation and minimal technical elements are highly desirable in 
such settings. In this respect, DART has been a pioneering technology as it features a user-friendly 
interface and is simple to operate. DART is a thermal-desorption technique that does not require the use 
of solvents, has great potential for high-throughput (HT) analysis, and maintains adequate levels of 
repeatability by normalizing sample introduction.87,115 In DART, normalization can be achieved using a 
TM format,115 wherein the introduction of the sample into the MS is controlled by depositing it onto 
meshes with precisely controlled geometries.115  
Unsurprisingly, DART has been coupled to DBS to screen for phenylketonuria in newborns using Dip-
its® (glass-tips).208 Although satisfactory results were obtained, an LOQ of 3 µmol L-1 was reported for 
phenylalanine. In addition, concerns related to reproducibility were raised.208 This approach also required 
the samples to be pre-treated prior to analysing the Dip-its®.  In a slightly different approach, blood spots 
were deposited on a glass slide, dried, and desorbed in front of a DART source.209 An LOQ of 10 ng mL- 1 
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for verapamil in blood and plasma was obtained, and a significant reduction in signal response was 
achieved  by desorbing blood directly from paper.209  
Coupling DART to SPME can make it a suitable option for small-volume analysis. Over the last few 
years, the Pawliszyn group has pioneered the use of biocompatible SPME devices coated with PAN. 
PAN is a polymeric material with properties that minimize the attachment of interfering biologicals to 
the device’s surface,19,44,48,49,63,210 and that allow it to conveniently act as a biocompatible glue for a range 
of extracting phases/particles for the SPME substrate.50 These properties enable  analyses of very 
complex samples like blood and plasma that yield trace-level detection limits, while also offering reduced 
device fouling.19,206 Gómez-Rios et al. incorporated these properties into the design of SPME-TM meshes 
for DART-MS that fully maximized the advantages offered by SPME’s preconcentration step and 
DART’s desorbing/ionizing power.26 Since developing  these meshes, a number of reports detailing novel 
applications and further design configurations for this technology were published.117,134,136 However, 
there have been no reports for using SPME-TM for small volume analysis.159 This section documents the 
first reported use of SPME-TM HLB extractive particles for quantifying DoAs in small volume OF and 
human blood samples. Droplet extraction was performed in open-air conditions, and the experiment was 
carefully optimized with regards to extraction time. Satisfactory figures of merit were obtained for the 
examined analytes, and QC points were implemented to inspect the validity of calibration curves. In 
addition, OF from two male volunteers was examined for nicotine levels, thus showing SPME-TM’s 
usefulness for detecting substances following recent smoke inhalation/exposure. Percent recovery was 
also examined to investigate whether exhaustive extraction was achieved using this approach. The 
evidence presented herein—particularly the rapidity with which the low detection limits were obtained—




2.5.2 Experimental  
Chemicals/Materials  
The following standards and their isotopic analogues were ordered from Cerilliant at concentrations of 
1000 mg L-1 and 100  mg L-1, respectively: nicotine, benzoylecgonine, cocaethylene, EDDP, cocaine, 
LSD, methamphetamine, methadone, morphine, heroin, oxycodone, codeine, fentanyl, nicotine-d4, 
benzoylecgonine-d3, cocaethylene-d3, EDDP-d3, cocaine-d3, LSD-d3, methamphetamine-d5, 
methadone-d3, morphine-d3, heroin-d9, oxycodone-d3, codeine-d3, and fentanyl-d5. Human blood 
(stabilized with K2-EDTA) was ordered from BioreclammationIVT (Westbury, NY, USA). OF was 
obtained from 10 healthy volunteers (5 male and 5 female) through non-stimulated (chemical free) 
expectoration into 10 mL glass vials. A pooled batch was then made by combining 5 mLs of OF from 
each volunteer. The blood and OF samples were kept refrigerated at °4 C until use (no more than 7 days). 
SS meshes were obtained from IonSense, Inc. and HLB particles (5 µm) were obtained from Waters.  
LC/MS-grade solvents (H2O, MeOH, ACN, IPA) were obtained from Fisher Scientific. Finally, PAN, 
DMF, and HCl were obtained from MilliporeSigma. 
Mesh manufacturing protocol 
Meshes were made using a procedure that was already publishedand Section 2.2.2 provides greater 
details of the protocol.26  Microscopic images of the mesh were taken with an Olympus microscope 
(SZX10) with a SC30 digital camera, while SEM images were taken with a Zeiss FESEM 1530. 
Extraction procedure 
A stock mixture of all analytes was made to 100 mg L-1, with a corresponding IS stock mixture being 
made to 10 mg L-1. The stock mixture was then diluted to create OF spiking points (0.5, 1, 2.5, 5, 10, 25, 
50, 75, and 100 ng mL-1) and blood spiking points (0.5, 2.5, 5, 12.5, 25, 75, 150, and 325 ng mL-1). QC 
points of 3, 30, and 90 ng mL-1 were used for OF, while points of 37.5 and 250 ng mL-1 were used for 
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blood. The matrices were spiked with the appropriate concentrations of the stock standards and left to 
equilibrate for 2~4 h. Spiking was conducted using a method designed to keep organic content below 
1%, so as to not disturb the drug and matrix binding equilibria.7 IS was spiked at 25 and 50 ng mL-1 for 
OF and blood, respectively. To perform the droplet extractions, the meshes were removed from the 
preconditioning solution, washed with H2O, blotted with a KimWipe, and placed horizontally into an 
immobilization device. Fifteen µLs of OF and 25 µL of blood were then carefully deposited onto the 
horizontally imbedded mesh using a small pipette (10-100 µL). The calibration plots were built using a 
matrix-matched approach with IS correction, and the LODs and LOQs were determined based on S/N 
ratios of 3 and 10, respectively. Noise was determined using blank extractions of the matrices. Extraction 
times were done at 5, 10, 15, and 20 min for OF, and 5, 7, 9, 11, and 13 min for blood.  Following 
extraction, the mesh containing OF was washed with LC/MS-grade H2O using a 10 s vortex-assisted 
wash (3200 rpm); the meshes containing blood droplets were washed for 15 s on a vortex (3200 rpms), 
which was followed by an additional 5-10 s wash under a pressurized stream of LC/MS-grade H2O.  The 
meshes were then dried and placed in a custom-made DART holder for desorption/analysis. A schematic 
of this process is represented in Figure 2.36. To examine percent recovery, 25 µL of PBS, OF and blood 
spiked with 25 ng mL-1 of model analytes were placed onto an HLB mesh and the extraction was carried 
out for 10 minutes. Following a wash, the meshes were desorbed to 300 µL of ACN/MeOH/FA 
(80/20/0.1) for LC-MS/MS analysis.211 All extractions were done in triplicates (n = 3). SEM images of 




the mesh were taken following blood-droplet extraction and DART desorption in order to assess red 
blood cell (RBC) attachment to the mesh’s surface.    
Instrumentation 
DART-MS/MS experiments were performed using a QqQ MS system (TSQ Vantage) from Thermo 
Scientific, while a DART-SVP® source and a Vapur® interface was obtained from IonSense, Inc. and 
coupled to the MS to perform MRM acquisitions. The Vapur® interface was coupled to a membrane 
pump (blue, position 6) in order to maintain the integrity of the MS vacuum. DART runs were conducted 
using a source temperature of 450 °C and a rail speed of 0.2 mm s-1. He gas was used during acquisition, 
and N2 was used during standby. Details on the TSQ Vantage specifics of the standards used can be 
accessed in Section 2.2.2, while Table 2.8 offers details on the specifics of benzoylecgonine and 
respective ISs. LC-MS/MS runs were also done on a TSQ Vantage, which consisted of an Accela 
autosampler and pump. Chromatographic run details were obtained elsewhere (Reyes-Garcés et al.),211 
and Table 2.9-2.10 provides a summary of conditions used. 
Table 2.8 TSQ-Vantage specifics of benzoylecgonine and IS(s). 
Analyte Precursor m/z Product m/z S-lens Collision energy (CE) 
Benzoylecgonine 290.1 168.1 11 18 
Benzoylecgonine-d3 293.1 171.1 98 18 
Methadone-d3 313.1 268.1 93 13 
Morphine-d3 289.5 152.2 125 58 
Heroin-d9 379.2 272.1 171 46 
Oxycodone-d3 319.1 244.1 117 28 
Codeine-d3 303.1 152 125 68 
LSD-d3 327 226 116 23 
Fentanyl-d5 342 188 124 22 
Nicotine-d4 167.1 121.1 71 28 
Cocaethylene-d3 321.1 198.7 120 20 




Table 2.9 Chromatographic and ESI conditions used for the LC-MS/MS evaluation of mesh 
reproducibility and reusability.211 
Column Phenomenex: Pentafluorophenyl [PFP] (1.7µm, 2.1 mm x 10 mm) 
Mobile phase 
A: H2O + 0.1 % FA 
B: ACN + 0.1 % FA 
C: MeOH + 0.1 % FA 
Flow rate 400 µL/min 
Column temperature 35 °C 
Injection volume 10 µL 
Injection mode Full loop 
Spray voltage 1300 V 
Vaporizer temperature 275 °C 
Sheath gas 45 units 
Auxiliary gas 30 units 
Capillary temperature 280 °C 
 
Table 2.10 Summary of the ternary gradient used for the LC portion of the method.211 
 Mobile phase 
Time A B C 
0- 0.51 min 90 % 5 % 5 % 
0.51- 9.50 min 0 % 50 % 50 % 
9.51- 15.0 min 0 % 37.5 % 62.5 % 




Spot sampling using the mesh: OF analysis 
Over the last few years, OF has become more common for use in work-place and road-side drug testing, 
as well as in toxicology, pain management, and epidemiological research.212 OF’s main  advantage is 
that it is easy to collect, which reduces both invasiveness and the potential for sample adulteration.212 
Although OF is easier to obtain than blood, it is not readily available in large quantities (especially when 
individuals have difficulties expectorating), which makes it a suitable matrix for small volume analysis.  
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The main experimental concern during the initial stages of this study was whether the droplet would be 
sufficiently sustained on the mesh surface; that is, would the surface tension of the mesh prevent the 
droplet from leaking through the mesh holes? This concern proved to be unnecessary, as the initial 
experiments demonstrated that the mesh was capable of sustaining the droplet. Next, an adequate 
extraction time for selected analytes in OF was determined using 5, 10, 15 and 20 min points; time points 
past 20 mins were not considered due to the potential of OF drying on the mesh surface. The extraction 
time profile for 15 µL of OF spiked with 1 ng mL-1 of codeine, heroin, and oxycodone can be seen in 
Figure 2.37, which shows a gradual increase in signal as extraction time increases (see also Table 2.11 
for S/N ratios of examined analytes). Although higher responses were obtained at 15 and 20 min, 10 min 
was deemed adequate to achieve acceptable sensitivity and was used for the remainder of the 
experiments. With an adequate extraction time having been established, quantitation experiments were  
 
Figure 2.37 Extraction time plots for selected analytes spiked to 15 µL of OF at a concentration of 1 ng 









(min) Codeine Heroin Oxycodone 
5 3.7 13.4 18.1 
10 3.8 19.7 22.4 
15 5.4 25.4 42.6 
20 7.3 41.8 45.5 
 
then conducted by carefully placing the droplet onto the middle section of the mesh (to maintain spotting 
position). The results of the quantitation experiments are presented in Table 2.12. The LDR was 
maintained in the 0.5-100 ng mL-1 range, while the LODs and LOQs ranged from 0.1-1 ng mL-1 and 0.5-
5 ng mL-1, respectively. The lower detection limits obtained for such a small volume (15 µL) are 
primarily the result of two factors: sensitive DART desorption and SPME’s preconcentration ability, 
which is enhanced by the use of HLB particles. HLB is a very wettable material, which allows it to 
interact favourably with polar matrices. OF is mostly composed of H2O (99%),
213 with a contact angle 
(estimated ~70-90°) initially being present when it is placed onto an HLB-coated mesh. As the extraction 
time increases, the contact angle progressively drops until it is nearly 0° by the end of the extraction 
process. A similar occurrence has also been noted by Reyes-Garcés for pure H2O samples.
19 Additionally, 
the droplet interacts with the mesh’s large SA, thereby enabling greater extraction and contributing to 
lower detection limits. Higher LOQs were obtained for methamphetamine, methadone, morphine, 
codeine, LSD (5 ng mL-1), and nicotine (10 ng mL-1) and were compared to the cut-off levels outlined 
by the DRUID project of the European Commission.190 The concentrations of the analytes listed in Table 
2.12 are all below the cut-off levels proposed by DRUID.190 For example, LOQs of 1 and 0.5 ng mL-1 
were achieved for codeine and methadone, respectively, which are both well below the recommended 
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cut-off levels190 (94 and 22 ng mL-1, Figure 2.38A-B.). The examined QC levels can be observed in Table 
2.12, with accuracies ranging from 80.6-126.9%. The accuracy of 126.9% was obtained for oxycodone 
at 3 ng mL-1. This result indicates the presence of potentially co-extracted salivary constituents, which 
can lead to ionization enhancement. The process’s repeatability was found to be acceptable, with an % 
RSD range of 0.1-17.8%. In order to demonstrate the approach’s effectiveness in real-life applications, 
we used it to screen for nicotine in OF acquired from two male volunteers, one smoker and one non-
smoker. Five minutes after smoking a cigarette, each volunteer provided us with a 100 µL OF 
sample (via expectoration). Fifteen µLs of the sample were then placed onto the mesh and extraction 
Table 2.12  Figures of merit obtained for quantitative analysis of 15 µL of OF on SPME-TM mesh and 
DART-MS/MS. 
was performed for 10 mins. The obtained ion chronogram, which can be seen in Figure 2.39, shows 
desorption from a blank mesh (n = 2), desorption for the smoker’s OF (n = 2), and desorption for the 

















Calibration plot equation 
y = mx+b 





 30 ng mL
-1





Cocaine 0.1 0.5 0.9978 0.5-100 y=0.1614x+0.1881 90.7 (9) 93.7 (13.9) 97.5 (6.4) 170 
Methamphetamine 1.0 5.0 0.9989 5-100 y=0.2776x+0.2182 - 91 (2.9) 89.6 (3.9) 410 
Methadone 0.5 5.0 0.9989 5-100 y=0.1017x+0.1072 - 88.6(4.9) 95.1 (0.1) 22 
Morphine 0.5 5.0 0.9982 5-100 y=0.2944x+0.5293 - 91.7(6) 102.4(1.8) 95 
Heroin 0.5 1.0 0.9969 1-100 y=0.2216x-0.0564 90.4(17.8) 88.6(7.8) 99.4(3.1) - 
Oxycodone 0.1 0.5 0.9994 0.5-100 y=0.2201x+0.4048 126.9(5.5) 114.8(11.8) 112.9(3.4) - 
Codeine 1.0 5.0 0.9973 5-100 y=0.0775x-0.0004 - 87(1.3) 96.9(3.8) 94 
LSD 0.5 5.0 0.9915 5-100 y=0.105x+0.1222 - 92.2 (5.5) 94.8 (2) - 
Benzoylecgonine 0.1 0.5 0.9929 0.5-100 y=0.0849x+0.0227 89.4(6.22) 109.6 (6) 93.2(2.7) 95 
Fentanyl 0.1 0.5 0.9934 0.5-100 y=0.2292x-0.3538 92.3 (7.6) 80.6 (9) 91.6 (9) - 
Nicotine 5.0 10.0 0.9912 10-100 y=0.0448x+0.1160 - 92.4 (3.9) 112.6 (1.3) - 
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mesh and the non-smoker, while a very high signal was observed for the smoker. With the introduction 
of the Cannabis Act in Canada in October 2018,5 an increase in incidents related to driving under the 
influence of marijuana can be expected. As such, members of the law enforcement community could 
benefit from the availability of simple-to-use samplers, like SPME meshes, that can be coupled to  
portable MS instruments, like DART-QDa, as they offer a convenient way of detecting recent drug 
exposure/consumption QDa, as they offer a convenient way of detecting recent drug 
exposure/consumption.134  
 
Spot sampling using the mesh: Blood analysis 
Many clinical trials are done using blood,118 but there are difficulties that accompany the use of blood 
for analytical purposes. For instance, blood is a very complex matrix. It is a colloidal suspension214 that 
Figure 2.38 Selected examples of calibration plots obtained for the quantitative analysis of DoAs in 
OF (A. and B.) and blood (C. and D.). The cut-offs for codeine and methadone in OF suggested by 
DRUID190 are highlighted in blue (94 and 22 ng mL-1), while those for benzoylecgonine and fentanyl 
in blood are highlighted in red (50 and 10 ng mL-1). 
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contains a number of elements: blood plasma, which contains H2O, proteins, glucose, minerals, 
hormones, carbon dioxide, and blood cells,215 which consist of red (RBCs) and white blood cells (WBCs), 
as well as platelets.215 Once in open air, blood tends to attach to surfaces, with the adhesion of RBCs and 
proteins being irreversible in some cases.216,217 Droplet sampling can also be exacerbated due to blood 
drying,216,218 which tends to lead to the appearance of a ring on the edges of a bloodstain within 50 s.216 
While the drying process depends on volume, SA, temperature, humidity, air circulation, and VP, the 
appearance of the ring (known as the skeletonization effect) is almost immediate216,218 and can negatively 
affect the performance of sampling devices.219 Hence, different strategies have been developed to aid 
with blood analysis. For example, Zhang et al. used silica-coated chromatography paper (enhances 
resolving power) in combination with a DBS-PS approach to improve the recovery efficiency for a set 
of therapeutic drugs in 5 µL of blood.182 Huang et al. tried heating the DBS before coupling it to PS in 
order to enhance its detection limits for propranolol.220 Strategies for blood analysis with SPME have 
also been documented. For instance, Reyes-Garcés et al. were able to avoid significant RBC attachment 
Figure 2.39 Ion chronogram obtained for measurements of nicotine signal in blank mesh and OF samples 
from a male smoker and a male non-smoker male (n = 2, for all). 
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or ionization suppression/enhancement by using HLB-PAN and a post-extraction washing protocol in 
their analysis of a range of compounds in blood.19 Similarly, Gómez-Rios et al. implemented HLB-PAN 
CBS devices to analyse small volumes of blood and plasma.221 To reduce detection limits, small amounts 
of ACN were added to blood spots,221 as strong solvents disrupt drug-protein binding equilibria, which 
in turn enables lower detection limits.7,221 Zinc sulphate may also be used to reduce detection limits.222 
Since present study is the first examination of blood-spot extraction with SPME-TM and DART-MS, no 
matrix modifications (other than analyte spiking) were done. During the optimization stage, 15 µL of 
blood were initially used for the sampling. However, dry “patches” quickly formed on the droplet surface, 
leading to rapid drying. This issue was ameliorated by increasing the volume to 25 µL of blood. To 
reduce potential issues during the transmission portion of the experiments (arising from “stuck” blood 
cells), the meshes were cleaned post-extraction using a two-step wash procedure. Extraction time was 
evaluated for time points of 5, 7, 9, 11, and 13 min, with the highest signal being obtained for the 7 min 
time point (results are shown in Figure 2.40).  When the droplet is initially placed on the mesh, a high 
Figure 2.40 Extraction time plots for selected analytes (25 ng mL-1) spiked to 25 µL of blood and 
analysed via DART-MS/MS with a source temperature of 450 °C and a rail speed of 0.2 mm s-1. 
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contact angle is present (est. >90°) due to HLB’s poor interaction with non-polar matrices like blood. 
Consequently, a skeletonization ring starts to appear past the 7 min mark, with significant skeletonization 
being observable on the mesh surface after 10 min. At 11 and 13 min, the washing protocol is unable to 
remove the blood ring (see Figure 2.41 for blood ring observed on dummy mesh). Table 2.13 provides 
the S/N ratios obtained for extraction at different time points. Extending the wash time, even with vortex 
assistance, does not eliminate the dry ring.  Conversely, applying an additional layer of PAN to mesh 
surface may somewhat circumvent unwanted blood attachment, but this would also decrease SPME’s 
extraction kinetics.19,219 Therefore, no modifications were applied to the mesh; instead, the washing 
protocol and the extraction time of 7 minutes were tightly controlled, as the presence of unwanted blood 
constituents on the washed mesh represents a significant problem for DART desorption. Directing the 
heated gas flow of a DART source onto a mesh with unwanted blood attachment could cause blood 
“charring”, which can contribute to a significant level of ionization suppression and/or enhancement. 
This issue did not arise during this investigation, as no residual blood attachment was detected in SEM 
examinations of the mesh surface after blood extraction (Figure 2.42: A. unused mesh; B. used mesh). 
The results relating to the mesh’s quantitative performance are presented in Table 2.14, which shows 
LODs in the 0.5-5.0 ng mL-1 range, and LOQs in the 2.5-25.0 ng mL-1 range. These higher detection 
limits are unsurprising considering that blood is significantly more complex than OF. Extraction 
Figure 2.41 Formation of a “blood ring” or “skeletonization effect” on a dummy-mesh occurring in 
extractions exceeding ten minutes. 
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efficiency of analytes from the blood into the HLB polymer was reduced, with the drug-protein binding 
equilibria that took place in the blood resulting in a reduced amount accumulating on the coating. 
Examinations of the DRUID project cut-off values for blood analysis190 are available for 2 out of the 8 
analytes that were analysed in this study. The obtained LOQ for benzoylecgonine (5 ng mL-1) was well 
below DRUID’s recommended threshold (50 ng mL-1), but the LOQ for fentanyl (2.5 ng mL-1) fell 
between DRUID’s cut-off (1-3 ng mL-1, see Figure 2.38C-D.), indicating that the technology would 
require further improvements to be able to quantify lower concentrations. Furthermore, a comparison of 
oxycodone’s LOQ (25 ng mL-1) and the cut-off outlined by the Clinical Reference Laboratory223 (CLR, 
10-100 ng mL -1) reveals no significant reduction in detection limits. Lastly, the results of the QC 
validation were quite satisfactory for the points examined (37.5 and 250 ng mL-1), with accuracy ranging 
between 85.1-118.6 % and a repeatability between 1.5-18.5 % RSD. Ultimately, the higher detection 
limits obtained for blood analysis do not undermine the assay presented herein, but they do highlight the 
need to continue to develop more efficient and rapid methods for processing complex matrices like blood. 
The Pawliszyn lab is currently focused on investigating the mechanisms that take place during blood 
extractions via SPME-TM in order to gain a thorough understanding of the process, which will in turn 
enable enhancement of the technique. 










Extraction time (min) Codeine Heroin Oxycodone 
5 3.7 13.4 18.1 
10 3.8 19.7 22.4 
15 5.4 25.4 42.6 








Extent of recovery  
Percent recovery of model compounds was also investigated for potential exhaustive extraction. Percent 
recovery is defined as ratio of the amount of analyte extracted vs amount of analyte spiked to the sample 
and can be calculated by building an instrumental calibration curve (which covers expected concentration 
range) and injecting the samples which contain the portion extracted by SPME. Exhaustive extraction 
occurs when majority of the analyte is extracted, i.e., probe capacity is high and sample 

















Calibration plot equation 
y = mx + b  
Accuracy (%), % RSD (n=3) 





 250 ng mL
-1
 
Nicotine 5.0 12.5 0.9980 12.5-325 y=0.017x+0.0182 96.6 (10.2) 107.7 (2.2) - 
Benzoylecgonine 0.5 5.0 0.9975 5-325 y=0.0184x-0.0193 118.6 (8) 96.7 (2.9) 50190 
Cocaethylene 5.0 12.5 0.9996 12.5-325 y=0.0222x-0.0262 114 (9.4) 96.9 (3) - 
EDDP 2.5 5.0 0.9934 5-325 y=0.028x-0.0255 116.7 (13.8) 107.6 (3.6) - 
LSD 2.5 25 0.9998 25-325 y=0.0186x+0.0226 95.9 (1.5) 98.8 (4.9) - 
Fentanyl 0.5 2.5 0.9983 2.5-325 y=0.1239x-0.0556 110.2 (6.9) 94 (5) 1-3190 
Oxycodone 2.5 25 0.9956 25-325 y=0.0144x+0.1550 85.1 (18.5) 95.6 (10) 10-100223 
Figure 2.42 A. SEM image of a never-used HLB-coated mesh; B. image of a mesh used for a 7-minute 
blood extraction. Both images depict the mesh after the application of a wash step and DART desorption. 
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achieved when ≤ 10 % of the analyte is extracted.7 For this section, recovery was assessed by performing 
extractions from 25 µLs of PBS, OF, and blood. The results obtained can be seen in Figure 2.43 for all 
three matrices. Slightly greater recovery of more polar analytes is observed in case of PBS (morphine,   
Figure 2.43 Assessment for % of recovery for a set of model compounds in 15 µL of PBS, blood and OF. 
oxycodone). Codeine, despite its logP of 1.19, shows poorer recovery in comparison to the afore-
mentioned polar compounds. Analytes of medium polarity show some variability with regards to 
recovery for PBS, with methamphetamine being 94.2 %, LSD being 68.8 % and methadone being 63.4%. 
A slight trend is observed whereby non-polar analytes are extracted less by the HLB coating for PBS. 
For blood, the lowest recovery is observed for LSD (21%) and highest for methamphetamine (84.2 %). 
The poorer recovery appears to be related to the increase in logP value of the analytes. In general, 
recovery of analytes from blood is lower when compared to PBS and OF. In OF, the recoveries for 
compounds like LSD and methadone are slightly higher (72% and 79.3%, respectively) than those of 
PBS (69 % and 63.4 %, respectively), which might be caused by MEs, or in other words, co-extracted 
components with similar MRM transitions of LSD and methadone. Recovery for the remainder of 
analytes in OF is either comparable or slightly lower than the ones observed for PBS. Ultimately, truly 
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exhaustive extraction is achieved for methamphetamine in the case of PBS (94.2 %), while the remainder 
of recoveries for analytes examined in all three matrices ranges between 21.0-89.6 %. Hence, it is safe 
to say that spot extractions do not fully approach exhaustive extraction, but certainly are not within the 
negligible extraction regime. 
 
2.5.4 Conclusion for Section 2.5 
 
In this investigation, SPME-TM was applied for analyses of OF and blood droplets via DART-MS/MS, 
with satisfying figures of merit being obtained for both matrices. Unsurprisingly, the LODs and LOQs were 
lower for OF because it is a less complex bio-matrix. As a part of a real-life application, nicotine was 
successfully detected in a 15 µL OF sample obtained from a cigarette smoker. Conversely, the analysis of 
blood proved to be more challenging, but extraction parameters with regards to extraction time and washing 
procedure were carefully optimized to ensure reasonable analytical response. As demonstrated in this 
research, combining DART’s excellent sensitivity and high-throughput capabilities with SPME-TM can 
be an effective tool for small-volume analysis.  This report is limited to body fluids, but it is not difficult to 
imagine use of the SPME/DART technology to screen for pesticide residues in small samples of food 




 High-Throughput Quantification of Drugs of Abuse in Biofluids via 96-Solid-Phase 
Microextraction–Transmission Mode (SPME-TM) and Direct Analysis in Real Time 
Mass Spectrometry (DART-MS) 
 
2.6.1 Introduction  
 
As mentioned in the introductory chapter, AIMS comprises a group of direct-to-MS techniques that focus 
on open-air sample processing (desorption/ionization).84 Within this field, the combination of minimal 
or no sample preparation, real-time sample processing, and subsequent data acquisition allows analysts 
to obtain information in a matter of minutes or even seconds.84 Given AIMS’s ability to provide speedy 
analysis and results, it is anticipated that a demand for such methods will continue to grow in clinical 
laboratories.193,224 The development and implementation of high-throughput (HT) methods is perhaps the 
most efficient approach to managing these ever-growing workloads and producing shorter turnaround 
times.225 While there is no official definition of HT as it pertains to laboratory testing, certain authors, 
such as Shevlin, have defined it as a set of techniques that allow many experiments to be completed 
simultaneously.225 Modern MS systems are capable of analyzing many samples in a short amount of 
time, but bottle-necking often occurs during sample preparation for hyphenated approaches. In response, 
researchers have invested much effort to making sample preparation more suitable for HT applications. 
These efforts have produced an array of approaches, including SPE,226,227 LLE,228 protein 
precipitation,229 and automated disposable-pipette extraction.230 With the exception of SPE and 
automated disposable-pipette extraction, these methods carry an increased chance of ME(s). SPE and 
automated disposable-pipette extraction are less prone to MEs, but they are also exhaustive approaches 
that contain potential clogging issues, as well as the need for additional sample preparation steps for 
highly complex matrices (e.g., fibrous or viscous).231 Similar limitations also apply to certain highly 
automated systems, such as Agilent’s integrated SPE-MS RapidFire™  platform.232 Although 
RapidFire™  can easily accommodate an instrumental injection time of 15 seconds for a single sample, 
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there are a number of factors to consider when selecting this technology for HT applications, including: 
potential system clogging when working with extremely complex samples (e.g., plasma, blood, and 
meconium); restricted  cartridge chemistry, and high operational and maintenance costs (particularly 
when decommissioned).231  
The coupling of AIMS and HT approaches offer a perfect solution to the issues that laboratories 
worldwide are experiencing today, as the decreased turnaround times would allow researchers to focus 
more intently on matters of critical thinking.233 DART is a very popular AIMS approach that has 
tremendous potential for HT implementation due to its easy operation, speedy analysis, and high 
sensitivity.87 DART is a “dry” approach, which means that that it does not use any solvents; instead, 
heated gas is used to thermally desorb/ionize different sample surfaces.87 The DART module is able to 
analyze several samples simultaneously due to its cleverly designed interface, which consists of a 
motorized linear rail (x-direction or xy-directions) that carries samples between the DART source and 
the MS inlet.91 Among the devices that can be interfaced via this rail system, TM technology is 
particularly notable.115 TM’s potential has yet to be fully explored, with only a limited number of research 
papers having been published to date.83,115,234 In contrast, a number of publications have documented the 
implementation of DART for HT applications via the use of other sample introduction methods. For 
example, Danhelova et al. analyzed caffeine using a simple exposure method wherein Dip-it tips® were 
inserted into a hot water/coffee mixture and then processed using an AUTO/DART-96, which is a robotic 
system from CTC Analytics.235 Alternately, Grange et al. built a 91 cm long square aluminum rod capable 
of holding 76 cotton swabs in order to analyze 2-aminobiphenyl, 2-(methylthio)benzothiazole, and N-
butylbenzenesulfonamide236 but this apparatus consumes a fair amount of laboratory space. Furthermore, 
an additional problem commonly encountered with the sample-introduction methods used in many 
DART applications (including the ones mentioned above) is the lack of preconcentration of analytes of 
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interest,237 which is important given that the cut-off levels of certain compounds are on the lower ppb 
scale.223  
SPME is a sample preparation tool that is capable of solving this preconcentration issue and facilitating 
the development of a robust HT-DART method. SPME is renowned for its structural flexibility, as its 
format can be re-shaped in order to comply with the requirements of varying direct-to-MS 
approaches.27,205,238–240,241 SPME sampling only extracts a fraction of analyte, and the use of 
biocompatible protective coatings, such as PAN, helps to prevent the adherence of unwanted biologicals 
(reducing clogging issues and artifact formations), thus enabling a “cleaner” introduction of the sample 
to the MS.7,15 The coupling of SPME and DART is not novel,159,238 as applications using the classical 
fibre format165,244 (commercially known as SPE-itsTM) have previously been documented. In  2014, the 
TM format for SPME was optimized, which allowed analytes to be efficiently preconcentrated and 
quantified at low ppb levels.26 Since then, SPME-TM has been employed to detect pesticides in H2O, 
consumer beverages, and milk,117,134 and it has also been coupled to a portable MS for detecting DoAs 
in OF and urine.134 Sacks group at Cornell University has also explored its application towards 
determination of volatiles from wine samples.137,237  
DART, with its simple operation and ruggedness, is an AIMS approach that may have a long-lasting 
impact in the field. At the same time, SPME is a very efficient sample pre-concentration tool that can 
provide sufficient selectivity and sensitivity. Thus, these two technologies would seem to be the perfect 
partners for establishing a robust HT-AIMS technique. Given this potential, SPME-TM was arranged as 
a “96-brush” in order to enable the HT collection and quantification of analytes of interest from varying 
matrices. The 96-SPME-TM, described herein for DART, consisted of SS meshes with meticulous 
geometry (i.e., hexagonal honey-comb apertures), which were carefully etched and coated using C18 
particles embedded within PAN solution. Device features (i.e., coating stability, extraction capacity, 
collection capacity, and effect of sample pH) and DART parameters (i.e., source temperature and rail 
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speed) were investigated to identify the configuration that offered maximum instrumental sensitivity 
while also maintaining reliable operation throughout the analytical workflow. Finally, the 96-brush 
SPME-TM devices were implemented for the simultaneous extraction and quantification of opioids from 
PBS, urine, and blood plasma. Approximately 1.5 h were required to complete the analyte collection, 
desorption/ionization, and data analysis steps for a set of 96 samples. Our results demonstrate that the 
coupling of 96-SPME-TM to DART-MS can allow laboratories to handle large workloads while 
significantly reducing turnaround times.    
2.6.2 Experimental 
 
Chemicals and Materials 
The following standards (1000 mg L-1) and respective ISs (100 mg L-1) were obtained from 
MilliporeSigma: fentanyl, cocaine, cocaethylene, codeine, EDDP, oxycodone, meperidine, methadone, 
dihydrocodeine, hydrocodone, fentanyl-d5, cocaine-d3, cocaethylene-d3, codeine-d3, EDDP-d3, 
oxycodone-d3, meperidine-d4, methadone-d3, dihydrocodeine-d6, and hydrocodone-d3. Compound 
details and instrumental settings are documented in Section 2.2.2, 2.5.2 and Tables 2.15-2.17. Table 2.15 
lists compounds that were used for preliminary examination of mesh extraction efficiency as a part of a 
standard operating procedure (SOP) for interlaboratory assessment of the mesh performance at IonSense, 
Inc. and the University of Waterloo. PAN, DMF, and concentrated HCl were also obtained from 
MilliporeSigma, while LC/MS-grade MeOH, ACN, IPA, and H2O were obtained from Fisher Scientific. 
Bare photochemically etched custom-manufactured SS meshes and C18 particles (5 µm) were kindly 
provided by IonSense, Inc. and MilliporeSigma, respectively. A custom-designed N2 blower (see Figure 
2.44) was made at the UW machine shop in order to facilitate a speedy coating process for the meshes. 
A dedicated mesh holder (for desorption in front of the DART source) featuring three different 
immobilization positions was also custom made (see Figure 2.45). Details on preparation of PBS are 
116 
 
Table 2.15 Compounds used in preliminary mesh-performance assessments using an Exactive Orbitrap, 
including their logP values and exact mass. 
Analyte LogP Exact mass (m/z) 
Cocaine 2.30 304.1549 
Cocaine-d3 - 307.1737 
Cocaethylene 2.64 318.1705 
Cocaethylene-d3 - 321.1894 
Codeine 1.19 300.1599 
Codeine-d3 - 303.1788 
EDDP 5.26 278.1909 
EDDP-d3 - 281.2097 
Methadone 3.93 310.2171 
Methadone-d3 - 313.2359 
 
Table 2.16 Acquisition conditions used to obtain data on the Exactive Orbitrap for the DART-MS 
experiments. 
Resolution 50,000 
Mass range 100 - 500 
Polarity +ve  
Microscans 1 
Capillary temperature 250 °C 
S-lens RF level - 
AGC target 1,000,000 
Max injection time - 
 
Table 2.17 List of opioids used in the quantification experiments for the 96-SPME-TM, including their 
logP values, TSQ Vantage perimeters and structures. 




Hydrocodone 1.2 300.4 199 28 87.9 
Hydrocodone-d3 - 303.1 199.1 29 199.1 
Meperidine 2.7 248.1 219.8 29 110.7 
Meperidine-d4 - 252.1 223.8 20 68.6 
Dihydrocodeine 1.6 302.1 199.0 30 133.2 
Dihydrocodeine-d6 - 308.1 202.0 32 143.9 
 
provided in Section 2.2.2. These materials were all obtained from MilliporeSigma. The pH of the samples 
was adjusted using acetic acid (AA) and NH4OH, which were also obtained from MilliporeSigma. 
SurineTM negative urine control was obtained from MilliporeSigma. Human urine was collected from 
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two healthy volunteers in their mid-20s (male and female) and kept at 4 ˚C until use, while human plasma 
(K2-EDTA stabilized) was obtained from BioIVT and kept at -30 ˚C until use. 
 
Figure 2.45 The holder setup for the 96-SPME-TM mesh. Figures A. and B. show the schematic of the 
holder, with B. showing the “mounting stage”. Figures C. and D. show the completed 96-SPME-TM 
mesh holder, with Figure D. showing the holder immobilised on the linear rail. 
Figure 2.44 N2 blower designed for the high-throughput fabrication of the 96-SPME-TM meshes. 
Tubing was attached to the holder on the side of the blower and to a N2 tank. The valve on the N2 tank 
was opened each time excess slurry had to be blown out. 
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Preparation of Stock Solutions and Samples  
The selected standards were combined to make a 100 mg L-1 methanolic stock, and the ISs were also 
combined into a separate 10 mg L-1 methanolic stock. The standards were further diluted with MeOH to 
create samples for use in preliminary examinations of mesh performance, as well as for the construction 
of a calibration curve consisting of 14 points (0.5, 1, 2.5, 5, 7.5, 10, 25, 50, 75, 100, 120, 150, and 200 ng 
mL-1). The IS stock was also diluted in order to ensure that the final concentration in the samples was 
kept at 10 ng mL-1. All dilutions were performed using LC/MS-grade MeOH. In accordance with the 
guideline recommending that the partitioning equilibria for SPME not be disturbed, the spiking of organic 
content to the samples for extraction (PBS, urine, and plasma) was kept ≤ 1 %.7 After spiking, the samples 
were gently agitated at 200 rpm for 2-4 h to achieve matrix-drug equilibration.   
Preparation of the SPME-TM 12 Mesh Strip 
Unlike the previous work, which used hand-cut SS meshes,26,117,134 we employed photoetched SS meshes 
with a well-defined geometry in order to remove errors introduced from human handling. As can be seen 
in Figure 2.46, each pin on the SS mesh “comb” is divided into three areas, or desorption sites, which 
allows for the production of three distinct replicates for each sample using a single extraction step.  
Hence, it is important to investigate whether “loss of analyte” occurs on other coated areas of a given pin 
during desorption due to heat transfer on the metal surface. The SS sheets had very smooth surfaces as a 
result of being fabricated via photochemical milling; as such, the photomask that was used on the surfaces 
needed to be removed through extensive wet-etching in order to obtain the desired surface roughness. 
This process consisted of four stages of mesh sonication in various fluids: MeOH (2x, 20 min), HCl (1x, 
20 min with brief shaking every 5 min), MeOH again (1x, 10 min), and, finally, deionized H2O (2x, 10 
min). After these steps, the meshes were dried for 30 minutes at 120 ˚C and kept in a desiccator (under 
N2 atmosphere) until use. A slurry consisting of 10% PAN in DMF was mixed with 7% of 5 µm C18 
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particles and agitated overnight at 700 rpm to achieve homogeneity. The coating process was performed 
using a 2 mL 96-well plate that had 1 mL of coating slurry deposited into twelve of the wells. The brush 
was dipped into the wells, carefully withdrawn, and the excess slurry was removed using an N2 blower 
that uniformly blasted all twelve pins at the same time. Afterwards, the brush was pinched with a holder 
(to avoid tumbling) and cured at 100 ˚C in a fan-controlled oven. In order to establish a homogenous 
coating on both sides of mesh, the coating protocol was repeated for the other side as well. Before being 
used in real samples, the meshes underwent two 15 minute cleanings in a mixture of MeOH/ACN/IPA 
(50/25/25) and preconditioning in MeOH/H2O (50/50) for at least 30 minutes prior to use. These steps 
aim to remove any material remaining from the manufacturing step (e.g. oligomers, uncured PAN, among 
others). 
Extraction Procedure for Surine, PBS, Urine, and Plasma 
Prior to extractions, the meshes were immobilised and kept in a preconditioning solution using a 3D-
printed holder. A simplified schematic of the 96-well plate can be seen in Figure 2.47. PBS spiked with 
50 ng mL-1 of oxycodone was used for the evaluation of extraction repeatability via LC-MS/MS. The 
entire 96-well plate was filled with 0.9 mL of PBS spiked with 50 ng mL-1 of oxycodone, followed by 
washing of the meshes in H2O to remove residuals of the preconditioning solution. The meshes were 
then immersed into PBS to perform an agitated 10 minute extraction on an orbital shaker (500 rpm). 
Figure 2.46 Schematic of a single pin of SPME-TM with three distinct desorption sites. 
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After extraction was completed, the meshes were washed for 5 seconds in H2O (separate 96-well 
plate, 1.5 mL) and immersed into another 96-well plate filled with 0.9 mL of ACN/H2O/FA (90/10/0.1%) 
for a 10 minute desorption (also agitated). Once desorption was completed, the 96-well plate was 
analysed via LC-MS/MS. For DART experiments, three 2 mL 96-well plates were prepared: two plates 
were filled with 1.5 mL of H2O to perform the pre- and post-washing steps, while the extraction plate 
was filled with 1.2 mL (n = 3) of sample (0.9 mL of plasma was diluted with 0.3 mL of PBS to reduce 
viscosity). Matrix pH was adjusted by adding droplets ( < 20 µL) of either AA or NH4OH. To ensure that 
all solvent components were removed, the meshes in the preconditioning solution were pre-washed for 
10 secs using an orbital shaker (200 rpm) and then gently blotted with a Kimwipe to remove excess H2O. 
The extraction was carried out by fully immersing the brush into the 96-well plate and agitating via 
orbital shaking (500 rpm). A schematic of this process can be seen in Figure 2.48. Extraction time profile 
was evaluated at seven different time points (1, 3, 5, 10, 20, 30, and 60 min) for n = 4. After the extraction 
was completed, the samples were washed for 10 seconds using the orbital shaker (200 rpm) and then 











LC/MS, DART-MS & MS/MS Conditions 
LC/MS experiments were conducted on API 3000 (Sciex, Framingham, MA, USA) equipped with a 
Shimadzu binary pump (LC-10ADvp, Kyoto, Japan) and a HTC PAL autosampler (CTC Analytics, Leap 
Technologies, Zwingen, Switzerland). A binary gradient consisting of 20 mM ammonium acetate and 
0.1 % FA in H2O was used for phase A, while 0.1 % FA in ACN was used for phase B. The following 
gradient at 400 µL min-1 was used with a PFP column (1.7 µm, 2.1 mm x 10 mm): 0.5 min 95 % A, 3.5 
min 60% A, 5 min 0% A and 7 min 95% A ending with an re-equilibration for 1 min at 100% A. An 
injection volume of 10 µL was used, and oxycodone was monitored using SRM mode (316 → 241) at a 
55 V declustering potential (DP), 175 V focusing potential (FP), 5 V entrance potential (EP), 39 V 
collision energy (CE) and 16 V cell exit potential (CXP).  
All of the DART-MS experiments were performed using a DART-SVP® ion source set to the following 
conditions: +ve ionization mode, high-voltage electrode at −3000 V, discharge electrode at +350 V, and 
a grid voltage of +350 V. The DART-SVP® source was coupled to an Exactive Orbitrap (Thermo 




Scientific) and a TSQ Vantage. Since DART-SVP® utilises N2 and He gas during active runs, the amount 
of gas entering the MS was reduced using a membrane pump (adjusted to blue indicator, position 4) to 
avoid compromising the vacuum. The meshes that had been placed in the holder were mounted on a 
linear rail for desorption, while maximum sensitivity was obtained by adjusting the rail speed (0.2, 
0.3, and 0.4 mm s-1) and the DART source temperature (350, 450, and 500 °C). Prior to any DART-
MS/MS, the level of noise was assessed by obtaining a background signal of ambient air for the MS/MS 
transitions of the monitored analytes. Additionally, ion chronograms of monitored analytes were also 
obtained for unused meshes, i.e. meshes that had only been cleaned and preconditioned.  
2.6.3 Results/Discussion 
Initial performance of the 96-SPME-TM meshes for HT analysis 
In comparison to other AIMS methods, DART has the benefit of not requiring the addition of solvent 
post-extraction in order to desorb samples, thus eliminating the need for extraneous input. SPME-TM 
DART has already demonstrated its ability to handle time efficiently, but analyses had yet to be carried 
out on a one-by-one basis.26,117,134 It should be noted that, the use of a 96-SPME format is not a novel 
concept. In fact, it has garnered interest for nearly a decade, and almost every SPME configuration can  
be augmented to fit a 96 format.19,63,245,246 Our results demonstrate that SPME-TM can also be used to 
further decrease the total time required for DART. Figure 2.49 depicts the 96-SPME-TM design. Panel 
A shows an uncoated mesh pin with hexagonally-shaped apertures (opening diameter ~ 843 µm) and a 
single coated pin in the insert. Panel B shows the coated 12-pin set, alongside its dimensions.  Panel C 
shows the entire coated 96 set, which can be immobilized into a 3D printed holder so that the analyst can 
control the stages of SPME extraction and potentially implement Concept-96, which is a robotic arm 
used to control the preconditioning, washing, and extraction steps of the SPME protocol.246 The initial 
mesh performance evaluations focused on coating stability and visual examination whether strong 
agitation caused the coating to strip off. The results of these tests showed no significant issues related to 
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mesh stability. The next step was to perform assessment of extraction efficiency using LC-MS/MS. A 
plot for amount of oxycodone extracted (in ng) versus each pin (n = 96) can be seen in Figure 2.50. It is 
noticeable that the combs positioned in A1-12 and H1-12 extracted less oxycodone, likely related to 
improper positioning of the comb which resulted in insufficient interaction of the mesh pins with the 
bulk of the solution. Hence, it is important that the analyst ensures that the mesh movement is not 
obstructed in the well plate. The mean amount of oxycodone extracted (taking into consideration the 
afore-mentioned positions) was 19 ng, with a % RSD of 41.9 %. Excluding A1-12 and H1-12 positions 
yields a mean of 22.7 ng for extraction of oxycodone, with a % RSD of 20.9 %. The Shewhart chart 
observed in Figure 2.51 indicates amounts extracted for each pin with the exclusion of A1-12 and H1-12. 
Figure 2.49 The overall assembly of the 96-SPME-TM is shown in panels A., B., and C. Panel A. shows 
a close-up image of the uncoated mesh, while the insert shows a coated pin. Panels B. and C. show the 
dimensions and the full 96-SPME-TM “brush” designed to fit within a 96-well plate. Panel D. shows 
the signals obtained from 12 pins for extraction of 25 ng mL-1 of cocaine from surine which served as a 
preliminary assessment of the mesh’s performance. 
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The discrepancy observed due to positioning on the orbital shaker may not represent a major issue during 
DART desorption since only a portion of the mesh is actually exposed  to the desorbing stream 
of DART and the IS may conveniently correct for such discrepancy. Nonetheless, it is important to 
Figure 2.50 Amount of oxycodone extracted (ng) from 0.9 mL of PBS spiked with 50 ng mL-1 of 
oxycodone for a full brush set of SPME-TM meshes (n = 96) analysed via LC-MS/MS. 
Figure 2.51 Amount of oxycodone extracted (ng) from 0.9 mLs of PBS spiked with 50 ng mL-1 of 
oxycodone for a full brush set of SPME-TM meshes (n = 96) analysed via LC-MS/MS. 
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emphasize the fact that the agitation mode, i.e. orbital shaking could cause variance in the data. Next, 
extraction efficiency of meshes was assessed using DART-MS and an inter-laboratory SOP developed 
between IonSense, Inc. and UW which involved the use of Exactive-Orbitrap, surine negative control 
and methadone, cocaine, codeine, EDDP, and cocaethylene as model compounds. Figure 2.49D. shows 
the ion chronogram (Gaussian smoothing, seven points) along with the signal areas of cocaine (arbitrary 
units, AU) that was obtained from extraction of a 25 ng mL-1 spiked sample (10 minute extraction, 
300 °C, 0.3 mm second-1). A relatively repeatable trend in chronogram signal area (12.3 % RSD) can be 
observed, with a slight drop on the 10th and 11th pins. This drop could be attributed to either small amounts 
of turbulence that occur during the desorption process or a structural deviation in the device itself (i.e., 
differences in coating thickness). Ion chronograms for the remainder of the tested compounds can be 
seen in Figure 2.52. Since DART is very sensitive to small changes in air flow, a robust immobilization 











A Single Mesh for Multiple Desorptions? 
While HT is one important topic investigated by this study, another is the exciting idea that a single 
device could be used to obtain replicate measurements. In addition to being able to perform HT analysis, 
we wanted our mesh to be capable of obtaining three replicate measurements per pin, thus avoiding the 
need to use a new mesh when a replicate measurement is required. It was anticipated that thermal 
conductivity would be an important parameter in understanding how this concept would function. 
Thermal conductivity measures a material’s ability to transfer heat via conductance, with denser 
materials like metals and alloys usually providing better heat transfer. The thermal conductivity  of  SS 
is different at different temperatures; however, for reference purposes, the thermal conductivity of SS at 
25 °C is ~16 W mK−1247, while that of  paper is 0.05 W mK−1.247 Harding et al. examined how long it 
takes to heat different materials, such as aluminium and cardboard, for use with DART and found that 
cardboard reached a higher temperature faster than aluminum due to its thermal conductivity.146 
Therefore, the present investigation also examined whether the three sections of the mesh pin would be 
Figure 2.52 Ion chronograms of extracts from surine spiked with 25 ng mL-1 of EDDP, codeine, 
cocaethylene and methadone in A., B., C., and D. 
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affected by surrounding heat transfer. Specifically, we were interested in determining whether a pin’s 
sensitivity would be negatively affected by subsequent desorptions. In order to examine this, desorptions 
were performed on ten pins on n = 3 different meshes such that the ordering of the desorption sites was 
alternated for each mesh (i.e., mesh #1- bottom, top, middle; mesh #2-top, bottom, middle; mesh #3- 
middle, top, bottom). Fentanyl spiked at 25 ng mL-1 in PBS (1.2 mL, 10 min extraction) was used as a 
model compound, and no IS was used to assess the response, as the aim was to investigate the uncorrected 
signal. The obtained results can be seen in Figure 2.53. While it may appear that the middle position 
produces the least sensitive response, statistical analysis (single factor ANOVA, p = 0.96) did not show 
significant differences amount the three sites. Responses observed in the signal could be contributed to 
slight heat transfer, differences in coating homogeneity or both. Thus, further work shall focus on 




Figure 2.53 Assessment of signal response for 25 ng mL-1 of fentanyl (spiked to PBS, 1.2 mL, 10 min 
extraction) obtained after using 3 different desorption sites (top, middle, and bottom, indicated on left 
side of figure) per pin. Ten pins were used in total per mesh, and the experiment was repeated for a total 
of three meshes, starting with a different desorption site each time. No IS was used for data correction. 
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Investigation of Factors Impacting the Sensitivity of DART-MS/MS 
The response for the targeted analytes was optimised with respect to sample pH, DART source 
temperature, and SPME-TM rail speed relating to MS entrance. As Figure 2.54 indicates, the highest 
response was obtained at pH 7, which correlates to the pKa values of the majority of the targeted 
compounds. SPME coatings without cation/anion exchange moiety extract mainly the undissociated form 
of an analyte. Hence, considering the pKa values of analytes of interest, extraction from an acidified 
environment would be the worst option as predominantly dissociated forms of the analytes would be 
present. With regards to temperature, 3 different settings were used at 350, 450, and 500 ˚C to investigate 
the signal response. The greatest response was obtained at 450 ˚C, providing an adequate compromise 
for the majority of the analytes (Figure 2.55). Usually, the optimum DART source temperature is 
compound-specific.89 However, certain analytes, such as dihydrocodeine and oxycodone, did not show 
an increase in sensitivity as temperature was increased. The lower signal attained for these analytes may 
be due to a combination of a number of factors, including low VP, low PA, and poor thermal stability. 
Figure 2.54 Assessment of the signal response (n = 12) obtained for selected opioids (25 ng mL-1 in 
1.2 mL PBS, 10 min extraction, 500 rpm agitation on orbital shaker, 450 °C, 0.3 mm s-1) at pH levels of 
3 (treated with AA) 7, and 10 (treated with NH4OH).  Respective pKa values of the compounds are shown 
on the right side. 
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Indeed, the National Institute of Standards and Technology lists dihydrocodeine as a trimethylsilyl-
derived molecule (i.e., for GC analysis), which indicates that it is a potentially poorly volatile and a heat-
labile compound.248,249 On-coating derivatization could potentially be implemented prior to DART 
analysis to enhance ionization of labile analytes since certain authors have demonstrated derivatization 
feasibility with DART applications.144,250 The influence of rail speed was investigated at speeds of 0.2, 
0.3, and 0.4 mm sec-1 to determine whether significant sensitivity loss would occur at higher speeds, as 
this would reduce the amount of time the mesh was exposed in front of the DART source. As shown in 
Figure 2.56, the results indicate that there is no significant difference between speeds. Therefore, 
0.3 mm sec-1 was used for further experiments, as a slight drop in intensity did occur when the speed was 





Figure 2.55 Determining the optimum DART source temperature (n = 4) in order to maximize sensitivity 
using selected opioids (25 ng mL-1 in 1.2 mL PBS, 10 min extraction, pH 7, 500 rpm agitation on orbital 




















Figure 2.56 Determining optimum DART rail speed (n = 4) to maximize sensitivity using selected 
opioids (25 ng mL-1 in 1.2 mL PBS, 10 min extraction, pH 7, 500 rpm agitation on orbital shaker, 450 
°C). 
Figure 2.57 Ion chronogram showing the peak shape and areas obtained during the monitoring of 
fentanyl’s signal (n = 4) at 0.2, 0.3, and 0.4 mm s-1 rail speed in A., B., and C., respectively. 
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Extraction Time Profile of Selected Opioids  
It is important to establish an adequate extraction time because it significantly influences SPME’s 
sensitivity.7 However, it is not always necessary to achieve full equilibrium between the extraction device 
and the analyte of interest, especially if sufficient sensitivity can be obtained in the kinetic regime (i.e. 
pre-equilibrium).7 Thus far, SPME-TM publications have focused on using rapid agitation of  each mesh 
on a vortex (i.e., 3000 rpm).26,115,159 This approach has worked well due to the mesh’s high SA, which 
allows for adequate pre-concentration in a short period of time. However, it is not feasible to use such 
high speeds for the 96-SPME-TM format at present, as it may lead to collisions between the mesh and 
the well walls, which would result in the dispersal of samples from and into surrounding wells. To avoid 
this problem, an orbital shaker set at 500 rpm was used for all the experiments, as this speed provided 
adequate agitation without compromising the meshes and/or samples. Figure 2.58 shows the extraction 
time profile for 25 ng mL-1 of spiked opioids obtained at seven different extraction time points (1, 3, 5, 
10, 20, 30, and 60 min) for PBS. As can be seen, sensitivity peaks at 30 min, with a drop occurring by 
the 60 min mark. Further analysis of this drop using a t-test (two sample unequal variance) revealed that 
it was not statistically significant. Although ten minutes was deemed sufficient for achieving adequate 
Figure 2.58 Extraction time profile of opioids. 
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sensitivity in our experiments, one should keep in mind that the potential for extracting matrix 
components that can generate larger noise may become greater with longer extraction times.159  
High-Throughput Quantification of Opioids in PBS, Urine, and Plasma 
PBS 
AIMS techniques are generally regarded as methods that offer limited quantitative abilities, but over the 
last few years there has been a rise in publications reporting otherwise, particularly for DART 
applications.139,237,251–254 As mentioned in the introduction of this thesis, and as shown by Pérez et al.,115 
sample preparation devices that have been normalized (i.e., TM device with a defined geometry and 
coated area) are one of the crucial components for guaranteeing reproducible quantitative results. Several 
articles published by the Pawliszyn26,117,134 and Sacks137,139,237 groups have documented how coupling 
SPME-TM to DART-MS can provide analysts with reasonable quantitative results.  
The decision to select opioids as the model compounds for our quantification experiments was strongly 
influenced by the ongoing opioid crisis.255 In 2018, the United Nations Office on Drugs and Crime report 
indicated that in 2015 450,000 people around the world died due to drug abuse, with 167,750 of those 
deaths being related to opioid abuse.256 These startling figures indicate a potentially great demand for 
opioid testing within clinical settings. All LODs and LOQs obtained in this research were determined 
based on S/N ratios of 3 and 10, respectively. In order to dismiss any signals coming from the device 
itself, the response obtained from the coated mesh only (no extraction) was assessed. This result can be 
seen in Figure 2.59. To assess calibration quality, the first set of 96-SPME-TM mesh strips was used 
with PBS. Since PBS is an interference-free matrix, it can provide an insight into the mesh’s calibration 
ability without the interfering biologicals. The figures of merit obtained for PBS can be seen in Table 
2.18. Low LODs and LOQs were obtained, with validation levels (0.5, 30, and 90 ng mL-1) confirming 
very good accuracy (71.4-124.4 %) and repeatability (1.9-18.2 % RSD). The data in Table 2.18 was 
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obtained using deuterated analogs for each analyte, but calibration without an IS was also examined using 
PBS (selected analytes can be seen in Figure 2.61). DART relies on surface desorption, and the analyst 
is typically unable to control what happens outside of the MS region. If random/uncontrolled movements 
occur during the desorption process, the ion chronograms will be affected, causing fluctuations in the 
signal areas and leading to higher % RSDs.257,258 Therefore, quantitative analysis for DART is more 
robust if an IS implemented. However, ISs can be quite expensive for a single compound or may require 
special synthesis. Therefore, it is worthwhile to investigate calibration without the use of an IS. Gómez-
Ríos et al.117 examined IS-free calibration for the quantification of pesticides (metalaxyl, pyrimethanil, 
cyprodinyl, and pyriproxyfen) in grape juice, finding that linearity was maintained up to 10 ng mL-1 (on 
a LDR up to 100 ng mL-1). The loss of linearity observed in this study was attributed to either source or 
detector saturation.117 Figure 2.60 shows uncorrected calibration plots of the target analytes used in this 
research. The obtained calibration plots showed that linearity was predominately maintained at lower 
Figure 2.59 Ion chronogram obtained for the signal assessment of mesh only (i.e. no extraction, only 
cleaning and preconditioning of the mesh) for the targeted analysis of meperidine, hydrocodone, 
dihydrocodeine, methadone, oxycodone, and fentanyl.   
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concentration levels (up to 50 ng mL-1), while deviation was observed at higher concentration levels 
(mostly beginning at 100 ng mL-1). As with the loss of linearity, this deviation could also be attributed 
Table 2.18 Figures of merit obtained for the quantification of selected opioids in PBS. 






R2 LDR 0.5 ng mL-1  30 ng mL-1 90 ng mL-1 
Fentanyl 0.1 0.5 0.9995 0.5-200 115.0 (3.5) 108.6 (4.5) 109.5(2.6) 
Oxycodone 0.1 0.5 0.9981 0.5-200 123.6 (11.4) 89.8 (4.0) 100.3 (3.0) 
Hydrocodone 0.1 0.5 0.9952 0.5-150 71.4 (18.2) 129.4 (6.2) 110.3 (2.4) 
Meperidine 0.1 0.5 0.9975 0.5-200 97.3 (2.7) 82.9 (1.9) 97.9 (5.7) 
Methadone 0.1 0.5 0.9996 0.5- 200 84.8 (4.5) 104.8 (3.4) 109.5 (5.9) 
Dihydrocodeine 1.0 2.5 0.9986 2.5- 200 - 93.5 (3.7) 98.2 (3.1) 
 
 to detector saturation. In order to increase the method’s LDR, one could desorb a smaller amount of 









At present, the drug market is experiencing a marked supply-driven expansion (particularly for cocaine 
and opioids), and this expansion has highlighted the need to increase the throughput of certain tests, like 
urine toxicology.256 Urine toxicology is one of the most common procedures performed in analytical 
laboratories worldwide, as the matrix is available in large quantities, collection is minimally invasive, 
and its analysis can accurately detect the presence of drug metabolites.259 Hence, tools like 96-SPME-
TM-DART-MS could alleviate the high workloads faced by toxicology labs. Table 2.19 lists the obtained 
results for the quantification of selected opioids in urine. As can be seen, there is a notable increase in 
the LOQs of oxycodone and hydrocodone (25 ng mL-1) when compared to mere PBS. In the case 
Table 2.19 Figures of merit obtained for the quantification of selected opioids in urine. 












 LDR 0.5 ng mL
-1  30 ng mL-1 90 ng mL-1 
Fentanyl 0.1 0.5 0.9989 0.5-200 76.6 (4.6) 102.6 (3.0) 103.5 (4.3) 
Oxycodone 5.0 25.0 0.9923 25-200 - 93.7 (9.7) 101.5 (1.8) 
Hydrocodone 5.0 25.0 0.9789 25-150 - 96.2 (9.8) 105.3 (1.3) 
Meperidine 2.5 7.5 0.9976 7.5-200 - 87.4 (4.6) 103.1 (24.0) 
Methadone 0.5 2.5 0.9996 2.5-200 - 103.1 (0.7) 100.6 (1.6) 
Dihydrocodeine - - - - - - - 
 
Figure 2.60 Assessment of opioid (n = 3) quantification in PBS (1.2 mL, 10-min extraction, 450 °C, pH 
7, and 0.3 mm s-1) without the use of an IS for: a.) fentanyl, b.) oxycodone, c.) hydrocodone, d.) 
meperidine, e.) methadone, and f.) dihydrocodeine. 
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of dihydrocodeine, the selected MS/MS transitions (see Fig. 2.61) produced an elevated signal for the 
blank urine sample, thus making it difficult to quantify this compound. This difficulty could be due to a 
combination of factors, including the co-extraction of an interference with the same transition and/or the 
poor ionization of the analyte when it is in the presence of the matrix. Nonetheless, the validation levels 
for all of the other compounds provided good accuracy (71.4-129.4 % RSD) and repeatability (1.3-24 % 
RSD). In addition, the LOQs obtained are below the urine cut-off points suggested by CLR.223  
 
Plasma 
Given plasma’s complexity260 and the heavy binding of some target analytes to its constituent proteins,32 
one can expect the detection limits to increase when compared to PBS and urine. For the plasma 
experiments, we utilised a 3/4 dilution with PBS. Although the majority of reports indicate an expected 
drop in plasma protein binding when a dilution is utilised,32 this study was not concerned with 
Figure 2.61 Monitoring of different MS/MS transitions for dihydrocodeine (302.1 → 198.9, 200.9, 
194.8, 170.9, 226.8) in urine for a blank sample and 0.5, 1, and 2.5 ng mL-1 spiked samples (all tests 
were performed in triplicate using 1.2 mL of sample, a 10-minute extraction time, a pH of 7, agitation 
on an orbital shaker at 500 rpm, 450 °C, and a track speed of 0.3 mm s-1). The portion highlighted in 
blue indicates extractions from urine blanks. The transitions obtained from the TSQ Vantage during the 
optimization procedure included 198.9, 200.9, 194.8, 170.9, and 226.8, with 198.9,3 200.9,4 and 226.8 
being the most commonly reported transitions in the literature. 
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determining the % of plasma protein binding . Table 2.20 lists the results for the quantification of opioids 
in plasma. Certain analytes, such as oxycodone, meperidine, and dihydrocodeine, had higher LOQs when 
compared to PBS, which is partially associated with the elevated signal of the target compound on plasma 
blank (i.e., the co-extraction of a compound with a similar MS/MS transition). The obtained values for 
the validation point assessments had an accuracy of 86.6-108% and a repeatability of 2-11.2 % RSD. 
The 0.5 ng mL-1 validation point was not examined as it was below LOQ values. Except for methadone, 
the LOQs of the reported opioids are higher than cut-offs proposed by Marin et al. for serum or plasma.261   
Table 2.20 Figures of merit obtained for the quantification of selected opioids in plasma. 
 Considering the extraction and desorption time taken to perform analysis of 96 samples with the system 
presented herein, the total analysis time is approximately 30 s per sample. This includes extraction and 
desorption time. This is comparable to other SPME-AIMS technologies like CBS (29 s)245 and open port 
probe (15-20 s).205 In PS, drying time (minutes, in some cases hours)182,196,262 and spraying times196,263 
(seconds to minutes) tend to vary with applications, but total analysis times usually is not excessively 
long. When compared to hyphenated techniques like LC/MS264,265 (where processing can take hours), 
analysis time is significantly reduced with the 96-SPME-TM. Techniques like RF report analysis time of 
45 minutes for 384 wells or 7 s per sample,266 but it is important to keep in mind that, unlike SPME, RF 
 Validation level; accuracy (RSD, %, n = 3) 
Analyte LOD (ng mL-1) 
LOQ 
(ng mL-1) 
R2 LDR 0.5 ng mL-1 30 ng mL-1 90 ng mL-1 
Fentanyl 0.5 1.0 0.9950 1-200 - 86.6 (4.0) 93.0 (2.3) 
Oxycodone 2.5 25.0 0.9938 25-200 - 89.6 (11.3) 101.3 (2) 
Hydrocodone 0.5 2.5.0 0.9974 2.5-75 - 104.2 (13.2) - 
Meperidine 5.0 25.0 0.9998 25-200 - 114.8 (6.8) 94.1 (5.2) 
Methadone 2.5 10.0 0.9974 10-200 - 90.9 (5.4) 105.5 (8.5) 
Dihydrocodeine 2.5 25.0 0.9797 25-200 - 73.4 (4.3) 103 (1.1) 
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requires significant plasma pre-processing.267 Hence, one must carefully consider processing times as 
well as limitations of techniques prior to proceeding with a choice. 
2.6.4  Conclusion for Section 2.6 
A HT 96-SPME-TM system for DART-MS analysis was developed as a potential solution to the growing 
demands related to clinical testing faced by laboratories worldwide. This study has not only shown how 
HT and AIMS can play a key role in solving this demand issue, but it has also highlighted some of the 
challenges that must be addressed before AIMS can be considered a viable validated option for 
commercial laboratories. Significantly, the proposed system’s applications are not limited to clinical 
settings; rather, it can be used in the environmental and food-safety sectors, which also face high 
demands242. Regardless of which field this system is applied in, its ability to reduce the amount of time 
spent on sample preparation and monitoring direct coupling reactions will enable analysts to utilize their 
time more efficiently. The development of a fully automated robotic system that can take the 12-mesh 
strip (with extracts), mount it onto the rail, trigger the desorption step, and repeat the procedure for the 
next strip is one example of an innovation that could make DART and HT 96-SPME-TM even more 
productive. Moreover, the development of an integrated SPME-DART system, wherein one robotic 
component handles the extraction stage while the other performs mesh mounting and subsequent 
desorption, may prove to be an even more effective option. While there are existing engineering 
challenges to realizing this vision, the availability of such systems would undoubtedly prove extremely 




 Single-Use Poly(etheretherketone) Solid-Phase Microextraction-Transmission Mode 
Devices for Rapid Screening and Quantitation of Drugs of Abuse in Oral Fluid and 
Urine via Direct Analysis in Real-Time Tandem Mass Spectrometry 
 
2.7.1 Introduction 
Within the field of forensic science, there is a great need for a highly-robust and reliable tool that can 
rapidly detect the presence of DoAsx in biofluids.92 Driving under the influence of drugs (DUID) is a 
very serious criminal offense that can have dire consequences. According to the Canadian Centre on 
Substance Abuse, substance use played a primary role in approximately 34.2 % of fatal car crashes in 
2010.268 Due to an increase in such accidents, many methods have been developed to detect commonly 
abused prohibited substances in OF269–274 and urine.269,275,276 These methods generally use a 
chromatographic step as a confirmatory test, which places a time restraint on the whole procedure. This 
is especially problematic in DUID cases where obtaining reliable results rapidly is of prime importance. 
While still requiring extensive validation procedures for wide acceptance as a confirmatory method, it is 
unsurprising that AIMS84,193 has received considerable attention from forensic scientists, as this group of 
technologies is capable of rapidly determining target compounds while also reducing or avoiding the 
need for sample preparation, eliminating the chromatographic step, requiring minimal or no solvent use, 
and decreasing the overall time required to complete the process. Among the diverse array of AIMS 
techniques, DART has been of particular interest in forensic science. This technology uses heated and 
highly energetic He gas to desorb/ionize compounds from surfaces of various materials.87,91,277 Although 
DART can reveal important qualitative information about the forensic sample, its applicability for 
quantitative analysis was plagued in the beginning because it lacked the ability to normalize the sample 
(i.e., a homogenous and reproducible mechanism for introducing the analytes into the MS-system from 
one sample to the other). In an attempt to solve this issue, Prof. Fernandez’s group developed a mesh-
like device with fixed geometrical characteristics (i.e., strand size, pitch-to-pitch distance, percentage 
141 
 
opening) that provided better control over sample introduction.115 This device, known as TM, allowed 
gas to flow more efficiently through the mesh, which permitted better ion-transmission and 
reproducibility.115 Although this technology enabled the sample to be pragmatically positioned in front 
of the MS system (i.e., a spot of the sample is dried on the mesh prior to analysis), its lack of sample 
preparation prevented a dramatic enhancement in the limits of detection. In this regard, one of the sample 
preparation tools that has been successfully implemented with many AIMS techniques is SPME.27,117,278 
Depending on the experimental conditions, compounds of interest, and matrices under investigation, 
SPME can extract either a “small” amount of analyte (also known as negligible depletion), or it can be 
used in cases in which a significant amount of analyte is extracted (i.e., exhaustive extraction).7 SPME 
is cleverly designed, comprising the immobilization of a small amount of extractive material (coating) 
onto a designated substrate.7 This sample preparation tool has seen a rapid increase in bioanalytical 
applications over the last few years due to the development of matrix-compatible coatings49,63,211,279,280 
that allows SPME devices to be directly introduced into complex matrices, which in turn leads to 
negligible biofouling and remarkable target analyte extraction. In addition, SPME features efficient 
sample cleanup, which  reduces issues related to ionization suppression and ionization 
enhancement.281,282 Indeed, SPME is no stranger to DART, and diverse geometrical SPME formats (e.g., 
fiber, in-tube, mesh) have been interfaced with DART in numerous applications.63,165,283–285 Nonetheless, 
as the Pawliszyn team has recently demonstrated,26,117,134 the best results are obtained when SPME is 
implemented as a TM substrate. For instance, cocaine and diazepam were quantified in sub ng mL-1 
levels in urine and plasma samples using SS meshes that were adequately coated only on the strands with 
a C18-PAN slurry.26 Furthermore, it has been documented elsewhere how mesh coated with HLB 
particles can be used to efficiently detect pesticides in different food matrices.117,134 Over the last few 
years, various substrates have been used for the immobilization of extractive materials in SPME17,286–288 
devices, the most recent example being polybutylene terephthalate (PBT) plastic support, which was 
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developed by Reyes-Garcés et al.19 PBT proved to be a very useful material for single-use SPME, as the 
device provided satisfactory results for drug quantitation in plasma, urine, and blood, while also being 
very robust. PBT-based devices also showed no interferences from being used as a material in the 
method.19 It is evident that the use of alternative materials opens up a diverse array of potential 
applications for SPME; for example, on-site road testing. Given the rise in DUID accidents over the last 
few years, the primary goal of this research was to develop a single-use device that can be interfaced 
with DART, and that can eventually be used for rapid, in vivo, on-site drug detection. In order to fulfill 
such a requirement, it is essential to use a biocompatible material. As such, PEEK was selected in order 
to fulfill the substrate biocompatibility requirement.289 PEEK is a semi-crystalline polymer known for its 
great mechanical stability, a property arising from its aromatic structure,290 which can be seen in Figure 
2.62. In addition, PEEK is thermoplastic material, with a melting temperature of 343 °C,291 and, with the 
exception of 98 % sulfuric acid, it is chemically inert to most solvents and acids.292 It is important to 




of potential analyte adherence to plastics should be done prior to their use.259 PEEK’s biocompatible 
feature has allowed it to be used in dental surgery293 and maxillofacial reconstruction,294 as well as in 
spinal,295 orthophedic,296 and cardiac implants.297 Given PEEK’s many benefits, we decided to apply 
SPME coating to a PEEK-based mesh to rapidly detect and quantitate drugs in OF and urine via DART-
MS/MS. Different parameters were evaluated, such as coating robustness under strong agitation or high 
temperatures, as well as mesh reusability. Encouraging results led us to apply disposable SPME-TM 
meshes to quantitatively determine DoAs in ex vivo OF and urine analysis. In addition, we attempted a 
Figure 2.62 Structural formula of PEEK 
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semi-quantitative analysis of caffeine concentration in an OF sample obtained from a volunteer who had 
recently consumed coffee. Certainly, the results obtained show that SPME has tremendous potential as a 
simple, effective device for roadside drug testing.  
2.7.2 Experimental  
Chemicals/Materials 
 The following standards were obtained from Cerilliant (all standards had a concentration of 
1000 mg L- 1): cocaine, methamphetamine, nordiazepam, fentanyl, MDMA, heroin, phencyclidine 
(PCP), oxazepam, methadone, oxycodone, lorazepam, LSD, heroin, diazepam, caffeine and nicotine. The 
respective IS(s) were also ordered from Cerilliant (all at a concentration of 100 mg L-1), namely: cocaine-
d3, methamphetamine-d5, MDMA-d5, PCP-d5, nordiazepam-d5, oxazepam-d5, methadone-d3, 
oxycodone-d3, lorazepam-d4, LSD-d3, heroin-d9, diazepam-d5, fentanyl-d5, caffeine-C13, and nicotine-
d4. A pooled batch of urine and OF was collected by having 10 healthy individuals (5 male and 5 female) 
each expectorate into a 10 mL vial. PBS was made in lab and details are available for Section 2.2.2. In 
addition, a female volunteer provided 1mL of OF to measure for caffeine levels. For this test, OF was 
collected after a 24h caffeine fast, followed by collection at 5 minutes, 1 hour, 3 hours, and 5 hours post 
coffee consumption. PAN, DMF, NaCl, KCl, KH2PO4, Na2HPO4, and FA were all purchased from Sigma 
Aldrich. LC/MS-grade H2O, IPA, ACN, and MeOH were purchased from Fisher Scientific. The HLB 
particles were purchased from Waters and removed from the SPE cartridge for use.  
DART-MS/MS and LC-MS/MS  
A DART-SVP® model ion source (IonSense, Inc.) was coupled to a QqQ mass spectrometer (TSQ 
Vantage) by Thermo Scientific via a Vapur® interface (IonSense, Inc.). The needle valve of the 
membrane pump used with the Vapur® interface was adjusted to the blue indicator at position 4 in order 
to maintain adequate MS vacuum and provide sufficient sensitivity required for quantitative analysis via 
DART-TM. The DART-SVP® was fitted with a single-dimensional motorized linear rail that was 
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controlled through the DART-SVP® web-based software in order to reproducibly and consecutively 
automatically position the SPME-TM devices in front of the DART source (a speed of 0.2 mm s-1 was 
used). In order to guarantee good reproducibility and higher throughput of the desorption process, a 
custom-made holder (UW-12) able to allocate up to 12 SPME-TM devices was used.26 The DART source 
was operated using the following conditions: +ve ionization mode; HV electrode (−3000 V); discharge 
electrode (+350 V); and a grid voltage of +350 V. The gas heater was optimized at 350 °C in order to 
yield the optimum intensities for most of the analytes. LC-MS/MS conditions are detailed in section 
2.5.2. MRM details are listed in Tables 2.1, 2.8 and Table 2.21.   
Table 2.21 TSQ Vantage details of model analytes used in this investigation. logP obtained from 
PubChem.156 




MDMA-d5 - 199.1 165.0 12 61 
PCP 4.69 244.2 86 12 49 
PCP-d5 - 249.2 86 12 55 
Nordiazepam 2.9 271 243 20 141 
Nordiazepam-d5 - 276 213 28 111 
Oxazepam 2.24 287 241 21 133 
Oxazepam-d5 - 292 246 22 101 
Lorazepam 2.39 321 275 21 117 
Lorazepam-d4 - 325 279 21 117 
Diazepam 2.82 285 193 30 139 
Diazepam-d5 - 290 198 21 139 
Caffeine −0.07 195 138 19 64 
Caffeine-C13 - 198 148.1 19 19.3 
 
Preparation of PEEK mesh for SPME-TM coating  
A 12×12 cm mesh piece was cut and cleaned in IPA and H2O for 15 minutes by sonication. The meshes 
were then dried (100 °C) and etched for 90 s on both sides using an ATC-2020-IM ion mill (AJA 
International, Scituate, MA) at a setting of 400 V and 190 mA. The meshes were then purged with N2 
and left in a desiccator to ensure that the coating application remained unaffected by possible 
contaminants and moisture. A paper cutter was used to obtain mesh strips (2.5 × 0.5 cm, length by width). 
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Images of the mesh were taken using an Olympus microscope (SZX10) with a SC30 digital camera, and 
SEM images were acquired using a Zeiss FESEM 1530.  
Application of HLB-PAN coating to the meshes  
PAN solution was prepared by dissolving 7 g of PAN powder with 100 mL of DMF via periodical 
vortexing to ensure uniform dissolution. Oasis HLB particles were used to prepare the slurry for the 
coating application. Since the size of the particles (30 µm) was large for the application, the particles 
were ground using a ball mill for 2 h at 240 rpm. The ground particles were then collected, and 1 g was 
mixed with 10 mL of PAN solution to obtain a final HLB-PAN slurry. The slurry was then stirred for 12 
hours at 1800 rpm to provide adequate mixing of particles with PAN. The mixture was applied to the 
meshes by dip-coating using an in-house method26 developed at the UW. After the mixture had been 
applied, excess solvent was removed via gas pressure, and the coating was then cured at 100 °C. In order 
to facilitate the handling of the meshes, the meshes were attached to PBT with soldering tool to provide 
extra support (i.e., thermally attached). The meshes were then cleaned twice in a solvent solution 
consisting of MeOH/IPA/ACN (50/25/25) at 1500 rpm for 15 minutes to remove any leftover chemicals 
from the polymerization or coating procedures. To activate the extractive sites on the particles, the meshes 
were preconditioned in a mixture of MeOH/H2O (50/50).  
Evaluation of coating mesh endurance 
 The evaluation was conducted by exposing a new set of coated PEEK meshes to DART’s thermal 
desorption (350 °C, 0.2 mm s-1). After the first thermal desorption, the meshes (n = 5) were 
preconditioned and used to perform extraction from a PBS sample that had been spiked with 50 ng/mL 
of cocaine. After extraction, the meshes were desorbed in solvent (MeOH/ACN/FA, 80/20/0.1) for 
20 minutes using an agitator at 1800 rpm.211 LC-MS/MS analysis211 was then used to determine the 
meshes’ ability to retain their extractive capacity after one exposure to the DART source. Once the solvent 
had been desorbed, the same meshes were cleaned with the MeOH/IPA/ACN (50/25/25) mixture and 
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exposed to thermal desorption using the DART source (350 °C, 0.2 mm s-1) for a second time. The meshes 
were then preconditioned, and a PBS sample spiked with 50 ng mL-1 of cocaine was once again used to 
perform the extractions. The amount extracted was determined using solvent desorption. LC-MS/MS 
analysis was conducted to determine the extractive ability of the meshes after a second exposure to DART 
source. The entire procedure was repeated until the total number of thermal desorptions for the meshes 
was five. The amount extracted after each thermal desorption was compared to the amount extracted 
from a mesh that was never exposed to thermal desorption. 
Extractive procedure for OF and urine  
Stock solutions for all studied analytes and their respective deuterated analogues were made and the two 
matrices were spiked at the appropriate concentrations (0.5, 1, 2.5, 5, 10, 25, 50, 75, 100, 125, 150, 175, 
200 ng mL-1) for the calibration plot and the validation points (8, 40, 80, 140 ng mL-1). The IS was spiked 
at a fixed level of 10 ng mL-1, and all spiking was conducted so as to keep the organic content in the 
matrices below 1 % in order to simulate a “real” sample and to prevent any effects from the solvent 
during the extraction step.7 For the semi-quantitative measurements of caffeine, a calibration plot for 
caffeine was made in PBS; this calibration plot consisted of nine calibration levels (i.e., 1, 5, 10, 50, 100, 
250, 500, 750, 1000 ng mL-1). Caffeine-C133, spiked at 50 ng mL
-1, was used as an IS. After spiking, both 
complex matrices, urine and OF, were gently agitated on a vortex at 200 rpm for at least 2 hours to allow 
for proper equilibration between the analytes and the matrix. Prior to extraction, the meshes were briefly 
washed with H2O to remove the organic content which can affect the extractive capabilities of the mesh 
(i.e., disturbance of partition equilibria between analytes and coating)7,20 and then gently blotted with a 
KimWipe. The extractions were conducted by directly immersing the mesh into the vials containing the 
spiked samples. The extraction process was carried out according to a published procedure that consists 
of rapidly agitating the sample at 3200 rpm for 1 minute.26A 700 µL sample was used for urine analysis 
following a 10 sec agitated wash step in H2O. OF analysis was also carried out under the same agitation 
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conditions for 1 minute; however, a smaller volume (300 µL) and a longer wash step of 12 s were used. 
The longer wash step was employed due to OF’s viscosity and to remove any potential food residue that 
may have adhered to the mesh. Extraction of caffeine was done under the same agitation conditions 
described above, but, as with OF, a smaller volume was used (300 µL), and the extraction time was also 
reduced to 30 s in order to reduce the prospect of detector saturation. It is important to note that caffeine 
concentration in OF is very high (mg L-1 levels) immediately following coffee consumption.298 Thus, in 
order to avoid potential detector saturation and to fit the instrumental calibration, OF samples were 
diluted 1/100 with PBS. The dilution factor was chosen according to Liguori et al.’s results.298 Upon 
completion of the above extractions, the meshes were inserted into an in-house-developed mesh holder 
and subsequently analysed.26  
2.7.3 Results/Discussion  
Evaluation of PEEK as material for TM  
PEEK was chosen as a substrate for this study due to its attractive properties, which include: 
biocompatibility, inertness to the majority of solvents, and relatively greater stability when exposed to 
high temperatures. When choosing the proper PEEK substrate, it is worth remembering that the mesh 
robustness is extremely important, as sturdy connections between the filaments within the mesh are 
essential for a successful extraction and desorption process. Initially, the robustness of two meshes from 
two different providers was tested by exposing them to 100 °C in an oven. Although the first mesh tested 
(mesh opening: 450 µm, strand size: 200 µm, open area: 48 %; GoodFellow, Mississauga, ON, Canada, 
part #346-012-62, Figure 2.63a.,c.) allowed for successful coating application, it was not chosen for 
further experimentation because the filament attachment weakened after exposure to 100 °C (see Figure 
2.63e., g., and i.). Conversely, the second PEEK mesh, ordered from Building Materials Express (mesh 
opening: 220 µm, strand size: 75 µm, open area: 56 %), exhibited much better performance following 
148 
 
exposure to a high temperature (see Figure 2.63b., d., f., h., j. and 2.64); therefore, it was chosen for 
further experimentation.   
  
Figure 2.63 Mesh models assessed for the study. Bare PEEK mesh (part #346-012-62) ordered from Goodfellow (a.) with a 450 
µm mesh size, 200 µm monofilament diameter, and an open area of 48 %, and bare mesh ordered from Building Materials (b.) 
with a 220 µm mesh size, 75 µm monofilament diameter, and an open area of 56 %. Inserts (c.) and (d.) show both mesh types 
coated with HLB particles from Waters. The meshes were exposed to 100 °C for two minutes in a GC oven, and, as can be seen 
in (e.), the mesh from Goodfellow showed significant filament deformation, while the mesh from Building Materials (f.) remained 
the same. Figures (g.) and (h.) show a more detailed view of the deformed mesh purchased from Goodfellow. Figures (i.) and (j.) 
represent top view of the deformed Goodfellow mesh, and the Building Materials mesh, respectively. 
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Stability and analytical performance of PEEK SPME-TM  
Ultimately, PEEK meshes were developed for the purpose of performing in vivo OF sampling. To achieve 
the full potential of such an application, we had to ensure that proper coating stability was achieved. In 
order to examine proper coating attachment on the meshes, the meshes were inserted into a vial 
containing a mixture made of MeOH/IPA/ACN (50/25/25) and agitated at high speed in a vortex 
(i.e.,3200 rpm) for one minute and then again at 1800 rpm overnight (~12 h). After agitation, the meshes 
were observed under a microscope, which revealed no changes in the coating. In addition, the SEM 
images show good attachment between the particles and the substrate (Figure 2.64d-e.). The PBT support 
that had been affixed to the mesh via soldering iron also proved stable as no de-attachment occurred 
(Figure 2.64f). Another important point of consideration in assessing stability was whether the meshes 
would be able to withstand exposure to the DART source’s high temperature. Thus, a stability test was 
Figure 2.64 (a.) Bare PEEK mesh without any coating attached; (b.) mesh coated with the HLB 
particles; (c.) SEM of bare mesh at 500x magnification; (d.) SEM of coated mesh at 500× magnification; 
(e.) close-up of HLB particles attached to mesh at 5k× magnification; and (f.) coated mesh attached to 




conducted by exposing the meshes to the DART source at 250, 300, and 350 °C. Temperatures beyond 
400 °C were not explored due the PEEK’s reported melting point of 343°C.289–291 However, as noted by 
prof. Fernandez’s group the temperature indicated by the DART software is generally higher than the 
temperature of the region where the heated gas comes into contact with the coated surface;145 hence, it 
was not a concern that the material would be compromised at the set temperature of 350 °C. Indeed, the 
unravelling of mesh filaments was not observed (see Figure 2.63f. and Figure 2.64).  
Mesh repeatability was assessed by performing a rapid extraction (1 min) from a vial containing PBS 
solution spiked with 50 ng mL-1 of cocaine. Analysis was performed via LC-MS/MS to eliminate any 
errors associated with the desorption/ionization step, and, as such, to enable a strict evaluation of the 
coating’s repeatability. To determine the amounts of cocaine extracted, the meshes were desorbed in a 
80:20:0.1 MeOH/ACN/FA solvent mixture already described elsewhere.211 After the first desorption, the 
meshes were cleaned twice using the above-mentioned cleaning solution mixture, and the obtained 
samples were additionally analysed for carry-over. The results obtained for mesh repeatability (n = 5) 
can be seen in Figure 2.65. The amount of cocaine extracted by the meshes varied from 12.5-16 ng, with 
a mean of 14.4 ± 1.3 ng, and a % RSD of 9.5 % (without IS correction). These results were quite 
satisfactory given the short and non-automated extraction process. The cleaning solutions were tested for 
carryover, but the amounts remaining on the mesh were below the LOQ of the experiment. The analytical 
Figure 2.65 Assessment of mesh repeatability performed by extracting cocaine from a 50 ng mL-1 PBS 




performance of the PEEK meshes was further compared to that of SS meshes26 (mesh opening: 250 µm 
, strand size: 90 µm, open area: 55%). For this comparison, both the SS and PEEK meshes were coated 
with the same ground particles and analyzed under same DART parameters. A sample of PBS was spiked 
with 50 ng mL-1 of heroin, and extraction was carried out for one minute under the above-mentioned 
conditions (n = 3 for PEEK meshes; n = 3 for SS meshes). The two meshes were compared by monitoring 
the product ion of heroin (m/z 370→165), with the resultant ion chronograms revealing comparable 
analytical performance between PEEK and SS meshes (see Figs. 2.66 and 2.67).  
 
Assessment of potential re-usability  
Even though the plastic meshes are intended to be single use, the possibility of reusability was also 
investigated. Reusability was assessed by running the meshes in front of the DART source six times at 
350 °C at a rail speed of 0.2 mm s-1. After each run, the meshes were washed in a MeOH/IPA/ACN 
mixture and preconditioned in MeOH/H2O for at least thirty minutes. After the preconditioning step, the 
Figure 2.66 Comparison of signal responses of SS meshes, and PEEK meshes. Ion chronograms 
obtained after extraction from 1.5 mL of PBS spiked with heroin (50 ng mL-1) when using SS meshes 
(left) and PEEK meshes (right).   
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meshes were used to perform an extraction from PBS spiked at 50 ng mL-1 with cocaine, followed by a 
brief wash step and solvent desorption in 300 µL of MeOH/ACN/FA (80/20/0.1) mixture. The LC-
MS/MS conditions used for the run have already been described (see Section  2.5.2). As can be observed 
in Figure 2.68, extraction capability drops by approximately 37 % after DART desorption. A one-tailed 
student’s T-test and a one factor analysis of variance (ANOVA) was conducted (α = 0.05) to assess 
whether there is a significant difference between the meshes prior to and after exposure. The calculated 
p-values (< 0.001) revealed a significant difference in the amounts of cocaine extracted after the meshes 
had been re-used. An SEM image was also obtained in order to investigate the mesh surfaces and revealed 
that noticeable cracking in the coating occurs after five exposures (Figure 2.69). Nonetheless, this 
instrumental drop is expected due to the solid coating’s repeated exposure to a DART source temperature 
of 350 °C. Ultimately, the meshes still retain their extractive ability and can be easily implemented as 
screening tools. Therefore, mesh reusability was only tested aiming to evaluate the robustness of the 
device. Yet, PEEK SPME-TM devices are not intended to be reused when dealing with real samples so 
to prevent false positives/negatives due to inadequate performance. 
  
Figure 2.67 Signal response (in arbitrary units; au) obtained for ion chronogram in Figure 2.66 for SS 
meshes (n = 3) and PEEK meshes (n = 3). The respective values obtained for each mesh are highlighted 




Figure 2.68 Assessment of mesh reusability and retainment of extractive capacity done by performing 
repeated exposure of the mesh to DART source. The chart shows the amount of cocaine extracted in ng 
after five different meshes were exposed and run in front of the DART source five times at 350 °C using 
a rail speed of 0.2 mm s-1. 
 
 
Figure 2.69 SEM images of PEEK mesh in (a.) and (b.) before exposure to DART source.  Images 
obtained after a single mesh has been exposed to the DART source five times (c. and d.) at 350 °C and 
0.2 mm s-1. 
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Detection and quantification of drugs of abuse in urine and oral fluid  
Oral fluid  
The successful demonstration of the PEEK meshes’ robust performance paves the way for further ex vivo 
quantitative studies with both OF and urine. The use of OF as an alternative matrix in drug detection has 
been on the rise in the last few years due to ease of collection, minimum invasiveness, and remote 
potential for adulteration given that the collection can be carried out by the authority.299 Recently, there 
has been a rise in the number of publications on AIMS and OF drug analysis300–302 focusing on screening-
related questions, as well as some quantitative studies. The primary motivation for using OF in this work 
is to contribute to efforts to make rapid on-site detection with simple tools a reality. SS meshes could be 
used for in vivo application, but the sharp edges and the metallic flavor (potentially enhanced by the use 
of concentrated HCl for mesh etching) may be inconvenient for in vivo use. For example, filaments can 
become damaged and cause an injury to oral cavity. In addition, storage of SS meshes for extended times 
in strong solvents may lead to corrosion. Hence, PEEK has an advantage in relation to potential in vivo 
sampling due to its smoother surface, inertness and flexibility. These characteristics make the placement 
of the mesh on the tongue or buccal mucosa more convenient. Additionally, the use ion milling for etching 
makes PEEK mesh fabrication more environmentally friendly. The volume used for OF analysis was 
maintained at 300 µL in order to simulate this matrix’s limited availability. In general, OF is relatively 
less complicated to work with when compared to more complex matrices such as blood and plasma, 
which consist of higher amounts of protein.280 In fact, OF is composed of 99 % H2O, with the remaining 
1% consisting of proteins, electrolytes, enzymes, urea, ammonia, and immunoglobulins.213 As it can be 
seen in Table 2.22, remarkable figures of merit were obtained for the selected analytes despite their 
diverse physicochemical properties (e.g., logP). Although extraction was rapid (1 min), it was 
nevertheless sufficient for preconcentrating the analytes and establishing very low detection limits.26 The 
LODs and LOQs were calculated based on S/N ratios of 3 and 10, respectively. The majority of values 
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Oxycodone 0.5 1.0 0.9956 1.0-200 100-300 113.2 (1.7) 106.7 (3.5) 99.7 (4.8) 94.2 (1.6) 
Heroin 0.5 2.5 0.9978 2.5- 100 - 96.4 (10.7) 88.7 (10.1) 100.9 (6.8) - 
MDMA 2.5 10 0.9913 10- 200 5 - 90.5 (1.8) 106.4 (0.8) 99.4 (4.8) 
Methamphetamine 2.5 25 0.9955 25- 200 500 - 95.5 (4.6) 95.8 (3.4) 102.3 (5) 
Oxazepam 1.0 2.5 0.9963 2.5- 200 100 126.8 (3.6) 114.8 (8) 107.1 (3) 103 (2.3) 
Cocaine 0.1 0.5 0.9924 0.5-100 150 114.8 (6.1) 101.2 (6.8) 100.7 (1.8) - 
Lorazepam 0.5 2.5 0.9936 2.5- 75 100 121.9 (2.7) 120.1 (0.6) - - 
Diazepam 0.5 2.5 0.9999 2.5- 125 100 81 (6.6) 121.8 (2.8) 116.4 (5.5) - 
Nordiazepam 1.0 2.5 0.9983 2.5- 200 - 86.1 (10.2) 91.7 (3.3) 94.1 (4.9) 97.3 (3.5) 
LSD 0.5 2.5 0.9906 2.5- 200 0.1 93.5 (10.4) 116.1 (4.4) 111.1 (4.3) 100.8 (3.4) 
Methadone 0.5 1.0 0.9952 0.5- 200 200 119.3 (3.5) 90 (4) 83.2 (1.5) 97.6 (2.2) 
Fentanyl 0.5 2.5 0.9978 2.5- 125 1-5 88.3 (11.8) 94 (3.1) 88.1 (6.8) - 
PCP 1.0 2.5 0.9980 2.5- 175 25 121.6 (3.3) 112.1 (4) 108.3 (4.8) 102.8 (0.8) 
Figure 2.70 Detection and quantification of methadone (a.) and PCP (b.) in OF and urine, respectively. The 
highlighted points in (a.) and (b.) represent the cut-off levels used for these drugs by regulatory agencies, such 
as DRUID and CLR. 
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reported in this research are considerably lower than the values required by agencies such as 
SAMHSA,189 and DRUID.190 To account for any variation during the desorption ambient ionization 
process, IS calibration was chosen.303 The method’s LDR was maintained in the 0.5-200 ng mL-1 range, 
with acceptable precision (< 11 %). Regarding validation points for OF, the majority of data accuracy 
falls within the 83-115.1 % range. Validation points such as 8 ng mL-1 and 140 ng mL-1 could not be 
tested for some analytes because they fall below the LOQ or above the upper LOQ. At the lowest 
validation point of 8 ng mL-1 certain analytes (oxazepam, lorazepam and oxycodone) exhibit accuracy 
between 79.6-121.1 %, while MDMA’s accuracy lies at 75.1 %. At 40 ng mL-1 some analytes 
(methamphetamine, diazepam, fentanyl and PCP) lie in the 119-128 % accuracy range, which could be 
related to co-extracted small molecules from OF with similar SRM transitions to the ones of the target 
analytes. An example of a calibration curve for quantifying methadone in OF can be seen in Figure 
2.70(a.). In addition, it is worth noting that the 12 s rinsing step successfully removed food debris 
remaining on the mesh, which could have potentially caused major interferences in the analysis. Another 
notable factor was the use of HLB, which is a highly-wettable material that is capable of providing wide 
analyte coverage.19,117,134 Calibration plots of some selected analytes (nicotine, MDMA and fentanyl) are 
shown in figure 2.71b., d. and f., respectively. 
Urine  
Although OF shows great promise for use in toxicological investigations, urine is most commonly used 
for drug detection at present due to its availability in large quantities. The regulatory limits for urine cut-
off levels were taken from cut-off & toxicity levels for DoAs testing from the CLR;223 as Table 2.23 
shows, the large majority of LODs and LOQs achieved by the tests in this study were lower or close to 
those imposed by the CLR (with the exception of LSD where regulatory level of 0.1 ng mL-1 was not 
met). For example, we managed to achieve an LOQ for PCP in urine that was ten times lower than the 
level required by the CLR (Figure 2.70(b)). The SPME-TM device’s large SA allows for improved 
sensitivity,26,117,134 particularly at low ng mL-1 levels when compared to the fiber geometry.165 The LDR 
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of the method was maintained in the 0.5-200 ng mL-1 range, with acceptable precision (< 11 %). The 
validation points for urine gave satisfactory results, with the accuracy levels ranging from 83.9-115.1 %. 
However, certain analytes (oxazepam, lorazepam, nordiazepam, methadone, PCP) ranged from 119-127  
Table 2.23 Figures of merit for the determination of drugs of abuse in urine using coated PEEK mesh 
via DART-MS/MS. 
 
% at 8 ng mL-1. At 40 ng mL-1, lorazepam and diazepam were slightly elevated, giving an accuracy of 
120.1 % and 121.8 %, respectively. The cause of these elevated levels could be contributed to MEs 
(particularly at lower validation levels) carrying the same MS/MS transition as the analytes of interest. 
It is possible that matrix enhancement occurred due to co-extraction of small molecules present in 
urine.304 Additional calibration plots for selected analytes nicotine, MDMA and fentanyl are shown in 
Figure 2.71a., c. and e., respectively. It is worth mentioning that the detection of compounds with lower 
molecular weights (m/z < 150) at low concentration levels may yield higher detection limits due to the 
intrinsic level of background signal exhibited by DART for such compounds (e.g. when monitoring an 
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Oxycodone 0.5 5.0 0.9970 0.5-100 - 79.6 (1.8) 86.3 (7.1) 99.7 (4.8) 92.8 (6) 
Nicotine 2.5 5.0 0.9941 5-175 - 108.4 (7.2) 107.8(11.1) 
(((11.1) 
105.9 (6.6) 92.0 (9) 
MDMA 1.0 5.0 0.9949 5-200 270190 75.1 (4.8) 108.8 (5.6) 111.5 (6.8) 101.5 (10.2) 
Methamphetamine 1.0 5.0 0.9917 5-200 410190 115.9 (4.3) 119.3 (2.4) 115.1 (3.2) 107 (5.9) 
Oxazepam 0.5 1.0 0.9948 1-100 13190 121.2 (7.1) 106.8 (4.9) 109.9 (4.6) - 
Cocaine 0.1 0.5 0.9930 0.5-100 170190 112.2 (10.9) 111.6 (6.3) 
(6.8) 
103.1 (8.3) - 
Lorazepam 0.5 1.0 0.9935 1-50 1.1190 120.8 (5.8) 97.0 (2.6) - - 
Diazepam 2.5 5.0 0.9924 5-125 5190 83.9 (5.8) 123.2 (4.7) 119 (2.8) - 
Nordiazepam 0.5 1.0 0.9962 1-100 1.1190 87.1 (12.3) 86.6 (5.5) 105.5 (3.5) - 
LSD 0.5 1.0 0.9994 5-200 - 101.5 (5.8) 106.7 (1.9) 104.9 (12) 101.6 (5.9) 
Methadone 0.5 1.0 0.9943 1-100 22190 117.9 (6.6) 88.8 (3.4) 106.6 ((4.8) - 
Fentanyl 0.5 2.5 0.9988 2.5-125 - 109.7 (8.1) 128.1 (1.8) 110.1 (8.7) - 
PCP 0.5 5.0 0.9923 5-200 25189 115.4 (3.7) 122.0 (1.5) 108.1 (5.2) 93.4 (5.0) 
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m/z value, like methamphetamine, was 25 ng mL-1 in the case of urine, and 5 ng mL-1 for OF. In cases 
where major product ion yields higher background noise, it is advisable to investigate other transitions  
as they may give better results for quantification using DART (see Figure 2.72 for an example of 
monitoring of 2 transitions of amphetamine). It is important to note that the LDR for the majority of the 
compounds was adequate up to the highest calibration point (i.e., 200 ng mL-1); the lone exception to this 
was lorazepam, for which detector saturation started occurring at lower concentration levels (~ 50 
ng mL- 1; see Figure 2.73). When compared to OF, urine required a shorter rinsing step of 10 s to allow 
for sufficient mesh clean-up. It is possible that some co-extracted components were additionally 
introduced into the MS, but the use of MS/MS capabilities significantly reduces the chances that those 
co-extracted components will interfere with the analysis process. In addition, it is also worth noting that 
Figure 2.71 External calibration curves with IS correction of selected analytes in urine for LSD (a.), 
oxycodone (c.) and diazepam (e.) and OF for nicotine (b.), MDMA (d.) and fentanyl (f.).   
159 
 
the meshes are miniaturized, which allows for simple and less troublesome on-site handling for 
authorities. 
  
Figure 2.72 MS signal obtained for the SRM channels of amphetamine with DART-MS/MS. Figure (a.) 
shows the overlay of normalized chronograms for amphetamine for monitoring of m/z 136 » 119 and 
m/z 136 » 91 for ambient air in DART. Figure (b.) shows the ion chronograms obtained for desorption 
of 2 replicates of blank PBS extract and 2 replicates of 10 ng mL-1 of amphetamine spiked in PBS for 
m/z 136 » 119 and m/z  136 » 91. Note that m/z 136 » 119 transition exhibits lower background signal 
and higher S/N ratio.   
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 For example, sample extraction can be carried out on site and immediately processed using a portable 
instrument for drug detection.33 If portable instrumentation is not available, the meshes can be stored in 
a container that allows temperature to be carefully controlled. The influences of diverse storage 
conditions for these types of samples are currently under investigation in our laboratory.  
Caffeine analysis  
Since the major objective in developing these meshes is to provide law enforcement officers with a tool 
for in vivo OF analysis, an experiment was conducted in our lab wherein we semi-quantitatively measured 
caffeine levels in OF from a volunteer at different time points following the consumption of a single cup 
of coffee. Given that the literature points out that caffeine is typically concentrated in OF at mg L-1 levels, 
the samples were diluted with PBS in order to ensure they were within the instrument’s LDR. As a result, 
Figure 2.73 Data obtained for detecting lorazepam in urine and OF with IS correction in (a.) and (c.), 
with visible saturation after 75 ng mL-1 and 50 ng mL-1, respectively. Figures (b.) and (d.) show the area 
obtained for lorazepam (blue) and its IS (orange). The concentration of the IS (Lorazepam-d4) was kept 
at 10 ng mL-1. 
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a calibration curve was constructed in PBS as shown in Figure 2.74(a.). Furthermore, as can be seen in 
Figure 2.75, detector saturation was only observed above 1000 ng mL-1. Therefore, a calibration plot 
with an LDR of 5-1000 ng mL-1 was used to calculate the caffeine levels in the diluted OF samples. The 
results obtained for each point (n = 3) can be seen in Figure 2.74(b.). It is worth noting that the volunteer’s 
history reveals frequent coffee consumption (approximately 2 cups daily), and that 4.6 mg L-1 of caffeine 
were present in the OF sample following 24 hours of caffeine fasting. Five minutes after coffee 
consumption, the caffeine level was calculated to be 15.3 mg L-1; this figure fell to 7.6 mg L-1 one hour 
after coffee consumption, which is consistent with caffeine’s average half-life of 6.2 ± 1.6 hours.305 The 
figures for 3 and 5 hours post consumption revealed a small drop to 7.4 and 6.5 mg L-1, respectively. 
However, it is possible that other processes take place too, such as distribution of caffeine in OF 
immediately after drinking as well as slower metabolism of caffeine (~ 12 h). The ion chronograms 
obtained at the different time points can be seen in Figure 2.76. It is important to highlight that this 
experiment was used to perform a semi-quantitative analysis of caffeine levels in OF, and that one must 
Figure 2.74 Semi-quantitative caffeine levels measured in the OF of a female volunteer after 
consumption of a single cup of coffee. Figure (a.) shows the calibration curve obtained for spiking 
caffeine in PBS, while Figure (b.) shows the semi-quantitative trend in caffeine levels measured (without 
the dilution factor) by monitoring caffeine ion’s product (m/z 195.1→135.1). The chart includes 
caffeine levels (n = 3) measured after a 24 h caffeine fast, followed by measurements at 4 different post-
consumption time points.  
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be cognizant of the fact that MS systems can experience detector saturation at high analyte concentration 




























Figure 2.75 Figure (a.) shows the signal response in au (arbitrary units) of caffeine and caffeine-C13 
respectively up to 1000 ng mL -1 while (b.) shows the same as (a.) but with detector saturation caused 
by the inclusion of the 2000 ng mL-1 point.  The concentration of IS (Caffeine-C13) was kept at 50 ng 
mL-1. 
Figure 2.76 Example of the ion chronogram obtained for detection of caffeine (m/z 195.1 → 138.1) in 
OF for a 24 h caffeine fast period (2x), 5 min post coffee consumption (2x), 1 h post coffee consumption 
(2x), 3 h post coffee consumption, and 5 h post coffee consumption (2x). 
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2.7.4 Conclusion for Section 2.7 
 
This work details the development and application of biocompatible coated SPME plastic mesh for use 
in screening and quantitating prohibited drugs in OF and urine. The chosen material provided mechanical 
robustness and good resistance to high temperatures. Furthermore, the gentle ion milling method proved 
to be appropriate for etching the plastic material prior to the adhesion of the coating. A stability test for 
SPME-TM-PEEK revealed good coating attachment, as no fall-out was observed during the test 
conditions, and no issues were observed upon exposure to high temperatures from the DART source. The 
assessment of the coated PEEK mesh’s repeatability provided us with acceptable results, with a % RSD 
of less than 10 % without IS correction. Similar results were obtained when the plastic mesh was 
compared to the traditional SPME-TM SS-coated meshes. Drug quantification was successfully 
performed, allowing us to reach lower or comparable LODs and LOQs required by all the regulatory 
agencies with the exception of LSD cut-off for urine detection imposed by CLR. In addition, the detection 
of caffeine levels in OF obtained from a volunteer proved the method’s feasibility for on-site analysis. 
Tests for reusability showed that, although the meshes are intended for single use, they can be reused for 
screening purposes. This work demonstrates the great potential of these meshes for used in roadside drug 
testing, given the availability of proper portable DART instrumentation.134 Currently, our efforts are 
focused on demonstrating SPME-TM’s advantages as an analyte sampling technology for use following 
conventional sampling protocols with cotton swabs or polymeric adsorbents. Future work will be focused 
on demonstrating that coated meshes can collect analytes, either from pure OF, or from OF stored in 
clinically-accepted containers (i.e., stabilizing solution after sampling with adsorbent).  
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 Development of miniaturized SPME tips coupled to mass spectrometry 




Chapter 3 consists of content which has already been published in Talanta. The majority of content 
published in Talanta has been included in this chapter, but it also includes portions which have not been 
published elsewhere. Majority of chapter 3 is published as:173 
Vasiljevic, T.; Varoon, S. and Pawliszyn, J. Miniaturized SPME tips directly coupled to mass 
spectrometry for targeted determination and untargeted profiling of small samples, Talanta, 2019, 199, 
689-697, doi: 10.1016/j.talanta.2019.03.025. 
Text, table and figures are reprinted with the permission from Elsevier (Copyright 2019 Elsevier). 
I participated in all stages of the development of the SPME minitips, including optimization of its 
substrate and the coating recipe. I designed all of the experiments and carried them out with the aid of 
Dr. Varoon Singh. Dr. Varoon Singh provided crucial expertise for the synthesis of the required 
microporous HLB particles and their characterization. I prepared the manuscript, submitted it and carried 
out communication with reviewers of Talanta. Dr. Singh aided me in the manuscript writing process. 













Mass-spectrometric-based small volume analysis has recently become popular within analytical 
chemistry, with a growing number of publications exploring the development of suitable methods for 
analyzing small liquid volumes or sampling extremely small organisms (i.e., single cells).118,130,306,307 
Generating sensitive and reliable data for this type of analysis requires a high level of sophistication when 
it comes to equipment, materials, sensitivity, and even sampling, which may pose a challenge for an 
inexperienced analyst.8 To this end, several sample-preparation techniques have emerged as being 
potentially suitable for analyses of small volumes, including microsampling,308 DBS,119 microfluidics,204 
and probe-based sampling.307 
As the name suggests, probe-based sampling uses a dimensionally reduced probe to perform 
investigations, either by exposure to a small volume, penetration of the organism under study, or the 
removal of its contents via aspiration.309 Removing cell contents via hollow probes (like nESI) is an 
emerging field,128,129,131,310–312 but issues related to probe clogging, cost, instrument cleanliness, and 
associated MEs (no sample clean-up, all cellular contents directly sprayed into MS) have scarcely been 
addressed. In addition, such approaches are plagued by a lack of selectivity, with trace metabolites being 
difficult to detect due to ion suppression.309 In contrast, solid-probe-based approaches rely on directly 
exposing the probe to the desired sample and performing nonspecific or specific extraction via the 
probe’s coating material. As with nESI tips, solid probes can be ordered, but the material cost is often 
high.307,313,314  
 Solid probes can be coated with extractive materials, which allows for the pre-concentration of analytes 
of interest and improved sensitivity. This is important because the coating material ultimately determines 
the quality of the information obtained. Therefore, in order to achieve optimal selectivity, the 
physicochemical characteristics of the extractive material should be as close as possible to those of the 
analytes of interest (in case of charged analytes, coating with ion exchange groups can be used). It is 
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interesting that many authors have reported using un-coated probes, which rely on non-specific binding 
between the material (commonly metallic tips) and the compounds.127,131,307 Although this approach 
produces results that identify highly concentrated,25,313,314 mostly lipid-based (500-1000 m/z range), or 
pre-spiked compounds, it tends to ignore compounds with lower m/z values. As such, the information 
produced is limited at best. Additionally, a lack of preconcentration means that hyphenated approaches 
(i.e., chromatography) are generally avoided, which become problematic as sample and data complexity 
increase. Hence, there is a need for interference-resistant, cost-effective, reproducible and pre-
concentrating tool which offers adequate sensitivity and selectivity.  
SPME is one technology that meets these criteria. SPME is ideal for probe-based small-volume analyses 
because its simple design is easily customizable. Its dimensions can be conveniently reduced, and 
different coatings deposited depending on analytes being investigated. Undoubtedly, drop in sample 
volume challenges sensitivity of any sample preparation method. For SPME, this issue can be resolved 
by exploring more efficient extraction phases such as nanomaterials.315–318 However, the structure of 
these materials is often altered in order to obtain better extraction efficiency,319–322 which precludes 
investigations into the material’s ability to provide a broad range of coverage for analytes with different 
physico-chemical properties. Additionally, some of these materials raise problems, like large 
biomolecule adsorption,323,324 batch-to-batch variability and deterioration in the homogeneity of the 
material,325 limited extraction capability326,327 and release of heavy metals into surroundings which can 
be highly toxic for living organisms.328 Piri-Moghadam et al. reported the development of SPME “coated 
tips,” which consist of acupuncture needles with tips that have been electrochemically coated in the 150-
500 µm range using a biocompatible nanostructured conductive polymer polypyrrole (PPy).25 The tips 
were used to extract selected drugs from biological samples (Vs ≤ 20µL), as well as quercetin  (70 mg 
g−1 mean, onion skin)329 from a single cell of onion (Allium cepa L). PPy is a conductive polymer that is 
frequently used for SPME, but, similar to the above-mentioned materials, its properties must be tailored 
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through the addition of dopants in order to meet different mechanical and extractive requirements.42 
Furthermore, PPy’s robustness may pose problems, as the material has poorer stability (breakage) when 
it is immobilized onto a material like SS.7  
 In this chapter, development of biocompatible HLB-coated miniaturized SPME probes—conveniently 
named “minitips”—that can be used in small-volume/organism studies, is detailed. Our goal was to 
develop a tool that would be able to perform three tasks: 1.) efficiently analyze small liquid volumes 
(Vs < 20µL); 2.) extract samples from small subjects/organisms; and 3.) provide adequate coverage of 
polar and non-polar analytes. Mousavi et al.50 extracted over 1000 cellular E.coli metabolites within a 
broad logP range spanning from −7 to 15 using HLB coated SPME thin-film. HLB is a highly wettable 
(i.e., good interaction with aqueous samples) co-polymer that contains lipophilic non-polar DVB and 
polar hydrophilic NVP groups, which makes it an ideal sorbent for extracting both polar and non-polar 
compounds. In this study, we used in-house synthesized microporous (1.3 µm particle size) HLB 
particles that had been imbedded within an interference-resistant biocompatible binder PAN in order to 
assess how well HLB performs in small volume analyses, specifically in relation to extraction efficiency, 
sensitivity, and selectivity (i.e., extracting as many compounds as possible). Cost-effective SS 
acupuncture needles were used as substrates, carefully etched and dip-coated in the 100-1000 µm length 
range.  The minitips proved to be robust during preliminary performance assessments, which led us to 
apply the minitips for quantification of DoAs in 1 µL of OF via LC-MS/MS as well as 1 µL of human 
blood via ambient nESI-MS/MS. Next, a proof-of-concept study investigating the metabolomic profile 
of four different individual caviar eggs was conducted using the minitips and LC/HRMS. The results 
showed that this method was able to provide good statistical discrimination between the samples (PCA 





 Experimental  
Chemicals/Materials for the Synthesis of HLB particles   
The HLB particles were synthesized using DVB, NVP, and 2,2-Azo bis(isobutyronitrile) (AIBN). HPLC-
grade MeOH and ACN were purchased from Millipore-Sigma, and a mechanical stirrer with regulated 
speed controls (50-2200 rpm) was purchased from Scilogex LLC (Rocky Hill, Connecticut, USA). 
Temperature was controlled using a magnetic hot plate that was equipped with a temperature sensor; a 
stirring controller was also purchased from Scilogex LLC. All the monomers were passed through an 
alumina column to remove inhibitors before being stored in amber coloured vials at −23 °C until further 
use. 
Chemicals/Materials for the Remainder of the Experiments  
PAN, DMF, and mesoporous silica nanoparticles (SiNPs) with particle and pore sizes of 200 nm and 4 
nm, respectively, were all ordered from MilliporeSigma. LC/MS-grade MeOH, ACN, H2O, FA and IPA 
were also purchased from MilliporeSigma. The following compounds were ordered from Cerilliant at 
concentrations of 1000 mg L-1: diazepam, nordiazepam, oxazepam, lorazepam, cocaine, oxycodone, 
propranolol, carbamazepine, fentanyl, clenbuterol, cocaethylene, testosterone, benzoylecgonine, and 
LSD. Corresponding ISs were also ordered from Cerilliant at concentrations of 100 mg L-1: diazepam-
d5, nordiazepam-d5, oxazepam-d5, lorazepam-d4, cocaine-d3, oxycodone-d3, propranolol-d7, 
carbamazepine-d10, fentanyl-d5, clenbuterol (HCl)-d9, cocaethylene-d3, testosterone-C13, 
benzoylecgonine-d3, and LSD-d3. Diazepam, nordiazepam, oxazepam, lorazepam and their respective 
ISs constituted a group entitled benzodiazepines (BZDs). A pooled urine sample was created using 
contributions from one male and one female volunteer, while a pooled OF sample was created using 
contributions from five healthy individuals (three females, two males). Both matrices were kept at -20  °C 
prior to use. Human blood stabilised with K2-EDTA and plasma was ordered from BioreclammationIVT 
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and kept at 4°C until use. The caviar samples, which consisted of black lumpfish, red lumpfish, herring, 
and salmon, were purchased from a local supermarket (Waterloo, ON) and kept at 4 °C until sampling 
was conducted. 
Preparation of the SPME minitips substrates  
An MTS50/M-Z8E-Metric-Tapped 50 mm motorized stage with a controller and a PSU was purchased 
from ThorLabs, Inc. (Newton, MA, USA) and was used to construct an in-house coating station for tip 
fabrication (Figure 3.1). To ensure repeatability, a liquid-level sensor (conductivity based) was developed 
at UW (Figure 3.2) and was used to detect the contact point between the tip and the solution. SS 
acupuncture needles (gauge: 0.18 mm, length: 40 mm), shown in Figure 3.3, were ordered from Electro-
Therapeutic Devices Inc. (Markham, ON, Canada). Etching parameters were optimized with respect to 
etching solution type and concentration, voltage, and time required to etch one tip to a desired shape. 
With respect to solution type, both KOH and sodium hydroxide were tested, with KOH providing better 
results. The optimum etching concentration was determined to be 1M KOH, and voltage and etching 
time were kept at 11 V and 40 s, respectively.  After 40 s, the needle was carefully withdrawn from the  
Figure 3.1 Stage developed in-house at UW for manufacturing the SPME minitips. A.) motorized portion 
of the stage that controls the movement in z-axis; B.) Teflon-made holder used to accurately position the 



















Figure 3.2 Liquid level sensor developed at the electronic shop at UW. 
Figure 3.3 Acupuncture needles ordered from Electro Therapeutic Devices (gauge: 0.18 mm, length: 
40 mm). The needle shown here has not undergone any pre-treatment to enhance binding of HLB 
particles to the tip. Note how smooth the surface of the needle appears. Measurements were made at 
different points to examine tip diameter, which were 27.2, 48, and 64 µm at a., b., c., and d., respectively. 
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etching solution (with voltage still applied) at 0.2 mm s-1 to produce a conical shape. The tip was then 
gently sanded and sequentially cleaned in IPA, acetone (ACE), and H2O. Finally, the tips were dried at 
100 °C for 15 min and stored in IPA (to prevent oxidation) until further use.  
Synthesis of HLB particles 
HLB particles were synthesized via a modified form of precipitation polymerization.330 In the setup used 
in this study, 4 mL of DVB and 1 mL of NVP were added to a 500 mL three-necked round bottom flask 
containing 200 mL of ACN and degassed for 30 min. After 30 min, the reaction was immersed in a 
preheated oil bath at 70 °C. After immersion, AIBN (20 mg) dissolved in 1 mL ACN was added to the 
solution, which was then stirred for 24 h using an overhead stirrer equipped with a SS stirring rod 
containing a Teflon stirring blade. During stirring, the solution is sealed using polytetrafluoroethylene 
(PTFE) stirring seals for overhead stirrers to preserve the inert environment inside the flask. To avoid 
losing initiators during the reaction, the polymerization solution was jacketed with N2 above the reaction 
mixture throughout the reaction. After 24 h, the precipitated particles were separated from the reaction 
mixture via centrifugation at 10,000 rpm. The obtained HLB particles were then washed with ethanol 
(EtOH) to remove excess unreacted monomer, oligomers, and/or short chain polymers. The HLB 
particles were then dried in a vacuum oven at 80 °C for 24 h before being characterized by fourier 
transform infrared spectroscopy (FTIR) using a Tensor II spectrometer (Bruker Corp., Billerica, MA, 
USA). Spectrums ranging from 400-4000 cm-1 were collected in powder form using a Standard Pike 
ATR cell. Surface morphology and size were determined via SEM with a Zeiss FESEM 1530, and SA 
analysis was done using a Quantachrome Autosorb iQ-MP (Boynton Beach, FL, USA) for BET analysis 
on nitrogen adsorption isotherms obtained at 77.35 K and outgassing at 373 K. 
SPME-minitip HLB Coating Procedure  
In order to create effective coatings for the minitips, it was necessary to optimize the percentage of PAN 
binder and HLB particles in the slurry. To this end, the following PAN-to-DMF percentages were 
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evaluated to determine the optimum binder viscosity: 5, 6, 7, 10, 12, and 20 %. Furthermore, the 
following percentages of HLB-particles-to-PAN binder were also tested for this purpose: 7, 10, 12, and 
20%. The optimum ratio was determined to be 6 % of PAN mixed with 15% of HLB particles. The 
minitips were coated via dip coating, wherein 6 repeated dips were performed with a withdrawal speed 
of 3.5 mm s-1 (a = 5 mm s-2). Following dipping, each tip was cured at 100 °C for 20 s before being 
cleaned in a solvent mixture consisting of MeOH/ACN/IPA (50/25/25) and stored in MeOH/H2O (50/50) 
until further use. Subsequent images of the minitips were taken with an Olympus microscope (SZX100) 
equipped with an SC30 digital camera (Olympus, Tokyo, Japan). 
Preparation of stock standards 
Stock mixtures of the studied analytes and their corresponding ISs were made at concentrations of 100 
mg L-1 and 10 mg L-1. Urine and PBS (used for preliminary investigations) were spiked with appropriate 
concentrations of the stock solution to construct a 13-point calibration plot (0.1, 0.5, 1, 5, 10, 25, 50, 75, 
100, 200, 300, 400, and 500 ng mL-1) for the quantitation of BZDs in these matrices. BZD’s internal 
standards were spiked at a concentration of 100 ng mL-1 and a QC point of 100 ng mL-1 was used to 
assess accuracy and repeatability. DoA compounds were added to OF at a wider concentration range (1, 
5, 10, 25, 50, 75, 150, 300, 500, 650, 700, 850, and 1000 ng mL-1), as well as to blood at 0.5, 2.5, 5, 12.5, 
25, 37.5, 75, 150, 250, 325, and 425 ng mL-1. IS concentrations were kept at 100 ng mL-1 for OF and 50 
ng mL-1 for blood analysis, with selected QC points of 150 ng mL-1 and 37.5 ng mL-1 for OF and blood, 
respectively. Spiking was carried out in a manner that limited the organic content in the matrices to less 
than 1 % in order not to disturb any partition equilibria that may occur during the extraction process.7 
After spiking, the matrices were gently agitated at 200 rpm for at least 2 h to establish drug-matrix 
equilibration. No other modifications were made to the matrices under study. A pooled QC (PQC) sample 
for the metabolomics analysis was created using 10 µL of each desorbed caviar sample post-extraction.  
MEs in this study were assessed according to protocol by Mateuzewski et al.331 
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Preliminary assessment of HLB minitip performance using BZDs as model compounds 
Before the quantitative and profiling studies could be performed, we had to assess the stability, robustness 
and extraction efficiency of the tips. Potential coating fall-out was examined via rapid agitation at 
1800 rpm overnight (12 h) and by puncturing a piece of clay. Intra-tip (repeatability of a single minitip 
used multiple times) and inter-tip reproducibility (repeatability of multiple minitips) were investigated 
with and without IS for correction, by performing five subsequent extractions from both 50 µL of PBS 
and urine (200 ng mL-1 of BZDs, 10 min extraction, 5 min desorption to 50 µL of ACN/H2O (50/50). 
The same experimental conditions were used to: 1.) examine how sensitivity is influenced by the 
preconditioning solvents (MeOH/H2O at 50/50, 80/20, 100/0 and 20/80 %; ACN at 100 %; IPA at 100 
%; Ethanol (EtOH) at 100 % and MeOH/IPA at 50/50%), and 2.) whether tip pre-treatment 
(preconditioned, preconditioned & washed, cleaned only had an impact on the sensitivity. Furthermore, 
extraction (0.5, 1, 2.5, 4, 5, 10, 30, and 60 min) and desorption (0.5, 1, 5, 10 min) time profiles for BZDs 
(200 ng mL-1, 50 µL of PBS, desorption: 50 µL ACN/H2O (50/50)) were performed to examine the 
extraction kinetics and the desorption process. The influence of sample volume on the signal response 
was examined by performing 10 min extractions from 1, 2, 3, 5, 10, and 50 µL of PBS spiked with 200 
ng mL-1 of BZD(s) and desorbing them to 50 µL of ACN:H2O (50:50). Finally, preliminary investigation 
of quantitative capabilities of the minitips were done extracting from a 15 µL PBS sample for 5-mins, 
followed by a 1-min desorption to 15 µL of ACN/H2O (50/50).  All of the afore-mentioned experiments 
were done on an API 4000 equipped with a Shimadzu binary pump and a CTC PAL autosampler. 





Table 3.1 Summary of chromatographic conditions used for BZD separation via API 4000.7 
Column 
Agilent-Zorbax: Extend-C18 (3.5 µm, 2.1 mm x 
50 mm) 
Mobile phase 
A: 90/10 H2O/ACN + 0.1 % AA 
B: 90/10 ACN/H2O + 0.1 % AA 
Flow rate 150 µL min-1 
Injection volume 20 µL 
Injection mode Full loop 
Spray voltage  5000 V 










0-0.51 min 90 % 10 % 
0.51-2.50 min  10 % 90 % 
2.51-5.00 min  10 % 90 % 









Table 3.3 List of analytes monitored via API 4000, including logP values (PubChem),156 parent and 
product ions (m/z), DP, EP, CE and CXP. 
 
Extraction from 1 µL of OF  
The quantitation of DoAs in OF was performed using static 5 min extractions from 1 µL of sample placed 
into a 300 µL vial, followed by a wash step (10 s, 3200 rpm) and 1 min desorption to 50 µL of 
MeOH/ACN/FA (80/20/0.1). Schematic of this process is shown in Figure 3.4. Instrumental analysis was 
also performed using LC-MS/MS. Details on the chromatographic method used are available in section 
2.5.2.211 Details on compound specific optimization parameters are available in Section 2.2.2, 2.5.2 and 






DP (V) EP (V) CE (V) CXP (V) 
Diazepam 2.82 285 154 118.7 11.7 37 11.2 
Diazepam-d5 - 290.3 262.1 117.2 9.9 34.6 20.1 
Oxazepam 2.24 287.1 241 121 12.8 32.7 39 
Oxazepam-d5 - 292 246 107.1 11 35 21.5 
Nordiazepam 2.90 271 140 60.8 8.5 42.8 11.3 
Nordiazepam-d5 - 276 213 117.2 6.8 39.3 16.1 
Lorazepam 2.39 321.1 275.1 65.1 5.7 27 42.2 
Lorazepam-d4 - 325 279 94.5 10.8 34.4 20.2 




Table 3.4 List of analytes monitored via TSQ Vantage, including log P values, parent and product ions 
(m/z), collision energy (CE) and S-lens. 






energy (eV)  
S-lens 
Carbamazepine 2.45 237.1 194.1 19 86 
Carbamazepine-d10 - 247.1 204.1 20 127 
Clenbuterol HCl 2.94 277.1 202.9 14 91 
Clenbuterol-d9 HCl - 286.1 204.0 15 83 
Testosterone 3.21 289.1 97.0 23 114 
Testosterone-C133 - 292.1 100.0 23 114 
Propanolol 3.48 260.1 116.1 17 92 
Propanolol-d7 - 267.1 116.1 17 87 
Nanoelectrospray experiments 
Standard coated nESI sprayers (PicoTip, BG10-58-2-CE-20) were ordered from New Objective 
(Woburn, MA, USA). Prior to conducting the nESI experiments, the instrument was run overnight using 
a single solvent mixture (MeOH/ACN/FA, 80/20/0.1), a flow rate of 400 µL min-1, a spray voltage of 
1300 V, a vaporizer temperature of 275 °C, sheath gas of 45 (AU), auxiliary gas of 30 (AU), and capillary 
temperature of 280 °C. This was done in order to provide a primed environment for the nESI experiments 
(i.e. reduce noise from analytes previously run by other users on the TSQ-Vantage). Prior to performing 
the experiments, the optimum spraying voltage was determined by monitoring the signal of different 
analytes at varying voltages, i.e. at 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, and 1500 V. 
After 1500 V, a drop in signal was observed; therefore, 1300 V was used for the experiments. One µL of 
blood was placed into a 300 µL glass vial using a 0.5-2.5 µL Eppendorf pipette. The experiments were 
carried out by inserting the minitip into 1 µL of blood for a 5 min static extraction, which was followed 
by a 10 s wash under a stream of LC/MS-grade H2O and a 1 min offline desorption (static) into 3 µL of 
MeOH/ACN/FA (80/20/0.1). Following desorption, the solvent was transferred to the nESI sprayers 
using a 10 µL capillary syringe. The sprayers were then immobilised into a stage that had been specially 
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designed at UW for nESI desorptions.206 Next, a voltage of 1300 V was applied to the nESI tip, and the 
signal was acquired for 20 s. A schematic of this process can be observed in Figure 3.5. The calibration 
plots were generated using a matrix matched approach with IS correction, and the LODs and LOQs were 
determined based on S/N ratios of 3 and 10, respectively. Analysis was performed via MRM mode in 
+ve ionization mode using a TSQ Vantage (Thermo Scientific). Compound specific details pertaining to 
TSQ-Vantage can be accessed in Section 2.2.2, 2.5.2 and Table 3.4. 
 
Caviar sampling  
Caviar samples were purchased randomly from the store while ensuring that egg diameter was < 3.0 mm. 
Each caviar egg was measured as having a diameter of ≤ 2.9 mm. A single egg was carefully removed 
from the container, placed onto a microscope slide, and penetrated with a minitip that had been 
preconditioned and washed with H2O. Each extraction was carried out for twenty minutes, with a total 
of six (n = 6) replicates being performed for each caviar type. The sampling process is illustrated in 
Figure 3.6. Desorption was performed in 90 µL of LC/MS-grade ACN/H2O (50/50) for a total of 10 min 
via agitation at 500 rpm. The desorbed samples were analyzed in +ve ionization mode on an Exactive 
Orbitrap that was equipped with an Accela autosampler and a pump, using a generic method that had 
been developed and published by the Pawliszyn research team for global metabolomics (PFP column, 
binary gradient, 300 µL/min flow).45 The stability of the run was monitored by injecting a pooled QC 
(PQC) every 7th injection. Details pertaining to the instrumental run can be found in Table 3.5-3.6. 





Table 3.5 Summary of chromatographic conditions used for the separation of caviar samples via 
Thermo Exactive.45 
Column Phenomenex: PFP (1.7µm, 2.1 mm x 10 mm) 
Mobile phase 
A: 100 % H2O + 0.1 % FA 
B: 100 % ACN + 0.1 % FA 
Flow rate 300 µL/min 
Column temperature 25 °C 
Injection volume 10 µL 
Spray voltage 4 kV 
Vaporizer temperature 300 °C 
Sheath gas 30 AU 
Auxiliary gas 10 AU 
Capillary temperature 300 °C 
     
Figure 3.6 The set of samplings performed for the metabolomic profiling of caviar. 
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0-3 min 100 % 0 % 
3-25 min 10 % 90 % 
25-34 min 10 % 90 % 
34-40 min 100 % 0 % 
 
 Results/Discussion    
 
Characterization of the HLB particles 
FTIR was used to examine the presence of the monomers that were used to synthesize the HLB particles 
used in this study. The peak at 1687 cm-1 indicates the presence of C=O groups of lactams in NVP in the 
polymer backbone (Figure 3.7), while the peaks at 1603, 1507, and 1446 cm-1 confirmed the stretching 
frequency of the conjugated C=C bonds in the benzene ring. The peaks at 2921 cm-1 and 3100 cm-1 were 
respectively created by the –CH stretching of the alkane chain following polymerization and the terminal 
–CH2 groups of terminal alkenes that arise from the residual –HC=CH2 of the vinyl groups; these peaks 
also confirm the presence of DVB and NVP monomers in the final HLB particles. The size and shape of 
the HLB particles were imaged using SEM (Figure 3.8), and, as this image shows, the particles are 
monodisperse, spherical, and smooth on the surface with an average size of 1.33 µm. Furthermore, the 
particles do not show any signs of agglomeration or the formation of a core-shell structure consisting of 
two different monomers. Surface-area analysis revealed that the synthesized HLB particles were porous, 







Preparation of the SPME minitips: Optimization of etching conditions 
The development of a protocol for manufacturing of SPME minitips was an integral step in this study, 
as it is important to establish a controlled production setting. Given the difficulty of manually fabricating 
SPME minitips on a very small scale, a motorized stage and sensor were constructed at UW to ensure 
that the tip shape could be normalized and that a coating length of 1 mm could be reliably reproduced. 
Figure 3.7 FTIR image obtained from Tensor II spectrometer for the analysis of HLB particles. 
Figure 3.8 SEM image of HLB particles captured at 10kX. 
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SS acupuncture needles were selected for use in order to avoid the need for expensive materials (i.e., 
titanium tips). Since the diameter of the acupuncture needles was greater than required, we developed a 
protocol for diameter reduction via electrochemical etching that would also allow for the robust 
adherence of HLB particles. The fabrication protocol enables tip diameter manipulation through 
immersion in the etching solution at a fixed position. For instance, a sharper tip can be obtained by 
withdrawing it from the etching solution (1 M KOH) at a speed of 0.2 mm s-1 while voltage (11 V) is 
still being applied. The SEM images obtained for the untreated, etched, and sanded tips can be seen in 
Figure 3.9, and, as can be seen, the tip surfaces exhibit a tendency towards a coarser morphology. In 
controlling the etching conditions, it becomes possible to make tips with varying diameters, including 
diameters small enough that they can be applied for extractions from very small sample volumes (i.e. 
Figure 3.9 SEM images of acupuncture needles obtained from Electro-Therapeutic Devices. A.) 
Untreated acupuncture needle (no etching); B.) Close-up of untreated acupuncture needle (no etching); 
C.) Needle surface topology after etching in KOH for 40 s; D.) Close up of needle surface after etching 
in KOH for 40 s; E.) Topology of previously etched needle after sanding; F.) Close up of topology of 
previously etched needle after sanding revealing a rougher surface suitable for dip-coating.   
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small organisms or single cells). However, it is important to keep in mind that very thin SS tips can be 
more prone to bending and breakage, which can make sampling more difficult. As such, it would be 
useful to consider alternative materials for applications that require smaller minitips. 
Preparation of the SPME minitips: Dip coating procedure 
Initial attempts at ≤ 1 mm coating lengths proved troublesome. These attempts were carried out using a 
procedure established  by the Pawliszyn group48 and commercially available HLB particles (particle size 
range: 5-30 µm) from Waters. The commercial particles were ground using a ball mill, but the resulting 
slurry did not produce positive results (even after ten dip coats). Further attempts to increase the 
solution’s viscosity and particle percentage were unsuccessful, as they only yielded coagulated clusters 
(Figure 3.10). It became apparent that the thickness of the minitip’s cone region (d < 130 µm) posed 
significant challenges to the dip-coating process, as it resisted the viscous pull drag. Another contributing 
factor to these difficulties was the attempt to coat the minitip at a length of ≤ 1mm. According to 
Brinker,332 the process of dip-coating depends on factors such as particle size and structure, surface  
Figure 3.10 Attempt to coat an acupuncture needle using solution with higher viscosity and particle 
percentage. Note that simply increasing viscosity and the percentage of particles is insufficient to obtain 




tension, dipping speed, and gravitational draining. To the best of our knowledge, there is no reported 
research that has investigated how substrate size influences the dip-coating process. Several researchers 
have reported that the dip coating process becomes more difficult on a microscale due to surface-tension 
forces.333,334 It is important to note that we used the “draining regime” dip-coating process (withdrawal 
speeds > 1 mm s-1, Landau-Levich model).334 As such, the minitips were coated using the highest 
withdrawal speed offered by our device (3.5 mm s-1). Fang et al.333 reported that film thickness could be 
increased by increasing the concentration of polylactic acid (PLA), as the amount of PLA coated onto 
the tip will be greater due to increased drag force, which is directly proportional to solution viscosity. 
Given this relationship, we decided to investigate whether reducing particle size (< 5 µm) and increasing 
the percentage of particles in the slurry would result in a successful dip-coat. To test this idea, we used 
200 nm sized silica nanoparticles (SiNPs) and adjusted the coating recipe to 6 % PAN viscosity and 15 
% particles, which produced a successful minitip coating process (Figure 3.11). However, since SiNPs 
are limited in terms of extraction efficiency, we synthesized HLB particles at a size of 1.3 µm and used 
them with the same recipe that we used for SiNPs. The coated SPME minitips and the respective SEM 
images can be seen in Figure 3.12. The dip-coating process causes a gradual reduction in coating 
thickness, which is most evident at the thinnest parts of the minitip. Therefore, the solid coating does not 
have a uniform thickness; rather, the coating thickness decreases as the substrate thickness decreases. As 
Figure 3.11 SPME minitip coated with SiNPs (particle size: 200 nm; pore size: 4 nm) using a recipe 
consisting of 6% PAN and 15% SiNPs. 
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can be seen in the SEM images in Figures 3.13-3.14, the thickness of the coating is 4.1-4.6 µm at 
roughly 100 µm in length and 10.5 µm at 300 µm in length. This could be attributed to diminishment 
of gravitational pull at such a small scale. Hence, one must be aware that coating very thin probes 
(d ≤ 30 µm) may require nanosized particles. Furthermore, the minitips were also tested by using them 
to puncture a piece of clay and then performing a microscopic examination to see whether the coating 
had been compromised. The results of these tests showed that the minitip coating remained intact 
throughout the insertion and removal from the clay. It was important to ensure that the device was robust, 
as this study would require them to maintain their performance despite being exposed to conditions that 
would challenge their durability (i.e., rigid solid samples & aggressive agitation potentially causing strip-
off). For example, a limitation was found such that the minitip’s mechanical strength decreased when 
etched (diameter reduction) to extremely small   dimensions (i.e., tip apex diameter ≤ 30 µm). This 
resulted in the apex bending somewhat easily upon contact with sources of external pressure (finger 
pressure, contact with well-walls and rigid samples). It is important to highlight this issue, as it may be 
avoided in the future by using probe substrates with very sturdy characteristics. Potential highly sturdy 
substrates could include titanium and tungsten tips, but their cost and coating logistics (i.e., how to create 
a rougher substrate surface to allow coating deposition on a microscale) must be considered. To best of 
our knowledge, these practical aspects are rarely addressed in publications focusing on coated 
probes.313,314 Lastly, once the SPME-HLB minitips were made, we compared their performance to those 




Figure 3.12 SPME minitips coated with 1.3 µm HLB particles. a.) Minitip obtained after etching 1 mm of a SS needle with KOH;  b.) 1 mm 
coated HLB minitip obtained after sanding and 6 dip-coats of the 6% PAN & 15 % particle slurry; c.) SEM image of minitip surface after 
six layers have been deposited and cured; d.) close-up SEM image of the dense particle network on the minitip’s surface; e.) close-up view 





Figure 3.13 Determination of coating thickness near the minitip apex (roughly 100 µm away from the 
apex). Figures A. and B. show the portion from which the tip thickness was determined, while C. shows 







Figure 3.14 Determination of the coating thickness further away from tip (roughly 300 µm away from 
tip apex).  A.) Portion of tip that was used to determine the coating thickness; B.) Coating thickness at 
Portion A. shows measurement of ~ 10.5 µm. 
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Preliminary performance assessments: Repeatability of the SPME minitip   
Intra-tip repeatability was tested by performing five extractions (cleaned in-between each trial), while 
inter-tip repeatability was tested by performing eight individual extractions. The results of these tests, 
which used BZDs as model compounds, are presented in Tables 3.7-3.8. As can be seen, intra-tip 
repeatability was ≤ 26.4 % RSD (n = 6 tips, 5 re-uses of each) without IS correction, and ≤ 6.9 % RSD 
(n = 6 tips, 5 re-uses of each) with IS correction. While assessing the repeatability of a single tip is 
important in establishing whether a good manufacturing protocol has been achieved, it is also important 
to keep in mind that re-using sample-preparation devices is usually appropriate for screening applications 
but should be avoided when real biological samples are used. Therefore, we elected to use a cheaper 
material like SS rather than titanium and/or tungsten. Inter-tip repeatability was found to be ≤ 20% RSD 
(n = 8) without IS correction, and ≤ 5.4 % RSD (n = 8) with IS correction. This variability can be 
Figure 3.15 Chromatograms obtained for extraction of 500 ng mL-1 of BZDs from a PBS sample for 
SiNPs in A. and HLB minitips in B.   
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attributed to deviations that may occur during fabrication, particularly during the etching and coating 
process (i.e., small differences in dip-coating process may result in thinner/thicker coatings). The 
thinner/thicker coating will extract either more or less of the analyte, which contributes to an elevated % 
RSD at a microscale. Therefore, the use of an IS is highly encouraged for this type of analysis. In addition, 
manufacturing protocols (including issues encountered), mechanical robustness, and repeatability should 
all become a greater focus of discussion, as the optimization of these elements would lead to the 
development of better micro-sized probes.309 It is unfortunate that most approaches that focus on small 
volume and single cell analysis discuss the resultant biological information but fail to rigorously assess 
the quality of sample preparation (robustness and repeatability). Indeed, such oversights are problematic 
because they prevent the establishment of standards of quality regarding the information that is being 
reported.   
Table 3.7 Assessment of intra-tip repeatability was conducted by using five different tips to perform 25 
extractions (5 per tip). Extraction was performed for 10 mins from 50 µL of a PBS sample (spiked with 
200 ng mL-1 of BZDs and 100 ng mL-1 of corresponding IS’s) and desorbed for 5 min to ACN/H2O 
(50/50). Repeatability was assessed using the signal obtained for the area of a chromatogram (Au), as 





(RSD %, n = 5) 
Lorazepam 
(RSD %, n = 5) 
Oxazepam 
(RSD %, n = 5) 
Nordiazepam 
(RSD %, n = 5) 
Tip 
number 
Area [AU] Area/IS Area [AU] Area/IS Area [AU] Area/IS Area [AU] Area/IS 
1 4.6 3.5 21.1 2.0 18.4 3.9 25.4 6.2 
2 18.6 4.5 18.6 2.7 18.2 2.9 8.4 4.2 
3 18.6 5.1 26.2 4.5 22.7 5.1 22.4 4.6 
4 24.9 2.0 2.4 1.3 8.0 3.6 26.3 5.4 




Table 3.8 Assessment of inter-tip repeatability was conducted according to the same 
extraction/desorption conditions described in Table 3.7. Eight different tips were used for this evaluation, 
and RSDs (%) were assessed with (diazepam-d5, lorazepam-d4, oxazepam-d5 and nordiazepam-d5) and 
without IS correction. 
Diazepam (RSD %, n = 8) Lorazepam (RSD %, n = 8) Oxazepam (RSD %, n = 8) Nordiazepam (RSD %, n = 8) 
Area [AU] Area/IS Area [AU] Area/IS Area [AU] Area/IS Area [AU] Area/IS 
18.8 5.4 18.0 3.7 19.2 4.2 20.0 4.4 
 
Preliminary performance assessments: Reusability of the SPME minitip  
Considering the intricacy and time invested in the process of making the SPME minitips, reusability was 
of special interest. Hence experiments were conducted to test the afore-mentioned by performing 5 
consecutive cycles of extraction (Vs = 50 µL, 200 ng mL-1 BZDs, 10 min) and desorption (50 µL 
desorption volume, 50/50 ACN/H2O, 5 min). These extractions were completed using PBS and urine. In 
between each cycle, the tips were cleaned and preconditioned. The data obtained from re-using a single 
Figure 3.16 Assessment of tip reusability (n = 5) performed via 10 min extractions from a 50 µL PBS 
sample spiked with 200 ng mL-1 of BZDs and 5 min of desorption to 50 µL of ACN/H2O (50/50).   
191 
 
HLB minitip in both PBS and urine is presented in Figures 3.16-3.17, with the % RSD values for each 
analyte presented beneath the figure. These values appear to be satisfactory, as the data suggests that the 
tips retain their extraction ability. Furthermore, a visual inspection of the tips after 5 
extractions/desorptions revealed no coating fall-out. It should be noted that the repeatability of 
nordiazepam in urine was 41.5 %, which could be due to the fact that a much smaller amount was 







Figure 3.17 Assessment of tip reusability (n = 5) performed via 10 min extractions from a 50 µL urine 
sample spiked with 200 ng mL-1 of BZDs and 5 min of desorption to 50 µL of ACN/H2O (50/50).   
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Preliminary performance assessments: Preconditioning of the SPME minitip  
The influence of the preconditioning solvent was also investigated, as the solvent’s properties can affect 
the minitip’s extractive ability. To conduct this assessment, we analyzed eight different 
preconditioning solvents. The results of these analyses are presented in Figure 3.18, and, as can be seen, 
a mixture of 50/50 MeOH/H2O produced the best results. Given the micro-scale of the device, we 
conducted further experiments to evaluate whether a preconditioning step is required in sample 
preparation process by testing the minitips in a “dry form”, i.e., without preconditioning (cleaning 
only). We compared the performance of the “dry form” tips  to “washed tips” that had been cleaned, 
preconditioned, and washed with H2O prior to extraction. Tips were also “conditioned” whereas only 
preconditioning was done without a wash step. As shown in Figure 3.19, the tips that were washed with 
H2O demonstrated better analyte extraction ability. Conversely, the active sites on the coating did not 
appear to be fully activated on the dry tips. When a tip is preconditioned but not washed, it is possible 
Figure 3.18 Investigation of the influence of eight different preconditioning solvents on the signal 
obtained (n = 4) for 10 min extractions from a 50 µL PBS sample spiked with 200 ng mL-1 of BZDs and 
5 min of desorption to 50 µL of ACN/H2O (50/50).   
193 
 
that some preconditioning solvent remains on the tip, which could potentially interfere with the 
partitioning equilibria. 
 
Preliminary performance assessments: Influence of sample volume  
According to the underlying theory of SPME, the amount of extracted analyte increases with the sample 
volume up to a certain point, after which sensitivity plateaus.7 To investigate how sample volume 
influences the response, we performed extractions from 1, 2, 3, 5, 10, and 50 µL of PBS spiked with 
200 ng mL-1 of BZDs. The results obtained can be seen in Figure 3.20. As can be seen, signal obtained 
(in AU) increases alongside sample volume up to 10 µL, where it appears to plateau. These results are in 
agreement of those obtained by Piri-Moghadam et al., who also found that sensitivity increased up to a 





Figure 3.19 Investigation of the influence of tip pre-treatment on amount extracted (n = 3) using 10 
min extractions from a 50 µL PBS sample spiked with 200 ng mL-1 of BZDs and 5 minutes of desorption 





Preliminary performance assessments: A Note on Biocompatibility, Matrix Effects, and Extraction 
Kinetics 
As it pertains to SPME, biocompatibility refers to an extractive coating’s ability to resist the adherence 
of unwanted biologicals and to not cause toxic shocks within studied organisms.15 Overcoating SPME 
devices is one way to establish biocompatibility.335  
A number of investigations over the past 10 years have supported PAN’s suitability for use with 
SPME.19,44,48,49,336,337 While biocompatibility is not always a key requirement of general sample 
preparation, one must keep in mind that biocompatible coatings offer number of benefits, such as 
enabling in vivo sampling (in addition to reducing the level of biological interferences in the MS).  In 
this study, the MEs of the minitips were assessed using human plasma and urine. In order to determine 
whether any significant ionization suppression and/or enhancement occurred, blank urine and plasma 
extractions were performed using the minitip. The extractions were then desorbed and spiked with neat 
Figure 3.20 Assessment of the influence of sample volume (1, 2, 3, 5, 10, and 50 µL) on the signal 
obtained for BZD extraction from a PBS sample spiked with 200 ng mL-1 using a 10 min static extraction 
and a 1 min desorption.   
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standard, and the obtained signal area was compared to the area of neat standard (i.e., blank extraction 
not performed). This assessment was done using BZDs at 5, 50, and 100 ng mL-1. The results obtained 
for urine and plasma can be seen in Tables 3.9 and 3.10, respectively.  The obtained ME was acceptable 
for the BZDs examined in urine, with a range of 103-128.5 %. The exception to this result was 
nordiazepam, which showed an enhancement of 134 % at 50 ng mL-1, thus potentially indicating greater 
interference from either an exogeneous or endogenous source. The tested BZDs produced a ME range of 
95.8-109.7 %, which indicates that the minitips are not significantly affected by protein-dense matrices 
like plasma. While these are promising results, one must keep in mind that different analytes/matrices 
could yield a different response. Therefore, it is appropriate to investigate whether matrix co-extracts 
could interfere with analytes of interest.  
Extraction kinetics are also important in the development of SPME methods, as they directly influence 
method sensitivity. In this study, we examined the extraction time profile of BZDs in PBS by evaluating 
extraction times of 0.5, 1, 2.5, 4, 5, 10, 30, and 60 min. The extraction time profile and the desorption 
time profile can be seen in Figures 3.21-3.22. We observed a consistent increase in the amounts extracted, 
which may be attributable to the highly porous nature of the minitip. The desorption time profile shows 
Table 3.9 Results obtained for the assessment of the absolute MEs for the SPME-HLB minitips. Absolute 
ME was assessed by examining the signal response after blank extraction from urine, followed by 
desorption, and spiking the desorbate with 5, 50, and 100 ng mL-1 of diazepam, oxazepam, and 
nordiazepam (analysis done on an API 4000). 
 Absolute matrix effect for urine (Precision, RSD %, n = 3) 
 Spiked level 
Compound Low (5 ng mL-1) Medium (50 ng mL-1) High (100 ng mL-1) 
Diazepam 106.4 (5.0) 123.5 (15.0) 126.7 (11.8) 
Oxazepam 103.9 (2.5) 128.5 (14.3) 119.8 (12.4) 





Table 3.10 Results obtained for the assessment of the absolute ME arising from blank plasma extractions 
via SPME-HLB minitips, followed by spiking of 5, 50, and 100 ng mL-1 of diazepam, oxazepam and 
nordiazepam to the desorbate. Analysis was performed using an API 4000, and both ME analysis 
approaches were conducted according to procedure proposed by Matuszewski et al.331 
 Absolute matrix effect for plasma (Precision, RSD %, n=3) 
 Spiked level 
Compound Low (5 ng mL-1) Medium (50 ng mL-1) High (100 ng mL-1) 
Diazepam 100.2 (12.1) 108.0 (7.0) 104.5 (2.5) 
Oxazepam 105.8 (12.5) 101.3 (6.5) 109.7 (8.2) 
Nordiazepam 98.4 (12.2) 102.7 (6.2) 95.8 (6.2) 
that the analytes rapidly release from the minitips (i.e., one minute). This result is similar to those 
obtained by Piri-Moghadam25 and could be related to the device’s scale, i.e., very small amount of 
extractive phase allowing rapid release of analytes to desorbing solvent. The minitips’ ability to provide 
Figure 3.21 Extraction time profiles obtained at 0.5, 1, 2.5, 4, 5, 10, 30, and 60 min (n = 4) for the extraction of 
200 ng mL-1 of BZDs spiked to a 50 µL sample and desorbed to a 50 µL solvent mixture (ACN/H2O, 50/50) for 
LC-MS/MS analysis. Desorption was performed for five minutes. The highly porous nature of the HLB coating 
suggests that longer extraction times are needed to achieve full equilibrium due to the coating’s small pore size.435 
However, the achievement of full equilibrium is not always a pre-requisite for successful SPME extraction, 
especially if sufficient sensitivity is obtained in the pre-equilibrium regime. 
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quick desorption times is very useful for real-time direct-to-MS approaches that aim to produce rapid 
results.   
Preliminary performance assessments: Is the quantitation with SPME minitips satisfactory?  
Before proceeding with further experimentation, it was important to conduct assessments of quantitative 
performance of the minitips. These were performed using PBS as the interference free matrix and urine, 
as the more complex matrix. A matrix matched calibration with and without IS correction was employed. 
While it was in our interest to examine calibration without correction, the use of an IS is highly beneficial 
when working with small sample volumes because micro-scale analyses inevitably produce a greater 
Figure 3.22 Desorption time profile obtained at 0.5, 1,5, and 10 min  for a 10 min extraction of 
500 ng mL-1 of BZDs spiked to a 50 µL sample and desorbed to a 50 µL solvent mixture (ACN/H2O, 
50/50) for LC-MS/MS analysis. 
Figure 3.23 Quantitation of oxazepam in PBS using a.) IS correction approach (Area of standard/ area 
of IS, i.e., A/IS); b.) no IS correction (area of standard only) (note: same points are used in both cases). 
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number of errors. The calibration plots for oxazepam in PBS with and without IS correction are shown 
in Figure 3.23. As it can be seen, the plot with the IS (Figure 3.23a.) included yields a better R2 value 
(0.9987) in comparison to plot that does not employ an IS (Figure 3.23b.) for correction (R2 = 0.9711). 
Linearity appears to be maintained up to 100 ng mL-1 in the uncorrected plot, but then starts to veer off 
at subsequent concentration points (100, 200, 300, and 400 ng mL-1), which potentially could be caused 
by variation in coating homogeneity on some minitips. However, it would appear that the use of an IS 
provides adequate correction for the calibration. As it can be seen from Table 3.11, satisfactory figures 
of merit are obtained for diazepam, oxazepam and nordiazepam in both PBS and urine.   The tested QC 
level (100 ng mL-1) was in the 95-127.5% accuracy and 3.4-15.8% repeatability range for PBS. For urine, 
accuracy and repeatability were in the 104-116.4% and 5.7-12.5% ranges, respectively. Lorazepam was 
excluded from the quantitation due to a higher LOQ (50 ng mL-1). All the LODs and LOQs determined 
in this research were calculated based on S/N ratio of 3 and 10, respectively. The LODs (1 ng mL-1 for 
PBS, 1-5 ng mL-1 for urine) and LOQs (5 ng mL-1 for PBS, 5-10 ng mL-1 for urine) are satisfactory. 
Higher LOQs were obtained for urine which is not surprising since urine is a more complex matrix.  It is 
also important to keep in mind that the sensitivity is influenced by desorption volume and the flow of 
mobile phase employed for LC-MS/MS analysis. For this analysis, we employed a flow rate 
of 150 µL min-1 and injected 20 µL of sample. This appears to have been adequate, as satisfactory 
detection limits were achieved. Nonetheless, it is important to emphasize the fact that dilution free 





Table 3.11 Figures of merit obtained for the detection of diazepam, oxazepam, and nordiazepam in PBS 
and urine. 
Applications of the SPME minitip: Quantitative Detection of DoAs in 1µL of Oral Fluid via LC-
MS/MS 
To demonstrate the minitips’ efficiency in applications where sample volume is highly limited, we 
simulated an experiment wherein only 1 µL of OF was available for extraction. Such a scenario may be 
encountered in forensic settings, i.e., trace amounts of biological evidence. In addition to working with 
a very challenging sample volume, we also decided to employ an LC-MS/MS approach whose flow rate 
was 400 µL min-1.211 Higher flow rates provide greater sample dilution, thus resulting in an inevitable 
reduction or complete loss of sensitivity. In a way, the analytical capabilities of the minitips were pushed 
to their limits. Ten DoAs (logP: 0.3-4) were chosen for the investigation. Despite increased dilution, 
analysis of the afore-mentioned compounds was successful. Owing to the use of HLB microparticles, 
SPME minitips possess very good preconcentrating power. This allowed us to obtain LODs in the 
5 -  50  ng mL-1 range and LOQs in 10 - 75 ng mL-1 range (Table 3.12). The highest LOD and LOQ in 
each case is obtained for testosterone (50 and 75 ng mL-1), which could be related to poorer ionization 
efficiency of this compound. Furthermore, we performed QC analysis at 150 ng mL-1 and obtained 
accuracy in the 79.4 - 113.3 % range and repeatability in the 5.2-20.2 % range. Additionally, MEs were 
assessed at the following levels: 5, 50, and 100 ng mL-1. The results are shown in Table 3.13, and, as can 
be seen, they exhibited a range of 85.8-131.6 %. Certain compounds, such as oxycodone and cocaine, 
Matrix PBS 
QC point  
(RSD, %, n = 3) 
Urine 
QC point  
(RSD, %, n = 3) 
Compound LOD LOQ R
2
 LDR Slope Intercept 100 ng mL
-1
 LOD LOQ R
2
 LDR Slope Intercept 100 ng mL
-1
 
Oxazepam 1 5 0.9987 5-400 0.0161 0.0282 95.0 (6.7) 1 5 0.9996 5-400 0.0136 0.1443 104.0 (5.7) 
Diazepam 1 5 0.9994 5-400 0.0484 -0.0793 105.6 (15.8) 1 5 0.9990 5-400 0.0429 0.3236 107.1 (12.5) 
Nordiazepam 1 5 0.9984 5-400 0.0497 0.3457 127.5 (3.4) 5 10 0.9994 10-400 0.0544 0.4882 116.4 (8.5) 
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exhibited higher MEs (i.e., 130.6 and 131.6 %, respectively), which demonstrates a tendency towards 
matrix enhancement. 
Table 3.12 Figures of merit obtained for the quantitation of DoAs in 1 µL of OF using LC-MS/MS. 
 
Table 3.13 Absolute MEs and precision calculated for extraction from 1 µL of OF at 5, 50, and 



















150 ng mL-1; 
accuracy (RSD, 
%, n = 3) 
Oxycodone 10 25 0.9952 25-1000 0.0115 -0.3608 113.3 (17.8) 
Benzoylecgonine 25 50 0.9929 50-1000 0.0085 0.0835 96.0 (15.7) 
Cocaine 10 25 0.9940 25-1000 0.0279 -0.9347 104.0 (8.8) 
Carbamazepine 25 50 0.9930 50-1000 0.0484 -1.5198 110.4 (9.0) 
Cocaethylene 10 25 0.9955 25-1000 0.0177 0.1090 112.4 (20.2) 
Clenbuterol 10 25 0.9927 25-1000 0.0076 0.2060 79.4 (5.2) 
LSD 5 10 0.9948 10-1000 0.0106 -0.2005 100.7 (7.6) 
Testosterone 50 75 0.989 75-1000 0.0116 -0.5946 99.9 (18.7) 
Propanolol 25 50 0.9925 50-1000 0.0210 -0.8611 112.4 (7.1) 
Fentanyl 10 25 0.9947 25-1000 0.1200 4.1730 81.4 (11.1) 
 Absolute matrix effect (precision, RSD %, n = 3) 
Spiked level 
Compound Low (5 ng mL
-1
) Medium (50 ng mL
-1
) High (100 ng mL
-1
) 
Oxycodone 100.8 (22.1) 98.1 (27.6)  130.6 (10.1) 
Benzoylecgonine 110.9 (25.4)  123.3 (6.4)  123.0 (18.3) 
Cocaine 105.3 (19.8) 121.4 (24.5)  131.6 (20.3)  
Carbamazepine 95.7 (15.2)  104.1 (21.0)  119.3 (16.5) 
Cocaethylene 120.1 (27.1)  116.3 (5.9)  114.3 (8.2) 
Clenbuterol 106.6 (25.2) 122.2 (4.7)  121.6 (16.6) 
LSD 97.4 (14.9) 98.6 (20.7) 121.0 (8.1) 
Testosterone 107.5 (29.8)  85.8 (12.2) 101.2 (16.1) 
Propanolol 93.4 (9.4)  118.5 (19.4)  123.3 (2.6) 
Fentanyl 114.6 (15.4)  115.3 (10.8)  122.5 (2.4) 
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Applications of the SPME minitip: Quantitation of DoA(s) in 1 µL of Human Blood via nESI 
Ionization 
nESI ionization is a nanoscaled form of ESI wherein specialized nESI tips are filled with a small volume 
of solvent solution, which is then sprayed to produce a mist of charged droplets.86 nESI tips can be 
coupled to chromatography338 or AIMS,204 and are ideal for small-volume analysis because they produce 
a significant increase in sensitivity. nESI provides enhanced sensitivity through minimal dilution, which 
increases ionization efficiency and ion transmission due to the reduction of droplet sizes during the ESI 
process.339 SPME and nESI have already been used together in applications where the nESI tips 
functioned as spray emitters, with the SPME device being introduced to the emitter through either online 
or offline means.25,206,240 These applications are notable for their ability to obtain low LODs, despite 
using complex matrices such as blood, urine, or plasma. For example, Gómez-Ríos et al.206 were able to 
achieve a detection limit of 5 ng mL-1 for amitriptyline by performing extractions from 20 µL of blood 
using 4 mm SPME MM fibers. Additionally, Piri-Moghadam’s use of PPy microtips yielded detection 
limits of 0.3 (cocaine), 5 (oxycodone), and 25 ng mL-1 (amitriptyline) from 5 µL samples of urine, 
plasma, and blood, respectively.25 These detection limits are primarily attributable to SPME’s ability to 
efficiently pre-concentrate the analytes in addition to the “clean” introduction of the sample to MS (i.e., 
implementing a post-extraction wash step to remove any potential biological interferences that may have 
adhered to the coating). Given the results obtained by Gómez-Ríos206 and Piri-Moghadam,25 as well as 
the ever-present need for a sample preparation tool that can efficiently sample small volumes, an 
investigation was conducted to examine HLB’s suitability as a new sorbent for SPME-nESI. To this end, 
1 µL of blood was spiked with DoA(s) with different logP values (PubChem)156 and protein binding 
percentages (PB%) (DrugBank).161 PB% indicates the actual free concentration of an analyte that is 
available for extraction. SPME extracts via free concentration, which means that sensitivity may be 
compromised in scenarios where analytes are highly bound to proteins, as only a small portion of the 
analyte will available for extraction.7 Due to the complexity of blood and the use of static SPME 
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extraction (i.e. potentially reduced mass transfer to SPME), we opted to use a longer extraction time 
(5 min), while keeping the desorption time at 1 min. The results for the quantification of the DoAs and 
the QC point (37.5 ng mL-1) are provided in Table 3.14 and calibration plots can be seen in Figure 3.24. 
We did not examine a greater number of compounds due to the TSQ Vantage’s limitations on the number 
of scans that can be monitored simultaneously. Lower detection limits (< 2.5 ng mL-1) were obtained for 
most drugs, despite higher PB% for certain ones. For example, while propranolol is bound to proteins at 
> 90%, the obtained LOD was 1 ng mL-1. Certain drugs, such as clenbuterol and cocaethylene, had higher 
LOQs (12.5 and 25 ng mL-1, respectively), but a further review of the literature (PB % unavailable on 
DrugBank)161 revealed that these compounds also have a tendency towards higher PB %.340,341 It was not 
necessary to perform additional steps like diluting blood viscosity, which alters the matrix’s intrinsic 
properties, in order to achieve low detection limits. An examination of the tested validation 
point  (37.5 ng mL-1) revealed accuracy and repeatability in the 96.5-125.8 % and 1.7-7.7 % ranges, 
respectively. A higher response (125.8 %) was observed for cocaethylene, which could be attributed to 
co-extracted components from blood. Nonetheless, when compared to more conventional microsampling 
techniques (i.e., DBS and volumetric absorptive microsampling), SPME’s matrix-compatible coating 
and washing step allow for more efficient pre-concentration and sample clean-up. Since the need for 
smaller volumes of blood benefits animal welfare, child screening, and TDM, it comes as no wonder that 
the pharmaceutical industry is shifting towards the use of volume-effective tools.194 SPME could be 
integrated into an all-in-one package, allowing simultaneous sample collection and extraction. In fact, 
SPME offers the potential to make diagnostics more convenient for both the patient and laboratory 
personnel, as it can allow patients to collect samples in the comfort of their own home through a simple 
finger prick. In a sense, SPME and point-of-care MS could pave the way for a future where simply 
providing 1 µL of blood will be sufficient for diagnostic testing, thus alleviating physical distress for 
patients and allowing health-care professional to make faster decisions.193 
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%, n = 3) 
Oxycodone 2.5 5.0 0.9945 5.0-425.0 0.0173 0.0003 96.6 (2.7) 
Cocaine 1.0 2.5 0.9994 2.5-425.0 0.0243 -0.0754 99.5 (1.7) 
Carbamazepine 0.5 2.5 0.9991 2.5-425.0 0.0502 -0.1804 96.5 (5.1) 
Cocaethylene 2.5 25 0.9975 25.0-425.0 0.0246 0.0001 125.8 (7.7) 
LSD 1.0 2.5 0.9999 2.5-425.0 0.0212 -0.0250 96.4 (4.7) 
Clenbuterol 2.5 12.5 0.9926 12.5-425.0 0.0168 0.1447 106.6 (3.1) 
Propanolol 1.0 2.5 0.9938 2.5-425.0 0.0458 -0.0107 95.1 (4.4) 
Fentanyl 0.5 2.5 0.9990 2.5-425.0 0.1685 0.8156 118.0 (4.9) 





Application of the SPME minitip: Metabolic Profiling of Selected Caviar Species 
Since the goal of untargeted metabolomics is to obtain as much information about a system as possible, 
the key sample preparation requirement is to ensure reduced selectivity,59 as this allows for the extraction 
Figure 3.24 Calibration plots obtained for DoAs sampling from 1 µL of blood via SPME-HLB-minitips 
and nESI using a matrix-matched IS correction approach. Fentanyl, carbamazepine, propranolol, 
clenbuterol, EDDP, cocaine, oxycodone, cocaethylene, and LSD can be seen in plots A.-I., respectively. 
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of compounds with the widest range of physico-chemical characteristics. While common metabolomic 
sample preparation methods like LLE and SPE are inconvenient for small-volume analysis, SPME may 
offer a viable alternative.342 Since SPME’s format can be tailored for specific applications, it offers 
considerable potential for use in volume-limited metabolomics. Previous SPME applications for  
untargeted metabolomics have involved the use of C18 or MM (C18 with benzenesulfonic acid particles) 
(5-30 µm sized) embedded on nitinol wires. Due to their size, such particles proved unsuccessful for 
coating the extremely thin substrates used in our study. Nanomaterials were also considered, but they 
provide higher selectivity, hence reducing their effectiveness for untargeted metabolomics. This reduced 
effectiveness is also evidenced in the lack of reports on their use.343 Therefore, SPME minitips coated 
with micro-sized HLB particles were utilised as a compromise between selectivity and sensitivity. Their 
potential was investigated by sampling four different types of caviar eggs and performing LC/HRMS 
analysis using an Exactive Orbitrap. To the best of our knowledge, there has only been one other study 
that has investigated the lipidomic profile of caviar using a combination of direct-to-MS approaches, 
focusing mostly on high MW species.344   
The data obtained for caviar sampling from the Exactive was converted to mzXML format using 
MSConvert345 and processed using R-software.69 Without using any data filters, a total of 3034 features 
were detected. A table of m/z vs retention time (min) can be seen in Figure 3.25. A strict data treatment 
was then applied wherein peaks with an S/N < 5 when compared to PQC were first eliminated, which 
was followed by the elimination of peaks with a % RSD greater than 30%. This data treatment process 
left us with 177 features, which were subjected to analysis with Metaboanalyst.346 A PCA plot seen in 
Figure 3.26 was used to observe the data clustering trends. The best PCA plot was obtained based on an 
overview that Metaboanalyst provides that demonstrates which combination of components provides the 
best PCA model. For our data, we found that 2 PCs on the x-axis (24 %) and 1 PC on the y-axis (43.3%) 
provided us with a satisfactory PCA model (Figure 3.27a. shows a 3D PCA plot created for the further 
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inspection of data variance). A separation between salmon, herring and lumpfish can be observed in the 
2D plot, while the 3D plot reveals a slight separation between the black and red lumpfish. As shown in  
Figure 3.25 m/z values (total of 3034 features) vs their respective retention times (minutes). The data 
shown in this figure was obtained via an LC/MS-based approach wherein analysis was performed using 
a chromatographic 40-min binary gradient method with a flow of 300 µL min-1. We highlight this because 
over 3000 features were found in the data, despite the small size of the sample (fish egg). 
Figure 3.27b., the supervised PLS-DA model shows better separation between the red and black 
lumpfish, although a single replicate of the black lumpfish does fall within the red lumpfish region. To 
ensure that the PLS-DA plot was not “forced” into separation, we performed a LOOCV using Q2 as a 
performance measure. The optimum number of components was two, with R2 and Q2 being 0.61 and 
0.45, respectively. A permutation test using separation distance (B/W) and a permutation number of 100 
gave us a value of p < 0.01, indicating that the PLS-DA model was not the product of randomness 
(validation results can be seen in Figures 3.28-3.29). The “cleaned” features were subjected to one-way, 
rigorous, non-parametric ANOVA, resulting in 149 significant metabolites (a detailed list of these 
analytes can be found in Table 3.15). Next, the “blank” desorptions of the minitips (n = 3) were inspected 
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for false positives. Features were searched using the Metlin database,73 with a number of compounds 
commonly found in fish being detected, including:eicosapentaenoic acid (EPA), L-tryptophan, retinoic 
acid, 3,4-dimethyl-5-pentyl-2-furannonanoic acid, cholesterol, N-acetylhistidine, and octadecadienoic 
Figure 3.26 PCA plot obtained for the untargeted metabolomic analysis of four different types of caviar 
(light blue: salmon; green: herring; red: black lumpfish; dark blue: red lumpfish) with two components 
on the x-axis and one component on the y-axis. Notable separation between salmon, herring, and 
lumpfish (with exception of one black lumpfish sample) can be observed. 
Figure 3.27 3D PCA plot in a. and PLS-DA plot in b. for the untargeted data obtained from sampling 
different types of caviar roe. 
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acid. The distinguished chromatographic peaks of L-tryptophan (red lumpfish) and EPA (black lumpfish) 
are shown in Figure 3.30, alongside their normalized concentrations. Given potential compositional 
similarity between the fish, it is unsurprising that shared metabolites were found for both black and red 
lumpfish, as well as salmon and herring (Fig. 3.31). It is important to note that the discovered significant 
features are not mostly characterized by high MW species. Minitips could also be potentially useful for 
Figure 3.28 Results obtained for assessment of the PLS-DA model used to examine untargeted 
metabolomic data from caviar sampling. The model was examined using a LOOCV approach with Q2 
as a performance measure. Note the red star marking that the model is best fitted using two components. 
The R2 and Q2 values read 0.61 and 0.45, respectively. 
Figure 3.29 Permutation test conducted using separation distance (B/W) and a permutation number of 
100. Note that the observed test statistic (p) lies to the right of the test, indicating that the PLS-DA model 
built for the study is not the product of randomness. It is important to examine the validity of a PLS-DA 
model, as untargeted data may often be “over-fitted” using this approach.   
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detecting environmental pollutants. For example, they could be used to detect the presence of toxic 
arseno-containing lipids in marine species (particularly caviar eggs), which is an issue that is rapidly 
becoming more prominent.347 It is important to keep in mind that this study used dilution (LC) to 
profile caviar species and that the size of the sampled subjects could have significantly undermined 
detection capability. Nonetheless, satisfactory separation with defined chromatographic peaks and rich 
metabolomic information was still obtained. It is rather difficult to imagine the development of an 
optimum analysis agenda for trace compounds in complex matrices without using some sort of 
separation.348 Undoubtedly, separation would aid in resolving some of the issues associated with complex 
mass spectra, discrimination between isomeric and isobaric species, and elevated MEs.306 MEs cannot 
be completely eliminated, but they can be minimised, and using improved chromatography is an efficient 
way to eliminate interfering compounds from analytes.349 For example, combining the use of narrow-
bore columns with reduced internal diameters and nanoflow ultra-high performance LC and nESI can 
not only allow peaks to elute at greater concentration,339 but it has also been shown to efficiently reduce 
suppression effects.349,350 In fact, Kajiyama et al. have already implemented nanoflow LC and excision-
based sampling for analyses of certain low MW compounds in the petal tissues of Torenia hybrida.351 In 
addition, Dovichi’s team and others have also made efforts to introduce hyphenation into cell analysis 
by implementing both LC and capillary electrophoresis in the analysis of 1000-4000 proteins in Xenopus 
laevis embryos.352,353 While work is currently undergoing in our laboratory to produce probes with even 







Table 3.15 List of features and their adducts whose class, parent, and ID were tentatively identified using 
the Metlin and FoodBank databases. In addition, p values, false discovery rate (FDR) values, number of 
possible species, and the error associated with each feature have also been provided. Please note that 
identifications on databases are still unavailable for many m/z values. Hence, these fields were left as 










p value FDR 





170.5484 N/A N/A N/A 0.00049 0.001622 N/A N/A N/A 








233.1357 N/A N/A N/A 5.3E-03 6.6E-03 N/A N/A N/A 
241.0681 N/A N/A N/A 1.1E-03 1.7E-03 N/A N/A N/A 





acids & derivatives 
[M+2Na-H]+ 1.8E-03 2.5E-03 3 L-Tryptophan 0 
250.0646 N/A N/A N/A 3.6E-03 4.7E-03 N/A N/A N/A 
262.9872 N/A N/A N/A 1.0E-03 1.7E-03 N/A N/A N/A 
281.0948 N/A N/A N/A 1.8E-02 2.1E-02 N/A N/A N/A 
288.1606 N/A N/A N/A 0.00065084 1.6E-03 N/A N/A N/A 





PSs’ [M+3Na]+ 0.00014526 1.6E-03 6 N/A 5 
298.6257 N/A N/A N/A 0.0002552 1.6E-03 N/A N/A N/A 
301.2164 Lipids Retinoids [M+H]+ 9.3E-04 1.6E-03 3 Retinoic acid 0 









Alpha amino acids 
and derivatives 
[2M+ACN+H]+ 6.2E-03 7.7E-03 4 Creatine 2 
304.2356 N/A N/A N/A 9.4E-03 1.2E-02 N/A N/A N/A 
323.2582 Lipids 
Long chain FA, 
Furanoid FA 


















328.2559 Diazines Pyrazines [2M+2H+3H2
O]+ 
0.0049364 6.2E-03 7 2,3-Diethyl-5-
methylpyrazine 
4 
339.2137 N/A N/A N/A 0.0031428 4.1E-03 N/A N/A N/A 
341.2322 N/A N/A N/A 0.0016672 2.4E-03 N/A N/A N/A 










357.2914 N/A N/A N/A 0.018092 2.2E-02 N/A N/A N/A 
367.2454 Glyceroli
pids 
1,2-DAGs’ [M+Na]+ 0.00065496 1.6E-03 2 DG (8:0/8:0/0:0) 0 








[M+H-H2O]+ 0.018769 2.2E-02 10 Cholesterol 3 




[M+H+Na]2+ 9.2E-04 1.6E-03 10* ~ 0 
373.1854 N/A N/A N/A 3.0E-03 4.0E-03 N/A N/A N/A 








[M+ACN+2H]2+ 8.0E-04 1.6E-03 9 ~ 0 













Alkyl-DAGs’ [M+H+K]+ 2.4E-03 3.3E-03 5 N/A N/A 








1.1E-03 1.7E-03 27 N/A 2-5 
404.2871 Lipids PEs’ 
[M+ACN+2H]2+; 
[M+H+NH4]2+ 
2.1E-02 2.5E-02 50 ~ 3 
415.2535 Lipids PGPs’ 
[M+H+Na]2+; 
[M+2H]2+ 
9.2E-04 1.6E-03 4 ~ 0 




2.1E-03 3.3E-03 38 ~ 1-4 
432.2800 N/A N/A N/A 8.7E-04 1.6E-03 N/A N/A N/A 
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440.2085 N/A N/A N/A 1.5E-04 1.6E-03 N/A N/A N/A 
454.3291 Lipids PCs’ [M+H]+ 2.6E-04 1.6E-03 5 ~ N/A 







6.0E-03 7.4E-03 45 N/A 2-4 





460.2827 Lipids PEs’; LPEs’ [M+H-H2O]+ 2.5E-03 3.8E-03 4 ~ 0-1 



















7.1E-04 1.6E-03 8 ~ 1 
469.3112 Lipids PEs’ 
[M+3ACN+2H
]2+ 





























9.8E-04 1.6E-03 8 ~ 0 
481.2627 N/A N/A N/A 8.5E-04 1.6E-03 N/A N/A N/A 
481.3126 Lipids PEs’ [M+3ACN+2H]2+ 9.2E-04 1.6E-03 4 ~ 0 
482.3236 Lipids LPCs’; LPEs’ [M+H]+ 4.6E-04 1.6E-03 3 ~ 1 
482.3597 Lipids PCs’ [M+H]+ 8.0E-04 1.6E-03 6 ~ 1 
483.3275 Lipids PEs’ [M+3ACN+2H]2+ 1.1E-03 1.7E-03 4 ~ 2 
483.3631 N/A N/A N/A 4.4E-04 1.6E-03 N/A N/A N/A 















PSs’ [M+H+NH4]+ 1.7E-03 2.4E-03 1 PS(24:0/24:0) 3 










PSs’; PEs’; PAs’; 
PCs’; LPCs’ 
[M+H]+ 2.8E-04 1.6E-03 5 ~ 0; 1 
494.3545 N/A N/A N/A 1.5E-04 1.6E-03 N/A N/A N/A 
495.3267 Lipids PCs’ [M+H+K]2+ 2.0E-04 1.6E-03 3 ~ 2 
496.3410 Lipids PCs’; PEs’; LPCs’ [M+H]+ 1.2E-03 1.8E-03 11 ~ 2 





DimethylPEs’ [M+3ACN+2H]2+ 9.6E-04 1.6E-03 4 ~ 1 
498.3466 N/A N/A N/A 7.9E-04 1.6E-03 N/A N/A N/A 




6.1E-04 1.6E-03 5 ~ 1 
501.2814 N/A N/A N/A 2.2E-04 1.6E-03 N/A N/A N/A 
502.2913 Lipids 




2.4E-04 1.6E-03 1 ~ 1-3 
502.3748 N/A N/A N/A 3.3E-04 1.6E-03 N/A N/A N/A 
503.3054 N/A N/A N/A 8.5E-04 1.6E-03 1 N/A 2 






505.3416 Lipids PCs’ [M+2Na]2+ 8.5E-04 1.6E-03 2 ~ 4 
507.3290 N/A N/A N/A 6.8E-04 1.6E-03 N/A N/A N/A 
508.3314 N/A N/A N/A 3.4E-04 1.6E-03 N/A N/A N/A 
508.3389 Lipids 




6.0E-04 1.6E-03 7 ~ 1 
509.3437 n/a N/A N/A 2.2E-04 1.6E-03 N/A N/A N/A 
510.3554 Lipids 
LPCs’; LPEs’; 
PCs’; PAs’; PEs’ 
[M+H]+; 
[M+NH4]+ 
4.0E-04 1.6E-03 14 ~ 0 
516.3088 Lipids PCs’; LPCs’; PSs’ 
[M+H]+; 
[M+H-H2O]+ 
3.6E-04 1.6E-03 4 ~ 0-1 
517.3120 N/A N/A N/A 2.8E-04 1.6E-03 N/A N/A N/A 
518.3219 Lipids PCs’; PEs’; LPEs’ 
[M+H]+; 
[M+Na]+ 
9.7E-04 1.6E-03 17 ~ 0-4 








8.7E-04 1.6E-03 13 ~ 2-3 
521.3353 Lipids PEs’; LPEs’ 
[M+ACN+H]+; 
[M+NH4]+ 
8.4E-04 1.6E-03 12 ~ 0 







6.0E-04 1.6E-03 20 ~ 0; 1 
523.3253 N/A N/A N/A 8.9E-04 1.6E-03 N/A N/A N/A 




[M+H]+ 6.4E-04 1.6E-03 12 ~ 0 
525.2869 N/A N/A N/A 9.9E-04 1.6E-03 N/A N/A N/A 
525.3027 N/A N/A N/A 0.00093127 0.001622 N/A N/A N/A 
525.3392 N/A N/A N/A 0.0028319 0.003769 N/A N/A N/A 
525.3756 N/A N/A N/A 0.00039774 0.001622 N/A N/A N/A 
525.3994 N/A N/A N/A 0.00025482 0.001622 N/A N/A N/A 
526.2936 Lipids PEs’; LPEs’ [M+H]+ 7.7E-04 1.6E-03 3 ~ 1 
527.2956 N/A N/A N/A 1.2E-03 1.9E-03 N/A N/A N/A 
535.3596 N/A N/A N/A 2.2E-03 3.0E-03 N/A N/A N/A 
537.3764 N/A N/A N/A 1.1E-03 1.7E-03 N/A N/A N/A 
542.3246 Lipids PCs’; PSs’ 
[M+H]+; 
[M+H-H2O]+ 
6.5E-04 1.6E-03 2 ~ 0-1 
543.3263 N/A N/A N/A 8.5E-04 1.6E-03 N/A N/A N/A 
543.4017 N/A N/A N/A 1.5E-04 1.6E-03 N/A N/A N/A 
544.3298 N/A N/A N/A 4.4E-04 1.6E-03 N/A N/A N/A 




2.7E-05 1.2E-04 25 ~ 1-4 
544.4572 N/A N/A N/A 1.5E-04 1.6E-03 N/A N/A N/A 
545.4604 N/A N/A N/A 1.1E-03 1.7E-03 N/A N/A N/A 
548.3349 N/A N/A N/A 7.4E-04 1.6E-03 N/A N/A N/A 
548.3650 N/A N/A N/A 8.7E-04 1.6E-03 N/A N/A N/A 
549.3396 N/A N/A N/A 1.5E-04 1.6E-03 N/A N/A N/A 
550.3866 Lipids PCs’; LPCs’ [M+H]+ 2.9E-04 1.6E-03 11 ~ 0 
551.3572 N/A N/A N/A 8.1E-03 1.0E-02 N/A N/A N/A 
551.3890 N/A N/A N/A 3.9E-04 1.6E-03 N/A N/A N/A 
553.3347 N/A N/A N/A 5.1E-04 1.6E-03 N/A N/A N/A 
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564.3061 Lipids PCs’; LPCs’ [M+Na]+; 
[M+2Na-H]+ 
4.6E-04 1.6E-03 5 ~ 0-4 
565.3104 N/A N/A N/A 5.1E-04 1.6E-03 N/A N/A N/A 
568.3388 Lipids PCs’; LPCs’ [M+H]+; 
[M+Na]+ 
3.7E-04 1.6E-03 6 ~ 1-2 
569.3445 N/A N/A N/A 4.2E-04 1.6E-03 N/A N/A N/A 
570.3163 N/A N/A N/A 1.6E-03 2.3E-03 N/A N/A N/A 
570.3476 N/A N/A N/A 3.6E-04 1.6E-03 N/A N/A N/A 
570.3569 Lipids LPCs’ [M+H]+ 5.5E-04 1.6E-03 2 ~ 2 








590.3224 Lipids PEs’; PCs’; LPEs’ 
[M+K]+; 
[M+Na]+ 


















2.2E-02 2.5E-02 4 N/A 0 
668.4142 N/A N/A N/A 9.0E-04 1.6E-03 N/A N/A N/A 
675.5427 Lipids Ceramide PEs’ [M+H]+ 3.2E-04 1.6E-03 3 ~ 1 
719.5337 Lipids PCs’; PEs’ 
[M+ACN+H]+ ;  
[M+NH4]+ 
0.02127 0.025096 51 N/A 0 
764.5218 Lipids 








0.02623 0.029758 120 N/A 0-2 
778.5396 Lipids 








0.00032 0.001622 108 N/A 0-4 
806.5703 Lipids 








0.00053 0.001622 111 N/A 0-4 
807.5713 Lipids PIs’ [M+H-H2O]+ 0.00053 0.001622 3 N/A 4 
826.536 Lipids 








0.00031 0.001622 91 N/A 0-3 
827.5412 Lipids PIs’ [M+H-H2O]+ 0.03785 0.041608 23 N/A 3 
852.554 Lipids PCs’; PSs’ 
[M+H]+;  [M+H-
2H2O]+ ; [M+Na]+ 
0.00136 0.002004 32 N/A 0; 3 
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0.00147 0.002144 21 N/A 2; 3 
Phosphatidylserine (PS); Fatty acid (FA); Phosphatidylethanolamines (PE); Diacylglycerols (DAG); Phosphatidylglycerophosphate (PGP), 
Phoshatidylcholine (PC); Phospatidylinotisol (PI); Phosphatidic acid (PA); Triacylglycerol (TAG); Lysophosphatidylethanolamine (LPE); 
Lysophosphotidylcholine (LPC); Phosphoethanolamines (PEA) 
 
 
Figure 3.30 Chromatographic peaks obtained for the untargeted metabolomic analysis of red and black 
lumpfish using SPME-HLB minitips and LC/HRMS. In A. and B., tentatively identified L-tryptophan 
and eicosapentaenoic acid in red and black lumpfish can be observed. The boxplots with normalized 





Figure 3.31 Box plots of selected metabolites for black and red lumpfish (m/z 301.2164, 480.3083, 518.3219, 543.3263 and 482.3597) and 
herring and salmon (m/z 525.2869, 371.2268, 503.3054, 416.2857 and 459.2806). 
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 Conclusion  
To the best of our knowledge, this chapter presents the first documented use of a 1 mm SPME minitip 
coating consisting of solid-coated HLB-PAN microporous particles. The results of our tests showed that 
our minitips provide good extraction efficiency and adequate repeatability. Furthermore, the results from 
the drug sampling test using 1 µL of blood and the subsequent nESI analysis demonstrated that the 
proposed tips are suitable for applications involving limited liquid volumes, which could have potential 
benefits for sample collection in clinical or forensic settings. We conducted metabolomic profiling on 
different types of caviar eggs and were able to achieve adequate discrimination and tentative 
identification among the tested samples. To the best of our knowledge, this is the first reported study that 
has successfully discriminated between caviar samples using a miniaturized SPME device and 
LC/HRMS analysis. This result is exceptional given the miniaturized size of the device, the dilution 
inherent to LC/MS, and the volume of the matrices tested. Unlike uncoated probes, HLB-coated SPME 
minitips can efficiently pre-concentrate analytes with lower MWs and differing physico-chemical 
properties. The availability of sampling devices that are capable of pre-concentration and non-selective 
extraction is highly important for metabolomics of single cells, as they can provide thorough insights 
into metabolism on a cellular scale. Our approach may be of potential interest to many fields, as the 
coating on the minitips can be altered in order to extract more challenging analytes more effectively.309 
While the majority of single-cell approaches utilise direct coupling, the use of a hyphenated technique 
with minitips could potentially allow relevant compounds to be separated more efficiently, thus making 
data interpretation easier. Indeed, SPME-HLB minitips promise great potential for small volume 
analyses, as they are easily convertible to accommodate small formats, while still providing quality data. 
However, one must keep in mind that minitips have certain limitations, such as bending/fragility at 
reduced tip diameters (d ≤ 30 µm), as well as poorer repeatability (i.e., 20-30% RSD) due to slight 
deviations that occur during tip preparation. As such, our future research is oriented towards establishing 
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 Untargeted metabolomic analysis of patients afflicted with malignant 
hyperthermia using LC/HRMS and SPME 
 
 Preamble  
Chapter 4 describes a collaboration between UW and Toronto General Hospital and has been submitted 
for potential publication to Anaesthesia & Analgesia. Tijana Vasiljevic completed the sampling, sample 
processing, instrumental runs, data processing and data interpretation of 2015 and 2016/17 patient cohort. 
Dr. Barbara Bojko completed the sampling, sample processing, instrumental run, data processing and 
data interpretation of mice cohort. Dr. Sheila Riazi provided the grant, the human samples and was vital 
in providing mice samples as a part of collaboration with the Baylor College of Medicine. Dr. Anna 
Roszkowska contributed to experimental work and provided significant scientific discussion. Dr. Ezel 
Boyaci contributed to experimental work and some discussion as well. Dr. Natalia Kraeva aided in 
sampling of 2015 and 2016/2017 patient cohort. Dr. Susan Hamilton and Dr. Amy Hanna of Baylor 
College of Medicine provided old heterozygous MH (Y524S, YS) and wild type (WT, control) mice and 
aided in their sampling. Tijana Vasiljevic also wrote this chapter (portions on mice sampling were written 
by Dr. Bojko with some input of Ms. Vasiljevic) and Dr. Riazi contributed to writing of some portions 
of the introduction. The manuscript for submission to Anaesthesia & Analgesia was also written by 
Tijana Vasiljevic, with some contributions from Dr. Bojko and Dr. Riazi. Tijana Vasiljevic and Dr. 
Barbara Bojko were assigned as equal contributors, whereby Dr. Bojko was assigned as first co-author 
based on alphabetical order of last names as requested by prof. Janusz Pawliszyn.  
I, Barbara Bojko, authorize Tijana Vasiljevic to use this material in her thesis. 
I, Sheila Riazi, authorize Tijana Vasiljevic to use this material in her thesis. 
I, Anna Roszkowska, authorize Tijana Vasiljevic to use this material in her thesis. 
I, Ezel Boyaci, authorize Tijana Vasiljevic to use this material in her thesis. 
I, Natalia Kraeva, authorize Tijana Vasiljevic to use this material in her thesis. 
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I, Susan Hamilton, authorize Tijana Vasiljevic to use this material in her thesis. 
I, Amy Hanna, authorize Tijana Vasiljevic to use this material in her thesis.  
For this chapter it is important to emphasize that sample collection began in Spring 2015 and concluded 
in Spring 2017. While reading the chapter, one might note that the two human cohorts are described, 
2015 and 2016/2017. The two cohorts were analysed separately. The 2015 cohort was analyzed first, 
since our goal was to examine whether meaningful information can be obtained from the muscle samples. 
In other words, we did not want to continue sampling for 2 years to find out that the results were non-
informative. Hence, 2016/17 was analysed afterwards. The two were not analysed together due to a 
possibility of batch effect. Lastly, this chapter includes extensive statistical information pertaining to 
metabolomic analysis and validation of PLS-DA models. Section 1.4 of Chapter 1 includes key 






Malignant hyperthermia (MH), a potentially deadly pharmacogenetic disease of skeletal muscle, is 
triggered by exposure to certain anesthetics. It results in a dysregulated, sustained elevation of 
myoplasmic calcium (Ca2+) that leads, through as yet  not fully identified pathways, to a hypermetabolic 
state.354 Mutations in the ryanodine receptor-1 (RyR1) gene, the skeletal muscle L-type Ca2+ channel 
(CACNA1S) gene, and STAC3 gene have been associated with MH susceptibility.355 Products of these 
genes play key roles in muscle contraction in the process of excitation-contraction coupling and in 
maintenance of Ca2+ homeostasis in skeletal muscle cells. While we know how mutations in these genes 
result in the production of massive dysregulated Ca2+ fluxes during an MH episode (by reducing the 
threshold for luminal Ca2+ activation and store overload-induced Ca2+ release (SOICR),356 the details of 
the hypermetabolic processes associated with MH are not clear.  Moreover, because the aforementioned 
genes only comprise ~60% of the population at risk, genetic diagnosis cannot be a sensitive, routine 
perioperative (pre-surgery) screen for MH susceptibility.  The only test available for predicting MH 
susceptibility with a high sensitivity  (i.e., >97%) is a contracture test, known in North America as 
caffeine-halothane contracture test (CHCT).357 It involves measuring muscle strips contracture to 
increasing concentrations of caffeine or halothane.  The principle of the test is based on the sensitivity of 
the muscle to the triggers that induce an increase in intracellular Ca2+ and result in skeletal muscle 
contraction. MH susceptible (MHS) individuals have a higher contracture response at lower trigger 
concentrations when compared to MH negative (MHN) individuals. 
The emphasis on the episodic “MH event” obscures the fact that MH susceptibility is a pleomorphic 
(many formed) condition. MH is known to have variable penetrance,358 delayed onset,358 and is triggered 
by heat,359 exercise,360 and statin medications.361 The pleiotropic (one gene influences two or several 
phenotypic traits) nature of clinical presentation makes the timely diagnosis of MH challenging, and 
therefore may result in delayed treatment both in operating room, and emergency department settings. 
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This is particularly troubling in the setting of fatal events like exercise related heat stroke in young 
athletes, where there is an inability to predict individuals at risk, and a lack of knowledge base to diagnose 
this entity and treat appropriately.  Hence, there is a need to determine the characteristics of a potentially 
unique hypermetabolic pathophysiology in MH, which may ease perioperative or peri-event diagnosis, 
and also may account for the variety of clinical presentations. 
Using pig models of MH, Fletcher and colleagues showed that free fatty acids (FtAs) enhance the effects 
of volatile anesthetics on Ca2+ regulation in skeletal muscle.362 Studies on MHS RyR1-R163C knock-in 
mice exhibited an increase in mitochondrial matrix Ca2+, increased reactive oxygen species (ROS) 
production, in conjunction with lower myoglobin and glycogen contents as well as lower glucose 
utilization, suggesting a switch to a compromised bioenergetics state characterized by both low oxidative 
phosphorylation and glycolysis.363 With the exception of a study done by Chang et al., whereby 
respirometry was used to measure oxygen flux between MHS and MHN patients, comprehensive studies 
exploring the details of metabolic pathways of MH in humans are limited.364  
Metabolomics, which is the study of changes in cellular metabolites occurring after an intervention that 
affects physiology, is an attractive way of determining biomarkers involved in metabolic reactions, such 
as MH.278,365 SPME is a non-destructive sample preparation method that has recently been implemented 
for metabolite extractions in varying applications by using special solvent-resistant coatings which can 
be coupled to LC/MS. SPME allows one to identify subtle metabolic changes that typically occur within 
seconds or minutes.278 This technology has been extensively tested for both hydrophobic, and hydrophilic 
metabolites, and has been shown to demonstrate adequate sensitivity, and specificity for cellular 
metabolites.366–368  
We hypothesized that the differences between human MHS and MHN individuals are reflected in 
measurable differences in myoplasmic metabolites. We postulate that by defining the constellation of 
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metabolic pathways peculiar to MH, we can elucidate the role of these pathways in an MH-related 
hypermetabolic reaction and understand the phenotypic variability among MHS individuals.  To 
accomplish this, SPME fibers were used to detect MHS and MHN muscle metabolites before and during 
exposure to caffeine, and halothane, with particular reference to lipid metabolism. Our goal was to define 
the metabolic pathways activated during an MHS-defining contracture response. Two human cohorts 
collected within different time periods were used (2015; 2016/17). Analysis was performed using LC-
HRMS and when possible, semi-validation of features was performed using parallel reaction monitoring 
(PRM) and examination of their retention times (RTs) in comparison to those of standards. Tentatively 
identified metabolites corresponded to acylcarnitines (ACRs), vitamin-D metabolites, long chain fatty 
alcohols, fatty acids (FtAs), prostaglandins, amino acids as well as selected lipid species for the 2015 
cohort. A single metabolite (16:0 LysoPC) was semi-validated, further suggesting involvement of lipid 
species with the MH condition. The second cohort produced limited information with regards to 
statistically significant metabolites but due to its value, “informative” features were extracted using 
heatmaps. Additional SLE extractions were performed on the muscle samples as a means of examining 
the robustness of the data, i.e., whether the same biomarkers would be obtained using a different sample 
preparation technique. Indeed, similarities were noted as elevation of several metabolites including 
amino acids, lipids and compounds related to muscle energy metabolism was evident in both studies. 
Certainly, differences were noted in the SLE extracts (potential biological and technical variations). Also, 
sampling of heterozygous MH (Y524S, YS) and wild type (WT, control) mice also confirmed presence 
of certain metabolites linked to the MH condition.  
 Experimental  
Materials and methods  
Following institutional research ethics board approval, all individuals undergoing muscle biopsy and 
CHCT at MH investigation unit at TGH were approached, and informed consent were obtained from the 
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participants. For CHCT, a piece of gracilis muscle is harvested and placed into a Krebs-Ringer (KR; 
saline solution). North American CHCT protocol was followed for all steps of CHCT.357 
MS grade H2O, ACN, MeOH and FA were all purchased from Thermo Fisher Scientific. SPME fibers 
with a MM extractive phase (C18 with benzenesulfonic acid, 7 mm length) were obtained from 
Millipore-Sigma. KR solution was made by mixing NaCl, KCl, CaCl2 and NaHCO3 obtained from 
MilliporeSigma. 16:0 LysoPC was obtained from Avanti Polar Lipids (Alabaster, AL, USA). 
SPME sampling and SLE extraction 
The excess part of the muscle which was not used for CHCT was utilized for this study. Muscle sizes 
between 5×5 mm to 10×25 mm were used due to inter-individual muscle size variability. Before the 
SPME sampling was done, the fibers were removed from preconditioning solution (MeOH/H2O, 50/50) 
briefly washed with H2O (to remove organic content) and using tweezers, carefully inserted into the 
muscle. Focus was placed on establishing proper contact between fiber and the muscle, since certain 
muscle samples were quite thin, which can potentially compromise the extraction process. Once inserted, 
the fibers were kept in the muscle for 15 minutes (n = 3). These samples were labeled as “baseline”. 
Muscles exposed to halothane (3 %) and caffeine (2 mM) were also sampled. Once halothane and 
caffeine were administered to the CHCT chambers, the muscle strip was tied, penetrated with the SPME 
fiber and suspended into the chamber kept at 37 °C. See Figures 4.1-4.2 for schematic of the sampling 
for baseline, halothane and caffeine samples. Sampling was done for 15 minutes in triplicates. To avoid 
artifact identification, sampling was also done in the KR solution that was used to preserve the muscle 
sample (n = 3, 15 min extraction). These samples were simply labeled as “KR baselines”. In total, n = 30 
patient samples were examined (includes both cohorts). Once the sampling was completed, the fibers 
were carefully removed, washed briefly with H2O and packed individually in vials. The vials were then 
placed on dry ice, transported to UW and stored at −80˚C until analysis. Remaining muscle samples were 
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subjected to SLE extraction. MeOH was added to the muscle samples, followed by rapid vortexing and 




Figure 4.2 Schematic showing sampling of the MH muscle during exposure to halothane and caffeine. 
Briefly, the muscle is immobilised to a metallic support and secured with strings. The top of the support 
is attached to a string which allows the support to be suspended within a glass chamber filled with H2O. 
Once ready, the fiber is inserted into the immobilised muscle and suspended within the glass chamber 
while they are filled with either 3% halothane or 2mM caffeine.   
Figure 4.1 Schematic representation of ‘baseline’ muscle sampling using SPME fibers. 
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In vivo mice SPME sampling 
Mice sampling was performed at the Department of Molecular Physiology and Biophysics at Baylor 
College of Medicine Houston. The in vivo experiment was done using 8 weeks old heterozygous MH 
(YS, Y524S mutation) and wild type (WT, control) mice (n = 6, each group). The mice were 
anaesthetized, and a 10-15 mm incision was made to expose the muscles of the upper hindlimb. A 28G 
needle was used to puncture the superficial muscles of the hindlimb and the extraction fiber (7 mm MM 
coating) was then inserted into the muscle and left in it for 15 min. After extraction, fibers were 
withdrawn, and mice were euthanized by cervical dislocation. All of the experiments had undergone 
ethics clearance and were done in triplicates (n = 3). 
Analysis of samples by LC/MS and LC/MS/MS 
Before the instrumental run, the fibers were removed from −80˚C and desorbed to 200 µL of ACN/H2O 
(50/50) for 1 h on a vortex (1500 rpm). Immediately following desorption, a PQC sample was created by 
pooling predetermined volumes of the desorbed samples. The desorbed samples were analysed in +ve 
and −ve ionization modes in random order using an ESI source mounted on Exactive Orbitrap, coupled 
to an Accela autosampler and a binary pump. Additionally, instrumental QC was used to monitor 
instrument stability, and solvents blanks were used to establish system blanks. Due to the sample size 
and method length (40 min gradient) a PQC was injected every 10th sample to monitor the stability of the 
runs. The instrument was calibrated using Pierce™ LTQ Velos for +ve and Pierce™ ESI negative ion 
calibration solution for −ve ionization mode. The validation experiments were performed using PRM 
mode with 2 collision energies of 20 and 40 eV via LC-MS/MS done on Q-Exactive Quadrupole Orbitrap 
and a Dionex Ultimate 3000 UPLC system (Dionex Corporation, Bannockburn, IL, USA). Instrumental 
analysis of the extracts obtained for in vivo mice experiments was performed on Q-Exactive Focus 
orbitrap MS coupled to a Dionex UltiMate 3000 RS autosampler and a Dionex Ultimate 3000 RS pump 
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(Thermo Fisher Scientific).  Same chromatographic method was used for all three instruments and the 
details have already been described in Section 3.3. Some instrumental details of Exactive-Orbitrap, Q-
Exactive Orbitrap and Q-Exactive Focus Orbitrap can be seen in Table 4.1. 
Table 4.1 Details of MS acquisition specifications for Exactive-Orbitrap, Q-Exactive Orbitrap and Q-
Exactive Focus 
Instrument Exactive-Orbitrap Q-Exactive Orbitrap Q-Exactive Focus Orbitrap 
Experiment Full scan PRM Full scan 
In-source CID Disabled 0.0 eV Disabled 
Default charge 
state 
- 1 0 
Inclusion - On Off 
MS - - - 
Microscans 1 1 1 
Resolution 100,000 70,000 70,000 
AGC target 1e6 1e6 1e6 
Maximum IT 100 ms 100 ms 100 ms 
Loop count - 1 - 





Isolation window - 1.6 m/z - 
Isolation offset - 0.0 m/z - 
Fixed first mass - - - 
(N) CE/ stepped 
(N) CE 








All the data was obtained in raw format of Thermo Xcalibur. The data was converted using MSconvert345 
(filter = peak picking, algorithm = vendor, MS level = 1, mass detector centroid noise: 1e3, data output= 
.mzXML). After conversion, the data was analysed using R-software69 (R version 3.5.1 (2018-07-02) 
"Feather Spray"). Using R-software, features whose % RSD in the PQC was >30 % were removed, as 
per acceptance criterion proposed by Want et al.369 Further, features whose S/N ratio was <5 in 
comparison to PQC were also removed. After data filtering, analysis was done using MetaboAnalyst.346 
Normalization of the data was done using the mean of PQC samples. After normalization, the data was 
further autoscaled (recommendation for  biological interpretations).370 Visual examination of data 
clustering was done using PCA and PLS-DA plots. PCA was used to observe general clustering of the 
229 
 
data and whether any outliers were present.  Validation of the PLS-DA model was done by examining 
the maximum number of components (set to 5 max) and by using 10-fold cross-validation (CV) and Q2 
for performance measure. The number of components for PLS-DA was chosen based on the result of the 
validation test.  A permutation test (n = 2000) was done to assess the PLS-DA model validity using 
separation distance (B/W). Non-parametric tests (Wilcoxon’s rank t-test or ANOVA, unequal group 
variance) were applied for the identification of significant features with p-value and false discovery rate 
(FDR) set at <0.05. Any features that appeared relevant were investigated by examining their 
chromatograms and comparing to signal from solvent blanks and KR solution.  In order to evaluate 
whether some features were artifacts of KR solution, signal area of features elevated in KR of MHS 
patients were divided by signal area in KR of MHN patients. Features whose signal area ratio was < 3 
were removed.  Additionally, areas of chromatographic peaks found in MHS patients were divided by 
the signal areas found in the patient-specific KR solution. Any peaks that came from solvent blank and 
KR were removed. Tentative identification of the features was done using Metlin73 or HMDB72 whereby 
precursor m/z tolerance was set to 5 ppm. The following adducts were considered for +ve ionization 
mode: [M+H]+, [M+H−2H2O]
+, [M+NH4]
+, [M+Na]+ and [M+K]+ while [M+Na−2H]−, [2M−H]−, 
[M+FA−H]−, [M−H, M−2H, M−3H]−, [2M+FA−H]−, [M−H2O−H]− and [M+Br]− were considered for 
−ve ionization mode. Tentative IDs were assigned if the metabolite was of biological relevance. 
Metabolites deemed significant were examined by performing PRM on the PQC sample. Mass spectra 
obtained from the PRM analysis of features of interest was individually examined, and the fragments 
were searched using MS/MS spectrum mass search (precursor tolerance = 5 ppm, MS/MS tolerance = 
0.02 Da) on Metlin.73 Molecular formulas of the compounds were obtained using Thermo Xcalibur or 
Metlin and/or HMDB. When available, standards to confirm the presence of suspected metabolites were 
used to validate the data. Retention times (RTs) of the standards were compared against those of 
suspected metabolites. Metabolic pathway analysis was done using MetaboAnalyst.  
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For data processing of extracts of in vivo mice sampling, Compound Discoverer (CD) 2.1 software 
(Thermo Scientific) was used. The mass tolerance window was 3 ppm, S/N threshold was 3, max sample-
to-blank ratio was 5. For PQC-based area correction, minimum 80% coverage and maximum 30% RSD 
was used. The processed dataset was submitted to MetaboAnalyst. Normalization of the data was done 
using sample median and autoscaling. Statistical analysis was done using fold change analysis, volcano 
plots, PCA and PLS-DA. Similar to human data, PLS-DA model was assessed by cross validation using 
10-fold CV and validated by permutation test (n = 2000) using five components and based on separation 
distance (B/W). 
 Results/Discussion 
Statistical analysis of 2015 cohort 
Relevant patient details (age, gender, contracture of muscle at caffeine and halothane exposure and 
results of genetic testing) can be seen highlighted in blue in Table 4.2. Cohort from 2015 is highlighted 
in blue while 2016/17 is highlighted in yellow in Table 4.2. After analysis of the data with R-software, a 
total of 15945 features (m/z values) were obtained in +ve and 4985 in −ve ionization mode. Data filtering 
reduced the numbers to 4408 and 179, respectively. The −ve ionization mode for 2015 cases was filtered, 
and then analysed by Metaboanalyst but this led to significant reduction of information, yielding no 
statistically significant information. Hence, since results were considered non-informative results, they 
were excluded from further data interpretation. The PCA model (normalized using the PQC and 
autoscaling) for baseline samples can be seen in Figure 4.3A. with 3 PCs (9.5%) on the x-axis and 1 PC 
(31.5 %) on the y-axis. Cases diagnosed as MHS-halothane (MHH, positive CHCT test to halothane 
only) were excluded due to outlier behavior (excessively high signal areas pulling data in one direction, 
please see Figure 4.4A-B.). No clustering based on diagnosis was observed in the PCA plot. Figures 
4.3B-C. show the plots obtained for muscle samples exposed to 3% halothane and 2 mM caffeine. Some 
clustering of MHS and MHN cases can be observed in samples exposed to halothane, while those 
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exposed to caffeine show a more prominent separation. Better clustering of data was obtained using PLS-
DA (Figure 4.5), although some overlap was still present. Since PLS-DA tends to over-fit data (i.e. 
provide separation/clustering due to class assignment), a validation of the model is recommended.371 
The model was assessed by examining the results of a 10-fold CV and using Q2 as performance 
measure. According to the data obtained, the optimum number of components is 4, with R2 and Q2 value 
Table 4.2 Patient details including respective diagnostic (MHN, MHS-Both: caffeine and halothane 
positive, MHS-Halothane (MHH): halothane positive only), age at the time of biopsy, gender, 
contracture of muscle upon exposure to 2mM caffeine and 3 % halothane as well as result of genetic 
testing. Patients highlight in blue is 2015 cohort, and those highlighted in yellow represent the 2016-
2017 cohort 







27 F 0 0.4 - 
47 F 0.2 0.6 - 
58 F 0 0 - 
47 M 0 0.2 - 
64 M 0 1.1 Negative 
39 M 0 0 - 
38 M 0 0.6 - 
33 F 0 0.3 - 
42 F 0 0 - 
44 F 0 0.5 - 
27 F 0.1 0.5 - 
40 F 0 0 - 
41 M 0 0.6 - 
39 M 0 0.2 - 
36 M 0 0.6 - 
39 F 0 0.4 - 
43 M 0 0 - 
35 F 0 0 - 
MHS-Both 
     
27 M 0.3 1.6 RYR1+:  p.Glu3583Gln 
46 F 0.7 1 Negative 
41 F 0.3 1.1 
CACNA1S +: 
p.Tyr585Cys 
34 F 0.3 2 Negative 
37 M 0.3 1.1 - 
24 M 0.6 2.2 
RYR1 c.526G>A 
p.Glu176Lys 
23 M 2 10.6 
RYR1 c.526G>A 
p.Glu176Lys 
33 Male 3.4 6.6 p.His2204Gln 
MHS-Halothane (MHH) 
     
41 F 0 1.8 Negative 
22 F 0 2.5 Negative 
35 F 0.1 1.3 - 
52 M 0.2 1.2 - 
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 of 0.84 and 0.56, respectively (Figure 4.6; Table 4.3). The permutation test performed (n = 2000) resulted 
in a p value of 0.065 (Figure 4.7). While the p value is higher than 0.05, the test statistic lies on the right 
side of the permutation test, indicating that the PLS-DA model obtained is not entirely “forced” or 
obtained due to class assignment. PLS-DA plots of samples exposed to halothane and caffeine can be 
Figure 4.4 PCA plots of the data obtained for the MHS and MHN patients for the 2015 cohort including 
(A.) baseline, (B.) 3 % halothane and (C.) 2 mM caffeine exposed samples. Data visualized in these plots 
has been constructed by normalising the features using mean of the PQC and autoscaling. Note in the 
PCA plot that positive cases cluster close to negative cases, but still provide acceptable separation 
(segregation of  data is specific clusters) between the two. 
Figure 4.3 PCA plots of the data indicating outlier presence. Figure A. shows the first outlier evident 
during preliminary data processing, while B. shows the outlier after removal of PQC. Indeed, attempting 
to process the data (i.e., find significant features) using outliers led to erroneous results. Likely cause 
of outlier behavior could be contributed to batch effects of sample storage.  
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seen in Figure 4.8 with CV details in Tables 4.4-4.5. Optimum validation tests should be done using an 
external dataset, which is not always feasible.372 Since only a limited number of patients were available 
for the study, CV and permutation tests may be considered useful towards validation , but are not 
satisfactory as a diagnostic method.372 
Figure 4.5 PLS-DA plot for baseline samples normalized with PQC and autoscaling. Two outliers have 
been removed from the plot due to excessively high signals in the samples which initially led to erroneous 




Figure 4.6 Results of cross-validation test done on Metaboanalyst  for the PLS-DA model generated in 
Figure 4.5. The model was assessed by examining the results of a 10-fold CV and using Q2 as 
performance measure.. The red mark denotes the optimum number of components that should be used 
for the model. In this case, the optimum number of components is 4. 
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Figure 4.7 Results of the permutation test done using separation distance (B/W) as the test statistic and 
permutation number set at 2000 for Figure 4.5. Results return p = 0.0655, which can be deemed 
acceptable to classification since the ratio B/W sum of squares dos not lie completely on the left side. 
Further evaluation using non-parametric Wilcoxon’s rank T-test yielded a total of 829 significant features 
with 108 being elevated in susceptible cases. With the exception of carnitine, only up-regulated features 
were considered. The significant features elevated in MHS patients can be seen summarized in Table 
4.6 with details that include accurate mass, RTs, ion, predicted formula, tolerance (in ppm), % RSD 
(mean PQC), p-value, FDR and database reference. Tentative identifications were assigned to these 
features and box-whisker plots can be found in Figures 4.9-4.11.   
Table 4.3 Detailed results obtained for the cross-validation test seen in Figure 4.5. According to the 
table shown below, the optimum number of components is 4, with R2 and Q2 value of 0.84 and 0.56, 
respectively. 
Measure 1 comps 2 comps 3 comps 4 comps 5 comps 
Accuracy 0.78571 0.90476 0.83333 0.90476 0.80952 
R2 0.41348 0.67660 0.77262 0.84634 0.92470 














Table 4.4 Results obtained for cross-validation examination of the data in Figure 4.8. 
Measure 
Accuracy R2 Q2 
Halothane Caffeine Halothane Caffeine Halothane Caffeine 
1 comp 0.77 0.77 0.54 0.63 0.28 0.40 
2 comp 0.87 0.80 0.70 0.77 0.48 0.60 
3 comp 0.85 0.88 0.81 0.84 0.59 0.65 
4 comp 0.97 0.88 0.91 0.94 0.61 0.70 
5 comp 0.95 0.94 0.97 0.97 0.64 0.70 
 
Table 4.5 Results of permutation test done (n = 2000) for samples exposed to 3 % halothane and 2 mM 









Permutation test summary (n=2000) 
Group p-value 
3% halothane 0.64 
2 mM caffeine 0.91 




Statistical analysis of 2016/17 cohort 
Second set of samples consisted of n = 19 patients, with n = 4 MHS-both, n = 2 MHH and the remainder 
being MHN. After processing of the data with R-software, a total of 10973 features for +ve and 5871 for 
−ve ionization mode were detected. Removal of peaks using S/N 5 and 30 % RSD led to significant 
reduction of data volume. Instead, S/N of 3 and RSD of 50% was used. Due to length of run (440 
injections ~ 2 weeks of continual instrumental operation for one ionization mode mode) variability in 
PQC stability was observed in both ionization modes, although more prominent in +ve mode. Hence, 
only autoscaling was used to normalise the data. PCA plot of baselines for +ve ionization mode can be 
seen in Figure 4.12A., revealing a time dependent acquisition trend from negative to positive PC1. No 
clustering was observed based on diagnostics. Removal of first set of injected samples allows for a tighter 
cluster, but still does not achieve separation between MHH, MHS and MHN for PCA (Figure 4.13). 
Better separation for +ve ionization mode is observed using PLS-DA (Figure 4.14), but CV and 
permutation tests reveal that the model does not possess discriminating power (Table 4.7, Figure 4.15). 
Similar results with respect to PCA, PLS-DA and CV tests are observed in case of samples exposed to 
3% halothane and 2mM caffeine in +ve ionization mode (Figure 4.16, Tables 4.8-4.9). Scarce number of 
significant features were found using the non-parametric ANOVA test. Hence, heatmaps were used to 
determine features of potential interest, whereby significant features were identified on the basis of their 
variable importance in projection (VIP) scores. The features with tentative identifications can be seen in 
Table 4.10. Features with no hits on HMDB, Metlin and of irrelevant biological significance were 
excluded. Detailed examination of peak areas for these features indicated some elevation in one to three 
susceptible patients. Examination of -ve ionization mode revealed less variability in the PQC, allowing 
its use for data normalization (alongside autoscaling). As it can be observed in Figure 4.11B., separation 
between MHH, MHS and MHN was not present. The MHS cases are clustering within MHN, while 
MHH is clustering towards negative PC2 with some intertwining with MHN. PLS-DA of baseline 
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Table 4.6 List of tentatively identified features (+ve ionization mode) for the 2015 cohort. The table includes the accurate mass of the feature up to 
4 decimals, Rt of the respective metabolite in minutes,  its predicted formula, tolerance in ppm for the searched features, assigned identification 
(please note that some features produce more than one possible identity, hence the number of possible options was included under identification), 
% RSD based on the mean of the PQC samples (n=15), p-value and FDR value generated using non-parametric Wilcoxon’s rank T-test and 
indication where the samples are elevated (i.e. baseline, caffeine or halothane exposed samples). In case of multiple options for adduct, formula 
and database reference “range” was used. 

























289.1800 25.7 M+H C18H24O3 1 
17-Epiestriol 
4-hydroxyestradiol 







349.2380 23.4 M+H C21H32O4 0 
15-(R)-15-methyl prostaglandin A2; 
PGA2 methyl ester 






















C22H43NO4 0 Pentadecanoylcarnitine 11.2 0.00422 0.04093 HMDB0062517 caffeine ↑ 
369.3509 25.0 M+H C27H45 1 3-Deoxyvitamin D3 9.5 0.00926 0.04922 METLIN42544 baseline ↑ 
372.1009 27.4 M+Na C12H19N3O9 1 Asp Thr Asp 28.76 0.00690 0.03948 METLIN21936 baseline ↑ 















387.2868 24 M+Na C23H40O3 0 
2-AG ether; 
Noladin ether 








405.2037 23.4 M+K C21H34O5 0 Prostaglandins (10; Metlin) 18.5 0.00142 0.03912 n/a 
halothane 
↑ 
411.3235 22.9 M+Na C26H44O2 0 Vitamin D and derivatives (4; Metlin) 21.5 0.00370 0.02467 range baseline ↑ 
417.3002 25.0 M+H C26H40O4 0 Vitamin D and derivatives (3; Metlin) 15.1 0.00001 0.00117 range baseline ↑ 
422.3266 25.3 M+H C25H43NO4 0 Alpha-linolenyl carnitine 22.9 0.00314 0.02203 HMDB0006319 baseline ↑ 
426.2607 23.9 range range 1 
Phosphatidylethanolamine (1); 
Phosphatidic acid (1); 
Lysophosphatidylethanolamine (1); 
Phosphatidylcholine (3); 
10.4 0.00265 0.01959 range baseline ↑ 





441.3343 23.3 M+Na C27H46O3 0 
(20R,22R)-20,22-
dihydroxycholesterol 














Diacylglycerols (24; HMDB); 
3-Deoxy-3-azido-25-hydroxyvitamin 
D3 (Metlin) 
15.5 0.02478 0.02478 range 
halothane 
↑ 













Vitamin D and derivatives (9); 
Leukotrienes (4) 
11.1 0.00001 0.00087 range baseline ↑ 
468.3086 25.0 range range 0 to 4 
Range of lipids (8);    
Tyrosine and derivatives (2) 
11.3 0.00003 0.00166 range baseline ↑ 




478.2718 22.9 M+K C21H46NO6P 4 
Phosphatidylcholines (2); 
Phosphatidylethanolamine (1) 






0; 3 Vitamin D and derivatives (5) 19.1 0.00314 0.02203 range baseline ↑ 
























































16.7 0.00049 0.00714 METLIN82326 baseline ↑ 




Phosphatidic acids (3) 




742.5765 28.0 range range 1 to 2 
Phosphatidylcholines (41) 
Phosphatidylethanolamines (17) 
Phosphatidic acids (3) 




750.5431 25.4 range range 0-4 
Phosphatidylethanolamines (62); 
Phosphatidylcholines (19) 




752.5596 26.2 range range 0 to 4 
Phosphatidylethanolamines (47); 
Phosphatidylcholines (15); 
Phosphatidic acids (3); 
Phosphatidic acids (2) 




760.5859 29.2 range range 0 to 1 
Phosphatidylethanolamines (16) 
Phosphatidylcholines (31) 
Phosphatidic acids (12) 



















782.5687 26.5 range range 0 -2 
phosphatidylcholines (77); 
phosphatidylethanolamines (25); 
phosphatidic acids (7); 
phosphatidylserines (16) 








804.5496 24.6 range range 2 
Phosphatidylcholines (46); 
Phosphatidylethanolamines (10) 





805.5507 24.6 range range 2 
Phosphatidic acid (1); 
Phosphatidylethanolamines (21) 









860.6104 25.4 range range 4 
Phosphatidylcholines (27); 
Phosphatidylethanolamines (2) 



























Figure 4.9 Box-whisker plots of metabolites that were elevated only in baseline cases with the red bar representing MHN patients while the 
green bar represents MHS  patients. Note that the concentration indicated in the plots was obtained from normalized values (i.e. values had 













Figure 4.10 Box-whisker plots of metabolites found to be elevated when the muscle samples (both MHN and MHS) are exposed to 2 mM caffeine. 






Figure 4.11 Box-whisker plots of metabolites found to be elevated when the muscle samples (both MHN and MHS) are exposed to 3% 




Figure 4.12 PCA plots for the baselines of the 2016/17 cohort for +ve ionization mode in A., and -ve 
ionization mode in B. Plots constructed using autoscaling for +ve and mean of PQC and autoscaling for 













Measure 1 comps 2 comps 3 comps 4 comps 5 comps 
Accuracy 0.76000 0.76000 0.78667 0.81000 0.83000 
R2 0.40176 0.66076 0.91381 0.97102 0.99499 
Q2 0.00223 0.07522 0.20235 0.26361 0.29371 
samples in −ve ionization mode (Figure 4.17) does provide for a better separation, with somewhat 
improved results of CV tests (Table 4.11, Figure 4.18). Examination of data for 3% halothane and  2 mM 
caffeine tested in −ve mode also reveals poor clustering based on diagnostics in PCA (Figure 4.19A. and 
C.). Better separation is observed in PLS-DA (Figure 4.19B. and D.) with improved CV results (Table 
4.12-4.13). Features of importance were examined using a heatmap and can be seen in Table 4.14. 
Similar to +ve ionization mode, the signal area of these features was not elevated in all patients affected 
Figure 4.14 PLS-DA plot of baseline samples run in +ve ionization mode. Data is normalized by 
autoscaling and one case is removed as an outlier. This data reveals some separation between the cases, 
but a single MHH case is within the MHN cluster. 
Table 4.7 Results of cross-validation test for Figure 4.14 done using 5 maximum searchable components, 





Figure 4.15 Results of the permutation test (n = 2000) used to test the validity of the mode in Figure 4.14. Test 
statistic used was separation distance (B/W). The p value is 0.97, indicating a non-predictive model. 
Figure 4.16 PCA and PLS-DA plots of samples treated with 3% halothane (A-B.) and 2 mM caffeine (C-
D.) for +ve ionization mode, respectively. In both instances, autoscaling was used as a form of data 
normalization and single outlier had been removed. 
248 
 
Table 4.8 Results obtained for cross-validation test of models in Figure 4.16. 
Measure 
Accuracy R2 Q2 
Halothane Caffeine Halothane Caffeine Halothane Caffeine 
1 comp 0.70 0.78 0.50 0.59 0.21 0.25 
2 comp 0.71 0.81 0.72 0.78 0.40 0.45 
3 comp 0.77 0.76 0.93 0.95 0.55 0.50 
4 comp 0.81 0.83 0.97 0.98 0.60 0.56 
5 comp 0.83 0.89 0.99 0.99 0.61 0.57 
 




Table 4.10 Features tentatively identified for +ve ionization mode for baseline, halothane and caffeine 
exposed samples. Selection was done using a heatmap. Features which did not provide hits or were 
biologically relevant are not shown. Rts are in seconds. 
with MH. Instead elevation was present in one to two cases. Possible contributors to difference in these 
results between the 2 cohorts could include phenotypic variability which in turn causes biomarker 
variation. Technical factors cannot be excluded as external contributors may also be responsible for the 
variations (instrumental effects, length of run, storage time). Hence, one must be careful in elimination 
of what appears as false positives, since different phenotypes could contribute to different biomarkers. 
Permutation test summary (n = 2000) 
Group p-value 
3% halothane 0.949 
2 mM caffeine 0.966 
Feature (m/z vs Rt) Tentative ID Reference Note Elevation 
244.1546/1112.82 Tiglylcarnitine HMDB0002366 Acyl carnitines 
MHH & MHS ↑, 
Caffeine (Both) ↑ 
244.2274/1066.77 5-Tetradecenoic acid HMDB0000499 
Linked to fatty acid chain 
oxidation diseases* 
MHS ↑ 
305.2476/1354.14 Arachidonic acid HMDB0001043 
Linked to ischemia, lipid 
metabolism disorder, amino 
acid metabolic disorder, 
muscular dystrophy * 
MHS (Halothane) ↑ 
378.2982/1289.32 Pristanoyl glycine HMDB0013303 - MHH (Halothane) ↑ 






- MHH (Caffeine) ↑ 
147.1128/2389.1 N-Methyl proline; L-Lysine 
HMDB0094696; 
HMDB0000182 
Linked to ischemia, lipid 
metabolism disorder, amino 
acid metabolic disorder, 
muscular dystrophy * 
MHH (Caffeine) ↑ 
* MalaCards: an amalgamated human disease compendium with diverse clinical and genetic annotation and structured search, 
https://www.malacards.org/   
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Figure 4.18 Result of permutation test (n = 2000, separation distance B/W as test statistic) done for 
examination of the PLS-DA model in Figure 4.17. 
Table 4.11 Results of cross-validation test done using 5 maximum searchable components, 10-fold CV 
as cross validation method and Q2 as performance measure for model in Figure 4.17.  
 
Measure 1 comps 2 comps 3 comps 4 comps 5 comps 
Accuracy 0.72667 0.65667 0.71000 0.78000 0.82000 
R2 0.44816 0.65134 0.84661 0.93176 0.96907 
Q2 0.24973 0.33978 0.48210 0.55758 0.61138 
Figure 4.17 PLS-DA model obtained for analysis of baseline samples done in -ve ionization mode on Exactive-




Table 4.12 Results obtained for cross-validation examination of the data in Figure 4.19. 
Measure 
Accuracy R2 Q2 
Halothane Caffeine Halothane Caffeine Halothane Caffeine 
1 comp 0.63 0.78 0.59 0.50 0.39 0.26 
2 comp 0.67 0.79 0.82 0.76 0.53 0.46 
3 comp 0.77 0.77 0.90 0.84 0.60 0.51 
4 comp 0.78 0.83 0.95 0.90 0.65 0.59 
5 comp 0.81 0.84 0.98 0.95 0.66 0.62 
 
Table 4.13 Results of permutation test done (n=2000) for samples exposed to 3% halothane and 2 mM 





Permutation test summary (n = 2000) 
Group p-value 
3% halothane 0.41 
2 mM caffeine 0.05 
Figure 4.19 PCA and PLS-DA plots of samples treated with 3 % halothane (A. and B.) and 2 mM 
caffeine (B. and D.) for −ve ionization mode. Normalization by PQC and autoscaling was used. 
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Table 4.14 Features tentatively identified for -ve ionization mode for baseline, halothane and caffeine 
exposed samples. Selection was done using a heatmap. Features which did not provide hits or were 
biologically irrelevant are not shown. Rt is in seconds. 
Feature (m/z vs 
Rt) 
Tentative ID Reference Notes Elevation 

























3-Methylglutaconic acid linked to 










Lipid linked to chronic pain, 
neuromuscular disease and spasticity* 
MHS (Caffeine) ↑ 
325.2747/1334.23 Triglycerides Range n/a MHH (Caffeine) ↑ 




Linolenic acid; a number 




Inflammation related, linked to 
ischemia, lipid metabolism disorder* 
MHH (Caffeine) ↑ 
279.2324/1345.21 












Prostaglandins ↑- Inflammation related, 
inks to ischemia, metabolic acidosis, 
spasticity, lactic acidosis* 
MHH (Caffeine) ↑ 
*MalaCards: an amalgamated human disease compendium with diverse clinical and genetic annotation and structured search, 
https://www.malacards.org/   
 
PRM investigation of significant features  
Significant features with matches on MS/MS spectra search included 17-Epiestriol, 4-hydroxyestradiol, 
15-(R)-15-methyl prostaglandin A2, PGA2 methyl ester, (±)19(20)-DiHDPA; 16,16-dimethyl-PGA2, 
7(S),17(S)-dihydroxy-8(E),10(Z),13(Z),15(E),19(Z)-Docosapentaenoic Acid, Aspartate Threonine 
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Aspartate (protein breakdown product), 1- Linoleoyl-rac-glycerol, 2-AG ether, Noladin ether and PC 
(16:0/0:0)U/PC(16:0/0:0, racemix ) (Metlin scores: 32, 56, 37, 29, 36, 36, 50, 43, 20, 31 and 51, 
respectively.  Standards were purchased to validate the metabolites, but promising results were obtained 
only for PC (16:0/0:0)U/PC(16:0/0:0). (Figure 4.20). Since PC(16:0/0:0)U/PC(16:0/0:0) is a racemix, 
16:0 LysoPC was used to perform semi-validation since they are structurally identical. Additionally, 
feature annotation indicated this metabolite as a unique feature corresponding to 16:0 LysoPC. In the 
PQC, this metabolite eluted as a double peak at 20.5 and 25.2 min (Fig. 4.21a.). The standard eluted at 
20.9 min which is close to the PQC peak at 20.5 min (Fig. 4.21b.). A second peak was not observed. 
Kyle et al. has shown that 16:0 LysoPC has two distinct LC peaks, which correspond to different acyl 
chain positions (i.e. sn-1 or sn-2 acyl chain position) with the more abundant later eluting peak correlating 
with a sn-1 position.373 Ability to separate such isomers using RPLC has been demonstrated.374   
Lysophosphatidylcholines occur in two forms, with fatty acyl groups at positions 1 (sn-1) and 2 (sn-2).375 
The sn-1 LysoPCs are produced by phospholipase-A1 and sn-2 LysoPCs are produced by phospholipase-
A2 (PLA2).
376 The position of the acyl group is important in understanding their biological roles as 
lysoPCs with different sn-positions are responsible for different metabolic roles.375 Interestingly, 16:0 
LysoPC has been reported as a biomarker in lung cancer375 and chronic renal failure.377–381 Endogenous 




phosphatidylcholines exist as isomers in biological matrices,382 but there is some discord in 
chromatographic reporting of 16:0 LysoPC.  Both single383 and double peaks384 have been reported. 
Additionally, reports of time and temperature related isomerization of 16:0 LysoPC factors also 
exist.385,386 The isomerization may also depend on analyzed media, i.e., different tissues, cells, organelles 
or even phospholipid classes.382 Hence, observation of a single peak in our case could be related to the 
use of a synthetic standard. Therefore, the evidence obtained points to possibility of up-regulated 16:0 
LysoPC in the 2015 cohort.  The metabolites that did not provide a MS/MS spectrum match during search 
possibly did not have enough intensity for the parent metabolite or could have potentially diminished due 
to storage- therefore not yielding sufficient fragmentation for fragment matches. Additionally, limitations 
in using commercially available databases exist, such as in silico predicted spectra which is obtained 
from different MS analysers and may not necessarily give the best prediction.387 For example, a 
metabolite of particular interest in our study was 3-deoxyvitamin-d3, seen in Table 4.6. A search on 
Metlin revealed that this metabolite could be 3-deoxyvitamin-d3 (1 ppm accuracy). However, MS/MS 
fragmentation yielded an MS product (327.0771) whose accurate mass did not match that of the database 
(327.3050, in silico predicted fragmentation), making it difficult to confirm its identity (Figure 4.22). 
Additionally, a commercially available standard for this compound is not available, which adds another 
layer of difficulty in confirming the identity of this metabolite. Regardless, 3-deoxyvitamin-d3 could be 
Figure 4.21 Extracted ion chromatograms for 16:0 LysoPC (496.3390, [M+H]+) in the pooled QC sample 
(a.) obtained from Q-Exactive at 20.5 and 25.2 minutes and validation standard (b.) obtained on Exactive 
Orbitrap at 20.9 minutes. 
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placed within the context of biological mechanism of MH, as vitamin-d3 is involved with regulation of 
Ca2+ levels in the body.388 Additional tentatively identified metabolites (m/z 457.2718, 471.2872, 
481.3657, and 492.3687) also point to vitamin D and its derivatives. However, it is important to point 
out that this information was not validated, and therefore could not be deemed entirely accurate.  
Statistical analysis of the in vivo mice data 
After processing of the data obtained from in vivo SPME sampling of remaining mice, the number of 
features detected in +ve and −ve ionization mode was 2244 and 1248, respectively. After processing and 
filtering in CD 2.1, the final number of peaks underwent statistical analysis in MetaboAnalyst yielding 
187 and 104 features for +ve and −ve ionization mode, respectively. No relevant information was found 
using −ve ionization mode, so the data will be focused on +ve ionization mode only. The PCA plot shown 
Figure 4.22 Figure labeled A. shows the MS/MS spectra obtained at 20eV for fragmentation of a 
metabolite with m/z of 369.3515 with a predominant fragment ion of 327.0777. Insert B. shows the 
identification provided on Metlin by searching [M+H]+ adducts only with a 0 ppm tolerance obtained 
for 3-Deoxyvitamin-d3. Insert C. shows the in silico predicted spectra of 3-Deoxyvitamin-d3 with a 
fragment ion of 327.3050, which did not match 327.0777. 
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in Figure 4.23 indicated separation between YS and WT groups by PC1 and PC3 explaining 23.2 and 
12.1% of the variances. The PLS-DA model (Figure 4.24) subjected to 10-fold cross validation 
assessment indicated PC3 as the best classifier with Q2 of 0.4006 and R2 of 0.9906 (Figure 4.25 and 
Table 4.15). The permutation test failed the validation criteria thus not exhibiting statistical significance 
in class discrimination (p = 0.9995, Figure 4.26). The fold change analysis resulted in identification of 
18 important features differentiating the studied group, while the Volcano plot analysis showed four of 
such features, which are all included in Tables 4.16-4.17. The tentative identification of the compounds 









Figure 4.23 PCA plot for the in vivo animal data in +ve ionization mode. Plot was constructed 
using autoscaling and normalized by sample median. 
Figure 4.24 PLS-DA plot of baseline samples. Data is normalized by autoscaling. This data reveals good 





Figure 4.26 Result of permutation test (n = 2000, separation distance B/W as test statistic) done for 
examination of the PLS-DA model for in vivo animal data in +ve ionization mode 
 
Measure 1 comps 2 comps 3 comps 4 comps 5 comps 
Accuracy 0.58333 0.83333 0.91667 0.83333 0.83333 
R2 0.84919 0.95776 0.99065 0.99588 0.99986 
Q2 0.06243 0.35163 0.4006 0.38564 0.38597 
Figure 4.25 Results of cross-validation test done on MetaboAnalyst for the PLS-DA model generated in 
Figure 4.23. The model was assessed by examining the results of a 10-fold CV and using Q2 as performance 
measure. Performance measurement of the PLS-DA model done on MetaboAnalyst detailing accuracy, R2 
and Q2 values. The red mark denotes the optimum number of components that should be used for the model. 
In this case, the optimum number of components is 3. 
Table 4.15 Results of cross-validation test done using five maximum searchable components, 10-fold CV 






Peaks (mass) Fold Change log2(FC) 
1 140.95039/1.4 0.00411 −7.9267 
2 704.49321/28.5 24.17800 4.5956 
3 528.45439/27.6 10.99100 3.4582 
4 724.40094/23.7 6.68580 2.7411 
5 647.42471/23.4 5.80960 2.5384 
6 652.38004/23.4 5.74630 2.5226 
7 159.06844/10.9 0.18322 −2.4483 
8 474.40752/27.2 5.03780 2.3328 
9 109.01302/1.1 4.45850 2.1566 
10 302.22442/19.3 0.24864 −2.0079 
11 439.40255/23.9 3.51010 1.8115 
12 97.97712/1.1 3.46850 1.7943 
13 411.37117/23.1 2.65070 1.4064 
14 418.30813/25.0 2.29600 1.1991 
15 136.03853/6.9 0.45124 −1.1480 
16 168.02854/1.5 0.45947 −1.1220 
17 268.08046/6.9 0.46595 −1.1018 












Peaks (mass) FC log2(FC) raw.pval -log10(p) 
1 418.30813/25.0 2.2960 1.1991 0.00587 2.2309 
2 704.49321/28.5 24.1780 4.5956 0.02132 1.6711 
3 528.45439/27.6 10.9910 3.4582 0.04618 1.3355 
4 474.40752/27.2 5.0387 2.3328 0.07868 1.1041 
Table 4.16 Important features differentiating YS and WT mice identified by fold change analysis. 
Table 4.17 Important features differentiating YS and WT mice identified by volcano plot. 
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Table 4.18 List of tentatively identified features of biological relevance for in vivo mice study. Rt is in 
seconds. 
 
Discussion   
Analysis of the extracts obtained from SPME sampling revealed that the levels of several classes of 
lipids, including phosphatidylethanolamines, phosphatidylcholines, and triglycerides were elevated in 
MHS patients from two cohort studies (Tables 4.6, 4.10 and 4.14), pointing to an affected lipid and FtA(s) 
metabolism. This observation is in accordance with previous studies, in which Cheah et al. were the first 
ones to report that the MH condition is influenced by an altered FtA metabolism, i.e., excessive 
production of FtA(s).389 However, Fletcher has proposed that the observed alterations in the FtA(s) 
metabolism in MH are related more to synthesis and breakdown of triglycerides and not phospholipids.390 
The authors suggested that FtA(s) (primarily unsaturated) are responsible in part for modulation of Ca2+ 
channels.390 However, the features found in our study (24 tentatively identified and 1 semi-validated) 
point to various lipid species, not only triglycerides. The semi-validated feature 16:0 LysoPC (Fig. 4.21 
and Fig. 4.27A.) is a product of hydrolysis of phosphatidylcholine, a reaction catalyzed by the enzyme 
PLA2, which is also involved in regulation of the metabolism of prostaglandins through modification of 
arachidonic acid. Interestingly, Wong et al. found that elevated Lyso:PC (particularly 16:0) in human 
endothelial cells led to enhanced arachidonate release, and subsequent increase of cellular Ca2+ and 
activation of protein kinase C,391 which is involved with contraction of smooth muscle cells. In fact, 






Identified metabolite FC log2(FC) -log10(p) regulation 
137.0459/88.2 M+H C5HN4O Hypoxanthine 1.97 0.98 1.30 up 
169.0358/88.2 M+H C5H4N4O3 Uric Acid 2.18 1.12 0.59 up 
204.1231/546 M+H C9H17NO4 Acetylcarnitine 2.02 1.01 0.58 up 
269.0879/88.2 M+H C10H12N4O5 
Inosine or 
Arabinosylhypoxanthine 
1.75 0.81 0.92 up 
412.3783/1383 M+H C25H49NO3 N-Tricosanoylglycine 0.38 -1.41 0.46 down 
440.4099/1436 M+H C27H53NO3 N-Pentacosanoylglycine 0.28 -1.81 0.57 down 
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Wieland et al. proposed a potential abnormal function of hormone sensitive lipase.393 In that study, it has 
been suggested that elevated PLA2 activity may lead to greater concentrations of lysophosphatidylcholine 
and lysophosphatidylethanolamines,393 a suggestion based on a greater free FtA release from MHS 
mitochondria.389,390,392,394 As mentioned in the above section, 16:0 LysoPC was the early eluting peak in 
the PQC, thus suggesting that the acyl chain might be positioned on sn-2, and its production is controlled 
by PLA2. The activity of PLA2 is regulated by phosphorylation and Ca
2+ concentrations.376 The group of 
PLA2 enzymes are classified into those that are calcium dependent (cPLA2) and independent 
(iPLA2).
395,396 PLA2 also plays a role in ROS formation, influencing contractile properties and fatigue 
characteristics of skeletal muscles.395,397  It has been already suggested that an increase in ROS is linked 
to hypermetabolic condition that occurs in MH. Oxidative stress occurs when formation of ROS exceeds 
the capacity of the anti-oxidant defense system.395 In absence of PLA2 regulation, pro-inflammatory 
mediators are produced376 resulting in oxidative stress. Interestingly, Yoda et. al. found that iPLA2-y null 
mice (i.e., no iPLA2-y) exhibited increased mitochondrial dysfunction and oxidative stress which led to 
loss of skeletal muscle structure and function.398 In a different study, Jurivich et. al.399 found that PLA2 
may affect transcriptional switches which mediate thermal stress in some cells. Secretion of cPLA2 is 
considered to induce inflammatory response in neighboring cells376 and iPLA2 is linked to lipid and 
energy metabolism,396 skeletal muscle contractile function by modulating cytostolic oxidant activity,400 
mitochondrial integrity and phospholipid remodelling396 and development of many diseases.396 
According to Carper et. al. acyl-CoA thioesterase activity of iPLA2-β could be an important contributor 
for optimal FtA oxidation by skeletal muscle.400 Even in the context of MH, Cheah et. al. obtained 
experimental evidence that supports the theory that increase in long chain FtA(s) by endogenous PLA2 
is responsible for enhanced release of Ca2+ from skeletal muscle mitochondria of porcine MH.401 
Interestingly, others have also noted connection between PLA2 and its role in muscle physiology. Duncan 
has considered PLA2 as a candidate which initiates changes in Ca
2+ concentrations that trigger cellular 
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damage in skeletal muscle.402 Boittin et. al.403 showed that iPLA2 enhances the entry of Ca
2+ in dystrophic 
skeletal muscle fibers while Malhotra et. al.404 identified iPLA2-IV as a potential target for therapeutic 
intervention in patients afflicted with Barth syndrome.  
In addition to the identification of 16:0 LysoPC, certain pro-inflammatory compounds were tentatively 
identified by our study (i.e.,1a,1b-dihomo-15-deoxy-δ-12,14-PGD2; 1a,1b-dihomo-PGJ2, arachidonic 
acid, etc.) indicating potentially elevated levels of prostaglandins and an affected arachidonic acid 
pathway (Figure 4.27B. shows box-whisker plot of one of such compounds). Prostaglandins belong to a 
group of oxidized FtA(s) and are involved in variety of physiological processes in the body, including 
the regulation of contraction of smooth muscle tissue.405 They also promote entry of Ca2+ ions into cells, 
and an increased concentration of prostaglandins has been linked  to muscle dystrophy.406 Also, in the 
2016/17 cohort, links to linoleic acid pathway (responsible for production of arachidonic acid and 
eicosanoids) were discovered (Figure 4.27F.). As mentioned in the introduction, free FtA(s) enhance the 
effects of volatile anesthetics on Ca2+ regulation in skeletal muscles. It is known that exposure of skeletal 
muscle to halothane increases the Ca2+ release from sarcoplasmatic reticulum.407 In our study it can be 
noted that the level of prostaglandins were elevated in halothane exposed muscle samples, suggesting 
that the exposure to the volatile anesthetic may stimulate formation of such metabolites (Table 4.6, 4.10 
and 4.14). Moreover, the level of arachidonate, a precursor of prostaglandins, was also elevated in 
halothane samples of MHS patients (Table 4.10).  Indeed, oxidative metabolism of arachidonic acid 
generates ROS production395 whereby iPLA2-y also potentiates arachidonic acid release from various 
subclasses of lipids.396 The use of anaesthetics is generally considered to have  an anti-inflammatory 
effect during an inflammatory process such as surgery,408 but this effect may be different in MHS 
individuals leading to increased metabolism of prostaglandins in skeletal muscles under halothane 
exposure. Other lipidomic features pointed to several different families of lipids, making tentative 
identification challenging. However, some features strictly returned hits for a family of lipids like 
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phosphoinositols. In fact, a study has shown that accumulation of inositol phosphate products was 
involved with the development of MH.409 Inositol phosphate products were measured in MHN and MHS 
swine, and the latter showed a 304-1330 % increase in accumulation of the lipid species.409  
Other tentatively identified species found in the baseline samples include octadecanol, a long chain fatty 
alcohol which has previously been detected in skeletal muscles of patients suffering from Sjögren-
Larsson syndrome, a condition whose symptoms includes spasticity, i.e., muscle spasms and stiffness.410 
Interestingly, other compounds, whose level was elevated in skeletal muscles of MHS patients are 
AcR(s), a group of endogenous compounds that participate in muscle energy metabolism via β-oxidation 
(Figures 4.27C-D. show carnitines elevated in the 2015 and 2016/17 cohort). In fact, muscles are sound 
sources for AcR(s) generation.411 In most tissues, including skeletal muscle, the rate of FtA β-oxidation 
is regulated by the carnitine-acylcarnitine shuttle. Among identified AcR(s) in this study, 
pentadecanoylcarnitine was present in the caffeine-exposed samples, and alpha-linolenyl carnitine was 
present in the baseline samples of MHS patients from 2015 cohort (Table 4.6), whereas tiglylcarnitine 
was extracted from skeletal muscles obtained from MHS patients in 2016/17 cohort (Table 4.10). The 
identified AcR(s) belong to long chain FtA(s), a group of compounds that are utilised by skeletal muscle 
during contraction412,413 and are considered markers of disordered conditions of perixomal and 
mitochondrial oxidation414 with a report linking elevated AcR levels to rhabdomyolysis.415 It was 
observed that increases in levels of AcR(s) are also associated with an increase in concentration of ROS 
species and intracellular Ca2+.411,416 Therefore, elevated levels of certain AcR(s) may indicate 
dysregulation of FtA pathways, or FtA oxidation disorders. Consequently, these oxidation disorders 
affect enzymes involved in long chain FtA catabolism, which leads to accumulation of both plasma and 
tissue AcR(s).411,416 Octadecanoic acids, found in MHS patients of 2015 are also involved in 
mitochondrial β-oxidation of long chain FtA(s). 5-tetradecenoic acid was found elevated in 2016/17 
cohort as well (Figure 4.27E.), and it is connected to defects in long chain FtA disorders.417 Interestingly, 
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levels of carnitine measured in 2015 MHS cases appeared to be down-regulated (Figure 4.28). Carnitine 
deficiency is linked to muscle weakness,418 which could be another possible indication of MH 
susceptibility. Engel and Angelini found that carnitine deficiency in human skeletal muscle is associated 
with myopathy, and accumulation of  lipids in the muscle tissue was considered to be a cause of excessive 
oxidative catabolism of FtA(s).418 Apart from the disturbances in FtA(s), arachidonic acid and linoleic 
acid metabolic pathways, alterations in the metabolism of amino acids, and di- and tripeptides were 
observed in skeletal muscles of MHS patients in two cohort studies. Elevated levels of tyrosine and L-
histidine pointed to potential dysregulations in the N2 metabolism.
419 They also indicate increased protein 
synthesis or formation of neurotransmitters, whereas elevated level of lysine, one of the precursors of 
Figure 4.27 Box-whisker plots of selected tentatively identified features, including 16:0 LysoPC, 15-
(R)-15-methyl prostaglandin A2 and alpha-lineoyl carnitine in A., B. and C., respectively (2015 cohort). 




carnitine, may be related with observed alterations in carnitine-dependent oxidation of long chain FtA(s) 
in the skeletal muscles. L-histidine, L-threonine and L-lysine provided connections to amino-acyl tRNA 
biosynthesis pathway, whereby some synthetases are believed to regulate glucose metabolism and are 
connected to disruptive metabolic conditions.420 N-palmitoylethanolamide was found in the 2016/17 
cohort, and while research on its role is still under-going, this metabolite is considered to regulate 
functions involved in pain and inflammation.421    
Interestingly, apart from the abovementioned compounds, SPME facilitated the extraction and 
identification of vitamin D and its multiple metabolites solely in human skeletal muscles obtained from 
MHS patients of 2015 cohort. The elevated level of those compounds was observed not only in the 
baseline samples, but also in the samples exposed to the action of halothane and caffeine. Vitamin D is 
well known compound involved in the regulation of Ca2+ homeostasis in the body, and its level is tightly 
regulated by parathormone (PTH) and fibroblast growth factor 23 (FGF23). In patients predisposed to 
develop the MH condition, the level of vitamin D3 was elevated and possibly not modulated by negative 
feedback loop by PTH and FGF23. In addition, increased level of vitamin D and its metabolites was not 
observed in SPME extracts obtained from the sampling of skeletal muscles of 2016/17 cohort and YT 
mice, therefore the underlying mechanism of altered vitamin D metabolism may not be related to genetic 
mutation in MH.  
Figure 4.28 Box-whisker plot of tentatively identified metabolite carnitine (162.1127, [M+H]+) in 
negative (MHN) and positive (MHS cases). Carnitine deficiency is also linked to muscle myopathy, which 
is one of symptoms of MH. 
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In vivo sampling of mice with RYR1 gene  
Altered metabolism of small molecules, mainly metabolites involved in FtA(s) and purine metabolism 
was observed in SPME extracts obtained from the in vivo experiments performed on mice with knock-
out RYR1 gene, pointing out that the reported imbalance in the metabolism of lipids in human skeletal 
muscles of MHS patients could be related to genetic basis of the disease (Table 4.18). The driving force 
to perform in vivo animal experiment was notable metabolic difference between MHS and MHN at 
baseline in human cohorts. At present, diagnostic of MH is based on CHCT, which is highly invasive. 
Therefore, alternative approach like SPME offering less invasive protocol would be desired. The results 
showed relatively good separation between YS and WT groups, but inter-animal variability was high in 
both groups. This is likely a result of technical issues related to sampling itself rather than biological 
variability. Simply, the muscle of the mouse is very small when compared to SPME probe. Therefore, it 
is very difficult to precisely control full penetration of the SPME fiber within the tight muscle. 
Nevertheless, the data showed number of features participating in separation of the MH and control 
cohorts. Some of the features could not be identified even putatively as the masses did not match any 
known metabolites from databases available. It was previously reported, that in vivo SPME may capture 
short-lived or unstable metabolites, but to draw conclusions of that matter, in-depth studies would have 
to be conducted. The metabolites presented in Table 4.18 indicate that genetic MH is associated with 
alteration in purine and FtA metabolism. Similar to human data, AcR(s) and acylglycines were found to 
be of particular importance. The AcR(s) in both human and animal studies showed increased muscular 
level, while in case of acylglycines the level was elevated in MHS patients but YS mice showed 
downregulation. The differences also concern the length of acyl chain of the acylglycines; with the longer 
ones being observed in mice data. To best of our knowledge, acylglycine were not discussed in the view 
of MH, but it was reported422 that they might be a good complement to analysis of AcR(s) and organic 
acids in diagnosis of mitochondrial energy metabolism disorders.  
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Interestingly, the in vivo mice experiments showed direct link between MH and purine metabolism by 
increased level of inosine, uric acid and its precursor hypoxanthine in YS cohort. All these metabolites 
are known to be involved in muscle movement via energy consumption as they are by-products of ATP 
breakdown. Xanthine and inosine were proposed as early biomarkers of cardiac ischemia because their 
concentration significantly increases under hypoxia/ischemia.423 The uric acid, which has strong 
antioxidative properties, was reported to be positively associated with muscle strength in older 
persons.424,425 Although the chemometric models built based on the in vivo data did not pass the validation 
because of the reasons described above, the obtained results may suggest that in muscles of MH subjects 
oxygen deprive-like conditions occur. The alteration of purine metabolism was also found in MHS 
patients’ muscles extracted with the solid liquid extraction (SLE) technique.  
Comparison to data from SLE extractions 
Similar results with respect to the changes in the metabolism of different lipid species, including 
phosphoethanolamines, amino acids and compounds involved in muscle energy metabolism were also 
observed in muscle samples obtained from MHS patients in comparison to MHN patients during the 
analysis performed using SLE.  A summary of features that are biologically similar, i.e. shared between 
SPME and SLE can be observed in Figure 4.29. Based on the results obtained, it was observed that the 
level of AcR(s) was elevated in the baseline samples, as well as certain amino acids (glycine, histidine, 
asparagine for SLE and expected metabolite prolyl-asparagine for SPME) and a range of 
phosphoethanolamines and palmitoylethanolamides. As expected, there were also certain differences in 
features reported between the two techniques. For example, SLE provided links to metabolites involved 
with creatine, nicotinamide, purine metabolism and urea cycle.  Since the SLE study is part of a larger 
on-going project being done at TGH, we will not represent all the features found in this study.  The SLE 
information reported in this research is provided to affirm the findings accomplished via SPME. As it 




Figure 4.29 Comparison of similar and shared metabolites obtained via SPME and SLE.  
Such discrepancy between the results obtained for the two techniques may be caused by different 
extraction mechanisms. SLE is an exhaustive sample preparation protocol which relies on tissue 
homogenization and protein precipitation. MeOH is also used, leading to tissue disruption and release of 
various metabolites from cellular binding. Such an approach facilitates the extraction of multiple 
endogenous compounds present in different forms (bound and unbound) in the living system but may not 
fully reflect the real metabolic profile of skeletal muscles. Variation in metabolite profiling via different 
techniques is recognized by the scientific community and for readers interested in this topic, detailed 
literature is available.59,426–430 
Summary  
The obtained results showed that, compared to the samples obtained from MHN patients, the levels of 
metabolites involved in different metabolic pathways, mostly related to lipid metabolism, were altered 
in skeletal muscle samples (baseline, halothane-exposed, and caffeine-exposed) collected from MHS 
patients in 2015 and 2016/2017 cohorts. The MHS group had elevated tissue levels of FtA(s) and AcR(s), 
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which could reflect inherent differences in muscle lipid metabolism in addition to providing evidence for 
a more readily utilization of β-oxidation as a source of energy in MH patients.   
The exposure of skeletal muscle to inhaled anesthetic (halothane) and caffeine resulted in alterations in 
several metabolic pathways mainly related to energy metabolism and composition of membrane lipids 
(phospholipids, glycolipids, phosphoglycerides). Additionally, presence of 16:0 Lyso:PC suggested 
elevated  PLA2 activity which might lead to increased breakdown of membrane phospholipids.  
Moreover, the presence of elevated levels of vitamin D and its metabolites in skeletal muscles added the 
complexity to altered biochemical profile of MHS patients. Comparison of data obtained via SPME to 
that of SLE showed similarities with respect to several compound groups, but also highlighted the fact 
that utilization of different sample strategies could lead to different results. Employment of conventional 
protocol for sample preparation, including tissue homogenization and application of organic solvent, 
could introduce errors in the interpretation of the metabolite profile. When compared to traditional 
sample preparation protocol, SPME as non-exhaustive technique facilitated extraction of several 
endogenous compounds, including amino acids, peptides, lipids and metabolites of vitamin D present in 
free form in the tissue matrix. Hence, metabolomics profiling should implement several sample 
preparation strategies to obtain a truly robust perspective of the studied subject.  
A novelty in the studies was implementation of in-vivo muscle sampling. This unique strategy may also 
provide insights into the involvement of intermediate or unstable compounds in MH, which are not easy 
to be preserved in biopsy samples. Moreover, the results from in vivo sampling are in good agreement 
with ex-vivo SPME and SLE indicating alteration of the same metabolic pathways i.e. FtA(s) and purine 
metabolism.  
It is important to keep in mind that metabolites and their levels are influenced by a synergy of factors 
which define the phenotype.431 Advancing our knowledge of MH from its metabolites to pathways would 
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allow for a better understanding of the disease mechanism as well as genetic, lifestyle and environmental 
risk factors.431 This could aid in early disease detection, development of new therapy and patient centric 
model of care, also known as personalized medicine.75,431 For example, findings with respect to 
dysregulation of muscle energy and lipid metabolism could be used to devise specific treatment options 
in clinical trials for MHS patients.75 Additionally, combining metabolomic investigations of MH with 
genome wide association studies would allow one to better discern between metabolites associated with 
genetically determined metabotypes.431 Indeed, MH is not always strictly expressed by individuals 
bearing the gene, so finding metabolites with consistent genetic association would be useful.   
Limitations of the study 
 It must be kept in mind that this study was completed based on a small number of cases where control 
of patient samples was very random (different ages, genders, diets, environment, physical activity) which 
increases the chance of finding general biomarkers related to MH condition. One inherent limitation of 
studying a condition like MH is the small sample size. In other words, collection of MH samples from 
susceptible human cohorts is difficult because of the small number of cases which turn out to be 
susceptible after CHCT. In other words, the condition is rare. This means that collections of samples are 
done over extended periods of time and their storage in −80 ˚C freezers might have an impact on the 
quality of data obtained. Determining how many samples are required for metabolomic investigations is 
currently not well understood. Monte-Carlo simulations may be used to determine the appropriate 
number of samples,371 but this requires high-level programming skills. Also, more controlled cohort 
studies are needed in the future to discern whether certain biomarkers are related to environment, lifestyle 
or are gene-associated.432 It is known that metabolomics profiles can vary with gender433 and genetics.434 
Our study did not have a sufficient number of patients to generate gender or gene specific patterns.  A 
larger patient cohort is required for a more thorough study as variation can often be seen in biomarkers 
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reported by various investigators which could be due to a number of factors (both population and 
technical based).433  
Features discovered in the 2016/17 cohort could be deemed informative (not strictly biomarker) due to 
concentration (sensitivity) differences between MHH and MHS and moderate differences in 
concentrations of some features between MHS/MHH and MHN patients. If the cause of this variability 
is phenotype related, then large groups of patient samples from various backgrounds should be used. 
Additionally, instrumental influence in metabolite discovery should not be ruled out as better 
understanding of recurring metabolites could be obtained by using a different analytical platform. 
Therefore, examination of both phenotype and technically-related variances would contribute in finding 
robust biomarkers for MH. 
With respect to animal study, technical issues which influenced reproducibility of the data have been 
already mentioned. The mouse model was selected as a proof of concept, because of cost effectiveness 
and relative easiness to be organized. Large animal or preferably human sampling should be performed 
to eliminate the problems with small muscle size. Moreover, the animal models represent only the genetic 
factor for MH pathogenesis, therefore moving directly to human study would enable screening of all 
factors having impact on the mechanisms of the disease. 
The analysis of the metabolites was done by focusing on a single platform (Metaboanalyst) as it is not 
uncommon to find that different biomarkers are reported by different analytical platforms.372 Also, the 
effect of a single biomarker may not be great- rather multiple correlated metabolites related to 
pathophysiology of MH would prove to be more useful.372,433 Also, as it was shown by our study, data 
variability was present in the analysis of the two cohorts and SLE extracts- hence robust investigations 
should make careful notes on both biological and technical data contributors.  
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Lastly, all the PLS-DA validation models provided in this chapter were strictly employed to assess 
relevant biological separation and applicability of SPME as a diagnostic tool. As shown, many of those 
PLS-DA models failed, and the answer why is not simple. Biology, sampling method, instrumental 
analysis and even data processing could have played a role. It is also important to acknowledge that 
disease pathophysiology of a large population is very complex. As such, it is rather difficult to imagine 
that a single biomarker (or even set of biomarkers) would always provide the correct diagnostic result 
for a group of individuals. This can downplay the use of SPME as a diagnostic tool, but it is important 
to acknowledge that the diagnostic potential of SPME does exist, but a lot of research and validation still 
must be done.  
 Conclusion 
In conclusion, we were able to obtain some insights into the disease mechanism of MH. Our findings 
pointed to potential dysregulation of predominantly lipid metabolism. Further metabolomic studies 
should focus on larger patient cohorts and implementation of different analytical platforms to discover 
recurring metabolic characteristics of MH. In addition, future efforts will be directed at a more thorough 
investigation of the lipid profile of the patients as well as looking at a greater population as the small 








This thesis was focused on the coupling of SPME to DART-MS and advancement of SPME technology 
for small volume analysis. In addition, current SPME technology (fibers) was investigated for 
metabolomics profiling of individuals affected by MH. Undeniably, DART-MS technology is simple to 
use, yielding rapid and sensitive results. DART-MS receives an additional benefit when coupled to a 
highly preconcentrating technique like SPME, which results in low detection limits in very complex 
matrices. In order to provide a better understanding of the mechanistic operation of SPME-DART-MS, 
several different experimental settings of DART and SPME were investigated. It was found that each 
factor has an impact on signal responses of SPME-DART-MS, but more importantly, there is a great 
likelihood of factor interaction, thus exhibiting somewhat of a synergistic effect. Analytical sensitivity 
of SPME-TM meshes and SPME fibers was also compared, and the evidence suggested that SPME-TM 
meshes of a very specific architecture (woven wire mesh) outperformed the SPME fibers. This 
highlighted the importance of using the appropriate format of SPME for the most sensitive detection. 
Applicability of SPME-TM-DART-MS was demonstrated for many scenarios, including coupling to 
portable MS instrumentation DART-QDa for simulated in-vivo detection of DoA(s) in OF. This could 
be particularly useful for law enforcement, as DUID accidents are expected to rise, particularly with the 
passing of the Cannabis Act. The prospect of using SPME-TM-DART-MS in small volume analysis was 
also successfully shown and can be of great benefit to TDM, animal welfare and forensic science. Within 
clinical settings, speedy results with high turnover rates are of great importance, especially with our ever-
growing population. Hence, a HT 96-SPME-TM system for DART-MS was developed and applied for 
detection of opioids in human urine and plasma, yielding quantitative results in less than 1.5 hours for a 
set of 96 samples. Lastly, the use of alternative, biocompatible materials like PEEK for manufacturing 
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of SPME-TM meshes and use in quantitative detection of DoA(s) in OF and urine was demonstrated. 
PEEK, in comparison to SS, is easier to handle, single use and more comfortable for in-vivo buccal 
swabbing. As such, PEEK SPME-TM meshes have great potential for on site in-vivo detection. 
Chapter 3 described the development of HLB coated SPME minitips and their subsequent application in 
small volume analysis. The problem of many approaches often used for small volume analysis is the 
implementation of poorly preconcentrating material on the probe surface. Certain published manuscripts 
had already demonstrated the use of preconcentrating materials on probe surface for compound isolation. 
However, the materials were selective, and the repeatability and limitations of the techniques were 
scarcely addressed. Hence, in chapter 3, the use of HLB microparticles for the manufacturing of SPME 
minitips was demonstrated in great detail, emphasizing the fact that microscale manufacturing is very 
challenging. The minitips developed had a 30 µm diameter on the tip apex and were coated 1 mm in 
length. Their accuracy, precision and technical problems were also discussed- particularly emphasizing 
the fact that microscale tip manufacturing can lead to deposition of slightly lower or higher amounts of 
the extractive phase, leading to pronounced errors. Use of IS can efficiently solve such problems, and 
this issue is not particularly problematic if probes are being used for extraction of highly concentrated 
compounds (ppm scale). However, the issue becomes more problematic if target analytes are present at 
lower concentrations. For example, a slightly “thicker” minitip could report a detection limit of 0.1 ppb, 
while a slightly “thinner” minitip could report a detection limit of 1 ppb. In chapter 3, a demonstration 
of analytical performance of SPME minitips coupled to LC/MS and nESI (AIMS) is provided for 
quantitation of DoA(s) in 1 µL of OF and 1 µL of blood, respectively. In addition, successful 
discrimination of four different types of fish eggs (caviar) is achieved, reporting over a hundred 
significant features. It is clear that LC/MS is a feasible instrumental analysis option, but its detection 
limits are much higher (due to dilution) when compared to nESI.  
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Chapter 4 was focused on investigation of metabolic markers of patients afflicted with MH. As explained, 
MH is hypermetabolic disorder, triggered by certain anesthetics which results in excessive release of 
calcium ions (Ca2+) within muscle cells. The details of metabolic derangements during an MH reaction 
or even after are unknown. In this study, muscle samples of patients afflicted with MH were sampled 
using SPME while the instrumental analysis was performed using LC/HRMS. Two cohorts were 
collected at TGH hospital, one in 2015 and the second in 2016/17. The analysis yielded variable but 
promising results for the two groups; with statistically significant metabolites for 2015 cohort and 
insignificant but informative features for the 2016/17 cohort, which served to highlight potential 
involvement of phenotypic variability in manifestation of MH. Tentatively identified metabolites pointed 
(but are not limited) to dysregulation in metabolism of membrane lipids, FtA(s), arachidonic acid, N2, 
amino-acyl-tRNA, long chain FA oxidation and linoleic acid metabolism in MH afflicted patients. 
Moreover, these results also pointed to potential involvement of PLA2 and AcR(s) in pathophysiology of 
MH. SLE was additionally used on muscle samples to examine whether metabolites obtained by SPME 
would recur using an alternate technique. Indeed, similar (as well as different) features were found by 
both techniques.  Additionally, in-vivo mice sampling was performed and confirmed alteration of lipids 
as well as purines metabolism.  While potential to use SPME as a diagnostic tool was shown, more 
research is still required since MH phenotypes and biochemistry are highly complex, variable and 
unlikely to yield a straight-forward answer to a single set of biomarkers of the MH condition.  
 Future directions  
 
While applicability of SPME-DART-MS has certainly been demonstrated, it is important to acknowledge 
that specific aspects of the technology would require further improvements and/or investigations. With 
respect to DART-MS technology, novel strategies should be implemented to enhance ionization of 
certain groups of analytes which traditionally yield poor results. A major hindrance of DART-MS is 
noise generated from the ambient air, which can interfere with detection capabilities of the device. In 
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other words, noise can overwhelm analyte signals at low concentrations or result in high detection limits 
for analytes of low MW(s). Hence, efforts should be made to improve and/or eliminate the generated 
noise by incorporating noise reduction components in the DART hardware. Lastly, DART would benefit 
from implementation of a fully robotic system which would be able to carry out all experimental steps, 
with minimal or no supervision since this would enable more efficient use of analyst’s time because 
“nobody wants to sit in front of the MS”.  
With respect to SPME-DART-MS, it is important to carry out an investigation focusing on potential 
interaction of experimental factors which determine system response. Considering the number of 
different factors involved with the approach, it is likely that a full factorial design would be the best 
strategy to examine factor interaction. Understanding factor interaction would allow for improved 
experimental throughput as only important factors would be considered, thus resulting in better use of 
time. 
The mechanism of thermal desorption of SPME devices during DART analysis should also be 
investigated, perhaps using modelling strategies, since it could potentially provide clues to optimum 
desorption conditions for the SPME devices. SPME is also capable of implementing derivatization 
strategies, which could be used concomitantly with DART-MS to improve ionization of thermally labile 
compounds, such as THC. Additionally, applicability of SPME-DART-MS has been insufficiently 
investigated for metabolomics. Coupling the two strategies together could lead to discovery of valuable 
information within a matter of minutes. Another aspect that should be considered is coupling of 
differential ion mobility MS (DIMS) with SPME and DART. While DART-MS has certainly shown that 
it can provide excellent analytical information, its lack of separation (chromatography) can be 
problematic if several target analytes have the same MRM transitions (i.e., isomers) or, if co-extracted 
components from working matrices (e.g., urine, OF, blood, plasma, etc.) have the same transition as the 
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target analytes. DIMS would not only aid in alleviating these issues, but also allow for further reduction 
of detection limits.  
Lastly, it is important that SPME-DART-MS technology is compared against validated “golden” 
standard techniques such as GC and LC. Proving that same results could be obtained with both techniques 
would be an important step in establishing effectiveness and legitimacy of AIMS techniques.  
With respect to SPME HLB minitips, further work should focus on improvement of protocol described 
in Chapter 3 to produce even smaller tips (i.e. tip apex ≤10 µm) which could penetrate tiny single cells. 
It is likely that the coating strategy would also have to change, as reduction of tip diameter would make 
it very challenging to use the existing dip-coating procedure. It is worthy to investigate formats other 
than acupuncture needles for the manufacturing of the minitips, but their cost must be considered, 
especially if minitip reusability is not an option. An example of this would be titanium. However, one 
must keep in mind that etching is often required for robust adherence of extractive particles to the SPME 
minitip. Hence, a careful and reproducible etching protocol should be devised as well for the titanium 
tips. While satisfactory results were obtained using HLB microparticles as the SPME minitip coating, it 
is worthy to investigate other coating chemistry options as they could yield even more information. 
Lastly, it is important to involve scientists from other fields to ensure the success of the SPME minitip. 
For example, devising a strategy to sample a single cell is not necessarily within the grasp of an analytical 
chemist, hence collaboration with researchers focusing on single cell analysis would be beneficial. 
It is undeniable that metabolomics has great potential for capturing disease related markers and 
elucidating their biochemical pathways. However, many metabolomics publications which focus on 
disease investigation vary greatly with respect to sampling protocols and the manner of information 
presentation. There is a need to enforce some general standards with respect to the aforementioned. This 
also applies to statistical tools used to process the data. Greater focus should also be placed on using 
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different sampling strategies, instrumental analysis and data processing to examine whether if the same 
results can be obtained using varying approaches. Metabolomics is still largely limited by the number of 
features which can be searched on online databases such as Metlin and HMDB. Lastly, implementing 
SPME as a diagnostic tool via untargeted (and targeted) metabolomics may have some potential, but it 
is important to conduct studies with more patients, since disease pathophysiology is far from simple. 
SPME in combination with metabolomics could also be coupled to AIMS for point-of-care diagnostics 
within a clinical/medical setting, thus providing rapid results in urgent settings. However, AIMS 
techniques still require more validation. Finally, greater focus should also be placed on critical 
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